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        Bacterial and fungal resistance to conventional antimicrobials is a burgeoning global 
health epidemic that necessitates urgent action. Even more alarming, the development of 
new antimicrobials to treat these multidrug-resistant pathogens has not kept pace with the 
rapid emergence of resistance to current antimicrobials. Antimicrobial drug development 
through the traditional de novo process is a risky venture given the significant financial and 
time investment required by researchers and limited success rate of translating these 
compounds to the clinical setting. This has led researchers to mine existing libraries of 
clinical molecules in order to repurpose old drugs for new applications (as antimicrobials). 
The main aim of this research endeavor was to screen and validate approved drug libraries 
and small molecules for their antimicrobial activity against multidrug-resistant bacterial 
and fungal pathogens, including Staphylococcus aureus and Candida albicans.  
        The present study identified four approved drugs (auranofin, ebselen, simvastatin and 
celecoxib) that exhibited potent antimicrobial activity against multidrug-resistant bacterial 
and fungal pathogens. Notably, auranofin, an FDA-approved anti-rheumatic drug 






by inhibiting multiple biosynthetic pathways including DNA, protein and cell wall 
synthesis. Furthermore, auranofin was found to be efficacious in a mouse model of S. 
aureus systemic infection, as it significantly reduced the bacterial load in murine organs, 
including the spleen and liver. Ebselen, an organoselenium compound known to be 
clinically safe, exhibited potent anti-staphylococcal activity by inhibiting bacterial protein 
synthesis. Other approved drugs including simvastatin (anti-hyperlipedmic drug) and 
celecoxib (non-steroidal anti-inflammatory drug) also possessed anti-staphylococcal 
activity against various clinical isolates of S. aureus.  Our study also revealed that three 
drugs (auranofin, ebselen and simvastatin) markedly reduced the production of major 
staphylococcal toxins including Panton-Valentine leucocidin (PVL) and α-hemolysin (Hla), 
thereby improving the treatment outcome against toxin-producing bacterial pathogens. 
Furthermore, all these drugs effectively reduced both the bacterial load and inflammatory 
cytokines in a mouse model of S. aureus skin infection.  
         In addition to their antibacterial activity, auranofin and ebselen were found to possess 
potent antifungal activity against two major pathogens, Candida and Cryptococcus; they 
exerted their antifungal effect through  inhibition of mitochondrial proteins (auranofin) and 
glutathione synthesis (ebselen) respectively. Additionally, these two drugs proved superior 
to control antifungals, as they reduced the fungal load in a Caenorhabditis elegans animal 
model. Taken altogether, the potent in vitro and in vivo antimicrobial activity (against 
bacterial and (or) fungal pathogens) of auranofin, ebselen, simvastatin and celecoxib 
indicates these four drugs have considerable promise to be successfully repurposed for use 





CHAPTER 1. DRUG REPURPOSING FOR THE DEVELOPMENT OF NOVEL 
ANTIMICROBIALS 
 (Thangamani S, Mohammad H, Younis W, Seleem MN. Drug repurposing for the 




           Bacterial and fungal resistance to conventional antimicrobials is a burgeoning 
global health epidemic that necessitates urgent action. Reports by the Centers for Disease 
Control and Prevention in the United States and the European Centre for Disease Control 
and Prevention indicate more than two million individuals in the United States and nearly 
400,000 individuals in Europe are stricken each year with infections caused by multidrug-
resistant pathogens, including methicillin-resistant Staphylococcus aureus (MRSA), 
carbapenem-resistant Klebsiella pneumoniae, vancomycin-resistant Enterococcus faecium 
and fluconazole-resistant Candida 1,2. Treatment of these infections are often expensive 
costing residents an estimated $55 billion in the United States and €1.5 billion in the 
European Union in total costs every year 1,2. Furthermore, the issue of bacterial and fungal 
resistance to antimicrobials around the world appears to be getting worse with the 





alarming, the development and approval of new antimicrobials capable of being used to 
treat infections caused by multidrug-resistant pathogens has not been able to keep pace 
with the rapid emergence of bacterial and fungal resistance to currently efficacious 
antimicrobials. Drug development of novel compounds is a time-consuming, costly, and 
high-risk venture given that few compounds successfully make it through stringent 
regulatory requirements to reach the marketplace. Collectively, this points to a critical need 
for the identification of novel strategies to develop antibiotics to deal with this challenging 
health issue. One strategy which warrants more attention as a unique method for identifying 
new antimicrobials is drug repurposing. 
          Drug repurposing, is a clever strategy to identify new applications (“off” targets) for 
drugs approved for other clinical diseases 6. This strategy has been successful employed to 
unearth new potential treatment options for different diseases including cancer, 
amyotrophic lateral sclerosis (ALS), Alzheimer’s disease, and malaria 7. On average, 20-
30 new drugs receive FDA-approval each year; of these, 30% are repurposed agents 8,9. 
Thus this points to repurposing being a quicker strategy to stock the drug discovery 
pipeline, particularly for antibiotics and antifungals, compared to the traditional process of 
de novo synthesis of new compounds which can cost pharmaceutical companies $800 
million to upwards of $1 billion in research and development expenditures and require 10-
17 years to attain regulatory approval 10,11. Repurposing existing approved drugs permits 
companies to bypass much of the preclinical work and early stage clinical trials required 
for new compounds (particularly toxicological and pharmacological analysis of drugs) thus 





 In addition to lower drug discovery-associated costs, repurposing approved drugs 
(particularly for identification of new antimicrobials) has several additional benefits. Given 
these drugs have already been tested in human patients, valuable information pertaining to 
pharmacokinetic and pharmacodynamics parameters are known 7. This permits a better 
understanding of the overall pharmacology of the drug, potential routes of administration 
(i.e. systemic versus local applications), and establishing an appropriate dosing regimen 
for patients. Moreover, as the toxicity profile of these drugs in humans has been extensively 
studied, valuable information has already been obtained regarding potential adverse side 
effects present with using the drug at certain therapeutic doses. This information is 
important as it pertains to antimicrobials as the concentration where toxicity is observed 
with host tissues can be correlated with the minimum inhibitory concentration (MIC) 
values obtained in standard bacterial susceptibility assays to determine if drugs are viable 
candidates for repurposing as antimicrobials.  
            Interestingly, several antibiotics have been repurposed for other clinical 
indications. For example, the third-generation cephalosporin, ceftriaxone, was initially 
approved for use in treating bacterial infections, including community-acquired pneumonia 
and meningitis 12-14. In bacteria, it interacts with penicillin-binding protein 2 to inhibit cell 
wall synthesis 15. Surprisingly, when tested in a neurodegenerative mice model of ALS, 
ceftriaxone was found to reduce the loss of neurons and muscle strength by increasing 
expression of glutamate transporter GLT1 thus decreasing the concentration of the toxic 
neurochemical glutamate present near motor neurons 16. This provided hope that this 
antibiotic could be repurposed as a novel treatment option for patients suffering from ALS. 





after it was suspected that the drug would not be able to help slow down progression of the 
disease or increase the rate of survival in affected patients 17. A recent study found that 
ceftriaxone also possesses antitumor activity and may be an alternative chemotherapeutic 
agent for use in lung cancer patients 6. In addition to ceftriaxone, the tetracycline antibiotic, 
minocycline, has been shown to slow down the emergence of ALS in mice and enhance 
patient survival in an ALS mouse model 18. Another antibiotic, fosmidomycin, that targets 
isoprenoid synthesis in bacterial cells, has been shown to have excellent activity against 
the parasite Plasmodium falciparum, thus permitting investigation for use as a treatment 
for malaria 19. Its mode of action in the malaria parasite involves inhibition of a key enzyme 
(1-deoxy-D-xylulose 5-phosphate reductoisomerase) in the non-mevalonate pathway 20. 
Clinical trials performed with fosmidomycin in combination with a second antibiotic 
(clindamycin) in malaria-stricken patients have obtained promising results thus far, further 
supporting the repackaging of fosmidomycin for use as a new treatment option against 
malaria 20,21. Furthermore, the antibiotic rapamycin (also known as sirolimus) was 
approved in 1999 by the FDA for use in patients to prevent organ transplant rejection; it 
was later found to have potential use in two other diseases - Autoimmune 
Lymphoproliferative Syndrome (ALPS) and the lung disease, lymphangioleiomyomatosis 
22-24.  
           Though antibiotics have entered clinical trials to be repurposed for other clinical 
indications, to date, not a single drug has been successfully repurposed for use as an 
antibiotic, particularly for hard-to-treat infections caused by bacteria such as S. aureus. As 
stated earlier, there are several approved drugs for different ailments that have been 





diseases (Table 1.1). Hence, given the significant problem posed by pathogenic bacteria 
and fungi, more effort and attention needs to be focused on using drug repurposing as a 
tool to uncover new treatment options for infections especially caused by multi-drug 
resistant pathogens, such as S. aureus. The present review will delve into approved drugs 
which have demonstrated promise to be repurposed as agents for S. aureus infections, 
discuss alternative applications for drugs possessing antimicrobial activity, and address 
current limitations to expedite the discovery and development of approved drugs to be 
repurposed for use as antibiotics.  
 
Table 1.1 List of drugs which have been repurposed as anti-infective agents 
Drugs Initial use Repurposed use References 
Auranofin Antirheumatic agent Amoebiosis 25 
Miltefosine Skin metastases (breast cancer) Vischeral leishmaniasis 26,27 
Amphotericin B Antifungal Visceral leishmaniasis 28 
Dapsone Pulmonary tuberculosis Malaria 29-31 
Eflornithine Antitumour agent/P. carinii 
infection in AIDS patients 
Human African sleeping 
sickness 
32-36 
Doxycycline Antibacterial Malaria 37 
Paromomycin Antibiotic Visceral and cutaneous 
leishmaniasis 
38-40 
Spiramycin Antibacterial Toxoplasmosis 41 
Chloroquine Malaria Amebiasis and 
sarcoidosis 
42,43 
Atovaquone Malaria Toxoplasmosis and  










1.2 Approved non-antimicrobial drugs with activity against S. aureus 
         Several studies have presented approved non-antibiotic drugs that possess 
antimicrobial activity, especially against S. aureus, indicating these drugs have potential 
alternative use for treatment of staphylococcal infections. However, the major hindrance 
for repurposing these drugs pertains to a lack of in vivo studies to confirm these drugs do 
possess antibacterial activity in an animal model. The primary criteria for in vivo systemic 
studies pertain to the availability of enough free drug in the plasma, when given at the 
tolerable dose, to ensure inhibition of bacterial growth. Hence considering the human 
plasma concentration of the approved non-antibiotic drugs, hereby we classify the 
antimicrobial activity of approved non-antibiotic drugs into two categories (a) drugs with 
activity in a clinical range that can be achieved systemically and (b) drugs with activity 
that cannot be achieved systemically (Table 1.2). 
 
1.2.1 Drugs with activity in a clinical range that can be achieved systemically 
            Several of the approved drugs discussed below have antimicrobial activity (denoted 
as the minimum inhibitory concentration (MIC) or lowest concentration of drug capable of 
inhibiting bacterial growth) several folds lower than the plasma concentration of the drug 
in humans. Therefore these particular drugs might be potential candidates to consider for 
treatment of systemic staphylococcal infections.  
 
Auranofin 
      Auranofin, a FDA-approved gold compound has been used for treating rheumatoid 





treating rheumatoid arthritis still remains unclear 49,50. Interestingly, independent of its anti-
rheumatoid action, auranofin has also been shown to have anti-parasitic effects. For 
example, auranofin has been shown to be capable of killing Schistosoma mansoni at a 
concentration of 5 μM and is also active against bloodstream and procyclic stages of 
Trypanosoma brucei with a half-maximal inhibitory concentration, IC50, of 0.5 µM 
51,52. It 
also inhibits the growth of the malaria parasite, Plasmodium falciparum, in vitro with an 
IC50 value of 142 nM 
53-55. Of particular interest, is the recent discovery of auranofin’s 
efficacy in treatment of human amebiasis caused by Entamoeba histolytica. Auranofin 
exhibited anti-Entamoeba activity with a half-maximal effective concentration (EC50 = 
concentration of drug necessary to reduce the culture density to 50%) of 0.5 μM. The EC50 
for E. histolytica was seven-fold lower than the clinically achievable blood concentration 
of the drug (3.5 μM).  Even though auranofin is rapidly metabolized and 60% is bound to 
plasma proteins, it was found to be effective in two animal models of amebic colitis and 
amebic liver abscess 25,56. Based on these studies, auranofin was granted orphan-drug status 
from the FDA for treatment of human amebiasis in 2012 25. 
  With regards to auranofin’s antibacterial activity, two recent studies have demonstrated 
that auranofin also possesses potent antimicrobial activity against S. aureus 57,58. The in 
vitro MIC reported for this drug ranges from 0.125 to 0.5 mg/L 57,58. More importantly, 
auranofin demonstrated bactericidal activity against several multidrug-resistant of S. 
aureus within an achievable clinical drug concentration in humans 25,57,58. Based on these 
promising preliminary studies, and its recent approval by the FDA as an anti-amoebic drug, 
auranofin might be a potential agent to repurpose for the treatment of systemic and topical 





action against S. aureus and establish its antibacterial activity in vivo in different animal 
models of S. aureus infection.  
 
Ebselen 
           Ebselen, an organoselenium compound also known as PZ51 or DR3305, has been 
widely investigated for its anti-inflammatory, anti-atherosclerotic and antioxidative 
properties 59-62. This particular drug has a well-studied toxicology and pharmacology 
profile and is currently undergoing clinical trials as a treatment option for different ailments 
including arthritis, cardiovascular disease, stroke, atherosclerosis, and cancer 60,63-66. In 
addition to being used as a treatment for multiple diseases, ebselen has also been shown to 
possess potent antimicrobial activity in vitro 67,68. It has activity against yeast and 
Escherichia coli and works by interfering with proton-translocation and inhibiting the 
thioredoxin reducatse (TrxR) enzyme respectively 68,69. Another interesting study has 
shown that it has potent antimicrobial activity against S. aureus with a MIC of 0.20 µg/ml 
67. This minimum inhibitory concentration is well within the plasma concentration (4-
6µg/ml) which is attained after1 mg/kg bolus injection combined with 1 mg/kg per hour 
intravenous infusion in rats 70. Surprisingly, this drug has not been investigated further as 
a treatment option for staphylococcal infections in spite of its excellent antibacterial 





Table 1.2 Approved drugs with activity against S. aureus 
Drugs Class/type MICs (µg/ml) References 
5-fluoro-2'-deoxyuridine antineoplastic 0.0007-0.002* 71 
Auranofin anti-rheumatoid 0.125-0.5* 57,58 
Ebselen organoselenium compound 0.2* 67 
5-fluorouracil antineoplastic 0.5 – 0.8 72 
Mitomycin-C antineoplastic 0.25 73 
Mithramycin antineoplastic 0.25 73 
Disulfiram alcohol deterrent 1.33 74 
Triflupromazine antipsychotic 2-5 75 
Dactinomycin antineoplastic 4 73 
Oxymetazoline  Vasoconstrictor(decongestant) 5 76 
Daunorubicin antineoplastic 8 73 
Doxorubicin antineoplastic 16 73 
Levocabastine  antihistamines 20 76 
Emadastine  antihistamines 20 76 
Dicyclomine antispasmodic 25 77 
Prochlorperazine antipsychotic 20-25  78 
Simvastatin antihyperlipidemic 29-74 79 
Celecoxib NSAIDs 32 80 
Tetrahydrozoline  vasoconstrictor (decongestant) 50 81 
Methotrexate antineoplastic 64 – 102 72 
Tegaserol  narcotic and analgesic  80 76 
Amitriptyline hydrochloride antidepressant 100 82 
Azelastine hydrochloride antihistaminic 125- 250 83 
Mitpranolol antiarrhythmic, antiglucoma  140 84 
Promethazine neuroleptic and  antihistaminic 125- 250 83 
Butorphanole narcotic and analgesic 180  84 
Diclofenac anti-inflammatory 200 85 
Tropicamide  anticholinergic  200 84 
Oxyfedrine vasodilator  200-250  86 
Aminopterin antineoplastic 256  73 
Fluvastatin antihyperlipidemic 400 76 
Ketamine anesthetic  450 76 
Proxymetacaine anesthetic 500  76 
Mequitazine Antihistaminic and 
anticholinergic 
625-125  83 
Cyproheptadine 
hydrochloride 
antihistaminic 625-125  83 
Ibuprofen NSAIDs 1250 87 







Table 1.3 continued 
Telmisartan  antihypertensive 2000 76 
Perazine   antipsychotic 2000 88 
Amlodipine  antihypertensive 3000 81 
Docusate sodium  laxative 3000 89 
Etodalac NSAIDs 4000 76 
Alverine  spasmolytic 4000 76 
Fluvoxamine thymoleptic 4000 88 
Tolfenamic acid  NSAIDs 5000  76 
Temozolomide  antineoplastic 5000 76 
Acepromazine  antiemetic, sedative 5000 81 
Riluzole  anticonvulsive, antiepileptic 5000 88 
Tamoxifen  anti-neoplastic  6000 88 
Solifenacin succinate  spasmolytic 7000 89 
Perphenazine  antipsychotic   8000 81 
Oxaprozin  NSAIDs 13000  76 
Citalopram  antidepressant 13000 89 
Zofenopril ACE inhibitor  15000 88 
Sertraline antidepressant 16000 90 
Chlorpromazine  antipsychotic 20000 81 
Acebutolol  antihypertensive 23000 81 
Clopidogrel anticoagulant 24000 89 
* MICs below the plasma concentration of the drug in humans 
 
Considering its potent in vitro anti-staphylococcal activity, studies on the antibacterial 
MOA of ebselen and evaluating its in vivo activity against S. aureus could be useful for 
developing ebselen as an antibacterial agent to treat multidrug-resistant staphylococcal 
infections 67,68. 
 
5-Flurouracil, 5-fluoro-2'-deoxyuridine, and mitomycin C 
           Antimetabolites such as 5-flurouracil, 5-fluoro-2'-deoxyuridine (FdUrd), and 
mitomycin C belong to a class of antineoplastic drugs which are used for treatment of 






91. In addition to their anticancer activity, these three drugs also exhibit potent antimicrobial 
activity below the concentration that can be achieved in human plasma 72. For example, 5-
fluorouracil has been shown to inhibit S. aureus at a concentration ranging from 0.5 – 8.0 
µg/mL, in vitro; at this concentration, these drugs fall within the mean plasma 
concentrations of 13.4 and 8.3 µg/mL, which is attained after a single intravenous (250 mg) 
and  oral dose (500 mg), respectively72,92,93. 
           Similarly, FdUrd, an interchangeable metabolite of 5-fluro uracil is capable of 
inhibiting S. aureus growth at a MIC ranging from 0.0007-0.002 µg/ml, which is several 
hundred folds lower than the mean plasma concentration of 14.1 + 2.7 µg/ml, which is 
attained after a continuous infusion of 1000 mg/m2 per 24 hour dose of 5-flurouracil for 5 
days 71,94,95. In addition, 5-fluoro-2'-deoxyuridine is a pro-drug which needs the 
deoxyribonucleoside kinase (dNK) enzyme to exert its action; this enzyme is present in S. 
aureus 71,95. 
          Another anticancer drug, mitomycin C, when given at a dose of 60 mg/m2 in humans 
has been shown to have a peak plasma concentration of 1.9 µg/ml. This drug inhibits S. 
aureus growth at a MIC of 0.06 - 0.25 µg/ml, which is well within the range capable of 
being reached in the plasma 72,93,96. Hence, considering promising in vitro antibacterial 
studies conducted this far, these drugs warrant further evaluation as anti-staphylococcal 
drugs. Future studies would need to be conducted to test their in vivo antibacterial efficacy 







1.2.2 Drugs with activity that cannot be achieved systemically 
           Most of the approved non-antimicrobial drugs that possess anti-staphylococcal 
activity have MIC values that are higher than their plasma concentration; thus, using these 
drugs for treatment of systemic infections might not be a viable option. However, they can 
be potentially used for topical application for treating staphylococcal skin infections. 
Community-associated methicillin-resistant S. aureus (CA-MRSA) strains have become a 
significant source of staphylococcal skin infections. In particular, the strain MRSA 
USA300 has emerged as one of the most highly prevalent isolates in United States 
responsible for skin and soft tissue infections 97,98. Additionally, MRSA colonization in the 
skin and mucosa is considered an important risk factor for invasive infections 99. Thus 
repurposing approved drugs, with high MIC values that cannot be achieved systemically, 
for use to treat MRSA skin infection and as decolonizing agents is a sensible approach 
which warrants further investigation. These drugs can be either used as single agents or can 
be combined with conventional antimicrobials to enhance the efficacy and extend the life 
span of traditional antimicrobials. Furthermore, several of these drugs have additional 
benefits that will permit their use as a topical antimicrobial agent. For example, the drugs 
simvastatin and celecoxib have been shown to inhibit the pro-inflammatory cytokines 
tumor necrosis factor-α (TNF-α) and IL-6 100,101. Controlling excess inflammation, 
particularly by limiting TNF-α and IL-6 production, in chronic wounds plays a beneficial 
role in wound healing 102-107. Additionally, simvastatin has been shown to enhance wound 
healing and angiogenesis in diabetic mice 108. Hence, taking into account the antimicrobial 






inflammatory properties), further investigation is warranted to test these approved drugs in 
topical S. aureus infection animal models.  
 
1.3  Novel uses of approved drugs 
             For the past few decades, the development of new antimicrobials has slowed down 
while the evolution of bacterial resistance has continued to rise; hence, there is an urgent 
need to identify alternative strategies to combat infections caused by multidrug-resistant S. 
aureus 109-111. Emergent approaches that have drawn great interest recently include drugs 
with indirect antimicrobial activity which work by (i) targeting virulence factors and toxins 
(anti-virulence agents) 110,112,113, (ii) enhancing host immunity (immunomodulators) 111,114, 
and (iii) enhancing entrance of other antimicrobials into target cells by increasing the 
permeability of the outer membrane  or by inhibiting efflux pumps (helper drugs) 115. These 
novel approaches can be combined with traditional antibiotics to enhance the efficacy and 
extend the life span of antimicrobial drugs and to minimize the evolution of bacterial 
resistance to these agents. Here we provide several examples of FDA-approved non-
antimicrobial drugs which do not have direct antimicrobial activity or have very high MIC 
in vitro that cannot be achieved clinically; though they cannot be used systemically, they 
have potential for use to disrupt bacterial pathogenesis or to modulate a host’s immune 
response to combat staphylococcal infections. 
 
1.3.1  Targeting virulence factors and toxins 
          Targeting staphylococcal virulence factors and toxins is an important strategy to 






play a role in promoting S. aureus invasion, pathogenesis, and persistence 110,113. Even 
though, S. aureus is not killed directly in this strategy, it greatly reduces the ability of 
bacteria to colonize the host 110.  
           Several FDA-approved drugs that do not possess direct antimicrobial activity in 
vitro have been shown to inhibit important virulence factors and toxins. For example, 
salicylic acid, the major metabolite of aspirin, inhibits the global regulators of virulence 
genes in S. aureus such as sarA and agr 116. Repression of these two genes, at a clinical 
achievable dose,  leads to the down regulation of various exotoxins and exoenzymes, such 
as fibronectin protein binding genes (fnbA and fnbB) and α-hemolysin (hla), which are 
responsible for S. aureus adhesion and host tissue cytolysis116,117. This may have the 
potential to be used as an adjunctive agent for the treatment of multidrug-resistant S. aureus 
infections 116. 
           Other drugs such as cisplatin and chloroquine are also known to protect infected 
hosts from the effects of bacterial toxins. Cisplatin is an anticancer drug that acts primarily 
by interacting with DNA to form DNA adducts, thereby leading to the activation of 
apoptosis 118. In addition to this, cisplatin also protects macrophages from anthrax lethal 
toxin (LT) by inhibiting LT translocation into cells 119. This protective effect has also been 
confirmed in murine models 119. Similarly, chloroquine, a well-known anti-malarial drug, 
blocks the entry of anthrax toxins and increases animal survival in anthrax-toxin 
challenge.120-122. Future studies are needed to gain more insights into the molecular actions 
of these drugs with bacterial toxins. Additionally, it will be worthy to investigate the effect 
of these FDA-approved drugs on S. aureus toxin production, toxin interaction with host 







1.3.2   Efflux pump inhibitors 
         Efflux mediated resistance towards antibiotics in S. aureus has been gaining more 
attention recently and is recognized as the first line of bacterial defense against 
antimicrobials 123. Several efflux pumps in staphylococci are associated with resistance to 
various antimicrobials. Efflux pumps such as Tet (K) and Tet (L) contribute to tetracycline 
resistance, NorA, NorB, NorC, MepA and MdeA are associated with fluoroquinolone 
resistance, while Mef(A) and Msr(A) mediate resistance to macrolides 123,124.  
         FDA-approved drugs have been shown to inhibit important efflux pumps in S. aureus. 
For example, the phenothiazine group of drugs such as chlorpromazine, fluphenazine, 
prochlorperazine, and thioridazine, which are primarily used for the treatment of 
schizophrenia and other psychotic disorders, showed marked inhibitory activity against 
efflux pumps in S. aureus 125,126. All four drugs have also been found to inhibit NorA-
mediated efflux in S. aureus and enhance the activity of norfloxacin several fold 127. 
Chlorpromazine and thioridazine have also been shown to reduce MRSA resistance to 
oxacillin 128. Similarly, reserpine, an antipsychotic and antihypertensive drug, also inhibits 
an efflux pump in S. aureus that subsequently makes it susceptible to both oxacillin and 
norfloxacin 127,128. Another antihypertensive drug, verampil, has also been shown to reduce 
fluoroquinolone-resistance in S. aureus 129,130.  
         Proton pump inhibitors, such as omeprazole and lansoprazole, which are used for the 
treatment of gastroesophageal efflux and dyspepsia in humans, have also been proven to 
be potent inhibitors of S. aureus efflux pumps 131. These drugs greatly enhance the activity 






aureus expressing NorA 131. Therefore, therapeutic development of bacterial efflux pump 
inhibitors (in combination with antimicrobials to permit entry of the antimicrobial into the 
pathogen) is a useful strategy to consider as a treatment for S. aureus infections. However, 
a limitation of the non-antibiotic drugs discussed above is none possess activity at a 
concentration lower than those achievable in human serum 131. Hence, future studies are 
needed to focus on making modifications to these drugs to enhance their activity against S. 
aureus. Additionally, screening of FDA-approved drug libraries can be done to identify 
more potent efflux pump inhibitors within the applicable clinical range in humans. 
 
1.3.3  Immuno-modulatory drugs 
       S. aureus possesses diverse immune evading mechanisms to alter the host immune 
response in such a way that favors their invasion, survival, and replication in the host 132,133. 
Hence, modulation of this complex host immune response to the pathogen is another 
reasonable approach to target these bacterial infections that has been widely investigated 
in recent years 111,114. In general, pathogens develop strategies to become invisible to the 
host immune system and in turn the host fails to mount an effective immune response to 
clear the pathogen 132-134. On the other hand, there are circumstances where pathogens, such 
as S. aureus and its virulence factors, are capable of hyper stimulating the host immune 
system, leading to the uncontrolled production of inflammatory markers and other 
mediators which result in tissue damage and septic shock 135,136. This happens more often 
in acute infections such as in sepsis where the strong inflammatory response and cytokine 
storm that follows may lead to shock and death 137-139. In addition, S. aureus is also known 






toxin (TSST-1) which can activate antigen-presenting cells (APCs) and T-cells leading to 
the induction of a strong inflammatory cascade reaction 135,136,140. Superantigens such as 
TSST-1 and enterotoxins also bypass normal antigen processing by APCs and induce direct 
proliferation of T-cells, even at a picomolar concentration 140,141. Hence, finding 
immunomodulatory agents that can be effectively combined with antibiotics may produce 
a better outcome in patients afflicted with a S. aureus infection. 142-145. 
            Non-antibiotic FDA-approved drugs with immuno-modulatory activity to treat 
bacterial infections have been investigated by various researchers. Even though some of 
these drugs have no direct antimicrobial activity in vitro, they have been shown to aid in 
achieving a better resolution of staphylococcal infections by reducing toxin production or 
by modulating host immune response to enhance bacterial clearance.  
 
Statins 
          Statins are one of the major classes of FDA-approved lipid lowering drugs that act 
on HMG-CoA reductase; these drugs have been widely used to prevent cardiovascular 
disease in humans 146-148. In addition to their role in cardiovascular disease, numerous 
functions of statins, independent of their lipid lowering property, have been studied 
recently 149. The antibacterial activity of statins, particularly simvastatin, has been explored 
by several groups 150-157. However, the high MIC value obtained for statins is a major 
concern with using statins directly as antimicrobial agents 158; this has led to researchers 
searching for alternative uses for statins for treating bacterial infections. 
         Statins act at various cellular and molecular levels and regulate multiple anti-






interactions and leukocyte migration. All these effect are beneficial in treating sepsis 159. 
Furthermore, statins inhibit several different cytokines including TNF-α, IL-1β, IL-6, and 
IL-8, thereby lowering the inflammatory activity of neutrophils and macrophages and 
dampening the immune response involved in sepsis 159-165. In addition to the extensive 
inflammatory response, the release of several mediators such as C-reactive protein also 
plays a major role in sepsis 166. C-reactive protein promotes thrombus formation by 
enhancing endothelial cell–monocyte interaction, increases tissue factor expression, and 
activates the complement system leading ultimately to organ dysfunction and death 
159,166,167. However, statins greatly reduce the levels of C-reactive protein and its subsequent 
actions in sepsis 168-170. Statins also inhibit leukocyte migration by reducing various 
adhesion molecules such as VLA4, P-selectin, CD11b, CD11a and CD18 171-173. In addition, 
a study demonstrated that simvastatin pre-treatment also reduces S. aureus α-toxin induced 
leukocyte rolling, adhesion, and transmigration 174. Furthermore, the overall beneficial role 
of statins in S. aureus septicemia is supported by a retrospective and clinical study which 
demonstrated significant reduction in mortality among patients with statin therapy 
compared with patients not taking statins 158,175,176. Hence, the promising evidence 
compiled thus far of statins in limiting the effects of sepsis make it worthwhile to 
investigate the exact molecular mechanism by which statins exhibit their action to propel 











           Beyond the use of nicotinamide (vitamin B3) as a supplement, it inhibits 
inflammatory cytokines such as IL-1β, IL-6, IL-8, and TNF-α and is used for the treatment 
of inflammatory skin disorders such as atopic dermatitis and acne vulgaris 177,178. In 
addition, nicotinamide, in combination with nafcillin, improved the survival outcome of 
staphylococcal septic shock in mice 179. However, the exact molecular mechanism behind 
this immune modulation activity remains unclear. Another study showed nicotinamide 
enhanced S. aureus killing in vivo by modulating host factors 180. Host factors, such as 
phagocytic ability of monocytes and macrophages, greatly influence bacterial clearance. In 
particular, a higher expression of anti-staphylococcal peptides such as lactoferrin (LTF) 
and cathelicidin in monocytes and macrophages greatly increases their phagocytic ability 
and bacterial killing 180-183. However, the expression of antimicrobial peptides (LTF and 
cathelicidin) in phagocytic cells is regulated by CCAAT/enhancer-binding protein ε 
(C/EBPε), a myeloid-specific transcription factor 180-183. Nicotinamide increases the 
activity of C/EBPε in neutrophils and enhances the killing of S. aureus up to 1000-fold in 
vivo 180. Hence, by manipulating C/EBPε expression, the phagocytic ability of certain 
immune cells can be enhanced, which further increases their bactericidal activity. 180. 
       Additionally, nicotinamide also reduces staphylococcal enterotoxin (SEB)-induced 
responses 184. Nicotinamide inhibits the SEB-induced T-cell proliferation and 
inflammatory cytokines such as IL-2 and IFN-γ, and protects mice from SEB-induced 
toxicity 184. Thus, taken collectively, nicotinamide with potent immuno-modulatory 
activities via increased S. aureus killing and damping the SEB-induced inflammatory 








         Dexamethasone is a steroid drug with potent anti-inflammatory and 
immunosuppressive activity that has been used for the treatment of various systemic and 
localized skin diseases. Being a potent anti-inflammatory drug, it also inhibits 
staphylococcal enterotoxin (SEB)-induced inflammatory cytokines such as TNF-α, IFN-γ, 
IL-1α, IL-2, and IL-6 and protects mice from hypothermia and shock 185-188. 
 
Rapamycin 
         Rapamycin, a FDA-approved immunosuppressive drug is used to prevent graft 
rejection in renal transplantation 189; it has also been shown to have a protective effect in a 
SEB-induced septic shock mice model by inhibiting cytokines such as TNF-α, IFN-γ, IL-
2, IL-6, and IL-1α.  Additionally, it inhibits production of chemokines such as chemo 
attractant protein 1 (MCP-1) and macrophage inflammatory protein 1(MIP-1) in peripheral 
blood mononuclear cell PMBC 190,191. When tested in vivo, rapamycin protected all treated 




           Pentoxifylline, a FDA-approved drug used for the treatment of intermittent 
claudication resulting from peripheral artery disease, has a protective role on SEB or 






cytokines TNF-α, IFN-γ, and IL-1α 192. Furthermore, pentoxifylline prevents mice lethality 
in a SEB-induced shock model 192. 
            The examples described above demonstrate the great potential of FDA-approved 
non-antimicrobial immunomodulators to be combined with traditional antimicrobials to 
modulate the host immune response and can be further explored as a novel viable 
therapeutic strategy for the treatment of staphylococcal infections. 
 
1.3.4 Anti-biofilm agents 
         Biofilm-forming S. aureus often cause serious complications leading to life-
threatening infections 194. Studies on staphylococcal biofilm present on indwelling medical 
devices such as catheters, implanted devices, and prosthetic heart valves have drawn great 
interest over the past few decades 194. S. aureus biofilm-associated infections are 
challenging to treat with conventional antibiotics 194,195. Hence, novel drugs and strategies 
are in immediate need to deal with biofilm infections 195. Several FDA-approved non-
antibiotic drugs have been shown to possess anti-biofilm activity. For example, 
nitazoxanide (NTZ), an anti-protozoal agent approved for the treatment of 
Cryptosporidium parvum and Giardia intestinalis infections in humans, is shown to have 
anti-biofilm activity 196. Nitazoxanide exhibits anti-staphylococcal activity at a MIC 
ranging from 8 to 16 μg/ml. Additionally, at sub inhibitory concentrations (IC50 of 1 to 3 
μg/mL), NTZ is shown to inhibit biofilm formation by Staphylococcus epidermidis 197. 
        Several FDA-approved drugs are known to disrupt adherent microbial biofilms. 
Examples include auranofin (anti-rheumatoid drug), benzbromarone (gout drug), 






and zotepine (antipsychotic) which have all been shown to be capable of inhibiting pre-
formed microbial biofilms 198. Further testing of these drugs against different 
staphylococcal biofilms, both alone and with conventional antimicrobials, should be 
considered as a new avenues to target multidrug-resistant staphylococcal infections and 
associated biofilms. 
 
1.4 Identifying new antibiotic leads from approved drugs which can serve as novel 
antibiotics 
         From 2008-2012, only three new antibiotics received approval from the FDA 199. 
Interestingly, in 2014, thus far the FDA has already approved three new antibiotics 
(dalvance, tedizolid phosphate, and oritavancin) indicating the agency is recognizing the 
urgent need for new antibiotics to treat difficult bacterial infections; all three approved 
drugs are indicated for use in treating acute bacterial skin and skin structure infections 
caused by pathogens such as MRSA 200,201. These antibiotics are not new drug classes but 
rather modified derivatives of older antibiotics which interfere with the same biochemical 
pathways and molecular targets known for many years. For example, dalvance and 
oritavancin belong to the glycopeptide class of antibiotics (which interfere with bacterial 
cell wall synthesis) while tedizolid phosphate is an oxazolidinone which inhibits bacterial 
protein synthesis.  
        Though numerous new molecular/druggable targets inside bacteria have been 
identified in recent years, no compounds have been successfully developed (and received 
approval) that interact and bind to these targets. Given that only four new antibiotic classes 






techniques need to be considered to discover drugs capable of binding to these unique 
targets 202. Drug repurposing presents a new method to screen for existing drugs that can 
interact with these critical targets inside pathogens. This could lead to the development of 
new antimicrobial classes which interact with different molecular targets compared to 
traditional antibiotics. Understanding which moiety on the drug interacts with the 
molecular target can also permit medicinal chemists to make rational modifications to the 
parent drug to construct analogues with enhanced binding affinity for the target (with the 
hope of improved antimicrobial activity), improved pharmacokinetic profile of the drug, 
and reduced toxicity to host tissues. Also this could permit the identification of new 
bacterial targets which have not been previously known. 
 
1.5 Challenges for repurposing non-antibiotic drugs for S. aureus  
         Though repurposing approved drugs for use as antimicrobials is an exciting avenue 
for discovery of new potential treatments for bacterial infections, there are multiple 
obstacles hindering progress in identifying and developing these agents. One of the biggest 
challenges in the field of antibiotic drug discovery is the lack of interest by pharmaceutical 
companies and industry to invest resources in this area. The reality is that the vast majority 
of drugs currently available in the market were discovered by the pharmaceutical industry. 
In the United States alone, only 9% of new drugs discovered between the years of 1960 
and 1969 came from government agencies, universities, and not-for-profit organizations 8. 
This trend continued to hold true in latter parts of the 20th century as over 93% of new 
drugs approved in the United States, from 1990 to 1992, were procured from industry; 






drugs in this time span 10. Thus industry is a key cog in the identification and development 
of drugs which are capable of reaching the healthcare setting. However, given the low 
return on investment for antibiotics, companies, particularly Big Pharma, have moved 
away from developing new antibiotics. This can be illustrated with a simple example; from 
2009-2012, Merck’s leading medication for diabetes (Januvia) outsold its top-selling 
antibiotic (Invanz, a carbapenem antibiotic) by US$11 billion 203. Moreover, a review of 
the top 100 best-selling drugs from April 2013 through March 2014 revealed treatments 
for chronic diseases such as rheumatoid arthritis (Humira, Enbrel, Remicade), depression 
(Cymbalta, Seroquel XR), asthma (Advair), high-cholesterol (Lipitor, Crestor, Zocor), 
multiple sclerosis (Copaxone, Tecfidera), Alzheimer’s disease (Namenda), diabetes 
(Lantus Solostar, Januvia), AIDS (Atripla, Truvada, {Prezista), high blood pressure 
(Diovan, Metoprolol), and cancer (Rituxan, Avastin, Gleevec) generated the most sales for 
pharmaceutical companies; interestingly no antimicrobials were found on this list. Given 
the associated costs involved with drug discovery, the lack of sales generated by antibiotics 
(in comparison to drugs developed for chronic diseases such as asthma, diabetes, and high 
blood pressure), and stringent regulations required for new antibiotics to receive regulatory 
approval, this significantly reduces the incentive needed by companies to pursue 
developing novel antimicrobials 199. This has led to several major companies, including 
Pfizer and Roche, to terminate their antibiotics research & development division; as of 
2013, only four major pharmaceutical companies have active antimicrobial drug discovery 
programs 202,203. This leaves government agencies, academic institutions, and small 
companies with the burden of filling this gap to generate new antimicrobials. While 






with the drug discovery process, most of these agencies lack the resources available to 
industry for drug discovery. Additionally, these organizations face a second major obstacle 
in the path to repurposing drugs as antimicrobials. 
         A second major challenge to repurposing approved drugs as antimicrobials pertains 
to the lack of accessibility to libraries containing clinical drug collections. As highlighted 
by Chong and Sullivan, no single collection of the nearly 10,000 known clinical drugs 
currently exists 7. Instead these drugs are dispersed throughout several different collections 
or are not available to researchers (in part due to existing patents present for certain drugs). 
Among the publicly available compound collections include the National Institute of 
Neurological Disorders and Stroke (NINDS) collection of 1,040 compounds, the Prestwick 
Chemical Library in Washington, DC (containing more than 1,000 approved drugs), and 
the Johns Hopkins Clinical Compound Library (consisting of more than 1,500 compounds) 
7. Combined with other drug collections available for commercial purchase, this amounts 
to only 40% of the total known approved drugs and clinical molecules which are available 
for screening for antimicrobial activity 7. However, redundancy and overlap between these 
different libraries presents an additional problem as a compound may be present in more 
than one collection making screening these compounds more difficult.  
           Obtaining access to the remaining 60% of clinical drugs, for screening for 
antimicrobial activity, is a significant impediment to identifying new clinical applications 
for these drugs. Moreover, it would be valuable to researchers if they can gain access to 
libraries of compound metabolites and drugs which entered phase II and III clinical trials 
but failed to receive approval for the initial clinical indication. Most drugs fail in phase II 






intended to be used for 11. Though these compounds may not have succeeded in gaining 
approval for their initial clinical application, they may still have promise for alternative 
uses, for example as antibiotics for S. aureus infections. Gaining access to these 
compounds, clinical data generated for these compounds, and information pertaining to 
why they failed in clinical trials will permit researchers to rationally design potential 
solutions to overcome these issues in repurposing these compounds for other clinical 
applications. However, many of these clinical failures are often not made publicly 
accessible by pharmaceutical companies (for competitive and financial reasons); 
additionally given these companies often are focused on developing drugs for specific 
diseases, they may not have the resources (i.e. models to study infectious diseases in 
humans) or personnel to identify new applications for these failed compounds 11. 
Establishing relationships and bridging the gap between industry (who would provide these 
compounds and clinical data garnered), academic research institutions (to screen these 
compound libraries for hits for antimicrobial activity), and government agencies (to assist 
with sponsoring clinical trials to test drugs to be repurposed as antimicrobials) is very 
important in order to find new applications for both approved drugs and compounds which 
have entered into late stage clinical trials but ultimately failed. 
  
1.6 Conclusion 
          Development of new antimicrobials is very slow and there are not enough new 
antimicrobials in the drug pipeline to keep pace with the emergence of multidrug-resistant 
bacterial strains. Moreover, pharmaceutical companies lacking interest in antimicrobial 






alternative strategies are in urgent need to battle against multidrug-resistant infections such 
as those caused by S. aureus. Repurposing approved drugs presents an emerging approach 
with reduced cost, discovery time, and risk associated with antibiotic development. We 
presented several approved drugs that possess potent anti-staphylococcal activity in vitro; 
with further mechanistic and in vivo studies, these drugs might be a potential candidate 
drugs that can be considered for systemic and (or) topical applications. Independent of 
antimicrobial activity, some drugs also have the ability to interfere with S. aureus 
pathogenesis and modulate host immune response to enhance bacterial killing and 
clearance. This is an additional novel application of the approved drugs which warrants 
further exploration. With the promising activity and the past success in drug repurposing, 
repositioning existing drugs might form a potential alternative strategy to discover new 
antimicrobials and might drive interest of researchers both in academia and the 






CHAPTER 2. DRUG REPURPOSING FOR BACTERIAL INFECTIONS 
2.1 Antibacterial activity and mechanism of action of auranofin against multi-
drug resistant bacterial pathogens 
 
(Thangamani S, Mohammad H, Abushahba MF, Hamed MI, Sobreira TJ, Hedrick VE, Paul 
LN, Seleem MN. Antibacterial activity and mechanism of action of auranofin against 
multi-drug resistant bacterial pathogens. Scientific Reports. 2016 Mar 3;6:22571.) 
 
2.1.1 Introduction 
               Bacterial resistance to antibiotics is a significant public health challenge, as 
infections caused by antibiotic-resistant bacteria claim the lives of nearly 23,000 people 
each year in the United States alone 204. A single pathogen, methicillin-resistant 
Staphylococcus aureus (MRSA), is responsible for nearly half of these fatalities. MRSA 
has been linked to invasive diseases including pneumonia 205 and sepsis 206, that affect a 
diverse population of patients including individuals with a compromised immune system 
207 such as young children 208. While a powerful arsenal of antibiotics was once capable of 
treating S. aureus-based infections, clinical isolates of MRSA have emerged to numerous 






           Most current antibiotics were discovered via the time-consuming and financially 
taxing process of de novo synthesis and screening of chemical compounds210. An 
alternative approach to unearthing new antibacterials that is garnering more recent attention 
is screening libraries of approved drugs (or drugs that made it to clinical trials but 
ultimately failed to receive regulatory approval) in order to identify candidates that can be 
repurposed as antimicrobials 210. Recently, we assembled and screened 50% of the 
commercially available drugs (~ 2,200 drugs) and small molecules tested in human clinical 
trials 7,211(727-NIH Clinical Collections 1 and 2, 1,600-Pharmakon from Microsource, 
Approved Oncology Drugs Set-NIH, and few small libraries) and identified three drugs 
that exhibited potent antibacterial activity at a dose that is clinically achievable. One of 
these drug, auranofin is capable of inhibiting growth of clinically-pertinent isolates of 
MRSA at submicrogram/mL concentrations in vitro. Auranofin is an oral gold-containing 
drug initially approved by the U.S. Food and Drug Administration (FDA) for treatment of 
rheumatoid arthritis. In a study by Debnath et al, auranofin was found to exhibit potent 
anti-parasitic activity against Entamoeba histolytica providing evidence that this drug 
could be repurposed as an antimicrobial agent 25. More recent studies have discovered this 
drug also possesses potent antibacterial activity including against important pathogens such 
as MRSA 25,212-215.  
Building upon this seminal work, the goals of the present study were to further 
investigate the antibacterial mechanism of action of auranofin and to examine potential 
applications of auranofin as an antibacterial agent for systemic MRSA infections. We have 
identified that auranofin appears to target multiple biosynthetic pathways in S. aureus, 






auranofin to mitigate specific virulence factors including reducing the production of key 
toxins such as α-hemolysin and Panton-Valentine leucocidin, a fact previously unknown. 
Auranofin is less effective against Gram-negative pathogens in large part due to the 
presence of the outer membrane in these pathogens. Furthermore, in vivo studies 
demonstrate that auranofin is capable of treating invasive MRSA infections, thereby 
expanding the potential therapeutic applications of this drug for use as a novel antibacterial 
agent. The findings presented in this study provide strong evidence that auranofin can be 
repurposed as a novel antibacterial agent for treatment of invasive MRSA infections in 
humans. 
 
2.1.2 Materials and Methods 
Bacterial strains and reagents 
             Bacterial strains used in this study are presented in Tables 1 and 2. Mueller-Hinton 
broth (MHB) was purchased from Sigma-Aldrich while Trypticase soy broth (TSB), 
Trypticase soy agar (TSA), and mannitol salt agar (MSA) were purchased from Becton, 
Dickinson and Company (Cockeysville, MD). Auranofin (Enzo Life Sciences), 
vancomycin hydrochloride (Gold Biotechnology) and linezolid (Selleck Chemicals) were 
al purchased from commercial vendors. 
 
Antibacterial assays 
              The broth microdilution method was employed to determine the  MICs of all test 
agents (tested in triplicate) as per the Clinical and Laboratory Standards Institute (CLSI) 






determining the MIC. The MIC was classified as the lowest concentration of drug capable 
of inhibiting visible growth of bacteria by visual inspection.  
 
Gram-negative bacteria outer membrane permeabilization assay 
             The MIC of auranofin and control antibiotics, in the presence of polymixin B 
nonapeptide (PMBN), against Gram-negative bacteria was measured as described in the 
antibacterial assay section above. A subinhibitory concentration of PMBN (10 µg/ml) was 
added to TSB to increase the outer membrane permeability and facilitate the entrance of 
auranofin, as described elsewhere 217,218.  
 
Macromolecular synthesis assay 
            S. aureus  ATCC 29213 was used for the macromolecular synthesis assay and the 
assay was carried out using auranofin and control antibiotics (ciprofloxacin, rifampicin, 
linezolid, vancomycin and cerulenin) as described elsewhere 211. 
 
Proteomics analysis 
             Sample Preparation:  An overnight culture of MRSA USA300 cells were treated 
with 10 × MIC of auranofin (1.25 µg/ml), linezolid (20 µg/ml) and vancomycin (10 µg/ml) 
for one hour at 37°C. Bacterial cells were centrifuged and sequence grade Lys-C/Trypsin 
(Promega) was used to enzymatically digest samples. Samples were reduced and alkylated 
prior to digestion. All trypsin digestions were carried out in a Barocycler NEP2320 (PBI) 
at 50°C under 20 kpsi for two hours.  After digestion, samples were cleaned using 






97% H2O/3% ACN/0.1% FA. A small aliquot (5 µL) of sample was analyzed via nanoLC-
MS/MS. 
LC-MS/MS: Samples were run on an Eksigent 425 nanoLC system coupled to the Triple 
TOF 5600 plus 219. The gradient was 120 min at 300 nl/min over the cHiPLC–nanoflex 
system. The trap column was a Nano cHiPLC 200 µm × 0.5 mm ChromXP C18-CL 3 µm 
120 Å followed by the analytical column, the Nano cHiPLC 75 µm × 15 cm ChromXP 
C18-CL 3 µm 120 Å. The sample was injected into the Triple TOF 5600 plus through the 
Nanospray III source. Data acquisition was performed at 50 precursors at 50 min/scan.  
Analysis: WIFF files from mass spectrometric analysis were processed using the 
MaxQuant computational proteomics platform version 1.5.2.8 220. The peak list generated 
was screened against the Bos taurus (41521 entries unreviewed) and Staphylococcus 
aureus (10972 entries reviewed) sequence from UNIPROT retrieved on 04/10/2015 and a 
common contaminants database. The following settings were used for MaxQuant: initial 
precursor and fragment mass tolerance set to 0.07 and 0.02 Da respectively, a minimum 
peptides length of seven amino acids, data was analyzed with ‘Label-free quantification’ 
(LFQ) checked and the ‘Match between runs’ interval set to 1 min, the FASTA databases 
were randomized and the protein FDR was set to 5%, enzyme trypsin permitted two missed 
cleavage and three modifications per peptide, fixed modifications were carbamidomethyl 
(C), variable modifications were set to Acetyl (Protein N-term) and Oxidation (M). The 
MaxQuant results used in-house script, and the average LFQ intensity values for the 
technical replicates were used for each sample. Both the Bos taurus and the common 
contaminant proteins were removed. Values were transformed [log2(x)] and the missing 






analyses were performed in the R environment (www.cran.r-project.org) and Qlucore 
OMICS explorer (version 3.0, Qlucore, Lund, Sweden). A one-way analysis of variance 
(ANOVA) was performed on the LFQ intensities and only proteins with P < 0.05 were 
selected for further analyses. 
  
Growth curve of E. coli in the presence of auranofin 
               Wild-type and trxB/gor double mutant E. coli strains (wild-type: novablue (DE3)-
K12, trxB/gor double mutant: Origami-2) were incubated with indicated concentration of 
auranofin in the presence and absence of PMBN (10 µg/ml) for 16 hours at 37°C. Bacterial 
growth was monitored using a spectrophotometer (OD = 600 nm). 
 
Analysis of S. aureus toxin production by ELISA 
                The effect of auranofin and two control antibiotics (vancomycin and linezolid) 
on production of two key S. aureus toxins (α-hemolysin and Panton-Valentine leukocidin) 
was measured by ELISA as has been previously described 211. 
 
Intracellular infection assay 
                 J774A.1 murine macrophage-like cells were infected with MRSA USA300 for 
30 min at a multiplicity of infection (MOI) ratio of 1:100. Infected cells were subsequently 
washed three times with DMEM medium containing 10 IU lysostaphin 221. Auranofin (0.5 
µg/ml), vancomycin (4 µg/ml) and linezolid (8 µg/ml), in triplicates, in complete DMEM 
medium containing 4 IU lysostaphin was then added. After 24 hours of incubation at 37°C 






and lysed with 0.1% Triton X-100 (Sigma-Aldrich). Cell lysates were plated onto TSA 
plates and MRSA colony forming units (CFU) were counted after incubation of plates for 
24 hours at 37°C. 
  
Mice studies 
              Eight week old female BALB/c mice (Harlan Laboratories, Indianapolis, IN) were 
used in all mice studies. The animal care and all experiments were approved and performed 
in accordance with the guidelines approved by Purdue University Animal Care and Use 
Committee (PACUC). Eight-week old female BALB/c mice (n = 10 per group) were used 
and the study was carried out as described before 222 
Systemic - lethal infection : An overnight culture of MRSA USA300 cells were washed 
and re-suspended in PBS. Each mouse received an intraperitoneal (i.p.) injection (200 µl) 
containing the bacterial suspension (9 × 109 CFU). One hour after infection, mice were 
divided into four groups (ten mice per group). Mice were treated orally with auranofin 
(either 0.125 or 0.25 mg/kg), linezolid (25 mg/kg), or the vehicle alone (10% ethanol). 
Treatment was provided once daily for three days following infection. Mortality was 
monitored daily for five days and the moribund mice were euthanized humanely using CO2 
asphyxiation.  
Systemic – non-lethal infection: The infection protocol was carried out as described above 
(systemic-lethal infection) with the following exceptions. Each mouse received an i.p. 
injection containing 2 × 107 CFU MRSA USA300. Mice were divided into three groups 
(five mice per group) and treated orally with auranofin (0.25 mg/kg), linezolid (25 mg/kg), 






hours after the last dose, mice were euthanized and their spleen and liver were excised, 
homogenized in TSB, plated onto MSA plates, and incubated at 37°C for 24 hours prior to 
counting MRSA CFU post-treatment. 
 
Combination testing of auranofin with commercial antibiotics 
                  Additive activity of auranofin with conventional antibiotics (ciprofloxacin, 
linezolid and gentamicin) was evaluated as described in a previous study223,224. Briefly, 
MRSA USA300 was incubated with auranofin, control antibiotics, or a combination of 
auranofin + a control antibiotic at different concentrations for 16 hours. Next, the optical 
density (at 600 nm) was measured using a spectrophotometer. Percent bacterial growth for 
each treatment regimen was calculated and presented.  
 
Growth curve of S. aureus in the presence of auranofin 
              MRSA USA300 was incubated with indicated concentration of auranofin for 16 
hours at 37°C and the percent bacterial growth was monitored using a spectrophotometer 
(OD = 600 nm). 
 
Time kill assay 
                An overnight culture of MRSA USA300 was diluted to 6 × 105 CFU/mL and 
treated with 5 × MIC of auranofin, vancomycin or linezolid (in triplicate) in Mueller Hinton 
broth and incubated at 37°C. Samples were collected at indicated time points, serially 
diluted in PBS, and transferred to TSA plates. Plates were incubated at 37°C for 24 hours 






DNA intercalation assay 
               DNA intercalation assay was carried out using pUC 18 plasmid as described 
elsewhere 225. Briefly, 250 ng of plasmid DNA was incubated with the indicated 
concentration of auranofin and doxorubicin in a total volume of 25 µl and the reaction 
mixtures were incubated for 30 min at 37°C. An electrophoretic assay was run using 1% 
agarose gel without ethidium bromide at 50 volts  for 4 hours. The gel was stained with 
ethidium bromide and visualized for DNA mobility. 
 
Cytotoxicity assay 
              In vitro toxicity assay was carried out in mouse macrophage (J774A.1) cells by 
MTS assay as described before 226. Briefly, auranofin at a concentration ranging from 0 to 
256 µg/ml was added to  the cells. After 24 hours of incubation, the cytotoxicity effect of 
auranofin was measured by the addition of MTS assay reagent 3-(4,5-dimethylthiazol-2-
yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H tetrazolium). Results are 
expressed as percent cell viability of auranofin-treated cells in comparison to cells treated 
with DMSO.  
 
Statistical analyses 
              Statistical analyses were assessed using GraphPad Prism 6.0 (Graph Pad Software, 
La Jolla, CA). P values were calculated via the Student t test or Kaplan-Meier  








Auranofin is a potent inhibitor of multidrug-resistant Gram-positive bacteria 
             The antimicrobial activity of auranofin was assessed against a panel of clinical 
isolates of multidrug-resistant Gram-positive pathogens using the broth microdilution  
 
 
Figure 2.1 Growth curve of MRSA USA300 in the presence of auranofin.  Bacteria were 
incubated with indicated concentrations of auranofin and the growth was measured using 
a spectrophotometer 
 
method (Table 2.1). Auranofin exhibited potent bactericidal activity against all tested 
bacteria including strains that are resistant to conventional antimicrobials such as 
methicillin and vancomycin. The minimum inhibitory concentration (MIC) of auranofin, 
required to inhibit growth of different MRSA strains, were found to be in the range of 






Table 2.1  MICs of auranofin and control antibiotics against Gram-positive bacteria 











MRSA (USA100) Resistant to ciprofloxacin, clindamycin, 0.125 2 2 
 erythromycin    
MRSA (USA200) Resistant to clindamycin, methicillin 0.0625 2 1 
 erythromycin, gentamicin,    
MRSA (USA300) Resistant to erythromycin, methicillin, 0.125 2 1 
 tetracycline    
MRSA (USA400) Resistant to methicillin, tetracycline 0.0625 2 1 
MRSA (USA700) Resistant to erythromycin, methicillin 0.125 4 1 
MRSA (USA800) Resistant to methicillin 0.0625 4 1 
MRSA (USA1000) Resistant to erythromycin, methicillin 0.125 2 1 
MRSA (USA1100) Resistant to methicillin 0.125 2 1 
E. faecalis ATCC49533 Resistant to streptomycin 0.125 2 1 
E. faecalis  ATCC7080 - 0.125 2 1 
E. faecalis ATCC 51229 
(VRE) 
Resistant to Vancomycin. Sensitive to 
Teicoplanin 
0.125 2 8 
E. faecium E0120 (VRE) 
Resistant to gentamicin and 
vancomycin 
0.25 2 >128 
E. faecium ATCC6569 - 0.125 2 1 
S. pneumoniae 51916 Resistant to cephalosporins 0.25 1 1 
S. pneumoniae 70677 
Resistant to erythromycin, penicillin, 
and tetracycline 
0.25 1 1 
Streptococcus agalactiae 
MNZ938 
Beta-hemolytic, Serogroup: Group B 0.0625 0.25 0.25 
Streptococcus agalactiae  
MNZ 933 
Beta-hemolytic, Serogroup: Group B 0.0625 0.25 0.5 
Streptococcus agalactiae  
MNZ 929 
Beta-hemolytic, Serogroup: Group B 0.0015 0.25 0.25 
 
The antibacterial activity of auranofin against MRSA is superior (16-fold lower MIC for 
auranofin) to several commercial antibiotics including vancomycin (MIC of 1 µg/ml) and 
linezolid (MIC ranged from 2-4 µg/ml); the MIC values determined for auranofin against 
MRSA correlate with MIC values reported in previous published studies 212,214. Auranofin 
retained its antibacterial activity against an array of MRSA strains exhibiting resistance to 
numerous antibiotic classes including glycopeptides, oxazolidones, tetracycline, β-lactams, 






antibiotics and auranofin is unlikely to occur. The bactericidal activity of auranofin was 
confirmed via a standard time-kill assay (Figure 2.2); auranofin, at 5 × MIC, exhibited slow 
bactericidal activity (similar to vancomycin), completely eliminating MRSA USA300 cells 
within 48 hours.  
 
 
Figure 2.2 Time-kill assay for auranofin tested against S. aureus. Killing kinetics of 
auranofin and antibiotics (vancomycin and linezolid) at 5 × MIC against MRSA USA300 
in MHB are displayed. The results are presented as mean ± SD (n = 3).  Data without error 
bars indicate that the SD is too small to be seen. 
 
Vancomycin required 24 hours to achieve the same effect, which is in agreement with 
previously published reports 227. In addition to possessing anti-MRSA activity, auranofin 
also exhibited potent antibacterial activity against vancomycin-sensitive enterococcus and 
vancomycin-resistant enterococcus (VRE), Streptococcus pneumoniae and Streptococcus 







The outer membrane in Gram-negative bacteria negates auranofin’s antibacterial 
activity 
              Confirmation of auranofin’s potent antibacterial activity against multiple Gram-
positive pathogens led us to analyze if auranofin exhibits broad-spectrum antibacterial 
activity by also inhibiting growth of important Gram-negative pathogens. Interestingly, 
auranofin alone did not show activity against Gram-negative bacteria which is in agreement 
with previous reports212-214.  We sought to investigate if the presence of the outer membrane 
(OM) in Gram-negative bacteria contributed to the lack of antibacterial activity observed, 
by preventing auranofin from gaining entry into the bacterial cell (as has been observed 
with conventional antimicrobials such as erythromycin and fusidic acid) 217,218. The 
inclusion of the permeabilizing agent polymixin B nonapeptide (PMBN), at a sub 
inhibitory concentration, in the culture broth resulted in auranofin exhibiting potent activity 
against all tested strains of Gram-negative pathogens including Pseudomonas aeruginosa, 
Escherichia coli, metallo-β-lactamase (NDM-1) and carbapenemase-resistant (KPC) 
Klebsiella pneumoniae, Salmonella Typhimurium and extremely drug-resistant (XDR) 
Acinetobacter baumannii with MICs ranging from 0.125 to 1 µg/ml (Table 2.2). In addition 
to this, a four-fold decrease in auranofin’s MIC (from 32 to 8 µg/ml) was observed when 
the efflux pump AcrAB was deleted in E. coli. AcrAB has been shown to contribute to the 
antibiotic-resistant phenotype in multiple strains of E. coli and has been implicated in E.coli 
resistance to numerous antibiotics including ampicillin, rifampicin, and chloramphenicol 
228. Thus, in addition to the physical barrier imposed by the Gram-negative OM, the ability 
of auranofin to gain entry into Gram-negative bacteria to exhibit its antibacterial activity 






Table 2.2 MICs of auranofin and control antibiotics against Gram-negative bacteria 
 
Bacteria 
Minimum Inhibitory Concentration (MIC)  (µg/ml) 
PMBN Auranofin Erythromycin Fusidic acid 
PMBN  PMBN PMBN 
(-) (+) (-) (+) (-) (+) 
Acinetobacter baumannii ATCC BAA19606 >256 16 0.25 64 0.5 64 0.5 
Acinetobacter baumannii ATCC BAA1605 >256 16 0.5 64 0.5 128 1 
Acinetobacter baumannii ATCC BAA747 >256 16 0.25 64 1 128 0.5 
Escherichia coli O157:H7 ATCC 700728 256 64 0.5 128 1 >256 16 
Escherichia coli O157:H7 ATCC 35150 256 32 0.5 128 1 >256 16 
Salmonella Typhimurium ATCC 700720 >256 128 1 256 2 >256 16 
Klebsiella pneumoniae ATCC BAA 2146 >256 256 0.5 >256 128 >256 32 
Klebsiella pneumoniae ATCC BAA 1705 >256 256 1 >256 64 >256 64 
Pseudomonas aeruginosa  ATCC 9721 >256 >256 0.25 >256 1 >256 1 
Pseudomonas aeruginosa  ATCC 27853 >256 256 0.125 256 1 >256 1 
Pseudomonas aeruginosa ATCC BAA-1744 >256 >256 0.25 >256 1 >256 1 
Pseudomonas aeruginosa  ATCC 25619 >256 256 0.25 256 1 >256 1 
Pseudomonas aeruginosa  ATCC 35032 >256 >256 0.5 >256 1 >256 1 
Pseudomonas aeruginosa  ATCC 10145 >256 256 0.25 256 1 >256 2 
Pseudomonas aeruginosa  ATCC 15442 >256 >256 0.25 >256 2 >256 1 
Escherichia coli 1411 >256 32 0.5 32 4 >256 4 
Escherichia coli SM1411∆ acrAB  >256 8 0.5 0.03 <0.03 8 <0.03 
Escherichia coli (Novablue (DE3)-K12)  256 16 0.5 16 0.5 >256 0.5 
Escherichia coli (Origami-2) (trxB/gor 
mutant)  
256 16 0.5 32 0.5 256 0.06 
       PMBN polymyxin B nonapeptide: (-) No PMBN was added to the media; (+) (10 µg/ml) of PMBN 











Auranofin inhibits multiple biosynthetic pathways in S. aureus 
                  After confirming auranofin possesses potent antibacterial activity in vitro, 
particularly against drug-resistant strains of S. aureus, we next moved to determine the 
antibacterial mechanism of action of auranofin. A macromolecular synthesis assay was 
employed to initially investigate auranofin’s antibacterial mechanism of action. The effect 
of auranofin on the incorporation of radiolabeled precursors into five major biosynthetic 
pathways of S. aureus was assessed. This assay revealed a clear dose-dependent inhibition 
of three pathways, indicating that auranofin might possess multiple targets (Figure 2.3). 
Auranofin, at a sub-inhibitory concentration, significantly inhibited cell wall and DNA 
synthesis. When tested at its MIC, auranofin was found to also inhibit protein synthesis. At 
higher concentrations (8 × MIC auranofin), partial inhibition of lipid synthesis was also 
observed. However, auranofin did not significantly inhibit RNA synthesis at any of the 
tested concentrations. The results from the macromolecular synthesis assay suggest that 
auranofin possesses a complex mode of action that involves inhibition of multiple 
biosynthetic pathways including cell wall, DNA, and protein synthesis.  
Primary disruption of DNA synthesis in the macromolecular synthesis assay is often 
associated with DNA intercalators. However, when auranofin was examined for evidence 
of DNA intercalation, no effect on DNA migration was observed in relation to the untreated 
control. Unlike doxorubicin, auranofin, even at a  concentration (1mg/ml) that is 8000-fold 
higher than the average MIC against MRSA, shows no evidence of a shift in plasmid DNA 
(Figure 2.4). These data suggest that the disruption of DNA synthesis by auranofin is not 








Figure 2.3 Antibacterial mechanism of action of auranofin examined via the 
macromolecular synthesis assay. Incorporation of radiolabeled precursors of DNA, RNA, 
protein, cell wall and lipid synthesis ([3H] thymidine, [3H] uridine, [3H] leucine, [14C] N-
acetylglucosamine and [3H] glycerol, respectively) were quantified in S. aureus ATCC 
29213 after treatment with 1 × and 8 × MIC of auranofin, and 8 × MIC of control antibiotics. 
Results are expressed as percent inhibition of each pathway based on the incorporation of 
radiolabeled precursors. Statistical analyses were done using the two-tailed Student’s‘t’ 











Figure 2.4  DNA mobility assay in the presence of auranofin and doxorubicin. pUC 18 
plasmid was incubated with the indicated concentration of auranofin and doxorubicin for 
30 min at 37°C. An electrophoretic assay was run using 1% agarose gel, stained with 
ethidium bromide and visualized for DNA mobility. 
     
 
Auranofin treatment in S. aureus leads to downregulation of proteins in five major 
biosynthetic pathways 
                Proteomic profiling is a powerful tool that can be employed to investigate the 
response of bacteria to antibacterial compounds and assess the impact of such compounds 
on different cellular pathways 229-231. Therefore, the alteration in the S. aureus proteome 
caused by auranofin was investigated and compared with linezolid and vancomycin in 
relation to an untreated control group. The proteomic analysis identified 530 proteins in all 
samples and found 222 of these proteins showed significant differential expression (P ≤ 
0.05). The PCA analysis demonstrated that the variance inside each group is very low with 







Figure 2.5 Auranofin treatment in S. aureus leads to downregulation of proteins in five 
major biosynthetic pathways. (a) The PCA analysis shown for auranofin, vancomycin, 
linezolid and control proteins quantified by proteomic analysis. The plot depicts the 
variance inside each group and the protein expression pattern of drug treated and 
control groups. (b) Heat map generated comparing auranofin-, vancomycin- and 
linezolid-treated cells to untreated control S. aureus cells is shown. Triplicate samples 
were used for each group. One-way analysis of variance (ANOVA) was used for 
statistical analysis and the proteins that were significantly differentially (P ≤ 0.05) 
expressed were mapped. Red color indicates significantly increased ratios and green 






expression pattern of the auranofin-treated group resembles that of the linezolid-treated 
group more so than either the control or vancomycin-treated groups (Figure 2.5a). The 
proteins were separated into five groups based on molecular function (DNA, RNA, protein 
synthesis, cell wall and lipid synthesis) (Figure 2.5b). Similar to the protein synthesis 
inhibitor linezolid, treatment with auranofin leads to the down regulation of most of the 
proteins involved in all five major biosynthetic pathways. The average fold changes (log2) 
of proteins between auranofin and the control group involved in each pathway was: -0.76 
(DNA), -0.37 (RNA), -0.26 (protein), -0.76 (cell wall) and -0.18 (lipid). In the presence of 
auranofin, approximately 55% of the proteins were significantly differentially expressed 
as compared to the control group (P ≤ 0.05). Of the 222 proteins that showed significant 
differential expression, only 20% of these proteins were upregulated in the auranofin-
treated group compared to 40% of proteins that were upregulated in the control group (P ≤ 
0.05). These results suggest that auranofin treatment leads to significant down regulation 
of most of the proteins involved in all five major biosynthetic pathways, which contributes 
to the bactericidal effect of auranofin against S. aureus.  
 
Thioredoxin reductase is not the sole target for auranofin in S. aureus 
                A recent investigation of auranofin as an antibacterial agent 213 reported that 
auranofin exerts its bactericidal activity by targeting thiol-redox homeostasis through direct 
inhibition of the thioredoxin reductase enzyme. The authors postulate that the glutathione 
system present in certain species of Gram-negative (and Gram-positive) bacteria limits 
their susceptibility to auranofin (as this system is functionally similar to the thioredoxin 






reductase enzyme is inhibited). This led the authors to conclude that auranofin’s primary 
antibacterial mechanism is through inhibition of thioredoxin reductase. While auranofin 
has been shown to inhibit thioredoxin reductase both in S. aureus and M. tuberculosis, we 
suspect that this enzyme is not the sole antibacterial target of auranofin for the reasons 
outlined below. First, we have confirmed that the lack of antibacterial activity of auranofin 
against Gram-negative bacteria (as presented in Table 2.2) is due to the permeability barrier 
conferred by the outer membrane (OM)  
 
Figure 2.6 Growth curve of novablue (DE3)-K12 wild-type and trxB/gor Origami-2 double 
mutant E. coli strains in the presence of auranofin.  E. coli strains were incubated with 
indicated concentrations of auranofin in the presence and absence of PMBN (10 µg/ml) 
and the growth was measured using a spectrophotometer. 
 
and is not glutathione-mediated. Second, an E. coli double mutant strain (Origami-2) 
containing mutations to both the thioredoxin reductase (trxB), the purported target of 
auranofin, and glutathione reductase (gor), responsible for maintaining redox homeostasis 






coli strain (Novablue (DE3)-K12) (MIC = 16 µg/ml) (Table 2.2).  However, there is a 
greater than 32-fold improvement in antibacterial activity of auranofin when combined 
with a subinhibitory concentration of PBNP (MIC = 0.5 µg/ml) (Table 2.2). This 
observation was further validated by assessing the growth of wild-type and the double 
mutant E. coli (Origami-2) strains in the presence of increasing concentrations of auranofin 
(with or without PBMN) (Figure 2.6). Once again, the viability of the Origami-2 double 
mutant was severely impacted by auranofin in the presence of a subinhibitory concentration 
of PBMN; however, in the absence of PBMN, the double mutant strain exhibited a similar 
growth pattern to the wild-type E. coli strain. This analysis, when combined with the 
macromolecular synthesis assay and proteomics results, supports the notion that 
thioredoxin reductase is not the sole target of auranofin in bacteria. Additionally, the outer 
membrane, and not the glutathione system alone, is responsible for limiting auranofin’s 
antibacterial activity against Gram-negative bacteria.  
 
Auranofin inhibits S. aureus toxin production 
                Confirmation that auranofin inhibits bacterial protein synthesis by 
macromolecular synthesis assay, led us to inquire whether this drug would be capable of 
suppressing the production of key virulence factors, such as toxins, produced by pathogens 
like MRSA. Antimicrobials capable of disrupting or suppressing bacterial protein synthesis, 
including agents like linezolid, are valuable and preferred options for treating patients 
impacted by toxin-mediated bacterial infections, such as toxic shock syndrome (TSS) and 
pneumonia caused by S. aureus 232-235. For example, inhibition of protein synthesis and the 






mechanism of action over vancomycin 232-235. Therefore to assess the capability of 
auranofin to dampen production of key S.-aureus toxins, ELISA was utilized to detect toxin 
production for MRSA USA300 treated with auranofin and two control antibiotics 
(vancomycin and linezolid). Auranofin significantly inhibited production of two major S. 
aureus toxins including Panton-Valentine leukocidin (PVL) and α-hemolysin (Hla) (Figure 
2.7a). These results indicate that auranofin, similar to linezolid, possesses an advantage in 
the management of toxin-mediated staphylococcal infections due to its ability to suppress 
production of key staphylococcal toxins. 
 
Auranofin effectively clears intracellular bacteria 
               As auranofin exhibited potent anti-MRSA activity against extracellular bacteria, 
we were curious to explore the ability of auranofin to eliminate MRSA harboring inside 
eukaryotic cells. MRSA is capable of entering multiple cell types, including macrophages, 
in mammalian tissues thus permitting it to evade host defenses and permitting an infection 
to persist for an extended time period 236. Such infections are particularly challenging to 
treat given many antibiotics are unable to permeate cellular membranes to gain entry into 
these intracellular niches to kill MRSA 226,237-242. One such example is the antibiotic 
vancomycin, which has a clinical failure rate of more than 40% in treating S. aureus 
pneumonia; failure is attributed in part to the inability of vancomycin to penetrate infected 







Figure 2.7 Auranofin inhibits MRSA toxin production and effectively clears intracellular 
bacteria. (a) Toxin production (ng/ml) in S. aureus MRSA USA300 after treatment with 
auranofin or control antibiotics (linezolid or vancomycin) for one hour (data corrected for 
organism burden). The results are presented as mean ± SD (n = 3).  Statistical analysis was 
done by two-tailed Student’s ‘t’ test.  Asterisks (**) indicate statistical significance in 
relation to the control (DMSO or water).  P values of (** P ≤ 0.01) are considered 
significant. (b) MRSA USA300 infected J774A.1 cells were treated with auranofin and 
control antibiotics (vancomycin or linezolid) for 24 hours and the percent bacterial 
reduction was calculated compared to untreated control groups. The results are given as 
mean ± SD (n = 3). Two-tailed Student’s ‘t’ test was employed and P values of (*, # ≤ 0.05) 






In order to investigate the efficacy of auranofin in clearing intracellular MRSA, this drug 
was tested against macrophage cells (J774.A1) infected with MRSA. At a non-toxic 
concentration of 0.5 µg/ml (Figure 2.9); auranofin effectively clears more than 60% of 
intracellular MRSA (Figure 2.7b). In contrast, conventional antibiotics such as linezolid (8 
µg/ml) and vancomycin (4 µg/ml) are not able to reduce the bacterial burden inside infected 
macrophages by more than 30% (Figure 2.7b). Altogether the results suggest that auranofin 
is capable of eradicating MRSA harboring inside mammalian cells. These findings suggest 
that auranofin is a potential valuable treatment option for challenging infections/diseases 
(such as pneumonia) where MRSA reside inside host cells. 
 
Auranofin rescues mice from MRSA septicemic infection 
            The efficacy of auranofin was evaluated in both a lethal and non-lethal systemic 
MRSA infection model. In the lethal septicemic study, mice were infected intraperitoneally 
with MRSA USA300. One hour post-infection, four groups of mice (n = 10 mice per group) 
were treated orally with auranofin at a clinical dose of 0.125 or 0.25 mg per kg, linezolid 
at a dose of 25 mg per kg, or the vehicle alone as a control. Mice were treated once daily 
for three days and monitored for a total of five days. Both auranofin and linezolid provided 
a significant protection from mortality (Figure 2.8a). The survival rate of infected mice 
improved dramatically when the dose of auranofin was increased. 80% of mice that 
received a higher dose of auranofin, (0.25 mg per kg) survived for five days. All mice in 
the group that received linezolid (25 mg per kg) survived for five days. These results 






Figure 2.8  Auranofin is effective in a mouse model of MRSA septicemic infection. (a) 
Ten mice per group were infected (i.p) with lethal dose of MRSA USA300 and treated 
orally with auranofin (0.125 or 0.25 mg/kg), linezolid (25 mg/kg), or the vehicle alone for 
three days (one dose per day). Mice were monitored for five days and the percent survival 
was calculated. A log rank test was performed using 95% confidence intervals and the 
statistical significance was calculated in order to compare treated to control groups. P 
values of (* ≤ 0.05) (** P ≤ 0.01) are considered as significant. (b) Five mice per group 
were infected (i.p) with non-lethal dose of MRSA USA300 and treated orally with 
auranofin (0.25 mg/kg), linezolid (25 mg/kg), or the vehicle alone for two days (one dose 
per day). 24 hours after the last treatment, mice were euthanized and their spleen and liver 
were excised and homogenized in TSB to count viable MRSA colonies. The number of 
CFU from each mouse is plotted as individual points. Statistical analysis was conducted 
using the two-tailed Student’s ‘t’ test and P values of (* ≤ 0.05) are considered as 
significant. (c) Auranofin in combination with systemic antimicrobials effectively inhibits 
the growth of S. aureus. Growth of MRSA USA300 was measured after incubating with 
auranofin, control antibiotics, or a combination of auranofin + a control antibiotic. The 
checkerboard assay was performed by diluting one drug along the ordinate and the second 







translates in vivo in protecting mice from septicemic MRSA infection. Next we moved to 
study the efficacy of auranofin in reducing the burden of MRSA in a non-lethal septicemic 
mouse model. Mice were infected with a non-lethal dose of MRSA USA300 and each 
group of mice received two oral doses of auranofin (0.25 mg per kg), linezolid (25 mg per 
kg) or the vehicle alone. As depicted in Figure 2.8b, auranofin and linezolid produced a 
significant reduction in mean bacterial load in murine organs including the spleen and liver. 
Both treatment with auranofin and treatment with linezolid reduced the mean bacterial load 
by more than 95% in the spleen (Figure 2.8b). However, in the liver, auranofin produced a 
90% reduction in MRSA load whereas linezolid was only able to reduce the burden of 
MRSA by 70% (Figure 2.8b).  
 
Combination therapy of auranofin with systemic antimicrobials 
            Utilizing a single agent to treat bacterial infections in the clinical setting appears to 
have become less effective with the rise of additional strains of multidrug-resistant S. 
aureus 244,245. Combining two or more antibiotics together for the treatment of MRSA 
infections has been explored as an alternative strategy in the healthcare setting in order to 
improve the morbidity associated with these infections and to reduce the potential 
emergence of additional resistant strains 244,246,247. Therefore, we investigated auranofin’s 
ability to be used in combination with antimicrobials frequently used to treat systemic 
MRSA infections. When tested against a highly-prevalent strain of MRSA USA300, 
auranofin exhibited an additive effect in inhibiting bacterial growth when combined with 
the antibiotics ciprofloxacin, linezolid and gentamicin (average fractional inhibitory 






is a potential candidate for further investigation as a partner with conventional 
antimicrobials for the treatment of systemic staphylococcal infections. 
 
 
Figure 2.9 Cytotoxicity assay in murine macrophage-like cells (J774A.1) cells. J774A.1 
cells were treated with different concentration of auranofin ranging from 0 to 256µg/ml. 
DMSO was used as a negative control. Cell viability was measured by MTS assay and IC50 





             Methicillin-resistant Staphylococcus aureus infections continue to pose a 
significant challenge to healthcare providers in part due to the diminishing arsenal of 
effective antibiotics available to treat infected patients. The development of novel 
antibacterial treatments utilizing the traditional approach in drug discovery has not kept 
pace with the rapid emergence of bacterial resistance to conventional antibiotics. This has 
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bacterial infections; one method that is less time-consuming and more financially viable is 
repurposing drugs (initially approved for other clinical indications) that possess potent 
antimicrobial activity. Auranofin is an example of a clinical drug that has been successfully 
repurposed recently for another indication. Initially approved as a treatment option for 
patients suffering from rheumatoid arthritis, auranofin was granted orphan-drug status 
from the FDA as an anti-parasitic agent intended for treatment of human amebiasis in 2012 
25 
 The successful repurposing of auranofin as an anti-parasitic agent paved the way 
for researchers to explore other clinical applications for auranofin. Recent studies, 
including the present work, demonstrate that auranofin possesses potent antibacterial 
activity against important Gram-positive pathogens, including MRSA. One of the key 
structural features of auranofin is that it is an organogold compound; however unlike other 
gold compounds including sodium aurothiomalate and sodium aurothioglucose hydrate 
(MIC >16 µg/ml), auranofin exhibits potent antibacterial activity against an array of 
different Gram-positive bacteria (including S. aureus, E. faecium, E. feacalis, S. 
pneumoniae and S. agalactiae) with an average minimum inhibitory concentration (0.125 
µg/ml) eighteen times lower than the achievable drug concentration in human plasma (2.37 
µg/ml which is equivalent to  a mean steady-state blood gold concentration of 3.5 μM)25 
This is in agreement with previous published studies 212,214; however several of these 
reports have indicated that auranofin lacks antibacterial activity against Gram-negative 
bacteria. A recent study suggested that this lack of activity was due to the presence of the 
glutathione system in Gram-negative bacteria which helps to mediate resistance to 






activity against both wild-type and Origami-2 (trxb/gor double mutant) E. coli mutant 
strains, neither strain was susceptible to auranofin even at a concentration of 16 µg/ml 248. 
This suggests an alternative mechanism may be responsible for the lack of activity 
observed with auranofin against Gram-negative bacteria. 
Further investigation revealed that the presence of the outer membrane in Gram-
negative bacteria is the main culprit responsible for the lack of antibacterial activity 
observed. When wild-type and Origami-2 E. coli strains were incubated with auranofin 
supplemented with a subinhibitory concentration of PMBN (to permeabilize the outer 
membrane), both strains showed similar sensitivity to auranofin with a MIC value of 0.5 
µg/ml (Table 2.2). This observation was further validated by assessing the growth of wild-
type and double mutant E. coli strains in the presence of increasing concentrations of 
auranofin (with or without PBMN). Once again, the viability of the Origami-2 double 
mutant was severely impacted by the presence of auranofin (in the presence of a 
subinhibitory concentration of PBMN); however, in the absence of PBMN, the double 
mutant strain exhibited a similar growth pattern to the wild-type E. coli strain. Thus the 
lack of direct antibacterial activity of auranofin observed against Gram-negative bacteria 
appears to be a byproduct of the barrier imposed by the outer membrane in addition to the 
presence of active efflux pumps more so than the presence of the glutathione system. 
Confirmation of auranofin’s potent antibacterial activity led us to next explore the 
potential mechanism of action (MOA) against S. aureus. Previous studies have found that 
auranofin inhibits Clostridium difficile and Treponema denticola growth through the 
disruption of selenium metabolism 249,250. We hypothesized that the MOA of auranofin in 






selenoproteins in S. aureus 251. In order to examine this hypothesis, we tested the activity 
of auranofin on S. aureus cultures supplemented with selenium in the form of selenite or 
L-selenocysteine 249,250. Unlike in C. difficile and T. denticola, our selenium 
supplementation did not reverse the inhibitory action of auranofin observed with S. aureus 
(data not shown). This clearly indicates that the MOA of auranofin differs between S. 
aureus and C. difficile. Next, we attempted to generate a S. aureus mutant that is resistant 
to auranofin. Determination of mutation frequencies for resistance to auranofin were 
carried out as described before 252. No colonies resistant to auranofin at three-, five-, or ten-
fold the MIC were detected which is in agreement with a previous report 213.  
The inability to generate a resistant mutant to auranofin suggests this drug may have 
multiple targets or possess a nonspecific mode of action against S. aureus 253. To assess 
this, a macromolecular synthesis assay was employed testing auranofin at different 
concentrations against S. aureus. Interestingly, at a subinhibitory concentration (0.5 × 
MIC), auranofin leads to significant reduction in both the cell wall and DNA biosynthetic 
pathways. At its MIC, auranofin also suppresses bacterial protein synthesis, indicating 
auranofin may in fact have a complex mode of action against S. aureus. Harbut et al’s 
recently reported auranofin exerts its antibacterial activity primarily by targeting thiol-
redox homeostasis through direct inhibition of the thioredoxin reductase enzyme (TrxB in 
Staphylococcus aureus and TrxB2 in Mycobacterium tuberculosis). While inhibition of 
TrxB activity in S. aureus can lead to inhibition of DNA synthesis, it does not explain the 
inhibition of cell wall synthesis observed with auranofin. Taken altogether, our analysis 
indicates that the thioredoxin reductase enzyme most likely is not the sole target of 






report investigating auranofin’s antibacterial activity against Streptococcus pneumoniae 
and S. aureus 215. Further studies are needed to fully elucidate the exact antibacterial 
molecular target(s) of auranofin. 
In the course of investigating auranofin’s mode of action via macromolecular synthesis, 
we discovered that auranofin inhibits protein synthesis in S. aureus. This discovery led us 
to analyze whether auranofin’s inhibitory activity against bacterial protein synthesis would 
lead to suppression in the production of key toxins in S. aureus. Our study revealed that 
auranofin is capable of inhibiting production of both Panton-Valentine leukocidin and α-
hemolysin, two pore-forming cytotoxins that injure host immune cells and promote 
infection 254. Thus, in addition to its direct –cidal effect on bacteria, auranofin may alleviate 
the morbidity associated with MRSA infections by limiting bacteria from generating 
harmful toxins.  
   We next moved to confirm auranofin’s antibacterial ability in vivo using two murine 
MRSA systemic infection models (non-lethal and lethal). Both in vivo studies performed 
in mice confirmed auranofin retains its antibacterial activity in vivo. In addition to this, 
auranofin demonstrated the ability to eradicate intracellular MRSA present inside infected 
macrophage cells; this expands the potential application if auranofin for use in treatment 
of systemic MRSA infections. Furthermore, auranofin demonstrated additive activity when 
combined with antibiotics traditionally used to treat systemic MRSA infections which is in 
agreement with previous a study 213. Thus, auranofin has potential use both as a single 
agent and as a combinatorial partner with conventional antibiotics to treat MRSA infections. 
This latter statement is important given the emergence of resistance to systemic 






stymie the rate at which resistance to these antibiotics arises. Finally, because of increased 
interest in repurposing auranofin, a Phase II clinical trial seeking to determine the 
pharmacokinetic parameters and the safety of increased doses of auranofin are currently 
underway (ClinicalTrials.gov identifier: NCT01419691 and NCT02089048). This strongly 
supports the postulate that auranofin has considerable promise to be repurposed as an 
antibacterial agent for the treatment of systemic bacterial infections. 
 
2.2 Repurposing auranofin for the treatment of cutaneous staphylococcal 
infections 
 
(Thangamani S, Mohammad H, Abushahba MF, Hamed MI, Sobreira TJ, Hedrick VE,   
Paul LN, Seleem MN. Repurposing auranofin for the treatment of cutaneous 
staphylococcal  infections. International journal of antimicrobial agents and 
chemotherapy. 2016 Jan 23; S0924-8579(16)00012-1) 
 
2.2.1 Introduction 
       Staphylococcus aureus, is the most frequently isolated pathogen from human skin 
infections and is the leading cause of nosocomial wound infections 107,211,255,256. Virulence 
factors and toxins (such as α-hemolysin and Panton-Valentine leukocidin) secreted by 
drug-resistant strains of S. aureus permit this pathogen  to evade the host immune system, 
leading to recurring/chronic infection, prolonged inflammation, and delayed healing of 
infected wounds 107,256. Furthermore, cutaneous staphylococcal skin infections can develop 






with biofilm-producing staphylococci have become an emerging clinical problem; 
treatment failure is occurring more frequently with topical drugs of choice including 
mupirocin and fusidic acid, indicating new treatment options are urgently needed 211,259,260. 
The recent FDA approval of drugs such as tedizolid phosphate and dalbavancin to combat 
skin infections caused by Gram-positive pathogens 261,262 further highlights the pressing 
need for the identification of new antibacterials capable of treating cutaneous MRSA 
infections. 
          Most current antibiotics were discovered by screening libraries of chemical 
compounds in order to find new lead “hits” that could be subsequently modified to enhance 
potency physicochemical properties and mitigate toxicity 210. However, this process is a 
risky venture given the significant financial and time investment required by researchers 
and limited success rate of translating these compounds to the clinical setting. An 
alternative approach to unearthing new antibacterials that has received more attention 
recently is evaluating the repository of approved drugs (or drugs that made it to clinical 
trials but failed to receive regulatory approval) in order to identify candidates that can be 
repurposed as antimicrobials 210. Recently, we assembled and screened half of all 
commercially available drugs (~ 2,200 drugs) and small molecules used in human clinical 
trials 7,211 and identified three drugs (auranofin, ebselen and 5-fluoro-2'-deoxyuridine) that 
exhibited potent antibacterial activity against important clinical pathogens. One of these 
drugs, auranofin, was found to inhibit growth of clinical isolates of MRSA at 
submicrogram/mL concentrations in vitro.  
Auranofin is an oral gold-containing drug initially approved for treatment of 






potent anti-parasitic 263 and antibacterial activity 249,264, including against MRSA and 
Streptococcus pneumoniae 58,212,213,265. Recent studies by Harbut et al. 213 and Aguinagalde 
et al 265 demonstrated that auranofin is efficacious in the treatment of invasive 
staphylococcal infections. However, the efficacy of auranofin for treatment of cutaneous 
MRSA infections remains unexplored. 
              Building upon these recent reports, the present study investigated the in vitro 
antibacterial and antibiofilm activities of auranofin against multidrug-resistant clinical 
isolates of S. aureus and tested the efficacy of auranofin in a mouse model of MRSA skin 
infection. In addition to this, our study aimed to examine the immune-modulatory activity 
of auranofin in MRSA infected skin lesions. The findings presented in this study lay the 
foundation for repurposing auranofin as a novel topical antibacterial agent for treatment of 
cutaneous MRSA infections in humans. 
 
2.2.2 Materials and Methods 
Bacterial strains and reagents 
         Bacterial strains used in this study are presented in Table 1. Auranofin (Enzo Life 
Sciences), mupirocin (AppliChem), clindamycin (Sigma-Aldrich), and fusidic acid 
(Sigma-Aldrich) were all purchased from commercial vendors. Mueller-Hinton broth 
(MHB) was purchased from Sigma-Aldrich while Trypticase soy broth (TSB), Trypticase 
soy agar (TSA), and mannitol salt agar (MSA) were purchased from Becton, Dickinson 









      In order to examine auranofin’s antibacterial activity against S. aureus, the broth 
microdilution method was utilized to determine the minimum inhibitory concentration 
(MIC) of each drug (tested in triplicate) following the guidelines outlined by the Clinical 
and Laboratory Standards Institute (CLSI). Each drug was incubated with the appropriate 
strain of S. aureus for 16 hours at 37°C before the MIC was confirmed. The MIC was 




        Eight week old female BALB/c mice (Harlan Laboratories, Indianapolis, IN) were 
used in this study. All animal procedures were approved by the Purdue University Animal 
Care and Use Committee (PACUC) (protocol number: 1207000676). An in vivo murine 
MRSA skin infection study was conducted, as described elsewhere 211,266. Briefly, mice 
(five mice per group) received an intradermal injection (40 µl) of MRSA USA300 
containing 1.65×108 colony forming unit (CFU). Approximately two days later, an open 
wound/abscess formed at the site of injection. Five groups of mice were then treated 
topically with a suspension containing 2% fusidic acid, 2% mupirocin, or 0.5%, 1%, or 2% 
auranofin in petroleum jelly. Another two groups were treated orally with 25 mg/kg of 
either linezolid or clindamycin. The control group was treated with petroleum jelly 
(vehicle). Mice were treated twice daily for five days. 24 hours after the last dose was 
administered, mice were humanely euthanized via CO2 asphyxiation. The region around 






precisely excised, homogenized, serially diluted in PBS, and then transferred to MSA 
plates. Plates were incubated at 37°C for 24 hours prior to counting MRSA CFU. 
 
Detection of cytokines from MRSA murine skin infection experiment 
Skin homogenates obtained from the murine skin infection experiment described above 
were centrifuged. The supernatant was collected and used to quantify the levels of 
inflammatory cytokines including tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), 
interleukin-1 beta (IL-1β), and monocyte chemo attractant protein-1 (MCP-1). Duo-set 
ELISA Kits (R&D Systems, Inc.) were used for cytokine detection using the 
manufacturer’s protocol. 
 
Combination testing of auranofin with commercial antibiotics 
     The additive activity of auranofin with conventional topical antibiotics (mupirocin, 
fusidic acid and retapamulin) was evaluated as described in a previous study 223,224. Briefly, 
MRSA USA300 was incubated with auranofin, control antibiotics, or a combination of 
auranofin + a control antibiotic at different concentrations for 16 hours. Next, the optical 
density (at 600 nm) was measured using a spectrophotometer. The percent bacterial growth 
for each treatment regimen was calculated and presented.  
 
Biofilm assay 
      Auranofin’s ability to disrupt adherent staphylococcal biofilm was analyzed using the 
microtiter dish biofilm formation assay 204,211. S. aureus (ATCC 6538) and S. epidermidis 






all wells of a 96-well tissue-culture treated plate. Bacteria were incubated at 37°C for 24 
hours to permit the formation of an adherent biofilm. The medium was removed and wells 
were carefully washed with PBS four times to remove planktonic bacteria. TSB was 
transferred to all wells of the 96-well plate prior to addition of auranofin and control 
antibiotics (linezolid and vancomycin). Drugs were added at the indicated concentrations 
and incubated again at 37°C for 24 hours. Afterward, plates were washed by submerging 
in tap water. The biofilms were stained with 0.1% (wt/vol) crystal violet for 30 min at room 
temperature before subsequently being washed four times with water. Plates were air dried 
for one hour prior to the addition of 95% ethanol to solubilize dye bound to the biofilm. 
The biofilm mass was quantified by measuring the optical density of wells (at 595 nm) 
using a micro plate reader (Bio-Tek Instruments Inc.). Data are presented as the average 
percent biofilm mass reduction of each test agent (tested in triplicate) in relation to 
untreated wells.  
 
Effect of auranofin and conventional antibiotics on persister cells 
       The effect of auranofin and conventional antibiotics (linezolid, retapamulin and 
vancomycin) on S. aureus planktonic cells that demonstrated tolerance to ciprofloxacin 
(persister cells) was investigated as described in a previous report 267. Briefly, an overnight 
culture of MRSA USA300 (1 × 1010 CFU) was incubated with ciprofloxacin (10 µg/ml) 
(80X MIC) at 37°C for six hours. Bacteria were then centrifuged and test agents (auranofin, 
linezolid, retapamulin, vancomycin, ciprofloxacin) were added at a concentration of 100 × 
MIC. MIC of  retapamulin and ciprofloxacin against MRSA USA300 were 0.5 and 0.125 






were collected after 0, 2, 4, 6, 24, and 48 hours, diluted in PBS, and transferred to TSA 
plates. Plates were incubated at 37°C for 24 hours before viable CFU for each treatment 
group was determined. 
Toxicity assay 
     Human keratinocyte (HaCat) cells were seeded at a density of 40,000 cells per well in 
a 96-well tissue culture plate and the MTS assay was carried out. Auranofin at a 
concentration ranging from 0 to 16 µg/ml was added to appropriate wells and the cells were 
incubated for 24 hours. Finally, the cells were washed with PBS and the MTS assay reagent 
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H 
tetrazolium) was added. After four hours incubation at 37°C, the absorbance was measured 
at 490 nm using an ELISA microplate reader (Molecular Devices, Sunnyvale, CA, USA). 
Results are expressed as percent cell viability of auranofin-treated cells in comparison to 
cells treated with DMSO. 
 
Statistical analyses 
     Statistical analyses were assessed using GraphPad Prism 6.0 (GraphPad Software, La 
Jolla, CA). P values were calculated using the Student’s t test or Kaplan-Meier (log rank) 
survival test, as indicated. P values of ≤ 0.05 were deemed significant. 
 
2.2.3 Results and Discussion 
In vitro antibacterial activity of auranofin 
      The antimicrobial activity of auranofin was assessed against a panel of clinically-






inhibited growth of all tested strains including those resistant to conventional 
antimicrobials such as methicillin and vancomycin. The minimum inhibitory concentration 
(MIC) of auranofin required to inhibit 50% (MIC50) and 90% (MIC90) of MRSA, VRSA 
and methicillin-sensitive S. aureus (MSSA) strains was found to be 0.0625 (MIC50) and 
0.125 µg/ml (MIC90), respectively. With regards to vancomycin-intermediate S. aureus 
(VISA), the MIC90 value were found to be 0.125 µg/ml. The MIC values determined for 
auranofin correlate with results reported in other studies 212,214,265.  
Table 2.3  Minimum Inhibitory Concentration (MIC) of auranofin and control antibiotics 
against Staphylococcus aureus and S. epidermidis 










aureus (MSSA) ATCC 6538 
Quality control and biofilm-forming 
strain 
0.0625 2 1 
 RN4220  0.0625 2 1 
 NRS72 Resistant to penicillin 0.125 2 1 
 NRS77  0.0625 2 1 
 NRS846  0.0625 2 1 
 NRS860  0.125 2 1 
Methicillin resistant 
S. 
aureus (MRSA) USA300 
Resistant to erythromycin, methicillin, 
and 
tetracycline 
0.125 2 1 
 NRS194 Resistant to methicillin 0.0625 2 1 
 NRS108 Resistant to gentamicin 0.125 2 1 
 
NRS119 
(Linr) Resistant to linezolid 
0.0625 >16 1 
 
ATCC 
43300 Resistant to methicillin 
0.0625 2 1 
 
ATCC 
BAA-44 Multidrug-resistant strain 
0.0625 2 1 
 NRS70 
Resistant to erythromycin, clindamycin, 
and 
spectinomycin 
0.0625 2 1 
 NRS71 Resistant to tetracycline and methicillin 0.0625 2 1 
 NRS100 Resistant to tetracycline and methicillin 0.0625 2 1 
 NRS123 Resistant to tetracycline and methicillin 0.0625 2 2 
 NRS107 Resistant to methicillin and mupirocin 0.0625 2 1 
Vancomycin-
intermediate S. 
aureus (VISA) NRS1 
Resistant to aminoglycosides and 
tetracycline; glycopeptide- 
intermediate S. aureus 
0.0625 2 8 
 NRS19 Glycopeptide-intermediate S. aureus 0.125 1 2 






Table 2.3 continued 
Vancomycin-
resistant S. 
aureus (VRSA) VRS1 Resistant to vancomycin 
0.0625 1 >16 
 VRS2 
Resistant to vancomycin, erythromycin, 
and spectinomycin 
0.0625 1 8 
 VRS3a Resistant to vancomycin 0.0625 2 >16 
 VRS3b Resistant to vancomycin 0.0625 2 >16 
 VRS4 
Resistant to vancomycin, erythromycin, 
and spectinomycin 
0.0625 2 >16 
      
 VRS5 Resistant to vancomycin 0.0625 2 >16 
 VRS6 Resistant to vancomycin 0.125 2 >16 
 VRS7 Resistant to vancomycin and β-lactams 0.0625 2 >16 
 VRS8 Resistant to vancomycin 0.0625 2 >16 
 VRS9 Resistant to vancomycin 0.0625 2 >16 
 VRS10 Resistant to vancomycin 0.125 2 >16 
 VRS11a Resistant to vancomycin 0.0625 2 >16 
 VRS11b Resistant to vancomycin 0.0625 2 >16 
 VRS12 Resistant to vancomycin 0.125 2 >16 
 VRS13 Resistant to vancomycin 0.0625 2 >16 
S. epidermidis NRS101 
Prototype biofilm producer; resistant to 
Methicillin and gentamicin 
0.0625 2 1 
 
     Interestingly,  auranofin (16-fold lower MIC) exhibited higher potent antibacterial 
activity against MSSA and MRSA compared to the antibiotics vancomycin (MIC of 1 
µg/ml) and linezolid (MIC ranged from 2-4 µg/ml). Auranofin managed to retain its 
antibacterial activity against MRSA strains that are resistant to several antibiotic classes 
including glycopeptides, oxazolidones, tetracycline, β-lactams, macrolides, and 
aminoglycosides; this suggests that cross-resistance between these particular antibiotics 
and auranofin is unlikely to occur.  
 
Auranofin is superior to conventional antibiotics in reducing the bacterial load in a 
mouse model of MRSA skin infection 
     Confirmation of auranofin’s potent in vitro anti-MRSA activity, led us to next 






particular MRSA, is a leading cause of skin infections in humans globally; of particular 
concern is MRSA USA300 which has been linked to the majority of skin and soft tissue  
infections present in the United States 255. To assess auranofin’s potential use as a topical 
antimicrobial agent in vivo, mice were intradermally infected with MRSA USA300 and the 
efficacy of auranofin and control antimicrobials on MRSA load were investigated.  . A 
significant reduction in the mean bacterial load was observed for each treatment condition 
when compared with the control group receiving the vehicle (petroleum jelly) alone (P ≤ 
0.05) (Figure 2.10). Mice treated with 2% auranofin produced the largest reduction in 
MRSA CFU (3.64±0.14 log10), followed by 2% fusidic acid (2.83±0.16 log10), 2% 
mupirocin (2.63±0.14 log10), 1% auranofin(2.51±0.11 log10), clindamycin (25 mg/kg) 
(1.90±0.24 log10), 0.5% auranofin (1.88±0.18 log10) and linezolid (25 mg/kg) (1.77±0.11 
log10) (Figure 2.10).  
Figure 2.10 Efficacy of treatment of MRSA murine skin lesions with auranofin 0.5, 1, and 
2%, linezolid and clindamycin (25 mg/kg), mupirocin (2%), fusidic acid (2%) and 
petroleum jelly (negative control) twice daily for five days were evaluated. Statistical 
analysis was calculated by the two-tailed Student’s t test.  P values of (*, # P ≤ 0.05) are 





























































































































Topical application of auranofin (2%) produced a more significant reduction (P ≤ 0.05) in 
the mean bacterial load when compared to treatment with drugs of choice including 
mupirocin (2%) and fusidic acid (2%). Thus auranofin shows promise for use as a topical 
antimicrobial and, in our study, is superior to conventional antimicrobials commonly used 
to treat MRSA skin infections. 
 
Auranofin reduces inflammatory cytokines induced by MRSA skin infection 
      Exotoxins including α-hemolysin, leukocidins and toxic shock syndrome toxin (TSST-
1) secreted by S. aureus during an infection induce a strong inflammatory cascade reaction 
107,256. This cascade is thought to play a greater role in the severity of S. aureus skin 
infections more than the size of the bacterial burden and can lead to an infection persisting 
for a longer time period 256. Therefore, we investigated the immunomodulatory activity of 
auranofin in a topical application against MRSA skin infection. Supernatants collected 
from the wounds of mice infected with MRSA USA300 were used to detect the levels of 
inflammatory cytokines such as  TNF-α, IL-6, IL-1β and MCP-1. Wounds treated with 
either a 1 or 2% ointment of auranofin significantly reduced all inflammatory cytokines 
tested (IL-6, IL-1β, TNF-α, and MCP-1) (Figure 2.11). Auranofin (at 0.5%) also 
significantly reduced IL-6 and TNF-α. Mice administered an oral dose of clindamycin 
reduced IL-1β and TNF-α, whereas oral treatment of mice with linezolid reduced only IL-
1β. Thus it appears that auranofin has more potent anti-inflammatory activity, due to the 
reduction in the presence of several pro-inflammatory cytokines, compared to the 






The results garnered from this study suggest auranofin’s anti-inflammatory properties 
warrant further investigation in the treatment of chronic wounds caused by S. aureus 
102,105,107. 
 
Figure 2.11  Effect of auranofin on inflammatory cytokines in MRSA skin lesions. 
Supernatants from skin homogenates were used for cytokine detection by ELISA. 
Statistical analysis was calculated by the two-tailed Student’s t test.  P values of (* P ≤ 
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Combinational therapy of auranofin with topical antimicrobials 
       With the rapid emergence of MRSA strains resistant to topical antimicrobials of choice, 
including to mupirocin and fusidic acid, combination therapy using multiple antibacterials 
is being explored 260,268,269. Therefore, we assessed the activity of auranofin against MRSA 
USA300 in the presence of topical antimicrobials such as mupirocin, retapamulin and 
fusidic acid. Auranofin, in combination with all three tested topical antibiotics, exhibits 
additive activity (average fractional inhibitory concentration (FIC) index ranges from 0.5  
to 1) in inhibiting MRSA growth (Figure 2.12). This suggests that auranofin can be 
potentially combined with traditional topical antimicrobials such as mupirocin, 
retapamulin and fusidic acid for the treatment of staphylococcal skin infections though 
further in vivo studies are needed to confirm this point. 
 
 
Figure 2.12 Auranofin in combination with three topical antimicrobials effectively inhibits 
the growth of S. aureus. Growth of MRSA USA300 was measured after incubating with 
auranofin, control antibiotics, or a combination of auranofin + a control antibiotic. The 
checkerboard assay was performed by diluting one drug along the ordinate and other drug 








Auranofin kills bacterial persister cells and reduces pre-formed biofilms 
       Treatment of bacterial infections with current antimicrobials are often challenging due 
to the inability of conventional antibiotics to target and disrupt adherent bacterial biofilms 
270. These problematic infections can become chronic when specialized dormant cells  
 
 
Figure 2.13 Auranofin effectively kills persister cells and reduces established biofilms of 
S. aureus and S. epidermidis. (A)  Effect of auranofin and control antibiotics on 
ciprofloxacin tolerant MRSA USA300 were determined by time kill assay. (B)  Effect of 
auranofin, vancomycin and linezolid on pre-formed Staphylococcus biofilms. The results 
are presented as means ± SD (n = 3).  Statistical analysis was calculated using the two-
tailed Student’s t test.   P values of (*, # P ≤ 0.05) are deemed significant. Auranofin was 







called persisters (that are normally resistant to antibiotics), become encased within these 
biofilms thus protecting them from exposure to and eradication by antibiotics 267. To assess 
the ability of auranofin to mitigate the impact of staphylococcal biofilms, we first 
investigated the effect of auranofin on persister cells. When treated with ciprofloxacin, 
MRSA USA300 (in exponential growth phase) produces a biphasic killing pattern that 
results in surviving persister cells (Figure 2.13a). The subsequent addition of conventional 
antimicrobials such as linezolid and retapamulin had minimal impact in reducing the 
number of persisters. However, treatment with auranofin resulted in complete eradication 
of persister cells after 48 hours, a result that is comparable to vancomycin (Figure 3.4a). 
Auranofin’s ability to kill S. aureus persisters led us to next assess auranofin’s impact on 
disrupting pre-formed staphylococcal biofilms. Auranofin, at 1 µg/ml, significantly 
reduced S. aureus biofilm mass by more than 60%; in contrast, even at high concentrations 
neither linezolid (256 µg/ml) nor vancomycin (128 µg/ml) were able to reduce biofilm 
mass by more than 30% (Figure 2.13b). Similarly, auranofin, at 4 µg/ml, was more 
effective at reducing S. epidermidis biofilm mass (60% reduction observed), compared to 
both linezolid (512 µg/ml) and vancomycin (256 µg/ml), which reduced biofilm mass by 
only 20% (Figure 2.13b). These results demonstrate that auranofin is capable of killing S. 
aureus persister cells and reducing adherent staphylococcal biofilms. This lays the 
foundation for further analysis using auranofin as a novel treatment option for both chronic 









In vitro cytotoxicity study 
Toxicity of auranofin to HaCaT cells was investigated using the MTS assay. Results 
indicate that the concentration of auranofin required to inhibit 50% (IC50) of  HaCaT cell 
growth is 6.38+0.29 µg/ml (Fig. 2.14). This value is nearly one hundred times larger than 
the MIC50 value for auranofin against MRSA. Additionally, auranofin is currently 
approved for long-term treatment of rheumatoid arthritis and patients have been taking the 
drug daily (6 mg/day) for more than five years, a much longer course of treatment than is 
traditionally prescribed for antibiotics (one to two weeks) 271. Thus toxicity with auranofin 
should not be a significant impediment to repurposing this drug as a novel antibacterial 
agent for the treatment of cutaneous MRSA infections. 
 
 
Figure 2.14 Cytotoxicity assay in human keratinocyte (HaCaT) cells. HaCaT cells treated 
with different concentration (0 to 16 µg/ml) of auranofin for 24 hours were assessed for 






















In summary, the present study demonstrates that auranofin, an antirheumatic drug, 
also possesses potent in vitro antistapylococcal activity against multidrug-resistant S. 
aureus. The in vitro results for auranofin were confirmed in a murine MRSA skin infection 
model that demonstrated that auranofin is superior to conventional antimicrobials 
(mupirocin and fusidic acid) in reducing the bacterial burden in infected wounds. In 
addition to decreasing the bacterial load, auranofin exhibits potent anti-inflammatory 
activity, reducing the presence of four key cytokines (IL-6, IL-1β, TNF-α, and MCP-1) 
known to increase the morbidity associated with skin infections. Furthermore, auranofin’s 
ability to disrupt adherent staphylococcal biofilms and kill persister cells combined with 
its excellent safety profile, collectively support the notion that auranofin is a good 
candidate for repurposing as a topical antimicrobial for the treatment of staphylococcal 
skin infections. 
 
2.3 Repurposing ebselen for the treatment of staphylococcal infections 
 
(Thangamani S, Younis W, Seleem MN. Repurposing ebselen for treatment of multidrug-
resistant staphylococcal infections. Scientific Reports. 2015, Jun 26;5:11596) 
 
2.3.1 Introduction 
           In 2013, the Centers for Disease Control and Prevention (CDC) reported that more 
than 11,000 people died from a methicillin-resistant Staphylococcus aureus (MRSA)-






caused by antibiotic-resistant bacteria. Apart from the high mortality rate, S. aureus is the 
most common pathogen associated with skin and soft tissue infections in humans272-274 . 
Furthermore, S. aureus and its secreted toxins, and ability to form biofilm, are responsible 
for interfering with the wound-healing process and causing systemic complications in 
affected patients. In addition, the rising prevalence of multidrug-resistant S. aureus strains 
and the extensive use of drugs of choice increase the likelihood that more challenging–to-
treat isolates will become a new scourge. Without a doubt, novel antimicrobials and novel 
approaches to developing them are urgently needed; however, new antimicrobials are 
becoming increasingly difficult to develop and are currently unable to keep pace with the 
emergence of resistant bacteria109. The concept of repurposing drugs to find new 
applications outside the scope of their original medical indication is recently gaining much 
attention and has resulted in successes in a number of disease areas275,276. Unlike de novo 
drug discovery, repurposing old drugs with known pharmacology and toxicology greatly 
reduces the time, cost, and risk associated with antibiotic innovation277,278. In an attempt to 
repurpose non-antibiotic drugs as antimicrobial agents, we screened National Institute of 
Health (NIH) Clinical Collection library against MRSA275. Ebselen (2-phenyl-1, 2-
benzisoselenazol-3(2H)-one, PZ51), a selenium-containing compound, showed potent 
activity, in an applicable clinical range, against S. aureus, which is in agreement with the 
previous finding67. 
              Previous studies reported that ebselen possesses anti- atherosclerotic, anti-
inflammatory and antioxidative properties59-62. In addition, antimicrobial properties of 
ebselen has also been explored. It has been shown to inhibit yeast and Escherichia coli in 






while in E. coli, it inhibits the thioredoxin reducatse (TrxR) enzyme69,68. However, clinical 
applications and the underlying mechanism of action for its antibacterial activity against S. 
aureus still remain unclear68. 
              Thus, the aim of our study is to assess the antibacterial action of ebselen and its 
spectrum of activity against clinical isolates of MRSA; to investigate its antimicrobial 
mechanism of action, anti-biofilm activity, and effect on toxin production in MRSA; and 
finally to validate its antimicrobial efficacy, anti-inflammatory properties, and potential 
clinical applications in MRSA infected animal model.  
 
2.3.2 Materials and Methods 
Bacterial strains and reagents 
Staphylococcus strains used in this study are presented in Table 1. Mueller-Hinton broth 
(MHB) was purchased from Sigma-Aldrich. Trypticase soy broth (TSB), Trypticase soy 
agar (TSA), and Mannitol salt agar (MSA) were purchased from Becton, Dickinson 
(Cockeysville, MD). Ebselen was purchased from (Adipogen corp, San Diego), 
vancomycin hydrochloride (Gold Biotechnology), linezolid (Selleck Chemicals), 
mupirocin (applichem, NE), and chloramphenicol (Sigma-Aldrich).  
 
Antibacterial assays 
          MICs of drugs and antibiotics were evaluated by broth micro dilution method in 
MHB according to the Clinical and Laboratory Standards Institute (CLSI)216. The MIC was 
interpreted as the lowest concentration of the drug that completely inhibited the visible 






in triplicate in at least two independent experiments and the highest MIC value was 
reported. 
 
Macromolecular synthesis assay 
           Macromolecular synthesis assay was carried out in S. aureus strain ATCC 29213. 
Briefly, 100 μl of S. aureus grown in TSB at exponential phase (OD600 = 0.2 to 0.3), was 
added to triplicate wells and different concentrations of ebselen and control antibiotics 
(ciprofloxacin, rifampicin, linezolid, vancomycin and cerulenin) was added. DMSO treated 
cells served as a negative control. Cells treated with drugs and DMSO were incubated at 
37°C to allow the drug to act on bacterial cells. After 30 min incubation, radio labeled 
precursors  for DNA, RNA, protein, cell wall and lipid synthesis such as [3H] thymidine 
(0.5μCi), [3H] uridine (0.5μCi), [3H] leucine (1.0 μCi), [14C] N-acetylglucosamine (0.4 
μCi),  [3H] glycerol (0.5 μCi), respectively, were added for each reaction. After 15 min, 
reactions of DNA and RNA synthesis were stopped using 12 μl of 5% trichloroacetic acid 
(TCA). Similarly, protein synthesis was stopped after 40 min using 12 μl of 5% TCA. 
Reaction wells containing cell wall and lipid synthesis were stopped after 40 min using 100 
μl of 8% SDS and 375 μl of chloroform/methanol (1:2) respectively. Reactions (DNA, 
RNA and protein) were incubated on ice for 30 min and the TCA precipitated materials 
were collected on a 25 mm GF/1.2 μM PES 96 well filter plate. After washing five times 
with cold 5% TCA, the filters were dried and counted using a Packard Top Count 
microplate scintillation counter. For cell wall synthesis, reaction tubes were then heated at 
95°C for 30 min, cooled, centrifuged, and spotted onto nitrocellulose membrane filters (0.8 






deionized water, allowed to dry, and then counted using a Beckman LS3801liquid 
scintillation counter. For lipid synthesis, reactions tubes were centrifuged at 13,000 rpm in 
a microfuge for 10 min, and then 150 μl of the organic phase was transferred to a 
scintillation vial and allowed to dry for at least 1 hour. Samples were then counted using 
liquid scintillation counting. Based on the incorporation of radiolabeled precursors of DNA, 
RNA, protein, cell wall  and lipid synthesis, results were expressed as percent inhibition of 
macromolecular synthesis pathways. 
 
 
Measuring toxin production by ELISA 
         We tested the effect of ebselen on production of two important toxins Hla and PVL 
by ELISA as described before279,280. Briefly, Overnight grown MRSA USA300 bacterial 
culture was diluted approximately to 5×108 CFU/ml in TSB. 10X MICs of drugs and 
antibiotics were added and incubated in the shaking incubator at 37°C. After 1hr the 
bacterial culture was centrifuged and the supernatants were used for toxin detection. 
          ELISA plates (Nunc) were coated with 2 μg/ml of sheep anti-Hla IgG (Toxin 
technology) in 100 μl of coating buffer and left overnight at 4 °C. Plates were then washed 
3 times with Tris-buffered saline (TBS) containing 0.05% tween 20 (wash buffer) and then 
blocking solution containing TBS with 2% bovine serum albumin was added. After 1hour 
incubation at 37°C, plates were washed 3 times with wash buffer. A total of 100 μL of 
bacterial supernatants were added and incubated the plates at 37°C for 2 hours. Purified 
Hla (Toxin technology) was used to generate a standard curve. Plates were again washed 
3 times with wash buffer and 100 μL of sheep anti-Hla HRP conjugate at a dilution of 






5′-tetramethylbenzidine substrate (Sigma-Aldrich) was added, and the reaction was 
stopped after 10 minutes with 100 μL of 0.2N H2S04. Plates were read on a 
spectrophotometer at optical density (OD) 450, and data were analyzed with SoftMax Pro 
(Molecular Devices). The nominal range of this assay was 0.1–6 μg /mL 
         For PVL Luk-S toxin, ELISA plates (Nunc) were coated as before with 2 μg /ml of 
mouse anti- PVL Luk-S monoclonal antibody (IBT Bioservices). Purified S. aureus LukS-
PV (His-tag) (IBT Bioservices) was used to generate a standard curve. The experiment was 
carried as before except detection antibodies rabbit anti-PVL Luk-S (2 μg/ml) and rabbit 
IgG HRP conjugate (R&D Systems) at a dilution of 1:6000 was used. The concentrations 
of each toxin was compared as unadjusted concentrations (ng/ml) and corrected for 
organism inoculum for each treatment (ng/ml to log10 CFU/ml). 
 
Biofilm assay 
        Biofilm assay was performed as described before216. Briefly, biofilm-forming clinical 
isolates of S. aureus (ATCC 6538) and S. epidermidis (ATCC 35984) were inoculated in 
96-well flat-bottom cell culture plates (polystyrene) in TSB supplemented with 1% glucose 
at 37°C for 24 h. Then culture medium was removed, and wells were carefully washed with 
PBS four times to remove planktonic bacteria. Ebselen and antibiotics (linezolid, 
mupirocin and vancomycin) were added at different concentrations in TSB, and plates were 
incubated at 37°C for 24 h. The wells were rinsed by submerging the entire plate in a tub 
containing tap water. Biofilms were stained with 0.1% (wt/vol) crystal violet for 30 min. 
After staining, the dye was removed and the wells were washed four times with water. The 






biofilm. The OD of biofilm mass was measured at 595-nm absorbance by using a micro 
plate reader (Bio-Tek Instruments Inc.) 
 
Cytotoxicity assay 
         Human keratinocyte (HaCat) cells were seeded at a density of 10,000 cells per well 
in a 96-well  tissue culture plate (CytoOne, CC7682-7596) in DMEM media containing 
10% fetal bovine serum (FBS) and incubated overnight at 37˚C. Then cells were treated 
with ebselen at different concentrations from 0 to 128 µg/ml for 24 hours.  Treated cells 
were washed four times with PBS and the DMEM media containing MTS assay reagent, 
3-(4,5-dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium) (Promega, Madison, WI, USA) was added. After 4hrs of incubation at 37˚C, 
absorbance was measured using ELISA microplate reader (Molecular Devices, Sunnyvale, 




       Eight weeks old female BALB/c mice were used for this study (Harlan Laboratories, 
Indianapolis, IN). All animal procedures were approved by Purdue University Animal Care 
and Use Committee (PACUC). The murine model of MRSA skin infection has been 
described before 266. Mice were injected intradermally with 40 µl of MRSA USA300 
(6.7×108) CFU per mouse. Forty-eight hours after infection and formation of open wound, 
the mice were divided into eight groups (n=5). Four groups were treated topically with 






in lipoderm (dermal and transdermal delivery cream base). Two groups received the 
vehicles alone (petroleum jelly or lipoderm). One group was treated topically with 2% 
mupirocin in petroleum jelly and the last group was treated orally with linezolid (25 mg/kg). 
All groups were treated twice a day for 5 days. Twenty-four hours after the last treatment, 
the area around the wound was lightly swabbed with 70% ethanol and the wound was 
excised for bacterial counting on MSA after homogenization.    
 
Cytokines detection 
       Skin homogenates were centrifuged and the supernatants were used to detect the 
cytokine level by ELISA. Tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), 
interleukin-1 beta (IL-1β), and monocyte chemo attractant protein-1(MCP-1) Duo-set 
ELISA Kits (R&D Systems, Inc.) were used for the quantification of cytokines The 
experiment was carried out as per the manufacture instructions 281.  
 
Bliss model of synergism 
        Synergism was calculated using the Bliss Independence Model, which calculates a 
degree of synergy using the formula: S = (fA0/f00)(f0B/f00)-(fAB/f00), where fAB refers to 
bacterial growth rate in the presence of the combined drugs at a concentration A, for one 
of the antibiotics, and B for the ebselen; fA0 and f0B refer to the bacterial growth rates in the 
presence of antibiotics (or) ebselen at a concentration of A and B, respectively; f00 refers to 
the bacterial growth rate in the absence of drugs; and S corresponds to the degree of synergy, 






interaction for negative ones. Growth rates at 12hr are determined and the degree of 
synergism was calculated as described before282. 
 
Statistical analyses 
       Statistical analyses were assessed by Graph Pad Prism 6.0 (Graph Pad Software, La 
Jolla, CA). P values were calculated by the two-tailed Student t test. P values of ˂ 0.05 
were considered as significant. 
 
2.3.3 Results 
Antibacterial activity of ebselen 
          The antimicrobial activity of ebselen was tested against a panel of clinical isolates 
of multi-drug resistant S. aureus (Table 2.4). Ebselen showed potent bactericidal activity 
against MRSA, vancomycin-resistant S. aureus (VRSA), linezolid-resistant S. aureus, 
mupirocin-resistant S. aureus, methicillin-resistant S. epidermidis, and multidrug-resistant 
strains with a minimum inhibitory concentration (MIC)  ranging from 0.125 µg/ml to 0. 5 










Table 2.4  MICs of ebselen and antibiotics against clinical isolates of Staphylococcus 
strains 




     
Methicillin resistant 
S. USA100 
0.125 2 2 
aureus (MRSA) USA200 0.125 2 1 
 USA300 0.125 2 1 
 USA400 0.5 2 1 
 USA500 0.125 2 1 
 USA700 0.125 4 1 
 USA800 0.125 4 1 
 USA1000 0.125 2 1 








0.25 2 1 
Linezolid-resistant 
S. aureus NRS119 
0.125 >16 1 
Mupirocin-resistant 





resistant S.   VRS1 
0.25 1 >16 
aureus (VRSA) VRS2 0.25 1 8 
 VRS3a 0.25 2 >16 
 VRS3b 0.25 2 >16 
 VRS4 0.125 2 >16 
 VRS5 0.25 2 >16 
 VRS6 0.25 2 >16 
 VRS7 0.5 2 >16 
 VRS8 0.125 2 >16 
 VRS9 0.25 2 >16 
 VRS10 0.25 2 >16 
S. epidermidis NRS101 0.5 2 2 









Mechanism of action 
          Given the potent anti-staphylococcal activity of ebselen in vitro, we investigated its 
anti-staphylococcal mechanism of action by macromolecular synthesis assay. As shown in 
Figure 2.15, ebselen primarily inhibited protein synthesis at 1X the MIC. However, 
additional secondary effects were observed at a higher concentration (8X MIC). At higher 
concentration, ebselen inhibited DNA, RNA and lipid synthesis similar to control 
antibiotics such as ciprofloxacin, rifampicin and cerulenin respectively.  
 
 
Ebselen inhibits MRSA toxin production 
        The effect of ebselen on production of important toxins such as Panton-Valentine 
leucocidin (PVL) and α-hemolysin (Hla) was tested by ELISA. The concentrations of each 
toxin were compared as unadjusted concentrations (ng/ml) and corrected for organism 
inoculum for each treatment (ng/ml to log10 colony-forming units, CFU/ml). Ebselen 










Figure 2.15 Macromolecular synthesis in the presence of ebselen. Incorporation of 
radiolabeled precursors of DNA, RNA, protein, cell wall and lipid synthesis ([3H] 
thymidine, [3H] uridine, [3H] leucine, [14C] N-acetylglucosamine and [3H] glycerol, 
respectively) were quantified in S. aureus ATCC 29213. Results were expressed as percent 











Figure 2.16  Effect of ebselen on toxin production. Toxin production (ng/ml) in S. aureus 
MRSA USA300 after antibiotic/drug exposure for 1 hour corrected for organism burden. 
The results are given as means ± SD (n = 3). ** indicate statistical significant different 









Figure 2.17 The effects of ebselen and antibiotics (linezolid, mupirocin, vancomycin and 
rifampicin) on established biofilms of S. aureus (a) or S. epidermidis (b). The established 
biofilms were treated with control antibiotics or ebselen and stained with crystal violet. 
Optical density of dissolved crystal violet was measured using a spectrophotometer. Values 
are the mean of triplicate samples with the standard deviation bars. P values of   (*,#P≤ 









Activity against biofilms 
          Considering the excellent broad-spectrum activity of ebselen against the MRSA and 
VRSA strains, we also considered the possibility that ebselen would be active against 
established biofilm. Biofilm-forming strains of S. aureus and S. epidermidis were used and 
the biofilm mass was estimated after treatment with ebselen and control antibiotics. Ebselen 
was significantly superior in reducing adherent biofilms of both S. aureus and S. 
epidermidis when compared to conventional antibiotics (linezolid, mupirocin, vancomycin 
and rifampicin). Ebselen (2µg/ml) at 16X MIC significantly reduced the biofilm mass, 
approximately by 60%. Control antibiotics, such as linezolid (256µg/ml), mupirocin 
(16µg/ml) and vancomycin (128µg/ml) at 128X MIC were able to reduce the biofilm mass 
only by 20%. Rifampicin (0.5µg/ml) at 16X MIC reduced the biofilm mass by only 40% 
(Figure 2.17a).  
             Ebselen (8µg/ml) at (16X MIC), significantly reduced the strong biofilms of S. 
epidermidis, by more than 50%. However, linezolid (512µg/ml), mupirocin (32µg/ml) and 
vancomycin (256µg/ml) at 256X MIC reduced biofilm mass by only 20% and rifampicin 
(2µg/ml)  at 64X MIC reduced biofilm mass by 40% (Figure 2.17b).  
 
Cytotoxicity study 
            Safety of ebselen in mammalian cells was evaluated against human keratinocyte 
cells (HaCat) by MTS assay. Ebselen did not show toxicity up to 32 µg/ml. The results 
demonstrated that half maximal inhibitory concentration (IC50) required by ebselen to 







Figure 2.18  Cytotoxicity assay in human keratinocyte (HaCat) cells. HaCat  cells were 
treated with different concentration of ebselen ranging from 0 to 128µg/ml. DMSO was 
used as a negative control. Cell viability was measured by MTS assay and IC50 of ebselen 
to cause cytotoxicity in HaCat cells was calculated. 
 
The therapeutic efficacy of ebselen in a mouse model of MRSA skin infection 
(i) Bacterial load 
Five groups of mice were treated topically either with vehicle alone (petroleum 
jelly) or control antibiotic (2% mupirocin) or ebselen (0.5%, 1%, or 2%) twice a day for 
five days. One group of mice was treated with linezolid orally. As shown in Figure 2.19a, 
ebselen (1% and 2%) significantly reduced the mean bacterial counts compared with the 






in CFU (2.28±0.25 log10), followed by 2% ebselen (1.71±0.11 log10), linezolid (25 mg/kg) 
(1.55±0.01 log10), and 1% ebselen (1.02±0.17 log10).  
 
Figure 2.19  Efficacy of treatment of MRSA skin lesions with ebselen 0.5, 1, and 2%, 
linezolid (25 mg/kg), mupirocin (2%) and petroleum jelly (negative control) twice daily 
for 5 days (a). Treatment with ebselen 1% and lipoderm (negative control) twice daily for 
5 days (b). Statistical analysis was calculated by the two-tailed Student t test.  P values of   






 (ii) Effect of vehicle 
             In order to investigate the effect of the vehicle on the efficacy of ebselen in the 
treatment of MRSA skin infections, two groups of mice were treated topically either with 
vehicle alone (lipoderm base)283 or ebselen 1% formulated in lipoderm base twice a  day 
for five days. Ebselen 1% significantly reduced the mean bacterial counts by 1.37±0.20 
log10 compared with the control group (P≤ 0.01) (Figure 2.19b). No significant difference 
was observed in reducing the mean bacterial count between the ebselen 1%  formulated in 
petroleum jelly and  lipoderm base (Figure 2.19a and 2.19b). 
 
Effect of ebselen on inflammatory cytokines induced by MRSA skin infection 
                  To study the immune-modulatory activities of ebselen in a topical application 
against MRSA skin infection, we used ELISA to measure the pro-inflammatory cytokines 
tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), interleukin-1 beta (IL-1β) and 
monocyte chemo attractant protein-1(MCP-1) in the infected wounds. As shown in Figure 
2.20, ebselen 2% and 1% significantly reduced all tested pro-inflammatory cytokines, 
including IL-6, IL-1β, TNF-α, and MCP-1. However, ebselen at 0.5% significantly reduced 
IL-6 and MCP-1 only. Ebselen had considerably higher anti-inflammatory activity 







Figure 2.20 Effect of ebselen on cytokines production in MRSA skin lesions. Supernatants 
from skin homogenates were used for cytokine detection by ELISA. Each points represents 
single mice and each group has 5 mice. Statistical analysis was calculated by the two-tailed 








Figure 2.21  Synergistic activity of ebselen with topical antimicrobials. The Bliss Model 
for Synergy confirms a synergistic effect, between ebselen and topical antimicrobials 
(mupirocin, fusidic acid, retapamulin and daptomycin) against various resistant strains of 
S. aureus. Degree of synergy was quantified after 12h of treatment with ebselen (0.0312 
µg/ml) in combination with sub-inhibitory concentrations of topical antimicrobials. (Circle) 
daptomycin + ebselen, (Square) retapamulin + ebselen, (Triangle) fusidic acid + ebselen 









Synergistic activity of ebselen with topical antimicrobials in vitro 
          The antimicrobial activity of ebselen in combination with topical antimicrobials 
(mupirocin, fusidic acid, retapamulin and daptomycin) was investigated in vitro by the 
Bliss model of synergism against four clinical isolates. With the exception of the VRSA5 
strain and the antibiotic daptomycin, ebselen acted synergistically with all tested antibiotics 
against S. aureus clinical isolates (Figure 2.21). 
 
2.3.4 Discussion 
              For the past few decades the rise of multi-drug resistant S. aureus has been an 
emerging issue in hospital and community settings109,206. More importantly, the 
management of S. aureus strains associated with skin infections is becoming a serious issue 
in community settings284,285. With the increasing incidence of multidrug-resistant S. aureus 
strains, there is a pressing need for new antimicrobials to circumvent this burgeoning 
problem.  However, the discovery and development of new antimicrobials has been 
slowing since 1960. Even today, the global antibiotic market is still dominated by a few 
classes of antibiotics that were discovered half a century ago109. Moreover, pharmaceutical 
companies are not interested in investing in antibiotic research and development because 
of low return compared to other drugs being developed for chronic ailments109,286,287. As 
an alternative to the traditional de novo antibiotic development, repurposing non-







            In an intensive search for antimicrobial activity among non-antibiotic drugs, we and 
others67,68 identified ebselen as a potent antimicrobial agent against Gram-positive 
pathogens including MRSA. Ebselen, an organoselenium compound, is known to be 
clinically safe with a well-known pharmacology profile and it is currently undergoing 
clinical trials for the prevention and treatment of various disorders such as cardiovascular 
disease, arthritis, stroke, atherosclerosis, and cancer60,63-66. Ebselen showed potent 
bactericidal activity against multiple clinical isolates of MRSA, including MRSA USA100, 
USA200, USA500, USA1000, and USA1100, which are resistant to various antimicrobials, 
including penicillin, fluoroquinolone, macrolides, and aminoglycosides. It also showed 
potent activity against multidrug-resistant clinical isolates of S. aureus strains, including a 
linezolid-resistant strain (NRS119), vancomycin-resistant strains (VRSA1-VRSA10), and 
a mupirocin-resistant strain (NRS107). Moreover, ebselen demonstrated excellent activity 
against MRSA USA300, a community-associated strain responsible for outbreaks of 
staphylococcal skin and soft-tissue infections (SSTI) in the United States288. 
           Although the antimicrobial activity of ebselen has been reported before67,68, its 
mechanism of action in S. aureus and its in vivo efficacy have never been explored. Ebselen, 
in our study, inhibited protein synthesis in S. aureus. Inhibition of protein synthesis at a 
concentration equivalent to the MIC demonstrates that, protein synthesis is likely primary 
antibacterial mechanism of action of ebselen. In addition, secondary effects  on DNA, 
RNA ,lipid synthesis and to a lesser extent on cell wall synthesis were also noticed at higher 
concentrations (8X MIC).   It is possible that disruption of protein synthesis could lead to 
downstream inhibition of other pathways. This provides valuable insight into ebselen’s 






of ebselen in S. aureus. For treatment of infections caused by toxin-producing pathogens 
such as S. aureus, inhibition of protein synthesis is an important consideration in the 
selection of antimicrobial agents280. Because antimicrobials that suppress translation in S. 
aureus markedly suppress the formation of toxins such as PVL and Hla , which will lead 
to better treatment outcomes280,289-291. In the light of our results, showing potent inhibition 
of bacterial protein synthesis, we tested the effect of ebselen on production of two 
important toxins in MRSA USA300 (Hla and PVL) by ELISA. Ebselen significantly 
suppressed toxin production after 1hour incubation with MRSA. Inhibition of protein 
synthesis and the subsequent inhibition of toxin production are great advantages of ebselen 
as an antimicrobial agent.  
              Bacterial biofilms, which serve to protect the bacteria and hinder penetration of 
antibacterial drugs, contribute significantly to the treatment failure of Staphylococcus 
infections216. Given the potent antibacterial activity of ebselen against planktonic 
multidrug-resistant strains, we also considered the possibility that ebselen would be active 
against established bacterial biofilms of S. aureus and S. epidermidis (a leading cause of 
hospital-acquired implant-based infections)292. Ebselen was superior in reducing adherent 
biofilms of both S. aureus and S. epidermidis when compared to conventional antibiotics 
(linezolid,  mupirocin and vancomycin).  
              In view of our results demonstrating the potent antimicrobial and antibiofilm 
activities of ebselen in vitro against MRSA, we moved forward with an in vivo experiment 
in a mouse model of MRSA skin infection. Ebselen 1% and 2% in petroleum jelly 






The lipoderm base enhanced the antimicrobial activity of ebselen but the reduction in 
bacterial load was not significant from petroleum jelly vehicle.  
           Since the clinical severity of S. aureus skin infections is driven by the excess host 
pro-inflammatory cytokines rather than by bacterial burden256,293, ebselen with its 
recognized immune-modulatory, anti-inflammatory, and antioxidant  activities59,294 should 
be superior to traditional antibiotics for treatment of skin infections107,293. In this study, 
topical treatment with ebselen 1 and 2% significantly reduced IL-1β, IL-6, TNF-α and 
MCP-1 which might benefit the healing of infected wounds102-106. Linezolid also inhibits 
IL-1β which is in line with previous findings293,295. Prolonged inflammation especially due 
to inflammatory cytokines such as IL-6, TNF-α, and MCP-1, greatly delays healing in 
chronic wounds107. Ebselen significantly (P≤ 0.01) inhibits all three cytokines (IL-6, TNF-
α, and MCP-1), which should provide a favorable outcome in wound healing107. 
            With the increasing incidence of MRSA strains resistant to topical drugs of choice, 
such as mupirocin and fusidic acid, combination therapies are being explored259,260,268,269. 
To investigate whether ebselen has the potential to act synergistically with topical 
antimicrobials against multidrug-resistant strains, the Bliss independence model was 
utilized282. Ebselen acted synergistically with topical antimicrobials against resistant 
strains of S. aureus, thus providing a strong platform to combine ebselen with topical 
antimicrobials in treating staphylococcal skin infections and reducing the likelihood of 






2.4 Repurposing clinical molecule ebselen to combat drug resistant pathogens 
 
(Thangamani S, Younis W, Seleem MN. Repurposing Clinical Molecule Ebselen to 
Combat Drug Resistant Pathogens. PLoS One. 2015 Jul 29;10(7):e0133877) 
 
2.4.1 Introduction 
         Infections caused by Gram-positive drug-resistant pathogens are a leading cause of 
mortality. Three species—methicillin-resistant Staphylococcus aureus (MRSA), 
Streptococcus pneumoniae and vancomycin-resistant enterococcus (VRE)—are 
responsible annually for at least 84% of the antibiotic-resistant bacteria mortality in the 
United States alone 1. Further exacerbating the issue of bacterial resistance is the slow rate 
of the development and approval of new antimicrobials. For almost 80 years, 
antimicrobials have been crucial allies in the treatment of bacterial infections caused by 
these pathogens. However,  multidrug resistant strains have recently emerged that are 
resistant to almost all antimicrobials once deemed effective, including fluoroquinolones, 
macrolides, and β-lactams 296. Collectively, this points to an urgent need for the discovery 
of new antimicrobials and novel strategies to develop them. One novel strategy that 
warrants more attention as a unique method for development of new antimicrobials is drug 
repurposing 276. Our recent attempt to identify non-antibiotic drugs with potent 
antimicrobial activity, within an applicable clinical range, identified organoselenium 
compound ebselen (EB) as having potent antibacterial activities against Gram-positive 







It has anti-oxidative, anti-inflammatory, and anti-atherosclerotic properties 59. Additionally, 
EB has been shown to exhibit antimicrobial activity in vitro and in vivo 67,68,298,299. EB 
exhibited antimicrobial activity by inhibition of  thioredoxin reducatse (TrxR) enzyme of 
Escherichia coli  and H+-ATPase function and proton-translocation function in yeast  67-69. 
However, the antibacterial mechanism of action of EB against Gram-positive bacteria 
remains unidentified 68.  
         The potent antimicrobial activity of EB against Gram-positive pathogens motivated 
us to further investigate the therapeutic applications of EB. The aims of the present study 
are to investigate the antibacterial activity of EB against Gram-positive clinical pathogens, 
including MRSA and VRE in vitro, to identify antibacterial mechanism of action, to 
analyze the ability of EB to clear MRSA intracellular infection, to evaluate antibacterial 
efficacy in MRSA-infected Caenorhabditis elegans whole animal models, to evaluate the 
effect on mitochondrial biogenesis and toxicity in C. elegans, and to assess whether EB is 
capable of  working synergistically with conventional antibiotics against MRSA in in vitro 
and in infected cell cultures. This study provided valuable insights into potential 
therapeutic applications of EB for use as antimicrobial agents for the treatment of 
multidrug-resistant Gram-positive infections.  
 
2.4.2 Materials and Methods 
Bacterial strains and reagents 
         Bacterial strains employed in this study are presented in Table 1. Mannitol salt agar 







(MHB) was purchased from Sigma-Aldrich (St. Louis, MO). Trypticase soy broth (TSB) 
and Trypticase soy agar (TSA) were purchased from Becton, Dickinson (Cockeysville, 
MD). EB was purchased from (Adipogen corp, San Diego), vancomycin hydrochloride 
(Gold Biotechnology, St. Louis, MO), linezolid (Selleck Chemicals, Houston, TX), 
clindamycin (TCI chemicals, Portland, OR), erythromycin, rifampicin, ampicillin, 
gentamicin, chloramphenicol and fetal bovine serum (FBS) were purchased from Sigma-
Aldrich. DMEM media were purchased from Life technologies and MTS reagent (Promega, 
Madison, WI, USA). 
 
In vitro antibacterial assays 
          Minimum inhibitory concentrations (MICs) were evaluated using micro dilution 
broth as per the standards of Clinical and Laboratory Standards Institute (CLSI)  300 . MICs 
of drugs were interpreted as the lowest concentration of the drug which inhibits the growth 
of bacteria after incubating for at least 16-24 h at 37 °C. The minimum bactericidal 
concentration (MBC) was determined by sub-culturing 10 μl from the wells were no 
growth was observed onto TSA plates.  The plates were incubated for 24 h before the 
MBCs were determined. The MBC was categorized as the concentration where ⩾99.9 % 
reduction in bacterial cell count was observed 296 .  
 
Intracellular infection assay 
         J774A.1 murine macrophage-like cells were seeded at a density of 20,000 cells per 
well in 96-well tissue culture plates. Cells were infected with MRSA USA300 (NRS 384-







washed three times with DMEM medium containing 10 IU lysostaphin to kill the 
extracellular bacteria 221. Drugs (vancomycin, linezolid and EB) were added at a 
concentration of 1 µg/ml to the DMEM medium supplemented with 10% FBS and 4 IU 
lysostaphin. After 24 h  incubation, the cells were washed three times with phosphate 
buffered saline (PBS) and lysed with 0.1% Triton X-100. Lysates were diluted and plated 
on TSA plates and MRSA colony forming units (CFU) were counted. 
 
Toxicity assay 
        The toxicity assays were performed in cell culture and C. elegans. (a) Cell 
culture:J774A.1 murine macrophage-like  cells at a density of 20,000 cells per well were 
seeded and allowed to adhere in a 96-well tissue culture plate in DMEM media containing 
10% FBS overnight. EB at various concentrations ranging from 0 to 256 µg/ml were added 
to the cells in DMEM media with FBS. After 24 h incubation with the drug, cells were 
washed with PBS and the MTS assay reagent,3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H tetrazolium) in DMEM medium was added 
and incubated for 4 h at 37 °C. Absorbance was measured at 490 nm using ELISA 
microplate reader (Molecular Devices, Sunnyvale, CA, USA). Cell viability after treatment 
with EB was expressed as a percentage of the control, DMSO. (b) C. elegans: Temperature-
sensitive C. elegans AU37 (sek-1; glp-4) strain (glp-4(bn2) was used for toxicity studies 
and the worms were synchronized as described before 301. Synchronized L4-stage worms 
were re-suspended in buffer containing 50% M9 buffer and 50% TSB. Then 100 µl of the 
buffer containing approximately 15-20 worms were deposited in each well in 96-well 







daily for three days and the percent of live worms was calculated in each group. At least 
triplicate wells were used for each treatment 
 
Cell-free bacterial and mammalian transcription/translation assay 
         The cell-free bacterial translation and mammalian translation assays were performed 
by the commercially available Escherichia coli S30 System and Rabbit Reticulocyte Lysate 
System (Promega), respectively. The assays were performed as described by the 
manufacturer, in conjunction with appropriate positive control (chloramphenicol) and 
negative control (ampicillin) antibiotics. In bacterial translation assay, the reaction 
mixtures were incubated at 37 °C for 1 h. Mammalian translation assay reaction mixtures 
were incubated at 30 °C for 1 h. Luciferase assay reagent was added to the reaction and the 
intensity of the luminescence was measured by luminescence microplate reader (FLx800 
BioTek Instruments, Inc. Winooski, Vermont) according to the manufacturer’s instructions. 
Average luciferase readout of protein production from two replicates from two independent 
experiments was calculated.   
 
Mitochondrial biogenesis assay 
           The mitobiogenesis assay was done using In-Cell ELISA Kit (MitoSciences Inc., 
Eugene, OR) as per the manufactures instruction 302. Briefly, J774A.1 cells were seeded 
(40,000 cells per well) in 96-well plates for overnight. EB and control antimicrobials 
(chloramphenicol and ampicillin) were added to the cells and the cells were allowed to 
grow for approximately 3 days with the drugs. Media were removed and cells were washed 







and permeabilization and blocking processes were done according to the manufacturer’s 
instructions. Primary antibodies to detect the levels of two proteins (subunit I of Complex 
IV (COX-I), which is mitochondrial DNA (mtDNA)-encoded, and the 70 kDa subunit of 
Complex II (SDH-A), which is nuclear DNA (nDNA)-encoded were added and incubated 
for overnight at 4 °C. After incubation, cells were washed with PBS and secondary 
antibodies were added and incubated at room temperature for 1 h. The expression of SDH-
A and COX-1 were measured after washing and development at 405 nm and 600 nm 
wavelength, respectively. The ratio between COX-I and SDH-A was calculated and the 
percent of inhibition of mitochondrial biogenesis was measured. 
 
Efficacy of EB in infected animal model (C. elegans) 
       L4-stage worms of C. elegans AU37 (sek-1; glp-4) strain (glp-4(bn2) were used to test 
the antimicrobial efficacy of EB as described before 301. Briefly, worms were infected with 
MRSA USA300 (NRS 384-0114; ST-8)  in nematode growth media plate for 8 h at room 
temperature. After 8 h of infection, worms were collected and washed with M9 buffer four 
times before incubation with the drugs. Worms were transferred to 96-well plates (20 
worms per well) and the drugs (EB and vancomycin) were added to the wells in triplicates 
to achieve a final concentration of either 4 or 8 μg/ml. After 24 h incubation with the drugs, 
worms were transferred to 2-ml centrifuge tubes, washed four times with PBS and 100 mg 
1.0-mm silicon carbide particles (Biospec Products, Bartlesville, OK) were added to each 
tube. The tubes were vortexed for one minute at maximum speed to disrupt the worms 
without affecting bacterial survival 301. The resulting suspension was diluted and plated 







divided by the number of worms in respective wells and the results were expressed as 
percent of bacterial reduction per worm. 
 
Synergistic activities of EB with conventional antibiotics in vitro and in cell culture 
 (a) In vitro synergistic assay: The synergistic activities of EB with conventional antibiotics 
were evaluated using the Bliss Independence Model as described before 282. Briefly, the 
optical density of the bacteria grown in the presence of antibiotics and EB (fAB), antibiotics 
alone (fA0), EB alone (f0B) and in the absence of drugs (f00) were measured and a degree of 
synergy (S) was calculated using the formula: S = (fA0/f00)(f0B/f00)-(fAB/f00). Positive and 
negative values represent the degree of synergism and antagonism, respectively. (b) 
Intracellular synergistic assay in J774A.1 cells: J774A.1 cells were seeded and infected as 
described before under intracellular infection assay. EB at concentration of 0.5 µg/ml was 
added to infected cells alone or in in combination with control antibiotics such as linezolid 
(4 µg/ml), clindamycin (1 µg/ml), vancomycin (4 µg/ml), chloramphenicol (4 µg/ml), 
erythromycin (8 µg/ml), rifampicin (0.5 µg/ml) and gentamicin (1 µg/ml). Untreated cells, 
and cells treated with antibiotics alone were used as a control. After 24 h incubation, the 
cells were lysed and intracellular MRSA CFU were determined as described above.. 
Percent bacterial reduction was calculated in relative to the untreated groups. Combination 











Statistical analyses were done using Graph Pad Prism 6.0 (GraphPad Software, La Jolla, 
CA). P values were calculated by the one-tailed Student t test. P values of ˂ 0.05 were 
considered as significant. 
 
2.4.3 Results and Discussion    
In vitro antibacterial assays 
      In an attempt to repurpose approved drugs as antimicrobial agents, we investigated the 
antimicrobial activity of EB against various multidrug-resistant clinical isolates of Gram-
positive and Gram-negative pathogens (Table 2.5). EB exhibited potent bactericidal 
activity, in a nanogram range, against all tested Gram-positive strains regardless of their 
resistance phenotype. EB showed potent activity against clinical isolates of Enterococcus 
faecalis and Enterococcus faecium with MIC90 of 0.5 µg/ml (see Table 2.5). EB also 
showed potent activity against vancomycin-resistant strains of Enterococcus (VRE). Next, 
we tested the activity of EB against the clinical isolates of multidrug-resistant S. aureus. 
EB showed more potent activity against methicillin-sensitive S. aureus, MRSA, 
vancomycin-intermediate S. aureus (VISA) and vancomycin-resistant S. aureus (VRSA) 
strains than VRE with MIC90 of 0.25 µg/ml (see Table 2.5). Finally, EB also showed potent 
activity against clinical isolates of Streptococcus pyogenes and Streptococcus agalactiae 
with MIC of 0.5 µg/ml (see Table 2.5). On the other hand, EB did not show potent 
antimicrobial activity (MIC ≥16 µg/ml) against Gram-negative pathogens, including 
Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumonia, Salmonella 







negative pathogens might be due to its reduced ability to enter the cells due to outer 
membrane barrier or the efflux pump rather than lack of target of EB inside Gram-negative 
bacteria 303-306.       
 
Intracellular infection and cell toxicity 
        Some extracellular pathogens such as S. aureus are also capable of invading and 
surviving within the mammalian host cells, leading to persistent chronic infections. 
Moreover, during the S. aureus intracellular invasion phase, treatment with antimicrobials 
is very challenging because most antibiotics do not actively pass through cellular 
membranes 237-242. Therefore, clinical failures of drug of choice, such as vancomycin, to 
cure S. aureus pneumonia have exceeded 40% and have been attributed mainly to poor 
intracellular penetration of the drug and consequently to the failure to kill intracellular 
MRSA in alveolar macrophages 307. Hence, finding antimicrobials that possess both extra- 
and intracellular activity would be an optimum strategy to treat such invasive intracellular 
S. aureus infections. Therefore, we investigated if EB possesses intracellular anti- 
staphylococcal activity. As shown in Figure 2.22, EB at a concentration of 1 µg/ml 
significantly reduced the intracellular MRSA by 32%. In contrast, the conventional 
antimicrobials such as vancomycin and linezolid (drugs of last resort for treatment of 
Staphylococcal infections) at the same concentration reduced intracellular MRSA by only 
16% and 21%, respectively. EB toxicity was assayed against J774A.1 cells at a 
concentration ranging from 0 to 256 µg/ml for 24 h. The results shown in Figure 2.23 











Strain ID Phenotypic Characteristics MIC/MBC 
(µg/ml) 
E. faecalis ATCC49533 Resistant to streptomycin 0.25/8 
E. faecalis  ATCC7080   -  0.25/8 
E. faecalis ATCC49532 Resistant to gentamicin  0.25/8 
E. faecalis ATCC14506 - 0.5/8 
E. faecalis ATCC 51229 (VRE) Resistant to Vancomycin. Sensitive 
to Teichoplanin 
0.5/0.5 
E. faecalis SF24397 Resistance to erythromycin (ermB+) 
and gentamicin 
0.125/4 
E. faecalis SF24413 (VRE) Resistant to erythromycin, 
gentamicin and vancomycin. 
0.125/4 
E. faecalis SF28073 (VRE) Resistant to erythromycin, 
gentamicin and vancomycin 
0.0625/8 
E. faecalis HH22 Resistance to penicillin, 
erythromycin, tetracycline and high 
levels of aminoglycosides 
0.125/4 
E. faecalis MMH594 Resistance to erythromycin and 
gentamicin 
0.125/4 
E. faecalis SV587 (VRE) Resistance to vancomycin 0.125/8 
E. faecium E1162 Resistance to ampicillin. 0.25/16 
E. faecium E0120 (VRE) Resistant to gentamicin and 
vancomycin 
0.5/32 
E. faecium ERV102 (VRE) Resistant to ampicillin and 
vancomycin, and displays high 
levels of resistance to streptomycin.  
0.5/16 
E. faecium ATCC6569 - 1/32 
E. faecium  ATCC 700221 (VRE) Resistant to Vancomycin and 
Teicoplanin 
0.5/1 
MSSA (NRS 72) Resistant to penicillin 0.25/0.5 
MRSA (NRS 384) Resistant to erythromycin, 
methicillin, and tetracycline 
0.125/0.125 
MRSA (NRS119) Resistant to linezolid 0.125/0.25 
MRSA (NRS 123) Resistant to methicillin; susceptible 
to nonbeta-lactam antibiotics 
0.25/0.5 
MRSA (NRS194) Resistant to methicillin 0.25/1 
MRSA (NRS108) Resistant to gentamicin 0.25/0.25 
MRSA (NRS70) Resistant to clindamycin, 
erythromycin and spectinomycin 
0.25/0.25 
VISA (NRS 1) Resistant to aminoglycosides and 
tetracycline (minocycline)  
0.125/0.125 
VISA (NRS 19) Glycopeptide-intermediate S. aureus 0.25/0.025 
VRSA11a 









Table 2.5  continued 
 
VRE: vancomycin-resistant Enterococcus; MSSA: methicillin-sensitive S. aureus; 
MRSA: methicillin-resistant S. aureus; VISA: vancomycin-intermediate S. aureus; 
VRSA: vancomycin-resistant S. aureus; ND: not determined 
 
causes 50% toxicity (half inhibitory concentration: IC50) in J774A.1 cells is 95.68 + 4.12 
µg/ml. This value is more than 380-fold higher than the concentration required to inhibit  
inhibit MRSA. Collectively, these results suggest that EB has great potential for treatment 
of S. aureus infections where not only is eradication of extracellular bacteria important, but 




Resistant to erythromycin and 
spectinomycin 
0.25/0.25 
VRSA12 Resistant to vancomycin 0.25/0. 5 
VRSA13 Resistant to vancomycin 0.25/0.25 
Streptococcus pyogenes ATCC 12344 Quality control strain 0.5/1 
Streptococcus agalactiae MNZ938 Beta-hemolytic, Serogroup: Group B 0.5/0.5 
Streptococcus agalactiae  MNZ 933 Beta-hemolytic, Serogroup: Group B  0.5/0.5 
Streptococcus agalactiae  MNZ 929 Beta-hemolytic, Serogroup: Group B  0.5/0.5 
Acinetobacter baumannii ATCC 
BAA1605 
Resistant to ceftazidime, gentamicin, 
ticarcillin, piperacillin, aztreonam, 
Cefepime, ciprofloxacin, imipenem, 
and meropemem 
16/ND 
E. coli O157:H7 ATCC 700728 - 32/ND 
Salmonella enterica serovar 
Typhimurium ATCC 700720 
- 32/ND 
Klebsiella pneumonia ATCC BAA 
2146 
Clinical isolate New Delhi Metallo-
β-Lactamase (NDM-1) positive 
64/ND 








Figure 2.22 Activity of EB, vancomycin and linezolid against intracellular MRSA USA300 
in J774A.1 cells. MRSA infected J774A.1 cells were treated with EB and control 
antibiotics (vancomycin and linezolid) for 24 h and the percent bacterial reduction was 
calculated compared to untreated control groups. The results are given as means ± SD (n=3). 
P values of (**, # ≤ 0.05) are considered as significant. EB was compared to controls (**) 




Figure 2.23  Cytotoxicity assay in murine macrophage-like cells (J774A.1) cells. J774A.1 
cells were treated with different concentration of EB ranging from 0 to 256µg/ml. DMSO 
was used as a negative control. Cell viability was measured by MTS assay and IC50 of EB 








Cell-free bacterial transcription/translation assay 
        Antimicrobials that target microbial protein synthesis such as oxazolidinones and 
lincomycins are considered excellent choices for the treatment of toxin-mediated bacterial 
infections caused by S. aureus, such as toxic shock syndrome (TSS) and pneumonia 232-235. 
In addition to the suppression of S. aureus toxins such as Panton-Valentine leucocidin 
(PVL), α-hemolysin (hla), and toxic shock syndrome toxin–1 (TSST-1), these 
antimicrobials also reduce excessive host-inflammatory responses associated with these 
toxins 309,310. Hence, protein synthesis inhibitors are often preferred in clinical practice for  
the treatment of toxin-associated staphylococcal infections 232-235. We tested the effects of 
EB in our study on bacterial, mammalian and mitochondrial protein-synthesis. For bacterial 
protein-synthesis inhibition, we used E. coli cellular extracts in a transcription and 
translation assay that monitors protein production via luciferase readout. Unlike the 
antibiotic ampicillin that inhibits cell wall synthesis, EB strongly inhibited bacterial 
transcription/translation process similar to chloramphenicol antibiotic that inhibits protein 
synthesis (Figure 2.24a). EB inhibited bacterial protein synthesis in the cell-free 
transcription-translation, exhibiting IC50 of 0.25±0.10 µg/ml which is comparable to IC50 
of chloramphenicol antibiotic 0.48 ± 0.10 µg/ml (Figure 2.24b). These results indicate that 
EB acts by a favorable mechanism of action and inhibits bacterial protein synthesis and, 
most likely, toxin production. However, inhibition of bacterial protein synthesis does not 









Figure 2.24 Effects of EB on coupled transcription-translation (TT)  in S30 extracts from 
E. coli. (a) Average luciferin protein production in the presence of EB, ampicillin and 
chloramphenicol at the concentration of  2µg/ml were shown.  The results are given as 
means ± SD (n = 3). (b) Concentration dependent TT-inhibition of EB and chloramphenicol 
were shown. IC50 of the drugs required to inhibit 50% TT-activity were determined. P 










Cell-free mammalian transcription/translation assay and mitochondrial biogenesis 
           Due to concern about the possible mitochondrial toxicities associated with many 
antibacterial protein synthesis inhibitors such as linezolid and chloramphenicol 311-317, we 
tested the effect of EB on the  inhibition of eukaryotic transcription/translation process 
using the rabbit reticulocyte lysate system with the cellular components necessary for 
mammalian protein synthesis 318,319. As shown in Figure 2.25a, EB showed high safety 
profile with IC50 of mammalian protein synthesis of 166.09 + 12.08 µg/ml. This value is 
more than 660-fold higher than the concentration required to inhibit protein synthesis in 
bacteria. However, in order to test the effect of EB more specifically on mitochondrial 
biogenesis and to confirm the above in vitro results obtained from rabbit reticulocyte lysate 
system, we measured the effect of EB on mitochondrial protein synthesis directly within 
the mammalian cells. In-cell ELISA was performed in J774A.1 cells treated with EB and 
chloramphenicol for three days to detect the levels of mtDNA-encoded COX-I and nDNA-
encoded SDH-A proteins. Results shown in Figure 2.25b indicate that EB had no 
significant inhibition (less than 10%) of mitobiogenesis, similar to the effect of ampicillin, 
which does not interfere with mitochondrial protein synthesis process. At the same time, 
chloramphenicol had more than 60% inhibition of mitochondrial protein synthesis. These 
results provide valuable information about EB’s safety profile and the lack of interference 










Figure 2.25  Effects of EB on mammalian protein synthesis. (a) Concentration dependent  
inhibition of protein synthesis were determined using rabbit reticulocyte lysate extract 
system. IC50 of the EB required to inhibit 50% translational activity were determined. (b) 
Effect of EB, chloramphenicol and ampicillin on mitobiogenesis. J774A.1 cell In cell- 
ELISA was carried out in the presence and absence of these drugs, and the levels of 
mitochondrial (mt)-DNA encoded protein (COX-I) and nuclear-DNA encoded protein 
(SDH-A) were quantified. Ratio of COX-I and SDH-A were calculated and the results were 









Efficacy of  EB in infected animal model (C. elegans) 
        To investigate if the potent in vitro antimicrobial activity of EB translates to 
antimicrobial efficacy in vivo, we tested antimicrobial efficacy of EB in an infected C. 
elegans whole animal model. A whole animal model, such as C. elegans, represents a great 
platform for drug discovery and enables simultaneous assessment of efficacy and toxicity 
of the tested drugs. Additionally, using a C. elegans model reduces the associated cost of 
drug discovery and lowers the burden for extensive animal testing 301,320. Prior to testing 
the efficacy of treatment with EB in infected C. elegans, we tested toxicity of EB in non-
infected C. elegans. As shown in Figure 2.26a, treatment of C. elegans with EB at 4 and 8 
µg/ml for three days did not show any significant toxicity, similar to control groups. With 
no observable toxicity noticed in EB treated groups at a concentration of 4 and 8 µg/ml, 
we moved forward with an in vivo infection model using C. elegans infected with MRSA. 
As seen in Figure 2.26b, treatment with EB had a significant reduction in bacterial load 
when compared to untreated groups. EB at a concentration of 4 and 8 µg/ml significantly 
reduced the mean bacterial count by 56% and 85%, respectively. Moreover, treatment with 
EB at a concentration of 8 µg/ml showed comparable effect to treatment with the drug of 
last resort vancomycin in reducing MRSA burden in infected C. elegans. Taken together, 
these results show that EB exhibits potent in vivo antistapylococcal efficacy in MRSA-










Figure 2.26  Evaluation of toxicity and antimicrobial efficacy of EB in C. elegans model. 
(a) C. elegans strain glp-4; sek-1 (L4-stage) were grown for three days in the presence of 
EB (4µg and 8 µg/ml) and vancomycin (8 µg/ml). Live worms were counted and the results 
were expressed as percent live worms in relative to the untreated control groups. (b) MRSA 
USA300 infected L4-stage worms were treated with EB (4µg and 8 µg/ml) and 
vancomycin (8 µg/ml) for 24 h. Worms were lysed and the CFU were counted and the 
percent bacterial reduction per worm in treated groups were calculated in relative to the 









Synergistic activities of  EB with conventional antibiotics in vitro and in cell culture 
           After confirming that EB has a potential use as an antibacterial agent for the 
treatment of infections caused by multidrug resistant pathogens, it was important to explore 
the synergistic relationship of EB with conventional antibiotics in vitro and in cell culture. 
With the rapid emergence of multidrug-resistant strains of S. aureus, monotherapy with 
single antibiotic has become less effective 244,245. Therefore, alternative strategies such as 
combinational therapy have been used in the healthcare setting to improve the morbidity 
associated with MRSA infections and to reduce the likelihood of emergence of resistant 
strains 244,246,247,296. To ascertain whether EB has the potential to be combined in vitro and 
in cell culture with conventional antimicrobials such as linezolid, clindamycin, 
vancomycin, chloramphenicol, erythromycin, rifampicin, and gentamicin against MRSA 
USA300, we used the in vitro Bliss independence model of synergism and infected cell 
culture assay 282. In vitro results from the Bliss independence model of synergism are 
presented in Figure 2.27a. EB was found to exhibit a synergistic relationship with all tested 
conventional antimicrobials in vitro against MRSA USA300. Results of synergistic 
relationship of EB with conventional antimicrobials in infected cell culture against 
intracellular MRSA USA300 are presented in Figure 2.27b. Conventional antimicrobials 
(clindamycin, erythromycin, and rifampicin) showed synergistic activity when combined 
with EB and significantly reduced intracellular MRSA when compared to monotherapy. 
However, EB did not show synergistic activity with linezolid, vancomycin, 









Figure 2.27  Synergistic activities of  EB with conventional antibiotics in vitro and in cell 
culture. (a) The Bliss Model for Synergy confirms the in vitro synergism with conventional 
antimicrobials (gentamicin, rifampicin, erythromycin, chloramphenicol, vancomycin, 
clindamycin and linezolid) against MRSA USA300. Degree of synergy was calculated in 
the presence of EB (0.0312 µg/ml) in combination with sub-inhibitory concentrations of 
conventional antimicrobials. (b) Synergistic activity of EB with conventional 
antimicrobials in infected cell culture. Efficacy of EB (0.5µg/ml) in combination with 
linezolid (4µg/ml), clindamycin (1µg/ml), vancomycin (4µg/ml), chloramphenicol 
(4µg/ml), erythromycin (8µg/ml), rifampicin (0.5µg/ml) and gentamicin (1µg/ml)  in 
clearing intracellular MRSA USA300 was determined in J774A.1 cells. Percent bacterial 
reduction was calculated in relative to the untreated groups. The results are given as means 
± SD (n=3). Combination therapy was compared to monotherapy and the P values of (**,  








can be synergistically paired with EB can potentially prolong the clinical utility of these 
antibiotics and reduce the likelihood of emergence of resistant strains. 
 
In conclusion, we have successfully explored the potential applications of EB in vitro, in 
cell culture, and in vivo to combat multidrug-resistant Gram-positive pathogens, especially 
MRSA. We demonstrated that EB inhibits the bacterial translation process without 
affecting mitochondrial biogenesis. Additionally, we demonstrated the efficacy of EB in 
vivo in a C. elegans MRSA-infected model. Finally, we identified potential antibiotics that 
can be synergistically combined with EB to prolong the clinical utility of these antibiotics 
and reduce the likelihood of the emergence of resistant strains. Taken together, our study 
results demonstrate that EB, with its potent antimicrobial activity and safety profiles, might 
be a potential candidate drug for systemic and (or) topical applications to treat multidrug 
resistant Gram-positive bacterial infections alone or in combination with other antibiotics 







2.5 Exploring simvastatin, an antihyperlipidemic drug, as a potential topical 
antibacterial agent 
 
(Thangamani S, Mohammad H, Abushahba MF, Hamed MI, Sobreira TJ, Hedrick VE, Paul 
LN, Seleem MN. Exploring simvastatin, an antihyperlipidemic drug, as a potential topical 
antibacterial agent. Scientific Reports. 2015 Nov 10;5:16407) 
 
2.5.1 Introduction 
         The blockbuster statin drugs have revolutionized the treatment of cardiovascular 
disease, primarily by reducing low-density lipoprotein cholesterol (LDL-C) levels, 
leading to a decline in the morbidity and mortality associated with coronary artery 
diseases 1. All statins drugs exert their effect by inhibiting the enzyme class I 3-hydroxy-
3-methyl-glutaryl- Coenzyme A reductase (HMG-CoA) leading to decreased synthesis of 
cholesterol and increased removal of low-density lipoprotein (LDL) circulating in the 
body 2,3. These drugs possess a good safety profile with limited side effects thus 
permitting their frequent use in reducing lipid levels in patients with high cholesterol levels 
4,5.  In addition to their lipid-lowering effect, statins have been found to have potential 
use for other applications including influencing the host immune response via the drugs’ 
anti-inflammatory and immune-modulatory properties 6. Furthermore, multiple reports 
have investigated the potential role of statins in preventing and treating various 
infectious diseases and have demonstrated that statins can prevent the establishment of 
infections (by decreasing host cholesterol synthesis 7-9  limiting certain bacterial species’
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ability to invade host cells) and potentially decrease the mortality rate attributed to  
bacterial infection 10-12.    Interestingly, several studies have shown that certain statins 
possess antimicrobial activity directly inhibiting growth of Staphylococcus, 
Streptococcus, Enterococcus and Moraxella spp. 13-17. In addition, simvastatin and 
atorvastatin are capable of increasing the mycobactericidal effect of rifampicin18. 
However, limited information is available regarding the mechanism by which statins 
exert their antibacterial effect, statins’ antimicrobial effect on Gram-negative pathogens, 
and potential applications for statins as novel antibacterial agents. 
 
         Given the tremendous pressure bacterial resistance to currently available antibiotics 
has placed on the healthcare system (with certain bacterial strains of Staphylococcus 
aureus and Pseudomonas aeruginosa exhibiting resistance to nearly every class of 
antibiotics), new antimicrobials are urgently needed to counter this significant public 
health challenge 19. Repurposing existing drugs (initially approved for treatment of 
one clinical indication such as lowering cholesterol levels) that also possess antibacterial 
activity has the potential to expedite the process to discovering new antibacterial agents 
(given much of the rigorous safety, pharmacokinetic, and pharmacodynamic studies have 
already been conducted) 20. Based upon preliminary studies performed to date, statins, 
in particular simvastatin, have potential to be repurposed as novel antibacterial agents. 
However additional research is required to understand statins’  antibacterial  spectrum  of  
activity,  their  antibacterial mechanism  of  action,  and  to elucidate potential clinical 
applications in the management of bacterial infections. In this study, we aim to lay the 
foundation for utilizing statins as topical antibacterial agents by investigating the 
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antibacterial activity of statins and their spectrum of activity on clinically-relevant Gram- 
positive and Gram-negative pathogens, elucidating the antibacterial mode of action of the 
most active statin (simvastatin), examining the effect of simvastatin on specific virulence 
factors (such as  bacterial  toxins  and  disruption  of  staphylococcal  biofilms)  and  
finally  to  validate  the therapeutic efficacy of simvastatin in an appropriate animal model 
of S. aureus infection. Our study reveals that simvastatin has considerable promise for 
use as a therapeutic agent to treat MRSA skin infections and does warrant further 
investigation as a novel topical antibacterial agent. 
 
 
2.5.2   Materials and Methods 
 
Bacterial strains and reagents 
       Bacterial strains used in this study are presented in Table 1 and Table 2. Mueller-
Hinton broth (MHB), gentamicin and tetracycline were purchased from Sigma-Aldrich  
while  mupirocin  (Applichem),  linezolid  (Selleck  Chemicals),  and  vancomycin 
hydrochloride (Gold Biotechnology) were acquired from other commercial vendors. 
Mannitol salt agar (MSA), Trypticase soy agar (TSA) and Trypticase soy broth (TSB) 
were purchased from Becton, Dickinson and Company (Cockeysville, MD). All statin 
drugs used in this study were purchased from Sigma-Aldrich (St. Louis, MO, USA), 
with the exception of pitavastatin and rosuvastatin which were obtained from 







        The antibacterial activity (MIC) of all test agents was examined using the broth  
microdilution method  as  per  the  guidelines  outlined  by  the  Clinical  and  Laboratory 
Standards Institute (CLSI)55. 
 
 
Gram-negative bacteria outer membrane permeabilization assay 
        The MIC of simvastatin and control antibiotics, in the presence of a sub-
inhibitory concentration of colistin, against Gram-negative bacteria was evaluated as 
described in the antibacterial assay section above. 
 
 
Macromolecular synthesis assay 
      The macromolecular synthesis assay was conducted as described elsewhere 56. 
Briefly, S. aureus strain ATCC 29213 was grown in TSB, until it reached exponential 
phase (OD600   = 0.2 to 0.3), and then treated with different concentrations of 
simvastatin  and  control  antibiotics  (ciprofloxacin,  rifampicin,  linezolid,  vancomycin  
and cerulenin). Bacterial cells treated with drugs were incubated at 37 °C for 30 min 
and the radio labeled precursors for DNA ([3H] thymidine (0.5μCi)), RNA ([3H] uridine 
(0.5μCi)), protein ([3H] leucine (1.0 μCi)), cell wall ([14C] N-acetylglucosamine (0.4 
μCi)) and lipid synthesis ([3H] glycerol (0.5 μCi)) were added for each reaction. The 
incorporation of radiolabeled precursors was  quantified  and  the  results  expressed  as  







        An overnight culture of MRSA USA300 was treated with 10 × MIC of simvastatin 
for one hour at 37 °C. Bacterial cells were centrifuged and sequence grade Lys- 
C/Trypsin (Promega) was used to enzymatically digest samples. Samples were 
reduced and alkylated prior to digestion. All trypsin digestions were carried out in a 
Barocycler NEP2320 (PBI) at 50 °C under 20 kpsi for two hours.  After digestion, 
samples were cleaned using MicroSpin C18 columns (Nest Group, Inc.) and the 
resulting pellets were re-suspended in 97% H2O/3% ACN/0.1% FA. A small aliquot (5 
µL) of sample was analyzed via nanoLC-MS/MS. 
           The WIFF files from MS analysis were processed using the MaxQuant 
computational proteomics platform version 1.5.2.8 (Cox and Mann, 2008). The peak list 
generated was screened against the Staphylococcus aureus (10972 entries reviewed) and 
Bos taurus (41521 entries unreviewed) sequence from UNIPROT retrieved on 04/10/2015, 
in addition to a common contaminants database. The following settings were used for 
MaxQuant: initial precursor and fragment mass tolerance set to 0.07 and 0.02 Da 
respectively, Minimum peptides length of seven amino-acid, data were analyzed with 
‘Label-free quantification’ (LFQ) checked and the ‘Match between runs’ interval set to 
one min, the fasta databases were randomized and the protein FDR was set to 1%, enzyme 
trypsin allowing for two missed cleavages and three modifications per peptide, fixed 
modifications were carbamidomethyl (C), variable modifications were set to Acetyl 
(Protein N-term) and Oxidation (M). 
         The MaxQuant results were used in in-house script, and the average LFQ intensity 
values for the technical replicates were used for each sample. All the Bos taurus and 
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the common contaminant proteins were removed. All the values were transformed 
[log2(x)] and the missing values were inputted using the average values of all samples. 
The volcano plot and statistical analyses were performed in the R environment 
(www.cran.r-project.org). A t-test was performed on the LFQ intensity and only proteins 
with P ≤ 0.05 were used for further analyses. A function-enrichment analysis of proteins 
was annotated using the Database for Annotation, Visualization and Integrated 
Discovery – DAVID 57 
 
 
Cell-free bacterial transcription/translation assay 
        The cell-free bacterial transcription/ translation assay was performed using 
Escherichia coli S30 System (Promega). The assay was carried out as per the 
manufacturer’s instructions. Gentamicin was used as a positive control. Briefly, 
simvastatin and gentamicin were added at the indicated concentrations to the reaction 
mixtures and incubated at 37 °C for one hour. The intensity of luminescence was 
quantified using a standard FLx800 microplate reader (BioTek Instruments, Inc. 
Winooski, Vermont) after addition of the luciferase assay reagent. 
 
 
Mitochondrial biogenesis assay 
        An In-Cell ELISA Kit (MitoSciences Inc., Eugene, OR) was employed to evaluate 
the effect of simvastatin and control antibiotics (tetracycline and vancomycin) on 
mitochondrial protein synthesis and the experiment was conducted as described 
previously 58. The ratio between COX-I and SDH-A was calculated and the percent 
inhibition of mitochondrial protein synthesis was determined. 
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Measuring toxin  production by  ELISA 
         The effect of simvastatin and control antibiotics (linezolid and vancomycin) on 
production of two important S. aureus toxins (Hla and PVL) was measured utilizing 




          The animal care and all experiments were performed in accordance with the 
guidelines approved by Purdue University Animal Care and Use Committee (PACUC). 
The murine model of MRSA skin infection utilized in this study has been described 
previously 56. Briefly, mice (eight week old female BALB/c mice, five mice per group) 
were injected intradermally with MRSA USA300 (1.65×108  CFU per mouse) and left 
for 48 h before an open wound formed at the injection site. Each group was 
subsequently treated with either 1% or 3% simvastatin or 2% mupirocin (using 
petroleum jelly as the vehicle) once a day for four days. Control group was treated with 
the vehicle alone. 24 h after the last treatment, the area around the wound was lightly 
swabbed with 70% ethanol and the wound (1 cm2) was excised, homogenized, serially 
diluted, and plated on MSA. Plates were incubated at 37 °C for 18 hours before counting 
viable bacterial CFU. 
 
Quantifying inflammatory cytokines by ELISA 
       Skin homogenates obtained from the mice skin infection procedure described above 
were centrifuged and the supernatants were assayed in order to measure the levels of 
three cytokines TNF-α, IL-6 and IL-1β by Duo-set ELISA Kits (R&D Systems, Inc.) The 
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quantification of cytokines and the experiment were carried out as per the 





         The effect of simvastatin and control antibiotics (vancomycin and linezolid) on 
disrupting established staphylococcal biofilm was evaluated using the microtiter dish 
biofilm formation assay 56. Briefly, S. aureus (ATCC 6538) and S. epidermidis (ATCC 
35984) were grown in TSB supplemented with 1% glucose in a 96-well tissue-culture 
treated plate. Bacteria were incubated at 37 °C for 24 h to permit the formation of an 
adherent biofilm. The medium was removed and washed with PBS. Drugs at indicated 
concentration were added and incubated again at 37 °C for 24 h. Plates were washed 
again and biofilms were stained with 0.1% (wt/vol) crystal violet. Plates were washed, 
air dried and biofilm mass was dissolved using 95% ethanol. The intensity of crystal 
violet was measured using a micro plate reader (Bio-Tek Instruments Inc.). Data are 





        Synergism was calculated using the Bliss independence model as described in 
previous reports 54,56. Briefly, bacterial strains were incubated with a sub-inhibitory 
concentration of simvastatin and control antimicrobials for 12 h and the degree of synergy 
was calculated using the formula: S = (fA0/f00)(f0B/f00)-(fAB/f00), where fAB  refers to 
128 
 
bacterial growth rate in the presence of the combined drugs at concentration A, for one of 
the antibiotics, and B for the simvastatin; fA0  and f0B  refer to the bacterial growth rates 
in the presence of antibiotics (or) simvastatin at a concentration of A and B, respectively; 
f00  refers to the bacterial growth rate in the absence of drugs. Positive values correlate 
with synergistic behavior while negative values are indicative of an antagonistic interaction 
between the drugs.  
 
ATP release assay 
     In order to determine if simvastatin and control antibiotics were capable of disrupting 
the MRSA cell membrane, MRSA USA300 cells were treated with 5 × MIC of simvastatin, 
tetracycline, or lysostaphin for one hour at 37°C. DMSO was used as a negative control. 
Bacteria were centrifuged and supernatants were analyzed using the Enliten ATP Assay 
System (Promega) per the manufacturer’s instructions. Aliquots (10 µl) of supernatant 
were mixed with 75 µl of luciferase assay reagent and the intensity of luminescence was 
recorded using a microplate reader (FLx800 BioTek Instruments, Inc. Winooski, Vermont).  
 
Electron Microscopy 
      An overnight culture of  MRSA USA300 was diluted (OD600 = 0.3) and incubated with 
5 × MIC of simvastatin before samples were subsequently collected at two time points (0 
and 12 hours). Samples were centrifuged and the bacterial pellets were fixed with 2.5% 
buffered glutaraldehyde for one hour. Cells were next treated with 1% osmium tetroxide 
and 1% uranyl acetate. Further dehydration was done using ethanol and embedded in white 
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resin. The samples were stained with 1% uranyl acetate and lead citrate prior to viewing 




        Statistical analyses were assessed using GraphPad Prism 6.0 (Graph Pad Software, 
La Jolla, CA). P values were calculated using the two-tailed Student t test. P ˂ 0.05 
was deemed significant.  
 
2.5.3 Results 
In vitro antibacterial assays 
       The antibacterial activity of eight statin drugs including simvastatin, atorvastatin, 
fluvastatin, lovastatin, mevastatin, pitavastatin, pravastatin and rosuvastatin were 
evaluated against two representative Gram-positive and Gram-negative bacterial 
pathogens (methicillin-resistant Staphylococcus aureus (MRSA) ATCC 4330 and 
Pseudomonas aeruginosa ATCC 15442 respectively) (see Table 2.6). Simvastatin was 
the only drug capable of inhibiting MRSA ATCC 4330 growth with a minimum 
inhibitory concentration (MIC) value of 32 µg/ml. Interestingly, none of the statin drugs 
examined possessed antibacterial activity against P. aeruginosa ATCC 15442 
(MIC>1024 µg/ml), indicating simvastatin’s effectiveness as an antibacterial activity 






























































































         Confirmation of simvastatin’s antibacterial activity against MRSA ATCC 43300 
led us to examine simvastatin’s ability to inhibit growth of important multidrug-resistant 
strains of Gram-positive pathogens (Table 2.7). Simvastatin exhibited bacteriostatic 
activity against all methicillin-sensitive S. aureus (MSSA), MRSA, vancomycin-
intermediate S.  aureus (VISA), vancomycin-resistant S.  aureus (VRSA), vancomycin-
sensitive Enterococcus, vancomycin-resistant Enterococcus (VRE) and Listeria 
monocytogenes strains, inhibiting 90% of the strains (MIC90) tested at a concentration 
of 32µg/ml. Simvastatin also inhibited growth of strains of Streptococcus pneumoniae 





Table 2.7 MIC of simvastatin against a panel of Gram-positive bacteria 
 




Methicillin-resistant S. aureus (18) 32 32 
Vancomycin-resistant S. aureus (15) 32 32 
Methicillin-sensitive S. aureus (6) 32 32 
Vancomycin-intermediate S. aureus (3) 32 32 
Vancomycin-sensitive Enterococcus (9) 32 32 
Vancomycin-resistant Enterococcus (7) 32 32 
Listeria monocytogenes (6) 32 32 
Streptococcus pneumoniae (2) 64 64 
Bacillus anthracis (3) 16 16 
 
 
         The antimicrobial activity of simvastatin was next assessed against various Gram-
negative pathogens (Table 2.8). Initial investigation indicated that simvastatin did not 
possess antibacterial activity against Gram-negative bacteria. However, when the outer 
membrane (OM) permeability in these bacteria was compromised using a sub-inhibitory 
concentration of colistin, simvastatin displayed antimicrobial activity against all tested 
strains of Gram-negative pathogens including Acinetobacter baumannii, Escherichia 
coli, Salmonella Typhimurium, Klebsiella pneumoniae, and P. aeruginosa with the MIC 
ranging from 8-32 µg/ml. The antibacterial activity of simvastatin was further 
investigated against E. coli SM1411∆ acrAB, a strain that is deficient in the multidrug-
resistant AcrAB efflux pump. Simvastatin alone was not active against E. coli SM1411∆ 
acrAB (MIC>256 µg/ml). However simvastatin was able to inhibit growth of this strain 




Table 2.8 MIC of simvastatin against a panel of Gram-negative bacteria 
 



























      
  Erythromycin 
(µg/ml) 
     
    Fusidic acid 
(µg/ml) 
   colistin colistin colistin 
(-) (+) (-) (+) (-) (+) 
Acinetobacter baumannii ATCC 
BAA19606 
 
0.25 0.0625 >256 16 64 2 64 0.5 
Acinetobacter baumannii ATCC 
BAA1605 
0.25 0.0625 >256 16 64 2 128 1 
Acinetobacter baumannii ATCC 
BAA747 
0.25 0.0625 >256 16 64 2 128 1 
Escherichia coli O157:H7 
ATCC 700728 
0.25 0.0625 >256 16 128 1 >256 4 
Escherichia coli O157:H7 
ATCC 35150 
0.125 0.0625 >256 8 128 4 >256 4 
Salmonella Typhimurium ATCC 
700720 
1 0.25 >256 16 256 0.5 >256 0.5 
Klebsiella pneumoniae ATCC 
BAA 2146 
0.25 0.125 >256 16 >256 0.125 >256 0.125 
Klebsiella pneumoniae ATCC 
BAA 1705 
0.25 0.125 >256 16 >256 8 >256 8 
Pseudomonas aeruginosa 
ATCC 9721 
0.5 0.25 >256 16 >256 2 >256 1 
Pseudomonas aeruginosa 
ATCC 9027 
0.5 0.25 >256 32 >256 0.5 >256 2 
Pseudomonas aeruginosa 
ATCC 27853 
0.5 0.25 >256 16 256 0.5 >256 0.5 
Pseudomonas aeruginosa 
ATCC BAA-1744 
0.25 0.125 >256 16 >256 1 >256 2 
Pseudomonas aeruginosa 
ATCC 25619 
0.125 0.0625 >256 16 256 2 >256 0.5 
Pseudomonas aeruginosa 
ATCC 35032 
0.5 0.25 >256 16 >256 1 >256 1 
Pseudomonas aeruginosa 
ATCC 10145 
0.25 0.125 >256 16 256 1 >256 2 
Pseudomonas aeruginosa 
ATCC 15442 
0.5 0.25 >256 16 >256 0.5 >256 1 
Escherichia coli 1411 0.25 0.0625 >256 16 32 0.03 >256 0.03 
Escherichia coli SM1411∆ 
acrAB 










Figure 2.28 Macromolecular synthesis in the presence of simvastatin. Effect of simvastatin 
and control antimicrobials  at  indicated  concentration  (in  fold  MICs)  on  incorporation  
of  radiolabeled precursors of DNA, RNA, protein, cell wall and lipid synthesis ([3H] 
thymidine, [3H] uridine, [3H] leucine, [14C] N-acetylglucosamine and [3H] glycerol, 
respectively) were quantified in S. aureus ATCC 29213. Results are expressed as percent 
of inhibition calculated based on the incorporation of each radiolabeled precursor. 
Statistical analyses were done using the two-tailed Student’s‘t’ test. P values of (* ≤ 0.05) 






Figure 2.29  Quantitative proteome analysis of  S.  aureus cells  treated with  simvastatin 
reveals extensive protein degradation. (a) S. aureus treated with simvastatin in biological 
triplicates was analyzed for changes in the global proteome in relation to untreated controls, 
as shown in the volcano plot. The volcano plot depicts the P-values (-log10) versus gene 
ratio in the simvastatin- treated group (log2). Genes marked in blue indicate an absolute 
fold change higher than 1. The genes marked in red represent an adjusted P-value lower 
than 0.05 and an absolute fold change higher than 1.5. (b) Function–enrichment analysis 
of proteins degraded by simvastatin were annotated using Database for Annotation, 
Visualization and Integrated Discovery (DAVID). The overrepresented pathways are 




Simvastatin inhibits multiple macromolecular synthesis pathways 
 
       Simvastatin’s antibacterial mechanism of action was investigated using a standard 
macromolecular synthesis inhibition assay in S. aureus ATCC 29213. As shown in Figure 
2.28, DNA, protein and lipid synthesis were significantly inhibited at concentrations 
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below the drug’s MIC (0.25×). In addition, simvastatin also significantly inhibited RNA 
synthesis at 0.5× MIC. Inhibition of cell wall synthesis was observed only at the MIC. 
 
 
Simvastatin causes extensive protein degradation and disrupts cellular homeostasis 
      In order to gain additional insight into the different cellular pathways regulated by 
simvastatin, proteomic profiling was employed to investigate the response of bacteria  to  
simvastatin  21-23.  The  alterations  in  the  proteome  caused  by  treatment  with 
simvastatin were compared to an untreated control group. The proteomic analysis 
identified 521 proteins with 85 proteins that were significantly differentially expressed (P 
≤ 0.05) in the simvastatin treatment group as compared to the control group (Figure 2.29a). 
The seven proteins marked in red have an adjusted P-value lower than 0.05 and absolute 
fold change higher than 1.5. An important protein that is regulated is adenylate kinase 
(adk) which is involved in the interconversion of ADP to AMP and ATP and helps to 
maintain the adenine nucleotide balance within cells 24.  From the six upregulated 
proteins, three are ATP-dependent enzymes; clpC (ATP- dependent Clp protease), clpB 
(chaperone protein ClpB) and thrS (threonine-tRNA ligase). The Clp proteases and 
chaperon proteins are central components in bacteria necessary to help mount an 




        The function-enrichment analysis found eight pathways showed a significant (P  ≤ 
0.05) fold enrichment ranging from 8.6 to 47 (Figure 2.29b). From these pathways, the 
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proteins involved in pyrimidine metabolism, valine, leucine and isoleucine biosynthesis 
and aminoacyl- tRNA biosynthesis were significantly downregulated (average log2 fold 
change: -1.42, -0.29 and -0.11 respectively). On the other hand, the proteome involved 
in 3-chloroacrylic acid degradation, butanoate metabolism, glycolysis/gluconeogenesis, 
pyruvate metabolism and the proteins that bind to one or more ribosomal subunits were 
significantly upregulated (average log2 fold change:1.98, 1.26, 1.26, 0.82  and 0.61  
respectively). Thus the  proteomic analysis suggests that simvastatin treatment leads 
to an extensive degradation of different proteins involved in various essential cellular 
pathways resulting in dysregulation of cellular homeostasis and ultimately leading to 
arrest of bacterial growth. 
 
 
Simvastatin inhibits bacterial but not mammalian protein synthesis 
         In order to confirm simvastatin is a potent, selective inhibitor of bacterial protein  
synthesis,  its  activity  against  both  bacterial  and  mammalian mitochondrial protein 
synthesis  was  assessed.  An  E.  coli  S30  coupled  transcription  and  translation  assay  
was performed to determine the concentration of simvastatin required to inhibit 50% of 
the bacterial translational process (IC50). As presented in Figure 2.30a, the IC50 of 
simvastatin was found to be 18.85 ± 0.95 µg/ml. The effect of simvastatin on 







Figure 2.30  Simvastatin inhibits bacterial protein synthesis and toxin production. (a) 
Transcription- translation (TT) assay was carried out using S30 extracts from E. coli.  
IC50  of simvastatin and gentamicin required  to  inhibit  50%  TT-activity in  bacteria  
were  determined. (b)  Effect  of simvastatin, vancomycin and tetracycline on mammalian 
mitobiogenesis was assessed via In cell- ELISA. J774A.1 cells were treated with 
indicated concentration of drugs and the levels of mitochondrial (mt)-DNA encoded 
protein (COX-I) and nuclear-DNA encoded protein (SDH-A) were quantified. The ratio 
of COX-I and SDH-A was calculated and the results shown are percent inhibition of 
mitochondrial biogenesis. (c) Effect of simvastatin on S. aureus toxin production. MRSA 
USA300 was treated with drugs for one hour and toxin production (ng/ml) (corrected for 
organism burden) was measured by ELISA. The results are given as means ± SD (n = 3). 







The change in expression level of subunit I of Complex IV (COX-I), which is 
mitochondrial DNA (mtDNA)-encoded, and the 70 kDa subunit of Complex II (SDH-
A), which is nuclear DNA (nDNA)-encoded proteins, after treatment with simvastatin 
and control antibiotics (tetracycline and vancomycin) was measured by In-cell ELISA. As 
presented in Figure 2.30B, simvastatin (40 µg/ml), similar to vancomycin (40 µg/ml), has 
a very minimal  effect  (less  than  15%  inhibition  observed)  on  inhibition  of  
mitochondrial  protein synthesis (Figure 6.3b). In contrast, the positive control antibiotic, 
tetracycline, inhibited more than 50% of mitochondrial protein synthesis, at a 




Simvastatin inhibits S. aureus toxin production 
       In  view of  results demonstrating the  specific effect  of  simvastatin on bacterial 
protein synthesis inhibition, its effect on production of S. aureus toxins such as Panton- 
Valentine leucocidin (PVL) and α-hemolysin (Hla) was investigated using ELISA. 
Simvastatin significantly  suppressed  two  key  toxins  (PVL  and  Hla)  produced  by  
MRSA  USA300  when compared to the control group. This mimics the results obtained 
with linezolid (an antibiotic that inhibits protein synthesis) which also significantly 
suppressed production of both PVL and Hla by MRSA USA300 (Figure 2.30c). 
 
 
Simvastatin effectively reduces pre-formed staphylococcal biofilms 
Given the challenge associated with bacterial biofilms and their role in promoting 
recurring infection in hosts, we next moved to investigate the effect of simvastatin on 
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disrupting established biofilms caused by S. aureus and S. epidermidis. Utilizing the 
microtiter dish biofilm formation assay, simvastatin was found to be capable of 
significantly reducing the adherent  biofilms  of  both  S.  aureus  and  S.  epidermidis  
when  compared  to  conventional antibiotics (linezolid and vancomycin) (Figure 6.4). 
Simvastatin, at 2 × MIC and 4 × MIC, significantly reduced S. aureus and S. epidermidis 
biofilm mass by approximately 40%. Contrary to simvastatin, the control antibiotics 
(linezolid and vancomycin) even at 64 × MIC and 128 × MIC were only able to reduce 
the biofilm mass of both S. aureus and S. epidermidis by 10% (Figure 2.31). 
 
Figure 2.31  The effects of simvastatin and antibiotics (linezolid and vancomycin) on 
established biofilms of S. aureus (a) or S. epidermidis (b) were evaluated. The pre-formed 
biofilms were treated with control antibiotics or simvastatin and then stained with crystal 
violet. The optical density of the dissolved crystal violet was measured using a 
spectrophotometer. Values are the mean of triplicate samples with standard deviation bars. 
P values of (*, # P ≤ 0.05) are considered as significant. (*) indicates simvastatin was 





Figure 2.32 Antibacterial and anti-inflammatory activities of simvastatin in a mouse 
model of MRSA skin infection. (a) Efficacy of treatment of MRSA skin lesions with 
simvastatin (1 and 3%), mupirocin (2%) and petroleum jelly (negative control) once daily 
for four days. Percent bacterial reduction was calculated and shown in the figure. Statistical 
analysis was performed via the two- tailed Student t test.  P values of (** P ≤ 0.01) are 
considered as significant. (b) Effect of simvastatin on cytokines production in supernatants 
from skin homogenates of MRSA skin lesions. Percent reduction in inflammatory 
cytokines was calculated. Statistical analysis was performed via the two-tailed Student t 








Simvastatin is effective in reducing bacterial load in a mouse model of MRSA 
skin infection 
    Four groups of MRSA-infected mice were treated topically either with simvastatin (1% 
or 3%), a control antibiotic (2% mupirocin), or the vehicle alone (petroleum jelly) once 
a day for four days. As shown in Figure 2.32a, all treatment groups significantly reduced 
the mean bacterial counts compared with the control group (P ≤ 0.01). Topical treatment 
with 1 and 3% simvastatin significantly reduced the MRSA load in infected skin wounds 
by 75 and 90% respectively. Mupirocin (2%) produced a 99% reduction in mean bacterial 
count as compared to the untreated group. 
 
 
Simvastatin reduces inflammatory cytokines induced by MRSA skin infection 
       The immune-modulatory activity of simvastatin against MRSA skin infection was 
evaluated by measuring levels of pro-inflammatory cytokines produced during infection 
including tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) and interleukin-1 beta 
(IL-1β) in the MRSA infected wounds of mice from the skin infection experiment 
described above. As shown in Figure 2.32b, topical application of simvastatin (1 and 3%) 
significantly reduced all tested inflammatory  cytokines.  Simvastatin-treated  (3%)  group  
reduced  production  of  all  three cytokines  examined  (IL-6,  TNF-α  and  IL-1β).  
Topical  application  of  1%  simvastatin  also decreased production of inflammatory 
cytokines in the MRSA infected wound lesions by 20%. However, mice treated with 
mupirocin (2%) did not show a significant reduction in the levels of all the tested 




Figure 2.33  Synergistic activity of simvastatin with topical antimicrobials. The Bliss 
independence model confirms a synergistic relationship between simvastatin and four 
topical antimicrobials (mupirocin, fusidic acid, retapamulin and daptomycin) against 
various clinical isolates of multidrug-resistant strains of S. aureus. The positive and 







Figure 2.34 Simvastatin does not disrupt the cell membrane of S. aureus. (A) MRSA 
USA300 cells were treated with 5 × MIC of simvastatin, tetracycline or lysostaphin and 
the level of ATP was measured in the supernatant for each treatment condition . (B) 
Transmission electron microscopy (TEM) images of untreated and simvastatin (5 × MIC) 
treated MRSA USA300 cells at the indicated time points, in hours (h), are shown.
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Simvastatin exhibits synergistic activity with conventional topical antimicrobials 
         Combination therapy employing two or more antibiotics together has been utilized 
for treating skin wounds and infections in the healthcare setting. Given simvastatin 
exhibited good antibacterial activity against MRSA both in vitro and in vivo, we 
examined the possibility of using simvastatin with antimicrobials commonly used to treat 
skin infections. The antimicrobial activity of simvastatin in combination with four topical 
antimicrobials (fusidic acid, mupirocin, daptomycin, and retapamulin) was investigated 
in vitro using the Bliss independence model of synergism against three S. aureus clinical 
isolates. As shown in Figure 2.33, simvastatin demonstrated a synergistic relationship 





        Antibiotics have long been key allies in the treatment of bacterial infections. 
However, the emergence of pathogens (in particular MRSA) exhibiting resistance to 
many antimicrobial classes including to therapeutic agents of last resort, such as 
vancomycin and linezolid, presents an ominous premonition that our current arsenal of 
antibiotics will no longer be effective in the near future 27-29. Thus there is an urgent 
need to drive research efforts to discover  new  antimicrobials in  order  to  circumvent 
this  burgeoning  health  challenge. The conventional strategies used to develop new 
drugs are highly unlikely to keep pace with acquired resistance  by  bacterial  pathogens  
and  often  comes  at  a  significant  financial  risk  to pharmaceutical companies (the 
success rate of receiving regulatory approval for a new antibiotic varies between 1.5 – 
3.5% even after investing nearly one billion dollars in research and development costs) 
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30  . Though government regulatory agencies have attempted to provide incentives to 
encourage pharmaceutical companies to re-enter the arena of antibacterial drug 
discovery, such as the U.S. Food and Drug Administration’s "reboot" pledge, it will 
take many years for these incentives to translate into the discovery of new antibiotics 
(using conventional methods of screening compound libraries for lead hits) 31. An 
alternative strategy that has promise to expedite the discovery and approval process is 
repurposing old drugs, such as statins that have already passed rigorous safety 
assessments, as novel antibacterial agents to combat multidrug-resistant pathogens 32. 
 
        Statins, widely used to control hyperlipidemia, are known to exhibit antimicrobial 
properties 13-17. We investigated the antibacterial activity of eight statin drugs 
including simvastatin, atorvastatin, fluvastatin, lovastatin, mevastatin, pitavastatin, 
pravastatin and rosuvastatin against a representative Gram-positive and Gram-negative 
bacterial species (methicillin-resistant S. aureus ATCC 4330 and P. aeruginosa ATCC 
15442). Our results correlate with previous reports that have found that only simvastatin 
exhibits antibacterial activity against Gram-positive bacteria 17. However its activity 
against Gram-negative bacteria was previously unknown. Our initial investigation 
indicated that simvastatin lacks antibacterial activity against the Gram-negative 
pathogen P. aeruginosa. However, further analysis revealed that the outer membrane in 
Gram-negative bacteria acts as an intrinsic barrier for simvastatin to gain entry into 
Gram-negative bacteria. When the OM is compromised using a sub-inhibitory 
concentration of colistin, simvastatin exhibits antibacterial activity against many 
clinically-pertinent Gram- negative pathogens including A. baumannii, E. coli, S. 
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Typhimurium, K. pneumoniae, and P. aeruginosa.. The enhanced antimicrobial activity 
of simvastatin in comparison to other statin drugs may be related to differences in their 
chemical characteristics, as described previously 14,17. However, further structure-
activity relationship studies need to be performed to confirm the structural elements in 
simvastatin that contribute to its antimicrobial properties. This will permit rational 
modifications to be made to the drug’s structure in order to potentially enhance its 
potency against bacterial pathogens and mitigate potential toxicity issues to host tissues. 
 
            In view of the broad-spectrum activity of simvastatin, its antibacterial mode 
of action was investigated. Simvastatin exerts its antihyperlipidemic effect in humans 
by inhibiting the enzyme class I HMG-CoA reductase present in the mevalonate 
pathway 2,3. We hypothesized that the mechanism of action (MOA) of simvastatin in 
S. aureus differs from the MOA in humans due to the absence of the class I HMG-CoA 
reductase enzyme in S. aureus 33. In order to confirm this hypothesis, we tested the 
activity of simvastatin on S. aureus cultures supplemented with mevalonate. As 
expected, mevalonate supplementation (0.1 and 1 mM) did not diminish simvastatin’s 
antibacterial activity against S. aureus (data not shown). This clearly indicates that the 
MOA of simvastatin differs between S. aureus and humans. In order to further explore 
the MOA of simvastatin on S. aureus, a macromolecular synthesis assay was performed. 
Treatment of S. aureus cells with a subinhibitory concentration of simvastatin resulted 
in the suppression of multiple biosynthetic pathways including DNA, protein, lipid and 
RNA synthesis indicating that simvastatin might have a complex mechanism of action 
involving multiple targets. Additionally, the impact of simvastatin on multiple 
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biosynthetic pathways might be due to dysregulation in pathways involved in general 
cellular homeostasis and energy metabolism such as glycolysis, pyruvate metabolism 
and butanoate metabolism as observed in the proteomic profiling. In order to ascertain 
whether cell membrane damage is the cause for inhibition of multiple  macromolecular 
synthesis  pathways,  as  noticed  in  antimicrobial peptides  such  as lactoferricin B and 
pleurocidin-derived peptides 34,35, we performed an ATP release assay. Our results  
strongly  suggest  that  simvastatin  does  not  physically  damage  the  bacterial  cell 
membrane as was validated using transmission electron microscopy (Figure 2.34). 
Finally, in an attempt to determine the exact molecular target of simvastatin, S. aureus 
was serially passaged for two weeks in the presence of simvastatin. Though S. aureus 
mutants that were resistant to simvastatin were generated, whole genome sequencing 
indicated that these mutants were not stable. This result provides indirect evidence that 
multiple targets might be a reason for the inability to form stable mutants resistant to 
simvastatin (data not shown). Future studies are needed to elucidate the exact molecular 
target(s) of simvastatin by which it exerts its antibacterial activity. 
 
          The  macromolecular  synthesis  assay  revealed  that  simvastatin  inhibits 
bacterial protein synthesis which raises an important question; is this action specific or 
can simvastatin also inhibit protein synthesis in mammalian cells? Multiple 
antibacterials that inhibit bacterial  protein  synthesis  (including  tetracycline,  linezolid  
and  chloramphenicol) are  non- selective and result in toxicity to the mitochondria in 
mammalian cells (given the similarity between the ribosomal subunits involved in 
protein synthesis in bacterial and human cells) 36,37. When simvastatin’s ability to 
inhibit protein synthesis was further examined it was found that, unlike tetracycline 
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which had a profound impact on inhibiting mitochondrial protein synthesis, simvastatin 
was a selective inhibitor of bacterial protein synthesis. The discovery led us to examine 
if this effect on protein synthesis inhibition would lead to suppression in the production 
of key toxins by S. aureus. Utilizing ELISA, we found that simvastatin is capable of 
inhibiting production of both PVL and αHla, two pore-forming cytotoxins that injure 
host immune cells and promote infection of host tissues 38. 
 
          Confirmation of simvastatin’s broad spectrum antimicrobial activity in vitro led 
us to proceed forward with an in vivo experiment in a mouse model of MRSA infection. 
However, given simvastatin’s high MIC value cannot be achieved systemically, this 
limits the application of this drug to being used as a topical agent 39. Due to the fact that 
S. aureus causes the vast majority of skin infections in humans and there is a demand 
for topical antimicrobial agents to treat these infections (given increasing resistance to 
first-line agents such as mupirocin), there is great potential for using simvastatin to 
treat/prevent bacterial infections in wounds 40,41. Therefore we assessed the 
effectiveness of simvastatin as a topical antibacterial in a MRSA skin infection mouse 
model. Simvastatin, both at 1% and 3%, significantly reduced the mean MRSA counts 
compared with the control group (P ≤ 0.01), producing a 90% reduction in bacterial 
burden at the higher concentration. Thus, this skin infection study appears to strongly 
suggest that simvastatin has potential use as a topical antimicrobial for treatment of 
MRSA skin infections. 
         The clinical severity of S. aureus-based skin infections is driven in large part 
by production of excess host pro-inflammatory cytokines more so than by bacterial 
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burden42,43. As simvastatin has known anti-inflammatory properties, it should be 
superior to traditional antibiotics for treatment of skin infection (as it should 
hypothetically suppress production of inflammatory cytokines) 44. To confirm this, 
we measured the levels of three inflammatory cytokines in the supernatant of 
homogenized skin tissues obtained from the MRSA murine skin infection experiment 
described above. As predicted, topical treatment with simvastatin, both at 1 and 3%, 
significantly reduced production of three inflammatory cytokines (IL-1β, IL-6 and TNF- 
α); the suppression of these cytokines may contribute to enhanced healing of infected 
wounds45,46. Prolonged inflammation, especially due to the presence of inflammatory 
cytokines such as TNF-α and IL-6, delays healing in chronic infected wounds 47. 
Simvastatin significantly (P ≤ 0.01) inhibits both cytokines (TNF-α and IL-6), which 
should provide a favorable outcome in wound healing 47. Additionally, simvastatin 
has been shown to play a beneficial role in the healing process of diabetic and 
infected wounds by enhancing the formation of new blood and lymphatic vessels and 
increasing the formation of new tissue; these three effects undoubtedly confer an added 
advantage for using simvastatin to treat bacterial skin infections 48,49 Recurring 
infection in skin wounds can persist and impair wound healing due to the presence 
of complex microbial communities called biofilms. Bacterial biofilms, contribute 
significantly to the treatment failure of staph infections, due to hindering penetration of 
antibacterial drugs 50. Simvastatin has been previously reported to exhibit anti-biofilm 
activity as it inhibited both growing and mature biofilms of Candida spp. and 
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Cryptococcus spp 51,52. Thus we decided to examine simvastatin’s capability to disrupt 
staphylococcal biofilms given their prevalence in the healthcare setting (in particular on 
medical implant devices). In addition to its broad-spectrum antibacterial activity, we 
confirmed that simvastatin is capable of disrupting established bacterial biofilms of two 
leading cause of hospital-acquired implant-based infections caused (S.  aureus and  S.  
epidermidis)17. The  ability  to  disrupt staphylococcal biofilms by simvastatin lends 
further support to its potential use as a topical agent in the treatment of skin wounds. 
          The final component of the present study involved examining simvastatin’s ability 
to  be  used in  combination with  other topical antimicrobials. Due  to  the  increasing 
incidence of MRSA strains demonstrating resistance to topical drugs of choice, such 
as fusidic acid and mupirocin, combination therapies are being explored as a potential 
mechanism to ward off the emergence of further resistance to these important agents 
53. The Bliss independence model was utilized to investigate if simvastatin has the 
potential to act synergistically with topical drug of choice against multidrug-resistant S. 
aureus 54. Simvastatin behaved synergistically with fusidic acid, mupirocin, 
daptomycin, and retapamulin against S. aureus strains resistant to vancomycin, linezolid, 
and methicillin. This result provides a strong platform to further examine combining 
simvastatin with topical antimicrobials to treat staphylococcal skin infections (and 
potentially contribute to reducing the likelihood of strains developing resistance to each 
agent if used alone). 
 
         In conclusion, the present study builds upon previous reports that demonstrate 
simvastatin possesses antimicrobial activity against important Gram-positive pathogens, 
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in particular methicillin-resistant S. aureus. We confirmed that simvastatin does possess 
antibacterial activity against Gram-negative pathogens as well, once the barrier imposed 
by the outer membrane is permeabilized, a finding not previously known. The 
antibacterial mechanism of action of simvastatin appears to be complex and involve 
inhibition of multiple biosynthetic pathways and cellular processes, including selective 
interference with bacterial protein synthesis. This property appears to play an important 
role in simvastatin’s ability to suppress production of key toxins (α-hemolysin and PVL) 
critical to permit skin wounds infected by S. aureus to fully heal. A murine MRSA skin 
infection experiment revealed simvastatin is capable of significantly reducing the 
bacterial burden present in infected wounds. Additionally, simvastatin demonstrates the 
ability to disrupt adherent staphylococcal biofilms and to be used in combination with 
other topical antimicrobials currently employed to treat MRSA skin infections. 
Collectively the present study lays the foundation for further investigation of  
repurposing simvastatin as a  topical antibacterial agent to treat skin infections caused 
by pathogens including MRSA.
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2.6 Repurposing celecoxib as a topical antimicrobial agent for staphylococcal skin 
infections 
 
(Thangamani S, Younis W, Seleem MN. Repurposing celecoxib as a topical antimicrobial 
agent. Frontiers in Microbiology. 2015 Jul 28;6:750) 
 
2.6.1 Introduction 
        Bacterial infections caused by multi-resistant pathogens have emerged as a major 
global crisis during the past few decades 109. In 2013, the U.S. Centers for Disease Control 
and Prevention indicated that at least two million individuals per year in the United States 
become infected with multidrug-resistant pathogens, including methicillin-resistant 
Staphylococcus aureus (MRSA), multidrug-resistant Pseudomonas aeruginosa, 
carbapenem-resistant Klebsiella pneumoniae, and vancomycin-resistant Enterococcus 
faecium 1. More importantly, the emergence and spread of multidrug-resistant S. aureus 
clones such as MRSA  USA300 are highly virulent and cause skin and soft tissue infections 
that lead to morbidity and mortality in infected patients 288. Furthermore, the exo-proteins 
and toxins secreted by these MRSA strains trigger excess host inflammatory responses and 
further complicate the situation, especially in the management of wound infections 
107,310,321,322. In addition, virulence factors secreted by MRSA strains hinders wound healing 
and often contagious staphylococcal skin infections lead to invasive infections resulting in 
septicemia 257,258,323. These observations speak to the specific need for topical antibacterial 
agents with novel mechanism of action  combined with anti-inflammatory and wound 
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healing property that can address the issue of skin infections cause by multidrug-resistant   
staphylococcal strains. 
        The number of conventional antimicrobials available to treat MRSA skin infections 
is highly limited and those that are available are becoming less effective 324,325. Though 
topical antimicrobials such as tedizolid and dalbavancin to treat Gram-positive pathogens 
including MRSA has been recently approved by FDA, still there is an unmet need exist for 
novel topical drugs to combat these pathogens 261,262. The development of new 
antimicrobials capable of being used to treat multidrug-resistant pathogens is very slow 
and has not been able to keep pace with the emergence of bacterial resistance 109. Hence, 
novel drugs and treatment strategies are urgently needed to combat these bacterial 
pathogens. Repurposing of approved drugs is a promising alternative strategy that can 
accelerate the process of antimicrobial research and development 276,326. Unlike 
conventional drug discovery, finding new uses for existing drugs is a proven shortcut from 
bench to bedside, that reduces the cost and time associated with antibiotic development 276-
278,326.  
Celecoxib (Celebrex) is a nonsteroidal anti-inflammatory drug widely used for the 
treatment of pain, fever, and inflammation 327,328. It specifically inhibits the enzyme 
cyclooxygenase-2 (COX2), thereby reducing the synthesis of proinflammatory 
prostaglandins 329. Beyond its anti-inflammatory activity, celecoxib has been shown to 
possess antimicrobial activity against several microbial pathogens. In a study by Pereira et 
al, celecoxib was found to reduce the total fungal load in Histoplasma capsulatum infected 
mice 330. Further, celecoxib treatment also increased the survival rate of the mice infected 
with lethal dose of  H. capsulatum 330.  Another study by Chiu et al, found that celecoxib 
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inhibited the growth of Francisella tularensis and F. novicida 331. In addition, celecoxib 
also exhibited antibacterial activity against S. aureus and S. epidermidis 80. Apart from 
antimicrobial activity, celecoxib inhibits multidrug efflux pumps in Mycobacterium 
smegmatis and S. aureus, and increases the sensitivity of bacteria to various antibiotics, 
including ampicillin, kanamycin, ciprofloxacin and chloramphenicol 332,333. However, the 
antibacterial mechanism of action of celecoxib and its potential clinical application remain 
underexplored. 
           In this study, we investigated the antibacterial activity of celecoxib, as well as the 
spectrum of its activity against various clinical isolates of multidrug-resistant Gram-
positive and Gram-negative pathogens. We also investigated its mechanism of action and 
validated its in vivo antimicrobial efficacy in two different animal models, including C. 
elegans and mouse models of MRSA infection. Finally, we tested the activity of celecoxib 
in combination with various antimicrobial agents to investigate the potential for synergistic 
activities. 
 
2.6.2 Materials and Methods 
Bacterial strains and reagents 
        The bacterial strains used in this study are presented in Tables 1-3. Mueller-Hinton 
broth was purchased from Sigma-Aldrich. Trypticase soy broth (TSB), Trypticase soy agar 
(TSA), and Mannitol salt agar (MSA) were purchased from Becton, Dickinson 
(Cockeysville, MD). Celecoxib was purchased from TSZ chemicals. Vancomycin 
hydrochloride was obtained from Gold Biotechnology; linezolid from Selleck Chemicals, 
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mupirocin from Aapplichem, NE, clindamycin from TCI Chemicals, and fusidic acid and 
rifampicin from Sigma-Aldrich.  
 
Antibacterial assays 
      Minimum inhibitory concentrations (MICs) were determined in triplicate,  in Mueller-
Hinton broth, using the broth micro dilution method described by the Clinical and 
Laboratory Standards Institute (CLSI) 216. The MIC was interpreted as the lowest 
concentration of the drug able to completely inhibit the visible growth of bacteria after 
incubating plates for at least 16 h at 37°C. The highest MIC value taken from two 
independent experiments was reported. 
 
Determining antibacterial activity in Gram-negative bacteria: (i) Outer membrane 
permeability assay 
       The MIC of celecoxib in the presence of colistin was measured as described in the 
antibacterial assays section, above. Sub-inhibitory concentration of colistin was added to 
the media to increase outer membrane permeability and facilitate the entrance of celecoxib. 
The following sub-inhibitory concentration of colistin was used for the strains used in this 
study. Pseudomonas aeruginosa ATCC15442 and Salmonella Typhimurium (0.25 µg/ml), 
P. aeruginosa ATCC BAA-1744 and Klebsiella pneumoniae (0.125 µg/ml), Escherichia 
coli O157:H7ATCC 700728 and Acinetobacter baumannii (0.0625 µg/ml). (ii) Inactivation 
of efflux pumps: Role of efflux pumps in contributing resistance to celecoxib in Gram-
negative bacteria was investigated by using an efflux pump inhibitor (reserpine) and an 
efflux pump deletion mutant strain of E.coli. The MIC of celecoxib was examined in the 
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presence of sub-inhibitory concentration of reserpine (32 µg/ml) against all the strains of 
Gram-negative bacteria used in this study. Efflux pump deletion mutant strain of E. coli 
SM1411 ∆ acrAB was employed to determine if acrAB efflux pump plays a role in 
contributing intrinsic resistance to celecoxib in E. coli as described 217. 
 
Time kill assay 
       The time kill assay was performed as described before 216. Briefly, MRSA USA300 
was diluted to 1 × 106 CFU/mL and treated with 4X MIC of control antimicrobials 
(vancomycin or linezolid),  4X and 8X MIC of celecoxib (in triplicates) in MHB. Samples 
were incubated at 37°C and collected at indicated time points to count MRSA colony 
forming units (CFU). 
 
Macromolecular synthesis assay 
         S. aureus strain ATCC 29213 was grown overnight on TSA plates and the isolated 
colonies cultured in 15ml of  MHB to an early exponential phase (OD600 = 0.2 to 0.3) was 
used for the macromolecular synthesis assay. Aliquots (100 μl) of the culture were added 
to triplicate wells of a 96-well microtiter plate. Antibiotics with known mechanisms of 
action (ciprofloxacin, rifampicin, linezolid, vancomycin, and cerulenin) and auranofin 
were added to the plate as controls. DMSO was added to the control groups. After 30 min 
of incubation at 37°C, radiolabeled precursors such as [3H] thymidine (0.5μCi), [3H] 
uridine (0.5μCi), [3H] leucine (1.0 μCi), [14C] N-acetylglucosamine (0.4 μCi), and [3H] 
glycerol (0.5 μCi) were added to quantify the amount of for DNA, RNA, protein, cell wall 
and lipid synthesis respectively. Reactions measuring the inhibition of DNA and RNA 
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synthesis were stopped after 15 min by the addition of 5% trichloroacetic acid (TCA). Then, 
the tubes were chilled on ice for 30 min. The TCA-precipitated materials were collected 
on a 25 mm GF/1.2 μM PES 96-well filter plate. Filters were washed five times with 5% 
TCA, dried, and then counted using a Packard Top Count microplate scintillation counter. 
Reaction wells measuring the inhibition of protein synthesis were stopped after 40 min, 
precipitated, and counted in a manner similar to that used for the DNA and RNA synthesis 
inhibition assays. Reaction wells measuring the inhibition of cell wall synthesis were 
stopped after 40 min by the addition of 8% SDS and then heated for 30 min at 95°C. After 
cooling, the material were spotted onto nitrocellulose membrane filters (0.8 μM) and 
washed three times with 0.1% SDS. Filters were dried and counted using a Beckman 
LS3801 liquid scintillation counter.  Reactions measuring the inhibition of lipid synthesis 
were stopped after 40 min by the addition of chloroform/methanol (1:2) and centrifuged at 
13,000 rpm for 10 min. Then, the organic phase was carefully transferred to a scintillation 
vial, dried, and counted using liquid scintillation counting. Incorporation of radiolabeled 
DNA, RNA, protein, cell wall, and lipid precursors was quantified using the scintillation 
data and inhibition was calculated. Results were presented as the percent inhibition of each 
macromolecular synthesis pathway. 
 
Toxicity assay in C. elegans 
      C. elegans AU37 (sek-1; glp-4) strain glp-4(bn2) were used for the toxicity studies. L4-
stage worms were synchronized as described previously 301. Synchronized worms 
(approximately 20 worms) in 50% M9 buffer and 50% TSB were added to each well of a 
96-well plate. Drugs (celecoxib and linezolid) at indicated concentrations (16 or 32 µg/ml) 
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were added to the wells and the plates were incubated for 4 days at room temperature. 
Worms were assessed every day; the percentage of worms remaining alive in each group 
was calculated. 
 
Efficacy of celecoxib in MRSA-infected C. elegans 
       C. elegans AU37 (sek-1; glp-4) strain glp-4(bn2) was used to test the in vivo 
antimicrobial efficacy of celecoxib as described previously 301. S. aureus strain MRSA 
USA300 was used for infection and the MIC of  control antibiotic (linezolid) and celecoxib 
against MRSA USA300 were 2 and 32 µg/ml. Briefly, L4-stage worms were infected with 
MRSA USA300 for 8 h at room temperature. The worms were washed with M9 buffer, 
and then drugs (celecoxib and linezolid) at indicated concentrations were added to the 96-
well plates containing approximately 20 worms per well. After 24 h, the worms were 
washed four times with PBS and 100 mg of sterile, 1.0-mm silicon carbide particles 
(Biospec Products, Bartlesville, OK) were added to each tube. Worms were disrupted by 
vortexing the tubes at maximum speed for one minute. The final suspension containing 
MRSA was plated onto MSA plates to count the bacteria. The total CFU count in each well 
was divided by the number of worms present in the respective well. The results shown are 
the percent reduction in CFU per worm, compared with an untreated control. 
 
Efficacy of celecoxib in MRSA-infected Mice 
       Eight-week-old female BALB/c mice (Harlan Laboratories, Indianapolis, IN) were 
used in this study. All animal procedures were approved by the Purdue University Animal 
Care and Use Committee (PACUC). The mouse model of MRSA skin infection was 
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performed as described previously 334-336. Briefly, mice were infected intradermally with 
1.65×108 CFU MRSA300. After 48 h of infection, open wounds formed and the mice were 
divided into five groups of 5 mice each. Two groups were treated topically with 20 mg of 
either 1%, or 2% celecoxib in petroleum jelly. One group received the vehicles alone (20 
mg petroleum jelly). Another group was treated topically with 20 mg of 2% fusidic acid in 
petroleum jelly and the last group was treated orally with clindamycin (25 mg/kg). All 
groups were treated twice a day for 5 days. 24 h after the last treatment, the skin area around 
the wound was swabbed with 70% ethanol and the wound (around 1 cm2) was precisely 
excised and homogenized. Bacteria in the homogenate were counted using MSA plates. 
 
Determination of Cytokine levels 
     Skin homogenates obtained from infected mice were centrifuged at 4000 rpm for 10 
min and the supernatants were used for the detection of cytokine levels. Tumor necrosis 
factor-α (TNF-α), interleukin-6 (IL-6), interleukin-1 beta (IL-1β), and monocyte chemo 
attractant protein-1 (MCP-1) ELISA kits (R&D Systems, Inc.) were used to determine the 
levels of these cytokines according to the manufacture’s instruction 281. 
 
Synergy assay 
      Synergy between celecoxib and conventional antimicrobials (gentamicin, clindamycin, 
vancomycin, linezolid, daptomycin, retapamulin, fusidic acid and mupirocin) in the 
treatment of four clinical isolates of S. aureus (MRSA300, NRS107, NRS119 and VRSA5) 
was evaluated using the Bliss Independence Model, as described previously 282. Synergy 
(S) was calculated using the formula: S = (fA0/f00)(f0B/f00)-(fAB/f00). The parameter fAB refers 
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to the optical density of the bacteria grown in the presence of celecoxib and antibiotics; 
parameters fA0 and f0B refer to the bacterial growth rate in the presence of antibiotics alone 
and celecoxib alone, respectively; the parameter f00  refers to the bacterial growth in the 
absence of drugs. Degree of synergy (S) values corresponds to the following cut-offs.: Zero 
indicates  neutral, values above zero (positive value) represents synergism and values 
below zero (negative values) correspond to antagonism. Drug combinations with higher 
positive value represents high degree of synergism. 
 
Statistical analyses 
       Statistical analyses were performed using Graph Pad Prism 6.0 software (Graph Pad 
Software, La Jolla, CA). P values were calculated by using two-tailed unpaired Student t 




      The antibacterial activity of celecoxib was tested using various important multidrug-
resistant strains of Gram-positive (Table 2.9) and Gram-negative (Table 7.2) pathogens. 
Celecoxib showed activity against most of the Gram-positive bacteria tested, including 
methicillin- and vancomycin-resistant S. aureus, Streptococcus pneumonia, Listeria 
monocytogenes, Bacillus anthracis, Bacillus subtilis, and Mycobacterium smegmatis, with 
MICs ranging from 16 to 64 µg/ml (Table 2.9). 
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      In contrast, celecoxib alone did not show antibacterial activity against Gram-negative 
bacteria. However, when the outer membranes of Gram-negative bacteria were 
compromised with a sub-inhibitory concentration of colistin, celecoxib showed 
antimicrobial activity against all Gram-negative pathogens tested, including P. aeruginosa, 
Escherichia coli, K. pneumonia, Salmonella Typhimurium, Acinetobacter baumannii, with 
MICs ranging from 8 to 32 µg/ml (Table 2.10). 
    Next, the activity of celecoxib was investigated in the presence of sub-inhibitory 
concentration of an efflux pump inhibitor reserpine. Celecoxib did not exhibited 
antibacterial activity against all tested strains of Gram-negative bacteria in the presence of 
Bacteria Description Celecoxib 
(µg/ml) 
Methicillin-resistant S. aureus  
ATCC 4330 




aureus  (VRSA10) 
Resistant to ciprofloxacin, clindamycin, 
erythromycin and gentamicin 
32 
Streptococcus pneumoniae   
ATCC 49619 
Isolated from sputum of 75-year-old male, 
Phoenix, AZ, USA 
64 
Bacillus anthracis  Stern vaccine strain 16 
B. anthracis UM23 
Weybridge strain which contains the 
toxigenic pXO1 plasmid and lacks the pXO2 
capsule plasmid 
16 
B. anthracis AMES35 
Isolated from 14-month-old heifer that died in 
Texas in 1981. It is a derivative of B. 
anthracis, strain Ames that was treated with 
novobiocin to cure it of the pXO2 plasmid. 
16 
Bacillus subtilis CU 1065 - 16 
Listeria monocytogenes  F4244 CDC. Clinical isolate from patient 




Reference strain 16 
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reserpine (Table 2.10). However, celecoxib showed activity against E. coli SM1411∆ 
acrAB which is deficient for acrAB efflux pump at a concentration of 64 µg/ml (Table 
2.10). 
Table 2.10 MIC of celecoxib against Gram-negative bacteria 
 
 
The antibacterial activity of celecoxib was also assessed using a series of multidrug-
resistant S. aureus clinical isolates (Table 2.11). The MIC of celecoxib required to inhibit 
90% (MIC90) of the MRSA and vancomycin-intermediate S. aureus (VISA) clinical 
isolates was found to be 32 µg/ml. However, the MIC90 of celecoxib against vancomycin-





MIC of celecoxib (µg/ml) 
(-) (+)colistin  (+)reserpine  
Pseudomonas aeruginosa 
ATCC15442 
Isolated from animal room 
water bottle 
>256 16 >256 
Pseudomonas aeruginosa ATCC 
BAA-1744 
Clinical isolate and VITEK 2 
GN identification card quality 
control organism 
>256 16 >256 
Escherichia coli O157:H7ATCC 
700728 
Nontoxigenic and quality 
control strain 
>256 16 >256 
Acinetobacter baumannii ATCC 
BAA1605 
 
MDR strain isolated from the 







Acinetobacter baumannii ATCC 
BAA747 
Human clinical specimen - ear 
pus 
>256 16 >256 
Salmonella Typhimurium ATCC 
700720 
Wild type strain isolated from 







Klebsiella pneumoniae ATCC 
BAA 2146 
 






Klebsiella pneumoniae ATCC 
BAA 1705 
 
Clinical isolate with 
Carbapenemase (KPC) 




Escherichia coli 1411 Wild type strain >256 ND ND 
Escherichia coli SM1411 ∆ acrAB Mutant for  acrAB efflux 
pump 
64 ND ND 
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Table 2.11  MIC of celecoxib against clinical isolates of Staphylococcus aureus strains 
 




S. USA100 Resistant to ciprofloxacin, clindamycin, 
32 
aureus (MRSA)    erythromycin  
 USA200 Resistant to clindamycin, methicillin 32 
    erythromycin, gentamicin,  
 USA300 Resistant to erythromycin, methicillin, tetracycline 32 
 USA400 Resistant to methicillin, tetracycline 16 
 USA500 Resistant to ciprofloxacin, clindamycin, 32 
    erythromycin, gentamicin,  
    methicillin, tetracycline, trimethoprim  
 USA700 Resistant to erythromycin, methicillin 32 
 USA800 Resistant to methicillin 32 
 USA1000 Resistant to erythromycin, methicillin 32 
 USA1100 Resistant to methicillin 32 
 NRS194 Resistant to methicillin 32 
 NRS108 Resistant to gentamicin 32 
 NRS119 (Linr) Resistant to linezolid 16 
 ATCC 43300 Resistant to methicillin 32 
 ATCC BAA-44 Multidrug-resistant strain 32 
 NRS70 Resistant to erythromycin, clindamycin, spectinomycin 32 
 NRS71 Resistant to tetracycline, methicillin 32 
 NRS100 Resistant to tetracycline, methicillin 32 
 NRS107 Resistant to methicillin, mupirocin 32 
   Vancomycin-        
   intermediate NRS1 Resistant to aminoglycosides and 
32 
S. aureus (VISA)    tetracycline; glycopeptide- intermediate S. aureus  
    
 NRS19 Glycopeptide-intermediate S. aureus 32 
 NRS37 Glycopeptide-intermediate S. aureus 32 
Vancomycin-
resistant S.   VRS1   Resistant to vancomycin 
128 
aureus (VRSA) VRS2 Resistant to vancomycin, erythromycin, spectinomycin 128 
 VRS3a Resistant to vancomycin 32 
 VRS3b Resistant to vancomycin 32 
 VRS4 Resistant to vancomycin, erythromycin, spectinomycin 128 
 VRS5 Resistant to vancomycin 16 
 VRS6 Resistant to vancomycin 16 
 VRS7 Resistant to vancomycin, β-lactams 128 
 VRS8 Resistant to vancomycin 32 
 VRS9 Resistant to vancomycin 64 
 VRS11a Resistant to vancomycin 32 
 VRS11b Resistant to vancomycin 32 
 VRS12 Resistant to vancomycin 32 
 VRS13 Resistant to vancomycin 32 
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Killing kinetics of S. aureus by celecoxib 
Celecoxib with broad-spectrum activity, we determined to investigate the rate of bacterial 
killing. As seen in Figure 2.35, MRSA USA300 treated with 4X and 8X MIC of celecoxib 
exhibits a typical biphasic killing pattern. Treatment with celecoxib consist of an initial 
rapid bactericidal phase (2.49±0.23 log10 and 3.01±0.26 log10 CFU reduction at 4 h with 
4X and 8X MIC) followed by a predominant regrowth. In comparison, vancomycin had a 
bactericidal activity after 24 h, while linezolid treatment results in single log reduction after 





Figure 2.35 Time-kill assay for celecoxib tested against S. aureus. Killing kinetics of 
celecoxib (4X and 8X MIC), vancomycin (4X MIC),  and linezolid (4X MIC),  against 
MRSA USA300 in MHB are shown. The results are presented as means ± SD (n = 3).  Data 





Mechanism of action 
         In view of the results demonstrating broad-spectrum antibacterial activity, we used 
macromolecular synthesis assays in S. aureus ATCC 29213 to investigate the antibacterial 
mode of action of celecoxib. As shown in Figure 2.36, RNA, DNA and protein synthesis 
inhibition were detected at concentrations significantly below the MIC (0.25X).  
 
 
Figure 2.36 Macromolecular synthesis assay in the presence of celecoxib and control 
antibiotics. Incorporation of radiolabeled precursors such as [3H] thymidine, [3H] uridine, 
[3H] leucine, [14C] N-acetylglucosamine and [3H] glycerol for DNA, RNA, protein, cell 
wall and lipid synthesis respectively were quantified in S. aureus ATCC 29213. Based on 
the incorporation of radiolabeled precursors, percent of inhibition by celecoxib at 
concentration dependent manner was examined. Control antibiotics including 
ciprofloxacin (DNA), rifampicin (RNA), linezolid (protein), cerulenin (lipid synthesis) and 
vancomycin (cell wall synthesis) at 8X MIC were used. Triplicate samples were used for 
each group and the statistical analysis was calculated by the two-tailed Student t test.  All 
treatment groups were compared to untreated control group. P value of   (*P ≤ 0.05) is 




However, a secondary effect was also observed at higher concentration, with a clear dose-
dependent disruption of  [3H] glycerol incorporation indicating decreased lipid synthesis. 
Cell wall synthesis inhibition was evident only at a concentration above the MIC (2X).  
 
Toxicity in C. elegans 
       The safety of celecoxib was evaluated in a C. elegans whole-animal model. As shown 
in Figure 2.37, C. elegans treated with 16 or 32 µg/ml of celecoxib for four days did not 
show any significant toxicity. These results are similar to those seen in the linezolid 




Figure 2.37 Evaluation of toxicity in C. elegans model. C. elegans strain glp-4; sek-1 (L4-
stage) were grown for four days in the presence of celecoxib (16 and 32 µg/ml) and 
linezolid (16µg/ml). Worms were monitored daily and the live worms were counted. 
Results were expressed as percent live worms in relative to the untreated control groups. 




Efficacy in animal models 
        Having demonstrated a comfortable safety profile, the antibacterial efficacy of 
celecoxib was tested in a C. elegans, whole-animal MRSA infection model. As seen in 
Figure 2.38A, celecoxib treatment significantly reduced the mean bacterial count, 
compared with the untreated control. Treatment with celecoxib at 16 and 32 µg/ml 
significantly decreased the bacterial CFU of  0.56±0.33 log10 and 0.94±0.43 log10 
respectively. For comparison, linezolid at 16 µg/ml also had significant reduction in 




Figure 2.38  Efficacy of celecoxib in MRSA-infected animal models (a) L4-stage worms 
infected with MRSA USA300 were treated with celecoxib (16 and 32 µg/ml) and linezolid 
(16µg/ml) for 24 h. At this point, the worms were disrupted and the amount of MRSA in 
the lysate (CFU) was determined. CFU per worm in treated groups relative to the untreated 
control groups were shown. Triplicate wells were used for each group and the results were 
means ± SD (n = 3). (b) Efficacy of treatment of MRSA-infected mouse skin lesions with 
celecoxib 1 and 2%, clindamycin (25 mg/kg), fusidic acid 2% and petroleum jelly (negative 
control) twice daily for five days were evaluated. Five mice per group was used and the 
results were means ± SD of five mice. CFU per wound was calculated and presented. . *P 
≤ 0.05 and *P ≤ 0.01 were considered as significant.  
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Figure 2.39  Effect of celecoxib on IL-6, TNF-α, IL-1β and MCP-1 production in MRSA 
infected skin lesions. Supernatants from skin homogenates were used for cytokine 
detection by ELISA. Each point represents single mice and each group has five mice. 
Statistical analysis was calculated by the two-tailed Student t test.  P values of   (*P ≤ 0.05) 






Next we tested the in vivo antibacterial efficacy of celecoxib in a mouse model of 
MRSA skin infection. As shown in Figure 2.38B, all treatment groups (1 or 2% celecoxib, 
2% fusidic acid, or clindamycin oral treatment) significantly reduced the mean bacterial 
counts, compared with the control group (P ≤ 0.05). Groups treated topically with 1% and 
2% celecoxib had a reduction in MRSA CFU of 0.66±0.19 log10and 1.02±0.27 log10  
respectively. Topical treatment with 2% fusidic acid and oral clindamycin (25 mg/kg) 
treatment reduced the bacterial load of 2.90±0.23 log10 and 2.40±0.32 log10  CFU 
respectively. 
 
Effect of celecoxib on inflammatory cytokine levels induced by MRSA skin infection 
       We investigated the immune-modulatory activity of celecoxib in MRSA skin infection 
by measuring the levels of the inflammatory cytokines IL-6, TNF-α, IL-1β and MCP-1 
using ELISA. As shown in Figure 2.39, treatment with 2% celecoxib significantly reduced 
the levels of all tested inflammatory cytokines, compared with an untreated control. 
Treatment with 1% celecoxib significantly reduced the levels of IL-6 and IL-1β. 
Clindamycin treatment also reduced levels of TNF-α and IL-1β. 
 
Synergism with topical and systemic antimicrobials 
The antimicrobial activities of combinations of celecoxib with topical and systemic 
antimicrobials were investigated in vitro, using the Bliss independence model, with clinical 
isolates of multidrug-resistant S. aureus. Celecoxib acted synergistically with all tested 
antimicrobials (with the exception of linezolid) against all strains of multi-drug resistant S. 
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aureus tested, including MRSA300, VRSA5, linezolid-resistant S. aureus (NRS119) and 
mupirocin-resistant S. aureus (NRS107). However, celecoxib showed slight antagonism 
when combined with linezolid against VRSA5 (Figure 2.40).  
 
2.6.4 Discussion 
        The emergence of bacterial resistance is not a new phenomenon. However, because 
only a few antibiotics have been developed over the past few decades, the continuous 
evolution and spread of multidrug-resistant bacterial strains is a serious threat to the public 
health 1.  The pharmaceutical companies’ lack of interest in antimicrobial research and 
development has also become a major concern 276. The World Health Organization has 
already warned that we are heading toward a “post-antibiotic era” and suggested that urgent 
measures need to be taken 337. Therefore, recent research had been directed toward finding 
new antimicrobials and novel strategies to combat multidrug-resistant bacterial pathogens. 
One promising approach gaining increased attention is the repurposing of existing 
approved drugs as antimicrobials.   
          In an attempt to repurpose approved drugs, we and others 80,330,331 have found that 
celecoxib exhibits broad-spectrum antimicrobial activity against Gram-positive and Gram-
negative bacterial pathogens. Celecoxib, a classical NSAID drug and inhibitor of the 
enzyme cyclooxygenase-2 (COX2), has been widely used as an anti-inflammatory drug for 






Figure 2.40 Synergistic activity of celecoxib with topical and systemic antimicrobials. 
The Bliss Independence Model confirms a synergistic effect between celecoxib and 
conventional antimicrobials against various drug-resistant strains of S. aureus (MRSA300, 
NRS119, NRS107 and VRSA5). The degree of synergy was quantified after 12 h of 
treatment with celecoxib (8µg/ml) in combination with sub-inhibitory concentrations of 
topical (mupirocin, fusidic acid, daptomycin and retapamulin) and systemic antimicrobials 




 Celecoxib also reduces H. capsulatum burden by enhancing phagocytosis of alveolar 
macrophages and decreasing levels of inflammatory cells and cytokines, thereby exhibiting 
a protective role in pathogenesis of H. capsulatum 330. Our study demonstrated that 
celecoxib possesses activity against various multidrug-resistant Gram-positive pathogens, 
including S. aureus, S. pneumonia, L. monocytogenes, B. anthracis, B. subtilis, and M. 
smegmatis. However, we noticed that Gram-negative pathogens are not susceptible to 
celecoxib, and the lack of activity was found to be due to the permeability barrier conferred 
by the outer membrane. This was further confirmed by the fact that the antimicrobial 
activity of celecoxib against Gram-negative bacteria was restored when the integrity of the 
outer membrane was compromised using a sub-inhibitory concentration of colistin 338-340.  
In addition, celecoxib also showed activity when an efflux pump such as acrAB was deleted 
in E. coli. AcrAB has been known to contribute for resistant phenotype for various 
antibiotics including ampicillin, chloramphenicol and rifampicin 228.. However, celecoxib 
did not restore its activity in the presence of efflux pump inhibitor reserpine in any of the 
Gram-negative bacteria tested in this study. This might be due to the variation in the efflux 
systems in different bacterial strains. Taken together, in addition to the intrinsic physical 
barrier outer membrane, celecoxib entry into Gram-negative bacteria is also influenced by 
efflux pumps such as AcrAB. Our results indicate that the target of celecoxib is present in 
both Gram-positive and Gram-negative bacteria and that celecoxib can be combined with 
other approved drugs that cause leakage in the outer membrane, such as colistin, to 
sensitize Gram-negative pathogens. Next, we investigated the activity of celecoxib against 
clinical isolates of multidrug-resistant S. aureus. Celecoxib inhibited the growth of all 
tested clinical isolates of MRSA, VISA, VRSA, linezolid-resistant S. aureus (NRS119) 
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and mupirocin-resistant S. aureus (NRS107). MIC values determined in our study for 
celecoxib against MRSA correlates with MIC values reported for celecoxib against F. 
tularensis and S. aureus in previous published studies  80,331.  
 
       Time kill kinetics of celecoxib against S. aureus revealed a unique biphasic killing 
pattern. The bactericidal effect of celecoxib lasted for only a short time, after which gradual 
regrowth of bacteria was noticed. This pattern was reported for azlocillin and tobramycin  
against Pseudomonas aeruginosa 341,342. The bactericidal activity and the extent of 
regrowth in P. aeruginosa after incubation with azlocillin and tobramycin  was 
concentration dependent manner 341,342. However, the bactericidal activity (at 4 h) of 
celecoxib at 8X MIC was found to be slightly higher than 4X MIC but the regrowth was 
found to be similar at both the concentration after 24 h of incubation.  
 
        The mechanism of celecoxib’s broad-spectrum antibacterial activity remains 
unidentified. In our study, we found that celecoxib inhibited the synthesis of DNA, RNA, 
and protein at concentrations significantly below the MIC . Additionally, the disruption of 
lipid synthesis was evident at higher MIC concentration, whereas no significant effect was 
observed on the cell wall synthesis.  These results indicate that perturbation of the lipid 
synthesis by celecoxib might be a secondary effect due to RNA and protein synthesis 
inhibition. The effect of celecoxib on multiple macromolecular synthesis pathways might 
likely due to the disruption in general cellular energy metabolism or membrane 
perturbation. Antimicrobial peptides such as pleurocidin-derived peptides at sub-lethal 
concentration cause cell membrane damage leading to the inhibition of multiple 
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macromolecular synthesis pathways 343. Lactoferricin B, a cationic peptide which also 
cause membrane permeabilization is believed to have effect on general energy metabolism  
which results in inhibition of multiple pathways 344,345. Celecoxib with initial rapid 
bactericidal property (biphasic killing pattern) might possibly also lead to the disruption of 
various macromolecular pathways. However, the cause for inhibition on multiple pathways 
is not yet clear. Further, we also attempted to generate a S. aureus that is resistant to 
celecoxib. No colonies resistant to celecoxib at three-, five-, or tenfold the MIC were 
detected. In addition, serial passage of S. aureus with sub-inhibitory concentration of 
celecoxib for twelve days did not resulted in colonies that were resistant to celecoxib. 
Therefore, future studies are warranted to identify the precise molecular target of celecoxib. 
 
        In view of the broad spectrum antibacterial activity exhibited by celecoxib in vitro, 
we decided to investigate the in vivo antibacterial activity of celecoxib in animal models of 
MRSA infection. First we tested the efficacy in MRSA infected C. elegans. Whole animal 
model including C. elegans, provides a great platform for validating the in vivo efficacy of 
novel compounds 301,320. Our results indicates that celecoxib at 16 and 32 µg/ml, which are 
concentrations without considerable toxicity to the host, significantly reduced the mean 
bacterial load (by 71% and 85% respectively) when compared with a control group (P ≤ 
0.05). Celecoxib at 32 µg/ml had an effect on the mean bacterial count that was comparable 
to that of linezolid (16 µg/ml). Next, we moved forward to validate celecoxib’s efficacy in 
a mouse model of MRSA infection. However, a high MIC that cannot be achieved 
systemically is a major impediment to the potential use of celecoxib as an antimicrobial 
agent. While the use of celecoxib to treat systemic bacterial infections is not currently 
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possible, local application of celecoxib for treating/preventing bacterial infections in 
wounds is a novel application for this drug that holds considerable promise. Therefore we 
decided to test the activity of celecoxib in a topical MRSA skin infection model. Celecoxib 
1% and 2% significantly reduced the bacterial load in the wounds (by 72% and 87%, 
respectively) when compared with a control group (P ≤ 0.05).  
 
        However, staphylococcal skin infections often induce excess host inflammatory 
cytokines, which in turn aggravate the pathogenesis 256,293Drugs with anti-inflammatory 
properties, especially those that inhibit pro-inflammatory cytokines such as IL-6 and TNF-
α, would accelerate the healing of chronic wounds. 107,293,328,346,347. Celecoxib, which is 
known to have anti-inflammatory activity, would potentially be able to limit the 
inflammatory process induced by MRSA infection. Therefore, we measured the 
inflammatory cytokines in MRSA lesions treated with celecoxib. Topical treatment with 
celecoxib 1% significantly (P ≤ 0.05) reduced levels of TNF-α and IL-1β, while celecoxib 
2% significantly (P ≤ 0.05) reduced the levels of all the inflammatory cytokines measured 
(IL-6, TNF-α, IL-1β and MCP-1). This ability of celecoxib to dampen the inflammatory 
response might aid the healing of chronic wounds 102-107. Celecoxib’s recognized beneficial 
role in the wound healing process, reducing scar formation without disrupting 
reepithelization, is an added advantage for the treatment of bacterial skin infections 348. 
 
         With increased emergence of resistant strains of S. aureus to topical drugs of choice, 
such as mupirocin and fusidic acid, combination therapies have recently been gaining 
attention 204,259,260,268,269,349. We, therefore, investigated whether celecoxib has potential to 
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be combined with antibiotics against multidrug-resistant S. aureus strains by using the Bliss 
independence model 282. Celecoxib was found to exhibit a synergistic relationship with 
topical (mupirocin, fusidic acid, daptomycin and retapamulin) and systemic antimicrobials 
(gentamicin, clindamycin, vancomycin and linezolid), against most of the tested multidrug-
resistant staphylococcal strains, including MRSA300, NRS119, NRS107 and VRSA5. This 
finding provides a potential basis for the combination of celecoxib with conventional 
antimicrobial drugs for the treatment staphylococcal skin infections and reducing the 
likelihood of strains developing resistance to monotherapy.  
 
Taken together, our results show that celecoxib exhibits several beneficial properties, 
including broad spectrum antimicrobial activity against various multidrug resistant Gram-
positive and Gram-negative pathogens, synergistic action with conventional 
antimicrobials, and anti-inflammatory activity that reduces excess host inflammation 
during infection. Celecoxib may, therefore, be a good candidate for repurposing for the 
treatment of topical bacterial infections. This emerging approach might form a novel 
alternative strategy in search of new antimicrobials.
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CHAPTER 3. DRUG REPURPOSING FOR FUNGAL INFECTIONS 
3.1 Repurposing approach identifies auranofin with broad spectrum antifungal 
activity that targets Mia40-Erv1 pathway 
 
(S. Thangamani, M. Maland, H. Mohammad, P. Pascuzzi, L. Avramova, C. Koehler, T. R. 
Hazbun and M. N. Seleem. Repurposing approach identifies auranofin with broad spectrum 




Invasive fungal infections, particularly those caused by Candida and Cryptococcus, afflict 
millions of patients annually resulting in more than 1,350,000 deaths despite the 
introduction of new antifungal agent 350-354. Unfortunately, current antifungal therapies 
have limited effectiveness in treating invasive fungal infections and suffer from restrictions 
in route of administration, spectrum of activity, and bioavailability in target tissues such as 
the brain 354,355. Further compounding this problem, the development of new antifungal is 
currently unable to keep pace with the urgent demand for safe and effective new drugs. 
Hence, there is a pressing and urgent need for novel, inexpensive, and safe antifungal drugs 
to combat these dangerous pathogens.
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The concept of drug repositioning has recently gained momentum and emerged as a viable 
approach to expedite anti-infective drug development 210,356. For example, several reports 
have demonstrated that auranofin, an orally bioavailable FDA-approved drug for treatment 
of rheumatoid arthritis, exhibits potent antibacterial and antiparasitic activities 
58,212,215,249,263,357,358. This discovery led to the FDA granting auranofin Orphan Drug status 
for treatment of amebiasis. Recent studies by Fuchs et al.359 and Stylianou et al.360 reported 
that auranofin also possesses antifungal activity. However, the antifungal mechanism of 
action and in vivo antifungal efficacy of auranofin remain unclear with several possible 
targets reported. Thus, the objectives of our study were to determine the antifungal activity 
of auranofin against clinical isolates of different fungal pathogens, to investigate the drug’s 
antibiofilm activity, to deduce auranofin’s antifungal mechanism of action using an 
unbiased chemogenomic approach, and to validate the drug’s in vivo antifungal efficacy in 
a C. neoformans-infected Caenorhabditis elegans whole animal model.  
 
3.1.2 Materials and Methods 
Fungal strains and reagents 
Fungal strains used in this study are presented in Table 1. Yeast peptone dextrose agar 
(YPD) was purchased from BD Biosciences (San Jose, CA). Auranofin (Enzo Life 
Sciences, Farmingdale, NY), fluconazole (Acros Organics, New Jersey), and flucytosine 
(TCI chemicals, Tokyo, Japan) were purchased from commercial vendors. XTT-sodium 
salt, menadione, RPMI powder, and MOPS were purchased from Sigma-Aldrich (St. Louis, 
178 
 
MO). Concanavalin A–conjugated with FITC 488 dye was acquired from Thermo Fisher 
Scientific Inc. (Waltham, MA). 
 
Antifungal susceptibility testing 
 Antifungal susceptibility testing was carried out as per the National Committee for Clinical 
Laboratory Standards M-27A3 (NCCLS) guidelines 361. Briefly, the inocula were prepared 
from 24 h old cultures of Candida spp. or 48 h old cultures of Cryptococcus spp. in YPD 
plates. Five colonies were then transferred to 5 mL of sterile 0.9% saline (PBS). The 
suspensions were adjusted to McFarland standard 0.5 and then diluted  1:2000 in RPMI 
1640 buffered to pH 7.0 with 0.165 M MOPS (RPMI-MOPS) to yield an inoculum of 5.0 
× 102 to 2.5 × 103 CFU/mL. An aliquot (100 µL) of the resulting suspension was incubated 
with serially diluted fluconazole, flucytosine, and auranofin for 24 h for Candida spp and 
72 h for Cryptococcus spp. The minimum inhibitory concentration (MIC) of fluconazole 
and flucytosine were determined as the prominent decrease (approximately 50%) in visible 
growth compared to untreated controls, as per NCCLS guidelines. Similarly the MIC of 
auranofin was determined as the lowest concentration resulting in 50% reduction in visible 
growth. All experiments were carried out in triplicate wells. 
 
Time kill assay 
Fungal cultures of Candida albicans and Cryptococcus neoformans were diluted 
approximately to 5 × 105 CFU/mL and treated with 5 × and 10 × MICs of auranofin and 
fluconazole (in triplicate) in RPMI-MOPS, at 35°C. Samples were collected at indicated 
time points and serially diluted in PBS and plated onto YPD plates. Plates were incubated 
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C. albicans ATCC 10231 was grown in YPD broth at 35°C for 24 h. Cells were washed 
with PBS and resuspended in RPMI-MOPS at 106 cells/mL 363,364. An aliquot (100 µL) of 
cell suspension was transferred to wells in a 96-well tissue culture plate. After 48 h 
incubation (at 37C), wells were washed with PBS and drugs (auranofin, fluconazole, and 
flucytosine) were added at indicated concentrations. After 24 h of incubation, the 
supernatant was removed and 100 µL of XTT/menadione solution was added to each well. 
The plates were covered with aluminum foil and incubated at 37°C for 1 hour. Aliquots 
(75 µL) were taken from each well and the absorbance (OD495) was measured using a 
spectrophotometer. The antifungal activity of each drug was expressed as a percentage of 
metabolic activity of treatment groups relative to the DMSO-treated control groups. The 
experiment was performed using triplicate samples for each treatment regimen. 
 
Confocal imaging of fungal biofilms 
 C. albicans ATCC 10231 was seeded on FBS-coated glass cover slips in 6-well tissue-
culture plates and grown in RPMI-MOPS medium with 0.2% glucose at 37°C 365. After 48 
h, wells were washed with PBS and drugs (auranofin, fluconazole, and flucytosine) were 
added at indicated concentrations. After 24 h of treatment, wells were washed with PBS 
and stained with concanavalin A– conjugated with FITC 488 dye (25 µg/mL in PBS) for 
45 minutes at 37°C. After incubation, the coverslips were washed three times with PBS 
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and mounted on glass slides. Stained biofilms were observed using Leica confocal laser 
scanning microscopy. Images were reconstructed using IMARIS software. 
 
Chemogenomics profiling of Saccharomyces cerevisiae 
 Initial testing of Saccharomyces cerevisiae sensitivity to auranofin was performed with 
the wild-type BY4743 diploid strain, the isogenic parent to the heterozygous diploid 
deletion collection. BY4743 was grown in YPD in 96-well plates with 1% DMSO or 
auranofin in concentrations ranging from 10 to 200 M to determine a suitable level of 
growth inhibition.  Auranofin (75 µM) was used for haploinsufficiency profiling because 
it delayed growth by 30% compared to the no drug control half-maximal optical density 
(OD).  All experiments were performed at 30°C and cultures were shaken at 300 rpm. The 
heterozygous deletion set was purchased in a pooled format (Thermo Fisher Scientific, 
Waltham, MA). A frozen aliquot (200 µL) was thawed and used to inoculate 2 mL of YPD 
and grown for 9 h to reach an OD600 of 4.0.  The culture was diluted to an OD600 of 0.13 
and either 1% DMSO or 75 µM auranofin was added (three replicates each, 1 mL) and 
grown for 7 h.  The cultures were grown again by diluting to an OD of 0.13 in 1 mL YPD 
with DMSO or 60 µM auranofin and grown for 8 h.  Cultures were harvested and genomic 
DNA extracted using the YeaStar Genomic DNA kit (Zymo Research, Irvine, CA). The 
UPTAGs were amplified by PCR with Phusion Hot Start II High-Fidelity DNA polymerase 
at 0.02 U/µL (Thermo Fisher Scientific, Waltham, MA) using 0.5 ng/µL genomic DNA. 
Primers are listed (Table S1). The PCR reactions were electrophoresed on an agarose gel 
and the 267 bp product extracted using a QIAquick Gel Extraction Kit (Qiagen, Valencia, 
CA).  Purified DNA was measured using a Qubit instrument and samples were normalized 
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and mixed together to a final concentration of 10 nM. Strains were grown and maintained 
on media according to standard practices 366.  
 
The pooled PCR products were sequenced using standard Illumina sequencing in a HiSeq 
2500 instrument. The reads were separated based on a 5 base multiplex tag unique for each 
experiment and an average of 5 million reads per replicate was obtained. The UPTAG 
barcodes in each experimental sample were separated based on a reference database of 
recharacterized barcode sequences 367. 
The resulting strain counts were imported into R and analyzed with edgeR 368. Sequencing 
library sizes were normalized using the default parameters. Only strains with one or more 
counts in three or more samples were analyzed further. Differential representation of strains 
was determined using the quantile-adjusted conditional maximum likelihood (qCML) 
method. False discovery rates were determined to control for multiple testing. 
 
Saccharomyces deletion strain haploinsufficiency validation 
Overnight grown yeast cells were diluted (O.D600 ~ 0.03) and grown in the presence and 
absence of auranofin, at indicated concentrations. Growth was monitored using a 
spectrophotometer (OD600) at indicated time points and the results were expressed as 
percent growth rate for each strain compared to the untreated control group. To assess 
growth on solid medium, 5 µL of ten-fold diluted yeast cells were spotted onto YPD agar 
containing DMSO or auranofin (6.25 µg/mL). Growth of yeast strains was monitored after 




Oxygen consumption and membrane potential measurements 
Mitochondria were purified from yeast cells grown on YPEG as described previously 370.  
Oxygen consumption measurements with isolated mitochondria were performed using an 
oxygen electrode (Hansatec) as described previously 371. Membrane potential 
measurements of purified mitochondria were performed with fluorescent 3, 3’-
dipropylthiadicarbocyanine iodide dye [DiSC3(5)]. 1% DMSO, carbonyl cyanide m-
chlorophenyl hydrazone (CCCP), MB-6, or MB-7 was added to mitochondria in import 
buffer (0.6 M sorbitol, 2 mM KH2PO4, 60 mM KCl, 50 mM HEPES-KOH, 5 mM MgCl2, 
2.5 mM EDTA,5 mM L-methionine, pH 7.1) for 10 min. Subsequently 0.2 μM DiSC3(5) 
in import buffer was added, incubated for 5 min, and fluorescence was measured at 
excitation and emission length of 620 nm and 670 nm, respectively.  
 
Purification of mitochondria 
Mitochondria were purified from wild-type yeast or yeast overexpressing Erv1 with a 
hexahistidine tag ([a2up] Erv1) grown in YPEG as described previously 372,373. Yeast 
cultures were kept at 25°C with vigorous shaking during growth. Mitochondria 
concentration was measured by BCA assay and stored at 25 mg/mL at -80°C. Mitochondria 
with increased levels of Erv1 were purified from a strain in which Erv1 was overexpressed 
from a 2-micron plasmid (Dabir et al., 2007).  
 
Import of radiolabeled proteins into yeast mitochondria 
Prior to import into purified mitochondria, [35S]-methionine and cysteine labeled proteins 
were generated with TNT Quick Coupled Transcription/Translation kits (Promega) and 
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plasmids carrying the genes of interest. Transcription of genes was driven by either a T7 
or SP6 promoter. Import reactions were conducted as previously described 370,371. After 
frozen mitochondria aliquots were thawed and added to the import buffer at a final 
concentration of 100 µg/mL, 1% DMSO or the small molecule was added as indicated. A 
final concentration of 1% DMSO was used in all experiments. Following incubation at 
25°C for 15 min, import reactions were initiated by the addition of 5-10 µl of translation 
mix. Aliquots were removed at intervals during the reaction time course and import was 
terminated with addition either of cold buffer or 25 µg/mL trypsin, or the combination. If 
trypsin was added to digest non-imported precursor protein, soybean trypsin inhibitor was 
subsequently added in excess after 15 min incubation on ice. After a final recovery of by 
centrifugation (12,000 x g, 6 min), mitochondria were disrupted in Laemmli sample buffer. 
Samples from import reaction time points were resolved by SDS-PAGE and visualized by 
autoradiography. For experiments to investigate the Cmc1-Mia40 intermediate, 
nonreducing conditions were used.  The import reactions were stopped in the presence of 
20 mM iodoacetamide and mitochondria disrupted in Laemmli sample buffer lacking β-
mercaptoethanol.  The imported products were separated by nonreducing SDS-PAGE. 
 
Caenorhabditis elegans (C. elegans) infection study 
L4-stage worms of C. elegans AU37 (sek-1; glp-4) strain (glp-4(bn2) were used to examine 
the antifungal efficacy of auranofin as described elsewhere 226,374. Briefly, L4-stage worms 
were infected with Cryptococcus neoformans NR-41292 for two hours at room temperature. 
After infection, worms were washed with M9 buffer and treated either with DMSO or drugs 
(auranofin, fluconazole, and flucytosine), at a concentration of 8 μg/mL. After 24 h, worms 
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were washed with PBS and disrupted using silicon carbide particles 226. The final 
suspensions were plated onto YPD agar plates containing ampicillin (100 μg/mL), 
streptomycin (100 μg/mL) and kanamycin (45 μg/mL) to determine the colony forming 




Statistical analyses were done using GraphPad Prism 6.0 (GraphPad Software, La Jolla, 
CA). P values were calculated via the Student t test and P values of ≤ 0.05 were deemed 
significant. 
 
3.1.3 Results and Discussion 
Antifungal activity and killing kinetics of auranofin 
Auranofin has a well-established pharmacological and toxicological profile that has 
permitted it to be used for the treatment of rheumatoid arthritis for more than 30 years 47,48. 
Independent of its antirheumatic effect, several studies have reported the anti-infective 
properties of this drug against important parasitic and bacterial pathogens including 
Schistosoma mansoni, Trypanosoma brucei, Plasmodium falciparum, Entamoeba 
histolytica, Staphylococcus aureus and Streptococcus pneumoniae 58,212,215,249,263,357,358.  In 
this study, the antifungal activity of auranofin was tested against various clinical isolates 
of Candida and Cryptococcus. Auranofin retains efficacy against clinically relevant drug-
resistant fungal strains including fluconazole-resistant C. albicans, C. glabrata, C. 
tropicalis and C. parapsilosis with the minimum inhibitory concentration (MIC) ranging  
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C. albicans NR 
29434 
Bloodstream isolate from a person with a bloodstream 
infection collected in Winnipeg, Manitoba, Canada, in 
2000 
8 4 0.125 
C. albicans 
ATCC 10231 
Isolated from a man with bronchomycosis 2 2 0.25 
C. albicans NR 
29449 
Is a vaginal isolate from a person with vaginitis 
collected in Ann Arbor, Michigan, USA, between 
1990 and 1992 
8 2 4 
C. albicans NR 
29435 
Is a bloodstream isolate from a person with a 
bloodstream infection collected in Iowa City, Iowa, 
USA, in 2000. 
1 4 0.0625 
C. albicans NR 
29448 
Is an isolate from a person with a bloodstream 
infection, collected in Arizona, USA. 
4 >64 0.0625 
C. albicans NR 
29437 
Is a bloodstream isolate from a person with a 
bloodstream infection collected in Brussels, Belgium 
in 2000 
4 2 0.0625 
C. albicans NR 
29446 
Is a bloodstream isolate from a person with a 
bloodstream infection collected in Utah, USA. 
16 >64 0.25 
C. albicans NR 
29453 
Is an oral isolate from an HIV+ person collected in 
Pretoria, South Africa 
8 2 0.0625 
C. albicans NR 
29438 
Is a bloodstream isolate from a person with a 
bloodstream infection, collected in Tel-Hashomer, 
Israel, in 2000. 
16 2 0.0625 
C. albicans 
ATCC 26790  
Pulmonary candidiasis 8 2 0.0625 
C. albicans 
ATCC 24433 
Nail infection 8 4 1 
C. albicans 
ATCC 14053 
Human blood, Bethesda, MD 8 4 0.125 
C. albicans 
ATCC 90028 
Blood, Iowa 16 4 1 
C. albicans NR 
29366 
Human isolate collected in China 16 >64 0.0625 
C. albicans NR 
29367 




- 8 4 0.0625 
C. glabrata 
ATCC 66032 
- 8 2 0.0625 
C. tropicalis 
ATCC 13803 
- 16 2 0.125 
C. tropicalis 
ATCC 1369 
- 4 1 0.25 
C. parapsilosis 
ATCC 22019 




from 1 to 16 µg/mL (Table 3.1). Auranofin also displayed potent activity against both C. 
neoformans and Cryptococcus gattii inhibiting growth of these fungal species at 
concentrations ranging from 0.5 to 8 µg/mL (Table 3.1).  
 
A time-kill assay was employed to investigate the killing kinetics of auranofin against both 
C. albicans and C. neoformans. Similar to fluconazole, auranofin (at 5 × MIC) exhibited 
Table 3.1 continued 
C.  neoformans 
NR-41291  
Obtained from human cerebrospinal fluid in China in 
July 2011. 
4 1 0.5 
C.  neoformans 
NR-41292  
Obtained from human cerebrospinal fluid in China in 
February 2012. 
0.5 1 0.5 
C.  neoformans 
NR-41296  
Obtained from human cerebrospinal fluid in China in 
February 2012. 
1 2 0.5 
C.  neoformans 
NR-41295  
Obtained from human cerebrospinal fluid in China in 
February 2012. 
4 2 0.5 
C.  neoformans 
NR-41294  
Obtained from human cerebrospinal fluid in China in 
June 2011. 
0.5 4 2 
C.  neoformans 
NR-41297 
Obtained from human cerebrospinal fluid in China in 
February 2012. 
1 8 4 
C.  neoformans 
NR-41298 
Obtained from human cerebrospinal fluid in China in 
February 2012. 
1 4 2 
C.  neoformans 
NR-41299 
Obtained from human cerebrospinal fluid in China in 
August 2009. 
4 4 2 
C.  neoformans 
NR-41291 
Obtained from human cerebrospinal fluid in China in 
July 2011. 




Isolated from a goat in Aruba prior to the outbreak in 
Vancouver, British Columbia, Canada. 
0.5 2 2 
Cryptococcus 
gattii - R265  
Isolated from a human on Vancouver Island, Canada 
during the outbreak that began in the late 1990's 
1 1 1 
Cryptococcus 
gattii - Alg40  
Progeny of a genotypic cross between C. gattii strains 
R265 and CBS1930. 
0.5 2 0.5 
Cryptococcus 
gattii - Alg75 
Progeny of a genotypic cross between C. gattii strains 
R265 and Alg40. 
8 8 8 
Cryptococcus 
gattii - Alg81 
Progeny of a genotypic cross between C. gattii strains 
R265 and Alg75. 
4 8 4 
Cryptococcus 
gattii - Alg99 
Progeny of a genotypic cross between C. gattii strains 
R265 and Alg81. 
4 8 4 
Cryptococcus 
gattii - Alg114 
Progeny of a genotypic cross between C. gattii strains 
R265 and Alg99. 
8 8 4 
Cryptococcus 
gattii - Alg115 
Progeny of a genotypic cross between C. gattii strains 
R265 and Alg114. 
8 8 4 
Cryptococcus 
gattii - Alg127 
Progeny of a genotypic cross between C. gattii strains 
R265 and Alg115. 
4 4 4 
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fungistatic activity against C. albicans and C. neoformans (Figure 3.1). However, at 10 × 
MIC, auranofin (unlike fluconazole) completely kills C. neoformans after 48 h of 
incubation (Figure 3.1). 
 
Figure 3.1Killing kinetics of auranofin. An overnight culture of C. albicans ATCC 10231 
and C.  neoformans NR-41291 were treated with 5 × and 10 × MIC of auranofin and 
fluconazole (in triplicate) in RPMI-MOPS and incubated at 35°C. Samples were collected 
at indicated time points and plated onto YPD plates. Plates were incubated for 24-48 h 
prior to counting the colony forming units (CFU). 
 
Antibiofilm activity of auranofin 
In addition to planktonic growth, fungi especially, Candida spp., are known to form 
biofilms that are recalcitrant to treatment with antifungal agents. Fungal cells encased 
within the biofilm are resistant to most clinically used antifungals, including azole drugs, 





Figure 3.2 Effect of auranofin on Candida biofilms. (A) C. albicans ATCC 10231 biofilm 
was treated with indicated concentrations of auranofin, fluconazole, and flucytosine for 24 
h. The percent metabolic activity of fungal cells in biofilms, after treatment, was 
determined using the XTT reduction assay. Results are presented as means ± SD (n = 3).  
Statistical analysis was calculated using the two-tailed Student’s t test.   P values of (** P 
≤ 0.01) are considered as significant. Auranofin was compared both to controls and 
antifungal drugs (**). (B) C. albicans ATCC 10231 biofilm was formed on FBS-coated 
glass cover slips and treated with indicated drugs for 24 h and stained with concanavalin 
A– conjugated with FITC dye and imaged by Leica confocal laser scanning microscopy. 
 
Therefore, the antibiofilm activity of auranofin, against C. albicans, was evaluated using 
the XTT reduction assay in order to measure the metabolic activity of fungal cells post-
treatment. The metabolic activity of C. albicans was reduced by more than 70% with the 
treatment of auranofin (Figure 3.2A). Fluconazole and flucytosine, were ineffective (less 
than 10% reduction observed) at reducing the metabolic activity of C. albicans biofilm, 
even at a concertation equivalent to 32 × MIC (Figure 3.2A). 
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The effect of auranofin on reducing fungal biofilm density was further evaluated using 
confocal microscopy. Fungal cells stained with ConA-conjugated with FITC revealed that 
auranofin (8 × MIC) eradicates a considerable portion of Candida cells in comparison to 
the control group (Figure 3.2B). However, treatment with fluconazole and flucytosine, 
even at 32 × MIC, appear similar to control group (Figure 2B). These findings illustrate 
that auranofin is a potential candidate for use in treatment of biofilm-related fungal 
infections. 
 
Chemogenomic profiling identifies Mia40 as a potential target of auranofin 
After verifying auranofin’s antifungal activity, we proceeded to investigate the antifungal 
mechanism of auranofin. Chemogenomic profiling was employed given it is a highly-
specific technique to investigate the target of unknown compounds 378-380. This technique 
uses drug-induced haploinsufficiency, where it causes a strain-specific fitness defect after 
treatment with compounds, and thereby aids in identifying the drug target 378-383. 
Haploinsufficiency profiling (HIP) allows for the simultaneous assessment of the 
sensitivity of the pooled genome-wide set of heterozygous deletion strains because each 
strain is uniquely identified with a synthetic DNA barcode. The method is an unbiased 
approach to survey the genome-wide strain set in order to identify the strains with the most 
sensitivity to auranofin. We first identified the concentration that reduced wild-type growth 
by 30% and used 75 M to profile the pooled heterozygous strains in biological samples.  
PCR was used to amplify the unique UPTAG DNA barcodes located at the gene deletion 
site and we tracked the barcode abundance with Illumina sequencing. The resulting counts 
were normalized and visualized using EdgeR (Figure 3.3A).  We identified 85 
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heterozygous deletion strains that were under-represented based on an FDR less than 0.1 
when comparing auranofin treatment to DMSO. These 85 strains were analyzed to identify 
associated gene ontology cellular component annotations and found to be enriched in 
several categories including the mitochondrial intermembrane space and chromatin 
components. Five heterozygous deletion strains within these categories (mia40, acn9, 
coa4, rad18 and nsi1) were selected to validate sensitivity to auranofin using a variety 
of growth assays (Figure 3.3A). 
 
Growth of these five heterozygous deletion strains and the wild-type (BY4743) strain were 
monitored in the presence of different concentrations of auranofin (6.25, 12.5 and 25 
µg/mL) in a liquid growth assay. The result indicated that only three heterozygous deletion 
strains (mia40, acn9, and coa4) exhibited drug-induced haploinsufficiency under these 
conditions. The growth of these deletion strains was suppressed, even in the presence of 
low concentrations of auranofin (6.25 µg/mL) (Figure 3B). However, auranofin does not 
induce haploinsufficiency in the other two deletion strains (rad18 and nsi1) as growth 
of these strains, in the presence of auranofin, mimics the pattern observed with the wild-
type strain (Figure 3.3B). These two deletion strains were not affected possibly because of 






Figure 3.3 Auranofin targets mitochondrial protein(s). (A) Chemogenomic profiling of S. 
cerevisiae with treatment of auranofin. The strain abundance were normalized using EdgeR 
and shown. (B) Growth curve of wild type (BY4743) and heterozygous deletion strains 
(mia40, acn9, coa4, rad18 and nsi1) in the presence of indicated concentration of 
auranofin in YPD broth were determined. (C) The percent growth of yeast cells (OD600 
after 24 h) incubated with auranofin (6.25 µg/mL) in YPD broth was determined in relation 
to the DMSO treatment. The results are presented as means ± SD (n = 3).  Statistical 
analysis was calculated using the two-tailed Student’s t test. P values of (* P ≤ 0.05) (** P 
≤ 0.01) are considered as significant. (D) Yeast cells grown in YPD broth overnight were 
serially diluted and spotted on solid YPD agar containing auranofin (6.25 µg/mL) or 
DMSO and the CFU were shown. (E) Comparison of Lee et al.’s HIP results with our 85 




For each strain, the growth of cells (OD600 after 24 h) incubated with auranofin (6.25 µg/mL) 
was determined in relation to DMSO treatment. The growth of three heterozygous deletion 
strains (mia40, acn9 and coa4) was drastically suppressed by more than 50% in the 
presence of auranofin (6.25 µg/mL). However, the remaining two deletion strains (rad18 
and nsi1) had a modest reduction in growth of approximately 10% compared to the wild-
type strain (Figure 3.3C). 
 
The growth of these five deletion strains was further confirmed by spotting serial dilutions 
of cultures on solid agar. As shown in Figure 3.3D, growth of the wild-type and five 
heterozygous deletion strains was normal in agar containing DMSO. However, the 
heterozygous deletion strain, mia40 exhibited a nearly two-fold reduction in colony 
forming units when spotted onto YPD agar containing auranofin (6.25 µg/mL). 
 
A study conducted by Lee et al. 384 previously analyzed a heterozygous deletion pool 
representing essential genes using haploinsufficiency profiling and identified 17 strains as 
possibly sensitive to auranofin. Comparison of Lee et al.’s results with our 85 strains 
showed that two strains, rho1 and mia40, overlapped in the data sets (Figure 3E).  An 
additional study by Gamberi et al. 369 specifically assessed sensitivity of haploid deletion 
strains involved in mitochondrial function and found them to be differentially sensitive to 
auranofin. Based on studies by Gamberi et al. 369 and Lee et al. 384, we next moved to 
examine sensitivity of the corresponding heterozygous deletion strains involved in 






Figure 3.4 Effect of auranofin on deletion strains related to ROS production and 
mitochondrial function. (A) The percent growth of wild type and heterozygous deletion 
strains incubated with auranofin (6.25 µg/mL) in YPD broth (OD600 after 24 h) was 
determined in relation to the DMSO treatment. The results are presented as means ± SD (n 
= 3).  Statistical analysis was calculated using the two-tailed Student’s t test. P values of 
(* P ≤ 0.05) (** P ≤ 0.01) are considered as significant. (B) Yeast cells grown in YPD 
broth overnight were spotted on solid YPD agar containing auranofin (6.25 µg/mL) or 






Heterozygous deletion strains including ndil, atp2, citl, sdh4, gsh1, gsh2, prx1, 
trr1 erv1, toa2, arp7, ydl63w and yjl086cexperienced a significant growth 
reduction when treated with auranofin (6.25µg/mL) relative to DMSO-treated cells (Figure 
3.4A). These results are in agreement with Gamberi et al.’s 369 and Lee et al.’s 384 reports. 
It should be noted that Gamberi et al. used haploid deletion strains which generally do not 
inform on direct targets of a compound as opposed to the heterozygous deletion strains 
used in our study. These results were confirmed using the YPD agar spotting assay. 
Interestingly, heterozygous deletion strains involved in ROS response and redox 
homeostasis (sdh4, gsh1, gsh2and prx1which had significant growth reduction in 
liquid medium did not demonstrate considerable reduction in growth when spotted onto 
YPD agar containing auranofin (6.25 µg/mL) (Figure 3.4B). Gamberi et.al. through various 
experiments also demonstrated that auranofin does not elicit the production of ROS 369 but 
some haploid deletion strains associated with ROS were sensitive suggesting they are 
selectively important for resistance to auranofin. Taken together it appears that the ROS 
response enzymes are not direct targets of auranofin but several of these enzymes do 
mediate resistance to the inhibitory activity of auranofin. 
 
As noted earlier, heterozygous deletion strains that encode genes required for 
mitochondrial function (including ndil, atp2, citl and erv1), showed a considerable 
decrease in colony count (almost one-fold log reduction) when spotted onto YPD agar 
containing auranofin (6.25µg/mL) (Figure 3.4B). More notably, the pos5 strain does not 
demonstrate any sensitivity to auranofin (Figure 4B). POS5 encodes a mitochondrial 
NADH kinase required to respond to oxidative stress. This is in contrast to the haploid 
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deletion version, which was demonstrated to have slight resistance to auranofin 369. 
Chemogenomic profiling by Lee et al. 369 also did not identify the pos5heterozygous 
deletion strain as sensitive to auranofin. Interestingly, a deletion strain (erv1), which 
forms a complex with Mia40, also showed considerable sensitivity to auranofin, which 
coincides with Lee et al.’s findings 385 (Figure 3.4B). Taken altogether, our findings 
support the notion that Mia40 is the probable antifungal target of auranofin. 
 
The Mia40 (mitochondrial intermembrane space import and assembly protein 40) –Erv1 
pathway is mainly involved in oxidation of several cysteine rich proteins that enter the 
mitochondria from the cytoplasm 385,386. These proteins, present in the inner mitochondrial 
space, are essential for cell viability and are functionally linked to the respiratory chain 
385,387. In addition, an erv1 mutant strain was shown to be deficient in respiration 388 
consistent with the metabolic shift from respiration to fermentation observed in auranofin 
treated cells 369. 
 
To further confirm the specific inhibition of the Mia40-Erv1 pathway by auranofin we 
employed several biochemical experiments using purified yeast mitochondria similar to a 
previous study that investigated the effect of several small molecule inhibitors of redox-
regulated protein import into mitochondria 371.  A possible indirect mechanism of inhibition 
of mitochondrial function and the Mia40-Erv1 pathway is by the disruption of membrane 
potential or diminished oxidative phosphorylation.  Maintenance of membrane potential 
was determined by mitochondrial uptake of DiSC3 (5) dye and subsequent quenching in 
the presence of membrane potential.  Auranofin had no effect on the membrane potential 
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compared to DMSO whereas the uncoupling agent, CCCP, caused a 4-fold increase in 
fluorescence indicating uncoupled mitochondria (Figure 3.5A).  The effect on 
mitochondrial respiration was determined by measuring dissolved oxygen in a chamber 
with purified mitochondria and respiration was initiated with NADH resulting in an oxygen 
consumption rate (-0.45 O2 nmol/s) consistent with well-coupled mitochondria.  The 
addition of DMSO did not increase respiration rate and auranofin at a concentration of 
34µg/mL only slightly increased the respiration rate (-0.64 O2 nmol/s) (Figure 3.5B). As a 
control, the addition of CCCP resulted in a severe increase in consumption rate (-1.15 O2 
nmol/s) suggestive of uncoupled mitochondria (Figure 3.5B). Overall, auranofin does not 
have a generalized mode of action resulting in the disruption of membrane potential or 
respiration and mitochondrial integrity is maintained in the presence of the compound. 
 To confirm that auranofin targets the Erv1/Mia40 pathway we measured the effect of 
compound on the import of mitochondrial protein substrates compared to control 
compounds previously identified as Erv1 inhibitors 371.  Radiolabeled precursor proteins 
were incubated with mitochondria in the presence of small molecules or DMSO and the 
reaction was terminated with protease and subsequently analyzed by gel electrophoresis.  
Protein substrates from different import pathways were assessed including the Tim23 
substrate, Su9-DHFR, and the Mia40 substrate, Cmc1. Auranofin at a lower concentration 
of 6.8 µg/mL inhibits import of Su-DHFR to a 60% level and Cmc1 to a 25% level 
compared to untreated samples (Figure 3.5C and 3.5D). These results indicate the 
preferential activity of auranofin towards inhibiting Cmc1 import compared to Su9-DHFR, 







Figure 3.5 Auranofin does not impair general mitochondrial function but inhibits the import 
of substrates of the Mia40 pathway. (A) Mitochondrial uptake and quenching of DiSC3(5) 
dye when membrane potential is present. Dye fluorescence was measured as relative 
fluorescence units (RFUs) in the presence of DMSO, auranofin and CCCP. (B) Respiration 
of mitochondria was initiated by NADH followed by the addition of auranofin and CCCP. 
Respiration levels measurements were performed using an oxygen electrode and rates 
represent the consumption of O2 nmol/s. (C, D) Radiolabeled proteins Su9-DHFR and 
Cmc1 were imported into mitochondria in the presence of varying concentrations of 
auranofin and MB-7. (E) Non-reducing gel demonstrating the formation of the Cmc1-
Mia40 intermediate in the presence of auranofin, MB-6 and MB-7. (F) Auranofin inhibition 
of protein import is dependent on in organello mitochondrial Erv1 expression level.  Wild-
type (WT) and Erv1 overexpressed (OE) mitochondria were treated with varying 
concentrations of auranofin and the level of radiolabeled Cmc1 was detected. The asterisk 
represents a large complex of unknown composition that is observed in most Mia40 




Strikingly, auranofin exhibits more potent activity than control compound, MB-7 with a 
drastic difference in import efficiency observed between the compounds at 10 M 
(6.8µg/mL for auranofin and 8.5µg/mL for MB-7; Figure 3.5D).  Although auranofin does 
inhibit Su9-DHFR import at high concentrations, these results demonstrate the compound 
has specificity towards the Mia40 pathway and increased potency compared to previously 
identified inhibitors from a large-scale chemical library screen 371.  It is not surprising that 
the import of Su9-DHFR is mildly inhibited because mitochondrial import pathways are 
interconnected. Mia40 has previously been demonstrated to form an intermediate with 
Cmc1 as part of the import process 389,390. The effect of compounds on the formation of a 
disulfide intermediate between Mia40 and Cmc1 was monitored in organello.  Auranofin 
inhibits radiolabeled Cmc1 from interacting with Mia40 in a similar dose dependent 
manner to MB-7 (Figure 3.5E).  The addition of another control, MB-6, causes the 
accumulation of the intermediate.  In sum, auranofin inhibits the heterodimer formation of 
the Mia40-Cmc1 intermediate and is a potent inhibitor of the Mia40 import pathway. 
 
To further validate the Mia40 pathway as a target of auranofin, import of Cmc1 was 
performed with mitochondria from WT and Erv1 overexpressing yeast.  Erv1 
overexpression is expected to maintain the Mia40 pool in an oxidized state, which is 
required for the interaction with substrate proteins 373,391 and hence should be more resistant 
to auranofin inhibition. As predicted, the Erv1 overexpressing mitochondria were resistant 
to auranofin (3.4 µg/mL) treatment as evidenced by the increased level of Cmc1 (60%) 
import compared to WT (30%) mitochondria providing further confirmation of Mia40 as 
a target (Figure 3.5F).   
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It should also be taken into account the affinity of auranofin to human Mia40 protein. The 
central part of the human homolog of Mia40 shares high sequence identity with most of its 
eukaryotic analogues. However, Mia40 in yeast differs from its human homolog in one 
major respect – yeast Mia40 lacks the N-terminal extension including a transmembrane 
region 386. Future studies are needed to examine the affinity and binding of auranofin to 
Mia40 and in vivo studies will determine if Mia40 function is affected.  It may be possible 
that a therapeutic window exists because human Mia40 is not accessible or affected by 
auranofin at the concentrations needed for antifungal activity. 
 
Previous studies in bacteria and parasites proposed thioredoxin reductase (TrxR) to be the 
target of auranofin 263,264. However, a recent crystallographic study conducted 
by  Parsonage et al. 392  revealed that auranofin most likely does not bind to the cysteine 
residues in TrxR of Entamoeba histolytica. As it pertains to yeast, Gamberi et al. used 
homozygous deletion strains and demonstrated that deletion of the mitochondrial 
thioredoxin reductase (TRR2) or glutathione reductase (GLR1) genes in S. cerevisiae do 
not display resistance to auranofin 369. However, the effect of auranofin on the cytoplasmic 
thioredoxin reductase (TRR1) gene was not explored in their study 369. Results from our 
investigation indicate that the heterozygous deletion strain (trr1) behaves similar to the 
wild-type (Figure 4b). We therefore conclude that auranofin does not primarily target the 






In vivo efficacy of auranofin in C. neoformans infected C. elegans model 
To investigate if the in vitro antifungal activity of auranofin translates in vivo, the 
antifungal efficacy of auranofin was examined in a C. neoformans-infected C. 
elegans animal model. As shown in Figure 3.6, treatment of infected C. elegans with 
fluconazole, flucytosine and auranofin, at 8 µg/mL, produced a significant reduction (P ≤ 
0.01) in mean fungal load when compared to the untreated control groups.  
 
 
Figure 3.6 Efficacy of auranofin in C. neoformans-infected C. elegans. L4-stage worms 
were infected with C. neoformans and treated with auranofin, fluconazole, and flucytosine, 
at a concentration of 8 μg/mL. After 24 h, worms were lysed and plated onto YPD plates 
to determine the CFU per worm. Each dot represents average fungal load in each worm per 
well. The results are presented as means ± SD (n = 3).  Statistical analysis was calculated 
using the two-tailed Student’s t test. P value of (** P ≤ 0.01) are considered as significant. 
 
Strikingly, C. elegans treated with auranofin (8 µg/mL) generated the largest reduction in 
C. neoformans CFU (0.87±0.03 log10), followed by fluconazole (8 µg/mL) (0.82±0.03 
log10) and flucytosine (8 µg/mL) (0.58±0.11 log10) (Figure 3.6). Altogether, results from 
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our study suggest that auranofin, with its unique mechanism of action and potent in vivo 
antifungal activity, warrants further investigation as an antifungal agent to combat drug-
resistant fungal infections. 
 
3.2 Ebselen exerts antifungal activity by regulating glutathione (GSH) and 
reactive oxygen species (ROS) production in fungal cells 
 
(S. Thangamani, H. E. Eldesouky, H. Mohammad, P. Pascuzzi, L. Avramova, T. R. Hazbun 
and M. N. Seleem. Ebselen exerts antifungal activity by regulating glutathione (GSH) and 




         Ebselen (2-phenyl-1,2-benzisoselenazol-3(2H)-one) is an organoselenium 
compound that is known to possess anti-atherosclerotic, anti-inflammatory, antioxidative, 
cytoprotective, anti-mutagenic and anti-lipoperoxidative properties 59-62. Several studies 
have demonstrated that ebselen, due to its highly electrophilic nature, interacts with 
cysteine rich proteins (such as thioredoxin) and non-proteins (thiols) 60,393-399. Ebselen 
specifically interacts with free thiols such as glutathione (GSH) to form ebselen selenenyl 
sulfide; this intermediate catalyzes reactive oxygen species (ROS) formation. Interestingly, 
ebselen selenenyl sulfide can be reduced by GSH to form ebselen selenol. This particular 
intermediate functions as a ROS scavenger, and thereby protects the cell from free radical 
damage 60,394,395. As a clinically safe molecule, ebselen has been investigated for the 
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treatment of various ailments such as arthritis, stroke, cardiovascular disease and cancer 
60,63-66. 
 
      In addition to the beneficial properties of ebselen in mammalian cells, ebselen has also 
been investigated for its antimicrobial activity against multidrug-resistant Staphylococcus 
aureus and Enterococcus 67,68,211,226,400,401. Recently, we demonstrated that ebselen exerts 
its antibacterial activity through the inhibition of protein synthesis in bacteria 211,226. 
Ebselen has also been shown to possess potent antifungal activity, though different 
molecular targets have been proposed 69,402,403. Studies by Billack et.al and Chan et.al 
demonstrated that ebselen inhibits the plasma membrane H(+)-ATPase pump (Pma1p) in 
yeast 69,403. Azad et.al proposed that ebselen inhibits glutamate dehydrogenase (GDH3) and 
induces ROS production in yeast 404. A follow-up study by their research group also 
proposed that ebselen activates the DNA damage response and alters nuclear proteins in 
yeast 405. The studies above highlight that the antifungal mechanism of action of ebselen is 
challenging to elucidate and currently remains unresolved. 
      Given the tremendous pressure imposed by the emergence of resistance to antifungal 
agents currently utilized in the clinic, identifying new classes of antifungal drugs remains 
an unmet challenge 355,356,406,407. However, the traditional pathway for drug discovery is an 
arduous process that yields few approved new antimicrobials annually. An alternative 
approach steadily gaining support is utilizing drug repurposing to identify promising new 
anti-infective agents and expedite their regulatory approval 210,356.  
      Based upon the preliminary data presented in literature, ebselen is a promising drug to 
repurpose as a novel antifungal agent. However, additional research is necessary to 
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elucidate ebselen’s antifungal mechanism of action. Thus, the objectives of our study were 
to examine ebselen’s spectrum of activity against an array of fungal clinical isolates, to 
deduce ebselen’s antifungal mechanism of action, and to confirm the drug’s in vivo efficacy 
in two Caenorhabditis elegans animal models of fungal infection.  
 
3.2.2 Materials and Methods 
Fungal strains and reagents 
Candida and Cryptococcus strains used in this study are presented in Table 1. RPMI 
powder, MOPS and L-reduced glutathione were purchased from Sigma-Aldrich (St. Louis, 
MO). Yeast peptone dextrose agar (YPD) (BD Biosciences, San Jose, CA), fluconazole 
(Acros Organics, New Jersey), flucytosine and ebselen (TCI chemicals, Tokyo, Japan) 
were purchased from commercial vendors.  
 
Antifungal susceptibility testing 
 Antifungal susceptibility testing was done as per the National Committee for Clinical 
Laboratory Standards M-27A3 (NCCLS) guidelines 361. Briefly, five colonies from 24-
hour old cultures of Candida spp. or 48-hour old cultures of Cryptococcus were transferred 
to 5 ml of sterile 0.9% saline (PBS). After adjusting to reach a McFarland standard 0.5, 
fungal suspensions were diluted 1:2000 in RPMI 1640 buffered to pH 7.0 with 0.165 M 
MOPS (RPMI-MOPS). The drugs (ebselen, ebselen, fluconazole, flucytosine and 
amphotericin) were serially diluted and the minimum inhibitory concentration (MIC) was 
determined as follows: (i) For fluconazole and flucytosine, the MIC was classified as a 
significant decrease (approximately 50%) in visible growth compared to untreated controls; 
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(ii) For ebselen and amphotericin B, the MIC was categorized as the lowest concentration 
that produced no visible fungal growth. All experiments were carried out in triplicate wells. 
 
Time kill assay 
Cultures of Candida albicans and Cryptococcus neoformans at a dilution of 5 × 105 
CFU/ml were treated with 5 × MICs of ebselen, fluconazole, flucytosine and amphotericin 
B (in triplicate) in RPMI-MOPS, at 35°C. At specific time points, aliquots were collected,  
serially diluted in PBS, and plated onto YPD agar plates. After incubation at 35°C for 24-
48 hours the fungal colony forming units (CFU) were obtained, as described elsewhere 362. 
 
Chemogenomics profiling of Saccharomyces cerevisiae 
The initial testing of Saccharomyces cerevisiae response to ebselen was performed with 
the wild type BY4743 diploid strain, the isogenic parent to the heterozygous diploid 
deletion collection. BY4743 was grown in YPD in 96-well plates with 1% DMSO or 
ebselen in concentrations ranging from 10 to 200 M to determine a suitable level of 
growth inhibition.  Ebselen (25 µM) was used for haploinsufficiency profiling because it 
delayed growth by 30% compared to the no drug control half-maximal optical density (OD).  
All experiments were performed at 30°C and cultures were shaken at 300 rpm. A frozen 
aliquot (200 µL) of the heterozygous deletion pool (Thermo Fisher Scientific, Waltham, 
MA) was thawed and used to inoculate 2 mL of YPD and grown for 9 hours to reach an 
OD600 of 4.0.  The culture was diluted to an OD600 of 0.13 and either 1% DMSO or 25 µM 
ebselen was added (three replicates each) and grown for 7 hours.  The cultures were grown 
again by diluting to an OD600 of 0.13 in 1 mL YPD with DMSO or 25 µM ebselen and 
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grown for 8 hours, harvested and genomic DNA extracted using the YeaStar Genomic 
DNA kit (Zymo Research, Irvine, CA). The UPTAGs were amplified by PCR with Phusion 
Hot Start II High-Fidelity DNA polymerase at 0.02 U/µL (Thermo Fisher Scientific, 
Waltham, MA) using 0.5 ng/µL genomic DNA. The 267 bp PCR product was 
electrophoresed on an agarose gel and the DNA extracted using a QIAquick Gel Extraction 
Kit (Qiagen, Valencia, CA).  Purified DNA was measured using a Qubit instrument and 
samples were normalized and mixed to a final concentration of 10 nM. Strains were grown 
and maintained on media using standard practices 366.  
 
The pooled PCR products were sequenced using standard Illumina sequencing in a HiSeq 
2500 instrument. The reads were separated based on a 5 base multiplex tag unique for each 
experiment and an average of 5 million reads per replicate was obtained. The UPTAG 
barcodes in each experimental sample were separated based on a reference database of 
recharacterized barcode sequences 367. 
The resulting strain counts were imported into R and analyzed with edgeR 368. Sequencing 
library sizes were normalized using default parameters. Only strains with one or more 
counts in three or more samples were analyzed further. Differential representation of strains 
was determined using the quantile-adjusted conditional maximum likelihood (qCML) 
method. False discovery rates were determined to control for multiple testing. 
 
Saccharomyces deletion strain haploinsufficiency validation 
Overnight grown saturated cultures of yeast cells were diluted to 1 to 10 and further to 1 to 
5000 before treating with indicated concentration of ebselen. After 24 hours of incubation, 
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yeast growth was monitored using a spectrophotometer (OD600) and the results were 
expressed as percent growth rate for each strain compared to the untreated control group, 
as described elsewhere 369.  
 
Determining fungal growth with L-reduced glutathione supplementation 
In experiments with L-reduced glutathione supplementation, indicated concentration of 
glutathione was added to the fungal cultures  (with or without ebselen) and the percent 
growth rate or MIC was determined as described above. 
 
Glutathione assay 
The assay was conducted as per the manufacturer’s instructions (Glutathione assay kit from 
Cayman chemicals, Michigan, USA). Briefly, saturated cultures of wild type and deletion 
strains of S. cerevisiae cells were diluted to 1:5 in YPD broth and treated with ebselen (20 
µg/ml) for 2.5 hours. After treatment, tubes were centrifuged. The cells were subsequently 
washed once with cold water and followed by 1 × GSH MES buffer (supplied by the 
manufacturer). After washing, cells were re-suspended in 250 µL of 1 × GSH MES buffer 
and sonicated for 45 seconds. Tubes were centrifuged and the supernatant was collected 
for the assay. An aliquot (50 µL) of cell supernatant was added to each well in a 96-well 
plate and then 150 µL of the assay cocktail, prepared per the manufacturer’s guidelines, 
was added. After two minutes of incubation, the intensity of yellow color produced was 
measured using a spectrophotometer (OD410). The results are expressed either as 




Measuring ROS production in yeast cells 
The Image-iT™ LIVE Green Reactive Oxygen Species (ROS) detection kit (Molecular 
Probes, Inc. Eugene, OR) was utilized and the ROS production was measured as per the 
manufacturer’s instructions. Briefly, saturated cultures of wild type and deletion strains of 
S. cerevisiae cells were diluted to 1:5 in YPD broth and treated with ebselen (20 µg/ml) for 
2.5 hours. Then 10mM of 5-(and-6)-carboxy-2',7'-dichlorodihydrofluorescein diacetate 
(carboxy-H2DCFDA) dye was added at a dilution of 1:500.   After  2 hours of incubation, 
the cells were washed once with PBS and the intensity of fluorescence produced was 
measured using spectrophotometer or imaged by Leica confocal laser scanning microscopy. 
 
Caenorhabditis elegans (C. elegans) infection study 
C. elegans AU37 (sek-1; glp-4) strain (glp-4(bn2) was used to investigate the antifungal 
efficacy of ebselen, as described elsewhere 226,374. Briefly, L4-stage worms were infected 
either with Cryptococcus neoformans NR-41292 or Candida albicans ATCC 10232 for 
two-three hours at room temperature. After infection, worms were washed with M9 buffer 
and treated for 24 hours either with DMSO or drugs (ebselen, amphotericin B, fluconazole, 
and flucytosine), at indicated concentrations. Post-treatment, worms were washed, 
disrupted using silicon carbide particles 226, and the resulting suspensions were serially 
diluted and transferred to YPD agar plates containing ampicillin (100 μg/ml), streptomycin 
(100 μg/ml) and kanamycin (45 μg/ml). Plates were incubated for 24-48 hours at 35°C 






Statistical analyses were done using GraphPad Prism 6.0 (GraphPad Software, La Jolla, 




Antifungal activity and killing kinetics of ebselen 
       Ebselen’s antifungal activity was examined against numerous clinical isolates of 
Candida and Cryptococcus. Ebselen inhibited isolates of Candida albicans, C. glabrata, 
C. tropicalis and C. parapsilosis at concentrations ranging from 0.5 to 2 µg/ml (Table 3.2). 
Ebselen retained its potent antifungal activity against Cryptococcus  neoformans and 
Cryptococcus gattii, as the drug inhibited growth of these fungal species at concentrations 
ranging from 0.5 to 1 µg/ml (Table 3.2).  
 
         In order to investigate the killing kinetics of ebselen against both C. albicans and C. 
neoformans, a time-kill assay was conducted. Unlike fluconazole and flucytosine, ebselen 
(at 5 × MIC) completely eradicated C. albicans ATCC 10231 and C. neoformans NR-
41291 within two hours of treatment (Figure 3.7). Ebselen’s fungicidal activity was 
superior to amphotericin which required at least four hours to completely eliminate fungal 


















C. albicans NR 29434 4 0.125 1 1 
C. albicans ATCC 10231 2 0.25 0.5 2 
C. albicans NR 29449 2 4 1 2 
C. albicans NR 29435 4 0.0625 0.5 2 
C. albicans NR 29448 >64 0.0625 1 2 
C. albicans NR 29437 2 0.0625 1 2 
C. albicans NR 29446 >64 0.25 0.5 1 
C. albicans NR 29453 2 0.0625 0.5 2 
C. albicans NR 29438 2 0.0625 1 2 
C. albicans ATCC 26790  2 0.0625 1 2 
C. albicans ATCC 24433 4 1 1 2 
C. albicans ATCC 14053 4 0.125 1 2 
C. albicans ATCC 90028 4 1 1 2 
C. albicans NR 29366 >64 0.0625 1 4 
C. albicans NR 29367 >64 0.0625 1 2 
C. glabrata ATCC MYA-2950 4 0.0625 1 0.5 
C. glabrata ATCC 66032 2 0.0625 2 0.5 
C. tropicalis ATCC 13803 2 0.125 1 2 
C. tropicalis ATCC 1369 1 0.25 1 2 
C. parapsilosis ATCC 22019 1 0.25 1 1 
C.  neoformans NR-41291  1 0.5 1 1 
C.  neoformans NR-41292  1 0.5 0.5 0.25 
C.  neoformans NR-41296  2 0.5 0.5 0.5 
C.  neoformans NR-41295  2 0.5 0.5 0.5 
C.  neoformans NR-41294  4 2 0.5 0.5 
C.  neoformans NR-41297 8 4 0.5 1 
C.  neoformans NR-41298 4 2 0.5 1 
C.  neoformans NR-41299 4 2 1 1 
Cryptococcus gattii - CBS1930  2 2 0.5 0.5 
Cryptococcus gattii - R265  1 1 0.5 0.5 
Cryptococcus gattii - Alg40  2 0.5 0.5 0.5 
Cryptococcus gattii - Alg75 8 8 0.5 2 
Cryptococcus gattii - Alg81 8 4 0.5 2 
Cryptococcus gattii - Alg99 8 4 1 2 
Cryptococcus gattii - Alg114 8 4 1 2 
Cryptococcus gattii - Alg115 8 4 1 2 





Figure 3.7 Killing kinetics of ebselen. An overnight culture of C. albicans ATCC 10231 
and C.  neoformans NR-41291 were treated with 5 × of ebselen, fluconazole, flucytosine 
and amphotericin (in triplicate) in RPMI-MOPS and incubated at 35°C. Samples were 
collected at indicated time points and plated onto YPD plates. Plates were incubated for 
24-48 h prior to counting the colony forming units (CFU). 
 
Glutathione as a potential target of ebselen 
        After verifying ebselen’s potent antifungal activity, we proceeded to investigate the 
antifungal mechanism of ebselen. Chemogenomic profiling, using drug-induced 
haploinsufficiency, was utilized due to its nature as a highly-specific technique to deduce 
the molecular mechanism of unknown compounds 378-380. Haploinsufficiency profiling 
(HIP) allows for the simultaneous assessment of the sensitivity of the pooled genome-wide 
set of heterozygous deletion strains due to the fact that each strain possesses a unique 
synthetic DNA barcode. The method is an unbiased approach to find strains exhibiting the 
most sensitivity to ebselen. After determining the concentration that reduced wild-type 
growth by 30%, we used 25 M of drug to profile the pooled heterozygous strains in the 
biological samples.  PCR was used to amplify the unique UPTAG DNA barcodes located 
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at the gene deletion site and the barcode abundance was tracked using Illumina sequencing. 
The resulting counts were normalized and visualized using EdgeR.  
 
      We identified 33 heterozygous deletion strains that were under-represented based on a 
FDR less than 0.01, when comparing ebselen treatment to DMSO.  These strains were 
enriched for glutathione metabolic process (p-value = 0.0026). In addition, we also 
included additional heterozygous deletion strains based on previous chemogenomic 
profiling using heterozygous and homozygous diploid strains. pma1 which was the fourth 
ranked strain from a heterozygous screen 384; glr, gsh1, gsh2 hits from a homozygous 
screen 384; ubx4, gsh1 trp2, brp1, ecm38, ylr287c, cts1, cda2, imh1 from a 
homozygous screen 380; and rad4 from a heterozygous screen 380. 
 
       The heterozygous strains including gsh1, gsh2, glr1, trr1, trr2 fks1, 
ylr287c, ylr282c, guf1, yle296w, est2, rrf1 and ycr006c experienced a 
significant reduction in growth when exposed to ebselen (Figure 3.8A). Importantly, two 
heterozygous deletion strains (gsh1 and gsh2) encoding genes involved in glutathione 
(GSH) synthesis were the most sensitive to ebselen. A haploid set of these two deletion 
strains (gsh1 and gsh2) was also tested. These haploid deletion strains (gsh1 and gsh2) 
were not resistant to ebselen and exhibited increased sensitivity to ebselen when compared 
to the diploid strains (Figure 3.8B). The results indicate that ebselen most likely does not 
directly target the proteins (Gsh1 and Gsh2) involved in glutathione synthesis but somehow  
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Figure 3.8 Glutathione as a potential target of ebselen. (A and B) The percent growth of 
yeast cells (OD600 after 24 h) incubated with ebselen (2µg/ml) in YPD broth was 
determined in relation to the DMSO treatment. The results are presented as means ± SD (n 
= 3).  (C) Saturated cultures of  yeast cells were diluted to 1:5 and grown for 2.5 h. The 
cells were sonicated and amount of glutathione was determined using glutathione assay kit. 
The absorbance measured using spectrophotometer indicates the glutathione production in 
each strain. (D) Yeast cells were treated with ebselen (20µg/ml) for 2.5 h and the 
glutathione concentration was measured as indicated above. The results are expressed as 
percent glutathione production relative to untreated control groups. Statistical analysis was 
calculated using the two-tailed Student’s t test. P values of (* P ≤ 0.05) (** P ≤ 0.01) are 




directly target the proteins (Gsh1 and Gsh2) involved in glutathione synthesis Based on the 
fact that ebselen binds directly to GSH and depletes GSH levels, leading to apoptosis in 
mammalian cells 398,408, we hypothesized ebselen exhibits a similar mode of action in yeast. 
Glutathione levels in wild type (BY4743 and BY4741), heterozygous and homozygous 
deletion strains (gsh1 and gsh2) were quantified using a glutathione assay kit. Results 
indicate that all deletion strains experienced a significant reduction in GSH levels 
compared to their respective wild-type strains (Figure 3.8C). Homozygous deletion strains 
have a very low presence of GSH compared to their heterozygous strain counterpart (Figure 
3.8C). However, treatment of homozygous deletion strains with ebselen further reduced 
GSH levels (approximately by 40%) compared to untreated control groups. On the other 
hand, the wild type and heterozygous deletion strains (gsh1 and gsh2) showed no 
considerable decrease in GSH levels when treated with ebselen at this concentration 
(Figure 3.8D). These results suggest that ebselen depletes intracellular glutathione levels 
in yeast cells. 
 
Depletion of glutathione by ebselen leads to increased ROS production 
            Glutathione plays a central role in maintaining redox-homeostasis in yeast 409,410. 
Significant decreases in GSH levels might lead to dysregulation of redox homeostasis and 
in turn increase ROS production 398,408-410. Given that ebselen was shown to deplete GSH 
levels in yeast cells, we investigated the effect of ebselen on ROS production. Basal level 
of ROS production in wild-type and GSH deletion strains were quantified. As expected, 
homozygous deletion strains (gsh1 and gsh2 displayed a considerable increase in ROS 




Figure 3.9 Depletion of glutathione by ebselen leads to ROS production in yeast cells. 
(A)Wild type and deletion strains of S. cerevisiae cells were grown in the presence of 
carboxy-H2DCFDA dye and the intensity of fluorescence produced was measured using 
spectrophotometer. (B and C) Yeast cells were grown in the presence of ebselen 
(20µg/ml) for 2.5 h and incubated with carboxy-H2DCFDA dye to determine the 
glutathione production by spectrophotometer or Leica confocal laser scanning 
microscopy. The results are expressed as percent glutathione in ebselen treated cells in 
relative to untreated control groups (B). Green fluorescence indicates the ROS production 
in yeast cells (C). Statistical analysis was calculated using the two-tailed Student’s t test. 
P values of (* P ≤ 0.05) (** P ≤ 0.01) are considered as significant. 
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However, when exposed to ebselen treatment, all strains (except the gsh2 heterozygous 
deletion strain) experienced a significant increase in ROS production (Figure 3.9B). As 
expected, gsh1 and gsh2homozygous deletion strains exhibited the largest increase in 
ROS production (almost two-fold increase) compared to untreated control groups (Figure 
3.9B). These results were confirmed using confocal microscopy. As presented in Figure 
3C, ROS production was prominently noticed only in the gsh1 and gsh2 homozygous 
deletion strains. Collectively, the results support the notion that ebselen exerts its antifungal 
activity by causing a sharp decrease in GSH levels that subsequently leads to increased 
ROS production in yeast cells. 
 
Supplementation of L-reduced GSH restored the cell growth 
         Based upon the above result, we hypothesized that GSH supplementation would 
reverse the inhibitory effect in yeast caused by ebselen. As expected, supplementation with 
L-reduced glutathione restored cell growth and reversed the inhibition caused by ebselen, 
in a concentration-dependent manner (Figure 3.10). GSH, at 25 µg/ml, completely restored 
the cell growth (Figure 3.10). In addition, the effect of GSH supplementation on 
susceptibility of Candida and Cryptococcus strains to ebselen were also examined. 
Interestingly, with GSH supplementation (0.25 mg/ml), all tested fungal strains including 
C. albicans, C. glabrata, C. tropicalis, C. parapsilosis, C.  neoformans and C. gattii 
become resistant to ebselen (MIC >128 µg/ml) (Table 3.3). On the other hand, the MIC of 
control antifungal drugs (fluconazole and flucytosine amphotericin) was not altered with 
GSH supplementation (Table 3.3). These results suggest a mode of action of ebselen that 
is specifically reversed by elevated GSH levels. 
216 
 
Figure 3.10 Supplementation of L-reduced glutathione restored the cell growth. Wild 
type and deletion strains of S. cerevisiae cells were grown in the absence (or) presence of 
indicated concentration of ebselen and glutathione and the percent growth rate (OD600 
after 24 h) was determined by using spectrophotometer. Statistical analysis was 
calculated using the two-tailed Student’s t test. P values of (* P ≤ 0.05) (** P ≤ 0.01) are 
considered as significant. 
 
 
Table 3.3 MIC of ebselen and control antifungal drugs against Candida and Cryptococcus strains 
with L-reduced glutathione supplementation 














GSH (-) GSH (+) GSH (-) GSH (+) GSH (-) GSH (+) GSH (-) GSH (+) 
C. albicans ATCC 10231 2 2 0.25 0.25 0.5 0.5 2 >128 
C. albicans - 18E 2 1 0.0625 0.0625 1 1 1 >128 
C. tropicalis ATCC 1369 1 1 0.25 0.25 1 1 2 >128 
C. tropicalis ATCC 13803 2 2 0.125 0.125 1 1 2 >128 
C. parapsilosis ATCC 22019 1 1 0.25 0.25 1 1 1 >128 
C. glabrata ATCC MYA-2950 4 4 0.0625 0.0625 1 1 0.5 >128 
C. glabrata  LRA 85.10.75 0.5 0.5 0.0625 0.0625 2 2 1 >128 
C. gattii - R265 1 1 1 1 0.5 0.5 0.5 >128 
C. gattii - CBS1930 2 2 2 2 0.5 0.5 0.5 >128 
C. neoformans  NR-41297 8 8 4 4 0.5 0.5 1 >128 
C. neoformans  NR-41299 4 4 1 2 1 1 1 >128 
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In vivo efficacy of ebselen in infected C. elegans model 
           To investigate if the in vitro antifungal activity of ebselen translates in vivo, the 
antifungal efficacy of ebselen was tested in a C. albicans and C. neoformans-infected C. 
elegans animal model. As shown in Figure 3.11, treatment of infected C. elegans with 
amphotericin, fluconazole, flucytosine and ebselen at 4 and 8 µg/ml, produced a significant 
reduction (P ≤ 0.05) in mean fungal load when compared to the untreated control groups. 
C. elegans treated with ebselen (8 µg/ml) completely eradicated C. albicans,. 
Amphotericin (8 µg/ml) produced a 1.53±0.08 log10 CFU reduction which was nearly 
identical to ebselen at 4 µg/ml (1.52±0.14 log10). Fluconazole, at 8 µg/ml, reduced the 
burden of C. albicans by 1.36±0.07 log10 followed by amphotericin (4 µg/ml) (1.05±0.16 
log10), flucytosine (8 µg/ml) (0.79±0.09 log10), flucytosine (4 µg/ml) (0.62±0.08 log10) and 
fluconazole (4 µg/ml)  (0.55±0.09 log10). 
Figure 3.11 Efficacy of ebselen in C. albicans (or) C. neoformans-infected C. elegans. L4-
stage worms were infected with C. albicans or C. neoformans and treated with ebselen, 
fluconazole, flucytosine and amphotericin at a concentrations of 4 and 8 μg/ml. After 24 h, 
worms were lysed and plated onto YPD plates to determine the CFU per worm. Each dot 
represents average fungal load in each worm per well. The results are presented as means 
± SD (n = 3).  Statistical analysis was calculated using the two-tailed Student’s t test. P 




Treatment of C. neoformans-infected C. elegans with ebselen (8 µg/ml) also generated the 
highest reduction in CFU count (2.31±0.02 log10), followed by amphotericin (8 µg/ml)  
(1.98±0.13 log10), (1.97±0.09 log10), ebselen at 4 µg/ml (1.97±0.09 log10), amphotericin (4 
µg/ml) (1.46±0.03 log10), fluconazole (8 µg/ml) (1.32±0.04log10), flucytosine (8 µg/ml)  




        Fungal infections are a significant healthcare challenge particularly in 
immunocompromised individuals, such as HIV patients 411,412. Candida albicans is the 
fourth leading cause of bloodstream infections in the United States and has been associated 
with a high mortality rate (50%) 413,414. In addition to infections caused by C. albicans, 
Cryptococci, particularly C. gattii, are a major source of infections in humans. 
Cryptococcal meningitis is a significant cause of mortality in HIV patients 412. The immune 
system in these immunocompromised patients is not capable of eradicating these fungal 
pathogens. Thus treatment is highly dependent on antifungal drugs successfully resolving 
the fungal infection 356. Unfortunately, recent clinical reports indicate current antifungal 
therapies are not effective in treating invasive fungal infections 355. Further compounding 
this problem, the number of antifungal drug classes currently available to clinicians is 
limited. This issue is exacerbated by the fact that resistance to antifungal agents is 
increasing and many current antifungal agents exhibit unusual toxicities thus further 
restricting their use 355,356,406,407. This highlights the pressing need to identify new 
antifungal drugs to combat these dangerous pathogens. The traditional route of antifungal 
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innovation and regulatory approval is a time-consuming, expensive venture. This has led 
researchers to explore alternative approaches, such as drug repurposing, to expedite anti-
infective drug development 210,356.  
 
        Ebselen is an organoselenium compound that is currently undergoing clinical trials 
for the prevention and treatment of cardiovascular disease, arthritis, stroke, atherosclerosis, 
and cancer 60,63-66. In an intensive search for non-antifungal drugs exhibiting antifungal 
activity, we and others 69,402,403 demonstrated that ebselen possesses potent broad-spectrum 
fungicidal activity against Candida and Cryptococcus spp with the MIC values ranging 
from 0.5 to 2 µg/ml. Although, its antifungal activity has been reported before, the 
antifungal mechanism of action and in vivo efficacy of ebselen remains unclear with several 
potential targets proposed 68,69,402,403. In the present study, we demonstrated that ebselen 
reduces GSH concentration in yeast cells leading to dysregulation of redox homeostasis. 
These results correlate with studies conducted by Yang et.al and Shi et.al that reported 
ebselen depletes GSH levels in mammalian cells, ultimately leading to apoptosis 398,408.  
 
        Although, ebselen has been shown to have an antioxidant effect and protects cells 
from free radical damage, it has also been shown to cause apoptosis by reducing thiol levels 
in mammalian cells 398,408. The present study indicates that ebselen also exhibits a similar 
mode of action in yeast cells. Decreased GSH levels subsequently leads to increased ROS 
production thereby placing cells under oxidative stress. This finding is in agreement with 
a recent study by Ngo et. al that demonstrated ebselen treatment induces ROS in Candida 
albicans 402. In addition, Azad et. al proposed that ebselen increases ROS levels in yeast 
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by inhibiting the Gdh3 enzyme involved in glutathione synthesis 404. However, we found 
that gdh3 heterozygous and haploid deletion strains were not susceptible to ebselen 
compared to both the gsh1 and gsh2 deletion strains. Studies conducted by Billack et. 
al and Chan et. al proposed that the plasma membrane H(+)-ATPase pump (Pma1) is the 
potential target of ebselen in yeast 69,403. However, we also confirmed that the pma1 
heterozygous deletion strain does not experience significant growth impairment when 
exposed to ebselen relative to the gsh1 and gsh2 deletion strains. Many of the proposed 
targets for ebselen have been demonstrated via biochemical based assays in which it is 
difficult to assess the specificity of ebselen for the protein target compared to other targets 
especially because of the molecules reactivity to cysteines.  Collectively, results from our 
study demonstrate that ebselen reduces intracellular GSH concentration leading to 
dysregulation of redox homeostasis and that deficiency in glutathione biosynthesis 
exacerbates this mode of action. 
 
            Glutathione is an essential metabolite required to protect yeast from oxidative stress 
409,410,415-418. S. cerevisiae lacking c-glutamyl cysteine synthase (Gsh1), the first enzyme in 
glutathione biosynthesis leads to glutathione autotrophy in which the cells dependent on 
exogenous GSH for its growth and survival 419,420.  In the absence of endogenous GSH, 
yeast has the ability to uptake GSH from an environment through high-affinity glutathione 
transporters such as Hgt1 419-421. In the present study, we also demonstrated that gsh1 and 
gsh2 homozygous deletion strains has relatively low amount of basal GSH when 
compared to wild type and the counterpart heterozygous deletion strains. The GSH 
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observed in the gsh1 and gsh2homozygous deletion strains is likely derived from 
growth medium. The presence of low amount of GSH in these deletion strains was further 
depleted by ebselen treatment and in turn places cells in oxidative stress. Importance and 
essentiality of GSH has also been demonstrated in other fungi species including Candida 
416,421, suggesting that glutathione might form an attractive novel target for the development 
of new antifungal drugs 422-424.  Future studies are required to delineate the interaction 
between ebselen and yeast GSH, and also the affinity of ebselen towards mammalian GSH. 
 
           Chemogenomic profiling was employed in this study, and it identified 33 
heterozygous deletion strains sensitive to ebselen that were under-represented based on an 
FDR less than 0.01. However, the hits recovered did not include the GSH1 or GSH2 genes. 
It is also interesting to note that these strains were also not identified as hits in other 
heterozygous chemogenomic profiling screens employed by two other groups 380,384. 
Potential hits obtained using this technique greatly depend on (i) the concentration of the 
drug/compound used to test the deletion pool (ii) Many technical factors such as the PCR 
quality and number of reads. These factors should be taken into consideration when 
utilizing chemogenomic profiling to identify the mode of action of unknown compounds. 
 
         The final segment of this study investigated the in vivo antifungal efficacy of ebselen 
in a C. albicans and C. neoformans-infected C. elegans animal model. Ebselen, at 8 µg/ml, 
completely eradicated the C. albicans load and produced a more than two- log10 reduction 
in C. neoformans CFU load. Ebselen’s antifungal activity was found to be superior to 
currently approved antifungal drugs including amphotericin, fluconazole and flucytosine 
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in reducing the fungal load in the C. elegans animal model. These results lay a strong 
foundation for future studies to test the antifungal efficacy of ebselen in appropriate mice 
models of fungal infection. Ebselen is also known to be capable of crossing the blood brain 
barrier 66. This quality provides an added advantage to investigate the potential use of this 
drug for the treatment of Cryptococcal meningitis infections particularly in HIV patients 
66,412.  
         In conclusion, the present study confirms ebselen, with its unique mechanism of 
action and potent in vivo antifungal activity, is a promising clinical molecule that 




















1 CDC.    (ed Centers for Disease Control and Prevention) 1-114 (2013). 
2 ECDC.    (ed European Centre for Disease Prevention and Control) 1-54 
(Stockholm, 2009). 
3 ECDC.    (ed European Centre for Disease Control and Prevention) 1-260 
(Stockholm, 2013). 
4 Hiramatsu, K. Vancomycin-resistant Staphylococcus aureus: a new model of 
antibiotic resistance. Lancet Infect Dis 1, 147-155, doi:10.1016/S1473-
3099(01)00091-3 (2001). 
5 Layer, F., Cuny, C., Strommenger, B. & Witte, W. Linezolid resistance in clinical 
isolates of Staphylococcus aureus and Staphylococcus epidermidis. Int J Med 
Microbiol 302, 102-102 (2012). 
6 Li, X. et al. Ceftriaxone, an FDA-approved cephalosporin antibiotic, suppresses 
lung cancer growth by targeting Aurora B. Carcinogenesis 33, 2548-2557, doi:DOI 
10.1093/carcin/bgs283 (2012). 
7 Chong, C. R. & Sullivan, D. J., Jr. New uses for old drugs. Nature 448, 645-646, 
doi:10.1038/448645a (2007). 
8 Cohen, F. J. Macro trends in pharmaceutical innovation. Nature reviews. Drug 
discovery 4, 78-84, doi:10.1038/nrd1610 (2005). 
9 Jin, G. & Wong, S. T. Toward better drug repositioning: prioritizing and integrating 
existing methods into efficient pipelines. Drug discovery today 19, 637-644, 
doi:10.1016/j.drudis.2013.11.005 (2014). 
10 DiMasi, J. A., Hansen, R. W. & Grabowski, H. G. The price of innovation: new 
estimates of drug development costs. Journal of health economics 22, 151-185, 
doi:10.1016/S0167-6296(02)00126-1 (2003). 
11 Petsko, G. A. When failure should be the option. Bmc Biol 8, doi:Artn 61 
            Doi 10.1186/1741-7007-8-61 (2010). 
12 Flanders, S. A., Dudas, V., Kerr, K., McCulloch, C. E. & Gonzales, R. 
Effectiveness of ceftriaxone plus doxycycline in the treatment of patients 
hospitalized with community-acquired pneumonia. Journal of hospital medicine : 
an official publication of the Society of Hospital Medicine 1, 7-12, 
doi:10.1002/jhm.8 (2006). 
13 Mandell, L. A. et al. Infectious Diseases Society of America/American Thoracic 
Society consensus guidelines on the management of community-acquired 





14 Molyneux, E. et al. 5 versus 10 days of treatment with ceftriaxone for bacterial 
meningitis in children: a double-blind randomised equivalence study. Lancet 377, 
1837-1845, doi:10.1016/S0140-6736(11)60580-1 (2011). 
15 Whiley, D. M. et al. Reduced susceptibility to ceftriaxone in Neisseria gonorrhoeae 
is associated with mutations G542S, P551S and P551L in the gonococcal penicillin-
binding protein 2. J Antimicrob Chemoth 65, 1615-1618, doi:Doi 
10.1093/Jac/Dkq187 (2010). 
16 Rothstein, J. D. et al. Beta-lactam antibiotics offer neuroprotection by increasing 
glutamate transporter expression. Nature 433, 73-77, doi:10.1038/nature03180 
(2005). 
17 Cudkowicz, M., Shefner, J. & Consortium, N. STAGE 3 Clinical Trial of 
Ceftriaxone in Subjects with ALS. Neurology 80 (2013). 
18 Zhu, S. et al. Minocycline inhibits cytochrome c release and delays progression of 
amyotrophic lateral sclerosis in mice. Nature 417, 74-78, doi:Doi 10.1038/417074a 
(2002). 
19 Shigi, Y. Inhibition of bacterial isoprenoid synthesis by fosmidomycin, a 
phosphonic acid-containing antibiotic. The Journal of antimicrobial chemotherapy 
24, 131-145 (1989). 
20 Ruangweerayut, R. et al. Assessment of the pharmacokinetics and dynamics of two 
combination regimens of fosmidomycin-clindamycin in patients with acute 
uncomplicated falciparum malaria. Malaria journal 7, 225, doi:10.1186/1475-
2875-7-225 (2008). 
21 Na-Bangchang, K., Ruengweerayut, R., Karbwang, J., Chauemung, A. & 
Hutchinson, D. Pharmacokinetics and pharmacodynamics of fosmidomycin 
monotherapy and combination therapy with clindamycin in the treatment of 
multidrug resistant falciparum malaria. Malaria journal 6, 70, doi:10.1186/1475-
2875-6-70 (2007). 
22 Teachey, D. T. et al. Treatment with sirolimus results in complete responses in 
patients with autoimmune lymphoproliferative syndrome. British journal of 
haematology 145, 101-106, doi:10.1111/j.1365-2141.2009.07595.x (2009). 
23 Dragana, J. M. et al. Rapid Regression of Lymphadenopathy upon Rapamycin 
Treatment in a Child With Autoimmune Lymphoproliferative Syndrome. Pediatr 
Blood Cancer 53, 1117-1119, doi:Doi 10.1002/Pbc.22151 (2009). 
24 Cai, X. et al. Sirolimus Decreases Circulating Lymphangioleiomyomatosis Cells in 
Patients With Lymphangioleiomyomatosis. Chest 145, 108-+, doi:DOI 
10.1378/chest.13-1071 (2014). 
25 Debnath, A. et al. A high-throughput drug screen for Entamoeba histolytica 
identifies a new lead and target. Nature medicine 18, 956-960, 
doi:10.1038/nm.2758 (2012). 
26 Smorenburg, C. H. et al. Phase II study of miltefosine 6% solution as topical 







27 Dorlo, T. P., Balasegaram, M., Beijnen, J. H. & de Vries, P. J. Miltefosine: a review 
of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis. The 
Journal of antimicrobial chemotherapy 67, 2576-2597, doi:10.1093/jac/dks275 
(2012). 
28 Meyerhoff, A. U.S. Food and Drug Administration approval of AmBisome 
(liposomal amphotericin B) for treatment of visceral leishmaniasis. Clinical 
infectious diseases : an official publication of the Infectious Diseases Society of 
America 28, 42-48; discussion 49-51, doi:10.1086/515085 (1999). 
29 Bukirwa, H., Garner, P. & Critchley, J. Chlorproguanil-dapsone for treating 
uncomplicated malaria. The Cochrane database of systematic reviews, CD004387, 
doi:10.1002/14651858.CD004387.pub2 (2004). 
30 Olson, K. B., Thompson, J. F. & Zintheo, C. J., Jr. Treatment of pulmonary 
tuberculosis with diasone. American review of tuberculosis 52, 474-482 (1945). 
31 Robitzek, E. H., Ornstein, G. G. & et al. Diasone in the treatment of pulmonary 
tuberculosis. Diseases of the chest 12, 185-204 (1946). 
32 Abeloff, M. D. et al. Phase II trials of alpha-difluoromethylornithine, an inhibitor 
of polyamine synthesis, in advanced small cell lung cancer and colon cancer. 
Cancer treatment reports 70, 843-845 (1986). 
33 Paulson, Y. J., Gilman, T. M., Heseltine, P. N., Sharma, O. P. & Boylen, C. T. 
Eflornithine treatment of refractory Pneumocystis carinii pneumonia in patients 
with acquired immunodeficiency syndrome. Chest 101, 67-74 (1992). 
34 Burri, C. & Brun, R. Eflornithine for the treatment of human African 
trypanosomiasis. Parasitology research 90 Supp 1, S49-52, doi:10.1007/s00436-
002-0766-5 (2003). 
35 Chappuis, F., Udayraj, N., Stietenroth, K., Meussen, A. & Bovier, P. A. 
Eflornithine is safer than melarsoprol for the treatment of second-stage 
Trypanosoma brucei gambiense human African trypanosomiasis. Clinical 
infectious diseases : an official publication of the Infectious Diseases Society of 
America 41, 748-751, doi:10.1086/432576 (2005). 
36 Robays, J., Raguenaud, M. E., Josenando, T. & Boelaert, M. Eflornithine is a cost-
effective alternative to melarsoprol for the treatment of second-stage human West 
African trypanosomiasis in Caxito, Angola. Tropical medicine & international 
health : TM & IH 13, 265-271, doi:10.1111/j.1365-3156.2007.01999.x (2008). 
37 Tan, K. R. et al. Doxycycline for malaria chemoprophylaxis and treatment: report 
from the CDC expert meeting on malaria chemoprophylaxis. The American journal 
of tropical medicine and hygiene 84, 517-531, doi:10.4269/ajtmh.2011.10-0285 
(2011). 
38 Ben Salah, A. et al. Topical paromomycin with or without gentamicin for cutaneous 
leishmaniasis. The New England journal of medicine 368, 524-532, 
doi:10.1056/NEJMoa1202657 (2013). 
39 Monge-Maillo, B. & Lopez-Velez, R. Topical paromomycin and gentamicin for 
new world cutaneous leishmaniasis in Panama. The American journal of tropical 





40 Sosa, N. et al. Randomized, double-blinded, phase 2 trial of WR 279,396 
(paromomycin and gentamicin) for cutaneous leishmaniasis in Panama. The 
American journal of tropical medicine and hygiene 89, 557-563, 
doi:10.4269/ajtmh.12-0736 (2013). 
41 Robert-Gangneux, F. & Darde, M. L. Epidemiology of and diagnostic strategies for 
toxoplasmosis. Clinical microbiology reviews 25, 264-296, 
doi:10.1128/CMR.05013-11 (2012). 
42 Baltzan, M., Mehta, S., Kirkham, T. H. & Cosio, M. G. Randomized trial of 
prolonged chloroquine therapy in advanced pulmonary sarcoidosis. American 
journal of respiratory and critical care medicine 160, 192-197, 
doi:10.1164/ajrccm.160.1.9809024 (1999). 
43 Cohen, H. G. & Reynolds, T. B. Comparison of metronidazole and chloroquine for 
the treatment of amoebic liver abscess. A controlled trial. Gastroenterology 69, 35-
41 (1975). 
44 Montoya, J. G. & Liesenfeld, O. Toxoplasmosis. Lancet 363, 1965-1976, 
doi:10.1016/S0140-6736(04)16412-X (2004). 
45 Baggish, A. L. & Hill, D. R. Antiparasitic agent atovaquone. Antimicrobial agents 
and chemotherapy 46, 1163-1173 (2002). 
46 Araujo, F. G., Huskinson, J. & Remington, J. S. Remarkable in vitro and in vivo 
activities of the hydroxynaphthoquinone 566C80 against tachyzoites and tissue 
cysts of Toxoplasma gondii. Antimicrobial agents and chemotherapy 35, 293-299 
(1991). 
47 Bernhard, G. C. Auranofin Therapy in Rheumatoid-Arthritis. J Lab Clin Med 100, 
167-177 (1982). 
48 Furst, D. E., Abruzzo, J. L., Katz, W. A., Dahl, S. L. & Ward, J. R. Mechanism of 
Action, Pharmacology, Clinical Efficacy and Side-Effects of Auranofin - an Orally-
Administered Organic Gold Compound for the Treatment of Rheumatoid-Arthritis. 
Pharmacotherapy 3, 284-298 (1983). 
49 Shaw, C. F. Gold-based therapeutic agents. Chem Rev 99, 2589-2600 (1999). 
50 Berners-Price, S. J. & Filipovska, A. Gold compounds as therapeutic agents for 
human diseases. Metallomics 3, 863-873 (2011). 
51 Lobanov, A. V., Gromer, S., Salinas, G. & Gladyshev, V. N. Selenium metabolism 
in Trypanosoma: characterization of selenoproteomes and identification of a 
Kinetoplastida-specific selenoprotein. Nucleic acids research 34, 4012-4024, 
doi:10.1093/nar/gkl541 (2006). 
52 Kuntz, A. N. et al. Thioredoxin glutathione reductase from Schistosoma mansoni: 
an essential parasite enzyme and a key drug target. PLoS medicine 4, e206, 
doi:10.1371/journal.pmed.0040206 (2007). 
53 Bonilla, M. et al. Platyhelminth mitochondrial and cytosolic redox homeostasis is 
controlled by a single thioredoxin glutathione reductase and dependent on selenium 







54 Sannella, A. R. et al. New uses for old drugs. Auranofin, a clinically established 
antiarthritic metallodrug, exhibits potent antimalarial effects in vitro: Mechanistic 
and pharmacological implications. FEBS letters 582, 844-847, 
doi:10.1016/j.febslet.2008.02.028 (2008). 
55 Ilari, A. et al. A gold-containing drug against parasitic polyamine metabolism: the 
X-ray structure of trypanothione reductase from Leishmania infantum in complex 
with auranofin reveals a dual mechanism of enzyme inhibition. Amino acids 42, 
803-811, doi:10.1007/s00726-011-0997-9 (2012). 
56 Gottlieb, N. L. Pharmacology of Auranofin - Overview and Update. Scand J 
Rheumatol, 19-28 (1986). 
57 Cassetta, M. I., Marzo, T., Fallani, S., Novelli, A. & Messori, L. Drug repositioning: 
auranofin as a prospective antimicrobial agent for the treatment of severe 
staphylococcal infections. Biometals : an international journal on the role of metal 
ions in biology, biochemistry, and medicine 27, 787-791, doi:10.1007/s10534-014-
9743-6 (2014). 
58 Hokai, Y. et al. Auranofin and related heterometallic gold(I)-thiolates as potent 
inhibitors of methicillin-resistant Staphylococcus aureus bacterial strains. Journal 
of inorganic biochemistry 138, 81-88, doi:10.1016/j.jinorgbio.2014.05.008 (2014). 
59 Schewe, T. Molecular actions of ebselen--an antiinflammatory antioxidant. 
General pharmacology 26, 1153-1169 (1995). 
60 Azad, G. K. & Tomar, R. S. Ebselen, a promising antioxidant drug: mechanisms of 
action and targets of biological pathways. Mol Biol Rep 41, 4865-4879, 
doi:10.1007/s11033-014-3417-x (2014). 
61 Muller, A., Cadenas, E., Graf, P. & Sies, H. A novel biologically active seleno-
organic compound--I. Glutathione peroxidase-like activity in vitro and antioxidant 
capacity of PZ 51 (Ebselen). Biochemical pharmacology 33, 3235-3239 (1984). 
62 Maiorino, M., Roveri, A. & Ursini, F. Antioxidant effect of Ebselen (PZ 51): 
peroxidase mimetic activity on phospholipid and cholesterol hydroperoxides vs 
free radical scavenger activity. Archives of biochemistry and biophysics 295, 404-
409 (1992). 
63 Handa, Y. et al. Effect of an antioxidant, ebselen, on development of chronic 
cerebral vasospasm after subarachnoid hemorrhage in primates. Surgical neurology 
53, 323-329 (2000). 
64 Kobayashi, T., Ohta, Y. & Yoshino, J. Preventive effect of ebselen on acute gastric 
mucosal lesion development in rats treated with compound 48/80. European 
journal of pharmacology 414, 271-279 (2001). 
65 Parnham, M. J. & Sies, H. The early research and development of ebselen. 
Biochemical pharmacology 86, 1248-1253, doi:10.1016/j.bcp.2013.08.028 (2013). 
66 Singh, N. et al. A safe lithium mimetic for bipolar disorder. Nat Commun 4, 1332, 
doi:10.1038/ncomms2320 (2013). 
67 Nozawa, R., Yokota, T. & Fujimoto, T. Susceptibility of methicillin-resistant 
Staphylococcus aureus to the selenium-containing compound 2-phenyl-1,2-





68 Lu, J. et al. Inhibition of bacterial thioredoxin reductase: an antibiotic mechanism 
targeting bacteria lacking glutathione. FASEB J 27, 1394-1403, doi:10.1096/fj.12-
223305 (2013). 
69 Chan, G., Hardej, D., Santoro, M., Lau-Cam, C. & Billack, B. Evaluation of the 
antimicrobial activity of ebselen: role of the yeast plasma membrane H+-ATPase. 
J Biochem Mol Toxicol 21, 252-264, doi:10.1002/jbt.20189 (2007). 
70 Imai, H., Masayasu, H., Dewar, D., Graham, D. I. & Macrae, I. M. Ebselen protects 
both gray and white matter in a rodent model of focal cerebral ischemia. Stroke; a 
journal of cerebral circulation 32, 2149-2154 (2001). 
71 Sandrini, M. P., Shannon, O., Clausen, A. R., Bjorck, L. & Piskur, J. 
Deoxyribonucleoside kinases activate nucleoside antibiotics in severely pathogenic 
bacteria. Antimicrobial agents and chemotherapy 51, 2726-2732, 
doi:10.1128/AAC.00081-07 (2007). 
72 Hamilton-Miller, J. M. Antimicrobial activity of 21 anti-neoplastic agents. British 
journal of cancer 49, 367-369 (1984). 
73 Jacobs, J. Y., Michel, J. & Sacks, T. Bactericidal effect of combinations of 
antimicrobial drugs and antineoplastic antibiotics against Staphylococcus aureus. 
Antimicrobial agents and chemotherapy 15, 580-586 (1979). 
74 Phillips, M., Malloy, G., Nedunchezian, D., Lukrec, A. & Howard, R. G. 
Disulfiram inhibits the in vitro growth of methicillin-resistant staphylococcus 
aureus. Antimicrobial agents and chemotherapy 35, 785-787 (1991). 
75 Dastidar, S. G., Debnath, S., Mazumdar, K., Ganguly, K. & Chakrabarty, A. N. 
Triflupromazine: a microbicide non-antibiotic compound. Acta microbiologica et 
immunologica Hungarica 51, 75-83 (2004). 
76 Kruszewska, H., Zareba, T. & Tyski, S. Search of antimicrobial activity of selected 
non-antibiotic drugs. Acta poloniae pharmaceutica 59, 436-439 (2002). 
77 Karak, P., Kumar, K. A., Mazumdar, K., Mookerjee, M. & Dastidar, S. G. 
Antibacterial potential of an antispasmodic drug dicyclomine hydrochloride. The 
Indian journal of medical research 118, 192-196 (2003). 
78 Rani Basu, L., Mazumdar, K., Dutta, N. K., Karak, P. & Dastidar, S. G. 
Antibacterial property of the antipsychotic agent prochlorperazine, and its 
synergism with methdilazine. Microbiological research 160, 95-100 (2005). 
79 Jerwood, S. & Cohen, J. Unexpected antimicrobial effect of statins. The Journal of 
antimicrobial chemotherapy 61, 362-364, doi:10.1093/jac/dkm496 (2008). 
80 Chiu, H. C. et al. Development of novel antibacterial agents against methicillin-
resistant Staphylococcus aureus. Bioorganic & medicinal chemistry 20, 4653-4660, 
doi:10.1016/j.bmc.2012.06.018 (2012). 
81 Kruszewska, H., Zareba, T. & Tyski, S. Estimation of antimicrobial activity of 
selected non-antibiotic products. Acta poloniae pharmaceutica 63, 457-460 (2006). 
82 Mandal, A., Sinha, C., Kumar Jena, A., Ghosh, S. & Samanta, A. An Investigation 
on in vitro and in vivo Antimicrobial Properties of the Antidepressant: 
Amitriptyline Hydrochloride. Brazilian journal of microbiology : [publication of 





83 El-Nakeeb, M. A., Abou-Shleib, H. M., Khalil, A. M., Omar, H. G. & El-Halfawy, 
O. M. In vitro antibacterial activity of some antihistaminics belonging to different 
groups against multi-drug resistant clinical isolates. Brazilian journal of 
microbiology : [publication of the Brazilian Society for Microbiology] 42, 980-991, 
doi:10.1590/S1517-838220110003000018 (2011). 
84 Kruszewska, H., Zareba, T. & Tyski, S. in Acta poloniae pharmaceutica Vol. 59   
436-439 (2002). 
85 Dutta, N. K. et al. Potential management of resistant microbial infections with a 
novel non-antibiotic: the anti-inflammatory drug diclofenac sodium. International 
journal of antimicrobial agents 30, 242-249, 
doi:10.1016/j.ijantimicag.2007.04.018 (2007). 
86 Mazumdar, K. et al. Antimicrobial potentiality of a new non-antibiotic: the 
cardiovascular drug oxyfedrine hydrochloride. Microbiological research 158, 259-
264, doi:10.1078/0944-5013-00204 (2003). 
87 Al-Janabi, A. A. In vitro antibacterial activity of Ibuprofen and acetaminophen. 
Journal of global infectious diseases 2, 105-108, doi:10.4103/0974-777X.62880 
(2010). 
88 Kruszewska, H., Zareba, T. & Tyski, S. Examination of antimicrobial activity of 
selected non-antibiotic products. Acta poloniae pharmaceutica 67, 733-736 (2010). 
89 Kruszewska, H., Zareba, T. & Tyski, S. Examination of antibacterial and antifungal 
activity of selected non-antibiotic products. Acta poloniae pharmaceutica 65, 779-
782 (2008). 
90 Munoz-Bellido, J. L., Munoz-Criado, S. & Garcia-Rodriguez, J. A. Antimicrobial 
activity of psychotropic drugs: selective serotonin reuptake inhibitors. 
International journal of antimicrobial agents 14, 177-180 (2000). 
91 Holohan, C., Van Schaeybroeck, S., Longley, D. B. & Johnston, P. G. Cancer drug 
resistance: an evolving paradigm. Nature reviews. Cancer 13, 714-726, 
doi:10.1038/nrc3599 (2013). 
92 Phillips, T. A., Howell, A., Grieve, R. J. & Welling, P. G. Pharmacokinetics of oral 
and intravenous fluorouracil in humans. Journal of pharmaceutical sciences 69, 
1428-1431 (1980). 
93 Bodet, C. A., 3rd, Jorgensen, J. H. & Drutz, D. J. Antibacterial activities of 
antineoplastic agents. Antimicrobial agents and chemotherapy 28, 437-439 (1985). 
94 Barberi-Heyob, M. et al. Evaluation of plasma 5-fluorouracil nucleoside levels in 
patients with metastatic breast cancer: relationships with toxicities. Cancer 
chemotherapy and pharmacology 37, 110-116 (1995). 
95 Roobol, C., De Dobbeleer, G. B. & Bernheim, J. L. 5-fluorouracil and 5-fluoro-2'-
deoxyuridine follow different metabolic pathways in the induction of cell lethality 
in L1210 leukaemia. British journal of cancer 49, 739-744 (1984). 
96 Schilcher, R. B., Young, J. D., Ratanatharathorn, V., Karanes, C. & Baker, L. H. 
Clinical pharmacokinetics of high-dose mitomycin C. Cancer chemotherapy and 
pharmacology 13, 186-190 (1984). 
97 Daum, R. S. Clinical practice. Skin and soft-tissue infections caused by methicillin-
resistant Staphylococcus aureus. The New England journal of medicine 357, 380-




98 DeLeo, F. R., Otto, M., Kreiswirth, B. N. & Chambers, H. F. Community-
associated meticillin-resistant Staphylococcus aureus. Lancet 375, 1557-1568, 
doi:10.1016/S0140-6736(09)61999-1 (2010). 
99 Miller, L. G. & Diep, B. A. Clinical practice: colonization, fomites, and virulence: 
rethinking the pathogenesis of community-associated methicillin-resistant 
Staphylococcus aureus infection. Clinical infectious diseases : an official 
publication of the Infectious Diseases Society of America 46, 752-760, 
doi:10.1086/526773 (2008). 
100 Gallelli, L. et al. The effects of nonsteroidal anti-inflammatory drugs on clinical 
outcomes, synovial fluid cytokine concentration and signal transduction pathways 
in knee osteoarthritis. A randomized open label trial. Osteoarthritis and cartilage / 
OARS, Osteoarthritis Research Society 21, 1400-1408, 
doi:10.1016/j.joca.2013.06.026 (2013). 
101 Yan, J., Sun, J., Huang, L., Fu, Q. & Du, G. Simvastatin prevents 
neuroinflammation by inhibiting N-methyl-D-aspartic acid receptor 1 in 6-
hydroxydopamine-treated PC12 cells. Journal of neuroscience research 92, 634-
640, doi:10.1002/jnr.23329 (2014). 
102 Jialal, I., Miguelino, E., Griffen, S. C. & Devaraj, S. Concomitant reduction of low-
density lipoprotein-cholesterol and biomarkers of inflammation with low-dose 
simvastatin therapy in patients with type 1 diabetes. The Journal of clinical 
endocrinology and metabolism 92, 3136-3140, doi:10.1210/jc.2007-0453 (2007). 
103 Wallace, H. J. & Stacey, M. C. Levels of tumor necrosis factor-alpha (TNF-alpha) 
and soluble TNF receptors in chronic venous leg ulcers--correlations to healing 
status. The Journal of investigative dermatology 110, 292-296, doi:10.1046/j.1523-
1747.1998.00113.x (1998). 
104 Cowin, A. J., Hatzirodos, N., Rigden, J., Fitridge, R. & Belford, D. A. Etanercept 
decreases tumor necrosis factor-alpha activity in chronic wound fluid. Wound 
repair and regeneration : official publication of the Wound Healing Society [and] 
the European Tissue Repair Society 14, 421-426, doi:10.1111/j.1743-
6109.2006.00141.x (2006). 
105 Donath, M. Y. Targeting inflammation in the treatment of type 2 diabetes: time to 
start. Nature reviews. Drug discovery 13, 465-476, doi:10.1038/nrd4275 (2014). 
106 Khanna, S. et al. Macrophage dysfunction impairs resolution of inflammation in 
the wounds of diabetic mice. PloS one 5, e9539, doi:10.1371/journal.pone.0009539 
(2010). 
107 Fournier, B. & Philpott, D. J. Recognition of Staphylococcus aureus by the innate 
immune system. Clinical microbiology reviews 18, 521-540, 
doi:10.1128/CMR.18.3.521-540.2005 (2005). 
108 Bitto, A. et al. Simvastatin enhances VEGF production and ameliorates impaired 
wound healing in experimental diabetes. Pharmacological research : the official 
journal of the Italian Pharmacological Society 57, 159-169, 
doi:10.1016/j.phrs.2008.01.005 (2008). 
109 Fischbach, M. A. & Walsh, C. T. Antibiotics for emerging pathogens. Science 325, 




110 Cegelski, L., Marshall, G. R., Eldridge, G. R. & Hultgren, S. J. The biology and 
future prospects of antivirulence therapies. Nature reviews. Microbiology 6, 17-27, 
doi:10.1038/nrmicro1818 (2008). 
111 Lebeis, S. L. & Kalman, D. Aligning antimicrobial drug discovery with complex 
and redundant host-pathogen interactions. Cell host & microbe 5, 114-122, 
doi:10.1016/j.chom.2009.01.008 (2009). 
112 Khodaverdian, V. et al. Discovery of antivirulence agents against methicillin-
resistant Staphylococcus aureus. Antimicrobial agents and chemotherapy 57, 3645-
3652, doi:10.1128/AAC.00269-13 (2013). 
113 Weinandy, F. et al. A beta-lactone-based antivirulence drug ameliorates 
Staphylococcus aureus skin infections in mice. ChemMedChem 9, 710-713, 
doi:10.1002/cmdc.201300325 (2014). 
114 Hilchie, A. L., Wuerth, K. & Hancock, R. E. Immune modulation by multifaceted 
cationic host defense (antimicrobial) peptides. Nature chemical biology 9, 761-768, 
doi:10.1038/nchembio.1393 (2013). 
115 Ejim, L. et al. Combinations of antibiotics and nonantibiotic drugs enhance 
antimicrobial efficacy. Nature chemical biology 7, 348-350, 
doi:10.1038/nchembio.559 (2011). 
116 Kupferwasser, L. I. et al. Salicylic acid attenuates virulence in endovascular 
infections by targeting global regulatory pathways in Staphylococcus aureus. The 
Journal of clinical investigation 112, 222-233, doi:10.1172/JCI16876 (2003). 
117 Needs, C. J. & Brooks, P. M. Clinical pharmacokinetics of the salicylates. Clinical 
pharmacokinetics 10, 164-177, doi:10.2165/00003088-198510020-00004 (1985). 
118 Siddik, Z. H. Cisplatin: mode of cytotoxic action and molecular basis of resistance. 
Oncogene 22, 7265-7279, doi:10.1038/sj.onc.1206933 (2003). 
119 Moayeri, M., Wiggins, J. F., Lindeman, R. E. & Leppla, S. H. Cisplatin inhibition 
of anthrax lethal toxin. Antimicrobial agents and chemotherapy 50, 2658-2665, 
doi:10.1128/AAC.01412-05 (2006). 
120 Artenstein, A. W. et al. Chloroquine enhances survival in Bacillus anthracis 
intoxication. The Journal of infectious diseases 190, 1655-1660, 
doi:10.1086/424853 (2004). 
121 Gordon, V. M., Leppla, S. H. & Hewlett, E. L. Inhibitors of receptor-mediated 
endocytosis block the entry of Bacillus anthracis adenylate cyclase toxin but not 
that of Bordetella pertussis adenylate cyclase toxin. Infection and immunity 56, 
1066-1069 (1988). 
122 Sullivan, D. J., Jr., Gluzman, I. Y., Russell, D. G. & Goldberg, D. E. On the 
molecular mechanism of chloroquine's antimalarial action. Proceedings of the 
National Academy of Sciences of the United States of America 93, 11865-11870 
(1996). 
123 Costa, S. S., Viveiros, M., Amaral, L. & Couto, I. Multidrug Efflux Pumps in 
Staphylococcus aureus: an Update. The open microbiology journal 7, 59-71, 
doi:10.2174/1874285801307010059 (2013). 
124 Poole, K. Efflux pumps as antimicrobial resistance mechanisms. Annals of 




125 Davis, J. M. & Casper, R. Antipsychotic drugs: clinical pharmacology and 
therapeutic use. Drugs 14, 260-282 (1977). 
126 Lader, M. Clinical pharmacology of antipsychotic drugs. The Journal of 
international medical research 17, 1-16 (1989). 
127 Kaatz, G. W., Moudgal, V. V., Seo, S. M. & Kristiansen, J. E. Phenothiazines and 
thioxanthenes inhibit multidrug efflux pump activity in Staphylococcus aureus. 
Antimicrobial agents and chemotherapy 47, 719-726 (2003). 
128 Kristiansen, M. M. et al. Thioridazine reduces resistance of methicillin-resistant 
staphylococcus aureus by inhibiting a reserpine-sensitive efflux pump. In vivo 20, 
361-366 (2006). 
129 Costa, S. S. et al. Exploring the contribution of efflux on the resistance to 
fluoroquinolones in clinical isolates of Staphylococcus aureus. BMC microbiology 
11, 241, doi:10.1186/1471-2180-11-241 (2011). 
130 McGoon, M. D., Vlietstra, R. E., Holmes, D. R., Jr. & Osborn, J. E. The clinical 
use of verapamil. Mayo Clinic proceedings 57, 495-510 (1982). 
131 Aeschlimann, J. R., Dresser, L. D., Kaatz, G. W. & Rybak, M. J. Effects of NorA 
inhibitors on in vitro antibacterial activities and postantibiotic effects of 
levofloxacin, ciprofloxacin, and norfloxacin in genetically related strains of 
Staphylococcus aureus. Antimicrobial agents and chemotherapy 43, 335-340 
(1999). 
132 Foster, T. J. Immune evasion by staphylococci. Nature reviews. Microbiology 3, 
948-958, doi:10.1038/nrmicro1289 (2005). 
133 Veldkamp, K. E. & van Strijp, J. A. Innate immune evasion by staphylococci. 
Advances in experimental medicine and biology 666, 19-31 (2009). 
134 Hornef, M. W., Wick, M. J., Rhen, M. & Normark, S. Bacterial strategies for 
overcoming host innate and adaptive immune responses. Nature immunology 3, 
1033-1040, doi:10.1038/ni1102-1033 (2002). 
135 McCormick, J. K., Yarwood, J. M. & Schlievert, P. M. Toxic shock syndrome and 
bacterial superantigens: an update. Annual review of microbiology 55, 77-104, 
doi:10.1146/annurev.micro.55.1.77 (2001). 
136 Fraser, J. D. Clarifying the mechanism of superantigen toxicity. PLoS biology 9, 
e1001145, doi:10.1371/journal.pbio.1001145 (2011). 
137 Cavaillon, J. M., Adib-Conquy, M., Fitting, C., Adrie, C. & Payen, D. Cytokine 
cascade in sepsis. Scandinavian journal of infectious diseases 35, 535-544, 
doi:10.1080/00365540310015935 (2003). 
138 van Hal, S. J. et al. Predictors of mortality in Staphylococcus aureus Bacteremia. 
Clinical microbiology reviews 25, 362-386, doi:10.1128/CMR.05022-11 (2012). 
139 Kwiecinski, J. et al. Sulfatide attenuates experimental Staphylococcus aureus sepsis 
through a CD1d-dependent pathway. Infection and immunity 81, 1114-1120, 
doi:10.1128/IAI.01334-12 (2013). 
140 Krakauer, T. Update on staphylococcal superantigen-induced signaling pathways 






141 Watson, A. R., Janik, D. K. & Lee, W. T. Superantigen-induced CD4 memory T 
cell anergy. I. Staphylococcal enterotoxin B induces Fyn-mediated negative 
signaling. Cellular immunology 276, 16-25, doi:10.1016/j.cellimm.2012.02.003 
(2012). 
142 Bowdish, D. M., Davidson, D. J., Scott, M. G. & Hancock, R. E. 
Immunomodulatory activities of small host defense peptides. Antimicrobial agents 
and chemotherapy 49, 1727-1732, doi:10.1128/AAC.49.5.1727-1732.2005 (2005). 
143 Scott, M. G. et al. An anti-infective peptide that selectively modulates the innate 
immune response. Nature biotechnology 25, 465-472, doi:10.1038/nbt1288 (2007). 
144 van der Does, A. M. et al. The human lactoferrin-derived peptide hLF1-11 exerts 
immunomodulatory effects by specific inhibition of myeloperoxidase activity. 
Journal of immunology 188, 5012-5019, doi:10.4049/jimmunol.1102777 (2012). 
145 Cirioni, O. et al. IB-367 pre-treatment improves the in vivo efficacy of teicoplanin 
and daptomycin in an animal model of wounds infected with meticillin-resistant 
Staphylococcus aureus. Journal of medical microbiology 62, 1552-1558, 
doi:10.1099/jmm.0.057414-0 (2013). 
146 Silva, R. R. et al. Short-term therapy with simvastatin reduces inflammatory 
mediators and heart inflammation during the acute phase of experimental Chagas 
disease. Mem Inst Oswaldo Cruz 107, 513-521 (2012). 
147 Al-Siyabi, K. et al. Safety of simvastatin and goal attainment for low-density 
lipoprotein cholesterol in sultan qaboos university hospital. Oman Med J 25, 264-
268, doi:10.5001/omj.2010.79 (2010). 
148 Zago, A. C. et al. First-in-man study of simvastatin-eluting stent in de novo 
coronary lesions: the SIMVASTENT study. Circ J 76, 1109-1114 (2012). 
149 Gazzerro, P. et al. Pharmacological actions of statins: a critical appraisal in the 
management of cancer. Pharmacological reviews 64, 102-146, 
doi:10.1124/pr.111.004994 (2012). 
150 Bergman, P. et al. Studies on the antibacterial effects of statins--in vitro and in vivo. 
PLoS One 6, e24394, doi:10.1371/journal.pone.0024394 (2011). 
151 Masadeh, M., Mhaidat, N., Alzoubi, K., Al-Azzam, S. & Alnasser, Z. Antibacterial 
activity of statins: a comparative study of atorvastatin, simvastatin, and rosuvastatin. 
Ann Clin Microbiol Antimicrob 11, 13, doi:10.1186/1476-0711-11-13 (2012). 
152 Farmer, A. R. et al. Effect of HMG-CoA reductase inhibitors on antimicrobial 
susceptibilities for gram-negative rods. J Basic Microbiol 53, 336-339, 
doi:10.1002/jobm.201100614 (2013). 
153 Cabral, M. E., Figueroa, L. I. & Fariña, J. I. Synergistic antifungal activity of statin-
azole associations as witnessed by Saccharomyces cerevisiae- and Candida utilis-
bioassays and ergosterol quantification. Rev Iberoam Micol 30, 31-38, 
doi:10.1016/j.riam.2012.09.006 (2013). 
154 Nalin, D. R. Comment on: unexpected antimicrobial effect of statins. J Antimicrob 
Chemother 61, 1400, doi:10.1093/jac/dkn089 (2008). 
155 Menezes, E. A. et al. In vitro synergism of simvastatin and fluconazole against 




156 den Hollander, W. J. & Kuipers, E. J. Commentary: simvastatin as the key to 
improving H. pylori eradication rates? Aliment Pharmacol Ther 36, 493; author 
reply 494, doi:10.1111/j.1365-2036.2012.05195.x (2012). 
157 Wu, B. Q. et al. Inhibitory effects of simvastatin on staphylococcus aureus 
lipoteichoic acid-induced inflammation in human alveolar macrophages. Clin Exp 
Med, doi:10.1007/s10238-013-0231-z (2013). 
158 Sun, H. Y. & Singh, N. Antimicrobial and immunomodulatory attributes of statins: 
relevance in solid-organ transplant recipients. Clinical infectious diseases : an 
official publication of the Infectious Diseases Society of America 48, 745-755, 
doi:10.1086/597039 (2009). 
159 Terblanche, M., Almog, Y., Rosenson, R. S., Smith, T. S. & Hackam, D. G. Statins 
and sepsis: multiple modifications at multiple levels. The Lancet. Infectious 
diseases 7, 358-368, doi:10.1016/S1473-3099(07)70111-1 (2007). 
160 Wang, H. R., Li, J. J., Huang, C. X. & Jiang, H. Fluvastatin inhibits the expression 
of tumor necrosis factor-alpha and activation of nuclear factor-kappaB in human 
endothelial cells stimulated by C-reactive protein. Clinica chimica acta; 
international journal of clinical chemistry 353, 53-60, 
doi:10.1016/j.cccn.2004.10.007 (2005). 
161 Grip, O., Janciauskiene, S. & Lindgren, S. Atorvastatin activates PPAR-gamma and 
attenuates the inflammatory response in human monocytes. Inflammation research : 
official journal of the European Histamine Research Society ... [et al.] 51, 58-62 
(2002). 
162 Rosenson, R. S., Tangney, C. C. & Casey, L. C. Inhibition of proinflammatory 
cytokine production by pravastatin. Lancet 353, 983-984, doi:10.1016/S0140-
6736(98)05917-0 (1999). 
163 Diomede, L. et al. In vivo anti-inflammatory effect of statins is mediated by 
nonsterol mevalonate products. Arteriosclerosis, thrombosis, and vascular biology 
21, 1327-1332 (2001). 
164 Chang, L. T. et al. Impact of simvastatin and losartan on antiinflammatory effect: 
in vitro study. Journal of cardiovascular pharmacology 49, 20-26, 
doi:10.1097/FJC.0b013e31802ba4ec (2007). 
165 Kanda, H. et al. Antiinflammatory effect of simvastatin in patients with rheumatoid 
arthritis. The Journal of rheumatology 29, 2024-2026 (2002). 
166 Devran, O. et al. C-reactive protein as a predictor of mortality in patients affected 
with severe sepsis in intensive care unit. Multidisciplinary respiratory medicine 7, 
47, doi:10.1186/2049-6958-7-47 (2012). 
167 Lobo, S. M. et al. C-reactive protein levels correlate with mortality and organ 
failure in critically ill patients. Chest 123, 2043-2049 (2003). 
168 Chan, K. Y., Boucher, E. S., Gandhi, P. J. & Silva, M. A. HMG-CoA reductase 
inhibitors for lowering elevated levels of C-reactive protein. American journal of 
health-system pharmacy : AJHP : official journal of the American Society of 






169 Arnaud, C. et al. Statins reduce interleukin-6-induced C-reactive protein in human 
hepatocytes: new evidence for direct antiinflammatory effects of statins. 
Arteriosclerosis, thrombosis, and vascular biology 25, 1231-1236, 
doi:10.1161/01.ATV.0000163840.63685.0c (2005). 
170 Marz, W., Winkler, K., Nauck, M., Bohm, B. O. & Winkelmann, B. R. Effects of 
statins on C-reactive protein and interleukin-6 (the Ludwigshafen Risk and 
Cardiovascular Health study). The American journal of cardiology 92, 305-308 
(2003). 
171 Pruefer, D., Scalia, R. & Lefer, A. M. Simvastatin inhibits leukocyte-endothelial 
cell interactions and protects against inflammatory processes in 
normocholesterolemic rats. Arteriosclerosis, thrombosis, and vascular biology 19, 
2894-2900 (1999). 
172 Weber, C., Erl, W., Weber, K. S. & Weber, P. C. HMG-CoA reductase inhibitors 
decrease CD11b expression and CD11b-dependent adhesion of monocytes to 
endothelium and reduce increased adhesiveness of monocytes isolated from 
patients with hypercholesterolemia. Journal of the American College of Cardiology 
30, 1212-1217 (1997). 
173 Yoshida, M. et al. Hmg-CoA reductase inhibitor modulates monocyte-endothelial 
cell interaction under physiological flow conditions in vitro: involvement of Rho 
GTPase-dependent mechanism. Arteriosclerosis, thrombosis, and vascular biology 
21, 1165-1171 (2001). 
174 Pruefer, D. et al. Simvastatin inhibits inflammatory properties of Staphylococcus 
aureus alpha-toxin. Circulation 106, 2104-2110 (2002). 
175 Liappis, A. P., Kan, V. L., Rochester, C. G. & Simon, G. L. The effect of statins on 
mortality in patients with bacteremia. Clinical infectious diseases : an official 
publication of the Infectious Diseases Society of America 33, 1352-1357, 
doi:10.1086/323334 (2001). 
176 Kruger, P., Fitzsimmons, K., Cook, D., Jones, M. & Nimmo, G. Statin therapy is 
associated with fewer deaths in patients with bacteraemia. Intensive care medicine 
32, 75-79, doi:10.1007/s00134-005-2859-y (2006). 
177 Niren, N. M. Pharmacologic doses of nicotinamide in the treatment of 
inflammatory skin conditions: a review. Cutis 77, 11-16 (2006). 
178 Ungerstedt, J. S., Blomback, M. & Soderstrom, T. Nicotinamide is a potent 
inhibitor of proinflammatory cytokines. Clinical and experimental immunology 
131, 48-52 (2003). 
179 Smith, I. M. & Burmeister, L. F. Biochemically assisted antibiotic treatment of 
lethal murine Staphylococcus aureus septic shock. The American journal of clinical 
nutrition 30, 1364-1368 (1977). 
180 Kyme, P. et al. C/EBPepsilon mediates nicotinamide-enhanced clearance of 
Staphylococcus aureus in mice. The Journal of clinical investigation 122, 3316-
3329, doi:10.1172/JCI62070 (2012). 
181 Gombart, A. F. et al. Aberrant expression of neutrophil and macrophage-related 
genes in a murine model for human neutrophil-specific granule deficiency. Journal 




182 Verbeek, W. et al. Myeloid transcription factor C/EBPepsilon is involved in the 
positive regulation of lactoferrin gene expression in neutrophils. Blood 94, 3141-
3150 (1999). 
183 Williams, S. C. et al. C/EBPepsilon is a myeloid-specific activator of cytokine, 
chemokine, and macrophage-colony-stimulating factor receptor genes. The Journal 
of biological chemistry 273, 13493-13501 (1998). 
184 LeClaire, R. D., Kell, W., Bavari, S., Smith, T. J. & Hunt, R. E. Protective effects 
of niacinamide in staphylococcal enterotoxin-B-induced toxicity. Toxicology 107, 
69-81 (1996). 
185 Krakauer, T. & Buckley, M. Dexamethasone attenuates staphylococcal enterotoxin 
B-induced hypothermic response and protects mice from superantigen-induced 
toxic shock. Antimicrobial agents and chemotherapy 50, 391-395, 
doi:10.1128/AAC.50.1.391-395.2006 (2006). 
186 Krakauer, T., Buckley, M. J., Huzella, L. M. & Alves, D. A. Critical timing, 
location and duration of glucocorticoid administration rescue mice from 
superantigen-induced shock and attenuate lung injury. International 
immunopharmacology 9, 1168-1174, doi:10.1016/j.intimp.2009.06.004 (2009). 
187 Krakauer, T. Differential inhibitory effects of interleukin-10, interleukin-4, and 
dexamethasone on staphylococcal enterotoxin-induced cytokine production and T 
cell activation. Journal of leukocyte biology 57, 450-454 (1995). 
188 Krakauer, T. & Buckley, M. Efficacy of two FDA-approved drug combination in a 
mouse model of staphylococcal enterotoxin B-induced shock. Military medicine 
178, 1024-1028, doi:10.7205/MILMED-D-13-00129 (2013). 
189 Saunders, R. N., Metcalfe, M. S. & Nicholson, M. L. Rapamycin in transplantation: 
a review of the evidence. Kidney international 59, 3-16, doi:10.1046/j.1523-
1755.2001.00460.x (2001). 
190 Krakauer, T., Buckley, M., Issaq, H. J. & Fox, S. D. Rapamycin protects mice from 
staphylococcal enterotoxin B-induced toxic shock and blocks cytokine release in 
vitro and in vivo. Antimicrobial agents and chemotherapy 54, 1125-1131, 
doi:10.1128/AAC.01015-09 (2010). 
191 Krakauer, T. & Buckley, M. Intranasal rapamycin rescues mice from 
staphylococcal enterotoxin B-induced shock. Toxins 4, 718-728, 
doi:10.3390/toxins4090718 (2012). 
192 Krakauer, T. & Stiles, B. G. Pentoxifylline inhibits superantigen-induced toxic 
shock and cytokine release. Clinical and diagnostic laboratory immunology 6, 594-
598 (1999). 
193 Huisinga, J. M., Pipinos, II, Stergiou, N. & Johanning, J. M. Treatment with 
pharmacological agents in peripheral arterial disease patients does not result in 
biomechanical gait changes. Journal of applied biomechanics 26, 341-348 (2010). 
194 Chung, P. Y. & Toh, Y. S. Anti-biofilm agents: recent breakthrough against multi-
drug resistant Staphylococcus aureus. Pathogens and disease 70, 231-239, 
doi:10.1111/2049-632X.12141 (2014). 
195 Chen, M., Yu, Q. & Sun, H. Novel strategies for the prevention and treatment of 
biofilm related infections. International journal of molecular sciences 14, 18488-




196 Dubreuil, L., Houcke, I., Mouton, Y. & Rossignol, J. F. In vitro evaluation of 
activities of nitazoxanide and tizoxanide against anaerobes and aerobic organisms. 
Antimicrobial agents and chemotherapy 40, 2266-2270 (1996). 
197 Tchouaffi-Nana, F. et al. Nitazoxanide inhibits biofilm formation by 
Staphylococcus epidermidis by blocking accumulation on surfaces. Antimicrobial 
agents and chemotherapy 54, 2767-2774, doi:10.1128/AAC.00901-09 (2010). 
198 Siles, S. A., Srinivasan, A., Pierce, C. G., Lopez-Ribot, J. L. & Ramasubramanian, 
A. K. High-throughput screening of a collection of known pharmacologically active 
small compounds for identification of Candida albicans biofilm inhibitors. 
Antimicrobial agents and chemotherapy 57, 3681-3687, doi:10.1128/AAC.00680-
13 (2013). 
199 Shlaes, D. M., Sahm, D., Opiela, C. & Spellbergc, B. The FDA Reboot of Antibiotic 
Development. Antimicrobial agents and chemotherapy 57, 4605-4607, doi:Doi 
10.1128/Aac.01277-13 (2013). 
200 FDA.   Silver Spring, MD  (2014). 
201 FDA.   Silver Spring, MD  (2014). 
202 Cooper, M. A. & Shlaes, D. Fix the antibiotics pipeline. Nature 472, 32-32 (2011). 
203 May, M. Drug Development Time for Teamwork. Nature 509, S4-S5 (2014). 
204 Mohammad, H., Mayhoub, A. S., Cushman, M. & Seleem, M. N. Anti-biofilm 
activity and synergism of novel thiazole compounds with glycopeptide antibiotics 
against multidrug-resistant Staphylococci. The Journal of antibiotics 68, 259-266, 
doi:10.1038/ja.2014.142 (2015). 
205 Gillet, Y. et al. Association between Staphylococcus aureus strains carrying gene 
for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young 
immunocompetent patients. Lancet 359, 753-759, doi:Doi 10.1016/S0140-
6736(02)07877-7 (2002). 
206 David, M. Z. & Daum, R. S. Community-associated methicillin-resistant 
Staphylococcus aureus: epidemiology and clinical consequences of an emerging 
epidemic. Clinical microbiology reviews 23, 616-687, doi:10.1128/CMR.00081-09 
(2010). 
207 Naber, C. K. Staphylococcus aureus bacteremia: epidemiology, pathophysiology, 
and management strategies. Clin Infect Dis 48 Suppl 4, S231-237, 
doi:10.1086/598189 (2009). 
208 Er, J., Wallis, P., Maloney, S. & Norton, R. Paediatric bacteraemias in tropical 
Australia. Journal of paediatrics and child health 51, 437-442, 
doi:10.1111/jpc.12750 (2015). 
209 Locke, J. B. et al. Elevated Linezolid Resistance in Clinical cfr-Positive 
Staphylococcus aureus Isolates Is Associated with Co-Occurring Mutations in 
Ribosomal Protein L3. Antimicrobial agents and chemotherapy 54, 5352-5355, 
doi:Doi 10.1128/Aac.00714-10 (2010). 
210 Thangamani, S., Mohammad, H., Younis, W. & Seleem, M. N. Drug Repurposing 





211 Thangamani, S., Younis, W. & Seleem, M. N. Repurposing ebselen for treatment 
of multidrug-resistant staphylococcal infections. Scientific reports 5, 11596, 
doi:10.1038/srep11596 (2015). 
212 Cassetta, M. I., Marzo, T., Fallani, S., Novelli, A. & Messori, L. Drug repositioning: 
auranofin as a prospective antimicrobial agent for the treatment of severe 
staphylococcal infections. Biometals 27, 787-791, doi:DOI 10.1007/s10534-014-
9743-6 (2014). 
213 Harbut, M. B. et al. Auranofin exerts broad-spectrum bactericidal activities by 
targeting thiol-redox homeostasis. Proceedings of the National Academy of 
Sciences of the United States of America 112, 4453-4458, 
doi:10.1073/pnas.1504022112 (2015). 
214 Hokai, Y. et al. Auranofin and related heterometallic gold(I)-thiolates as potent 
inhibitors of methicillin-resistant Staphylococcus aureus bacterial strains. J Inorg 
Biochem 138, 81-88, doi:DOI 10.1016/j.jinorgbio.2014.05.008 (2014). 
215 Aguinagalde, L. et al. Auranofin efficacy against MDR Streptococcus pneumoniae 
and Staphylococcus aureus infections. The Journal of antimicrobial chemotherapy 
70, 2608-2617, doi:10.1093/jac/dkv163 (2015). 
216 Mohamed, M. F., Hamed, M. I., Panitch, A. & Seleem, M. N. Targeting 
Methicillin-Resistant Staphylococcus aureus with Short Salt-Resistant Synthetic 
Peptides. Antimicrobial agents and chemotherapy 58, 4113-4122, 
doi:10.1128/AAC.02578-14 (2014). 
217 Randall, C. P., Mariner, K. R., Chopra, I. & O'Neill, A. J. The target of daptomycin 
is absent from Escherichia coli and other gram-negative pathogens. Antimicrobial 
agents and chemotherapy 57, 637-639, doi:10.1128/AAC.02005-12 (2013). 
218 Viljanen, P. & Vaara, M. Susceptibility of gram-negative bacteria to polymyxin B 
nonapeptide. Antimicrobial agents and chemotherapy 25, 701-705 (1984). 
219 Andrews, G. L., Simons, B. L., Young, J. B., Hawkridge, A. M. & Muddiman, D. 
C. Performance characteristics of a new hybrid quadrupole time-of-flight tandem 
mass spectrometer (TripleTOF 5600). Analytical chemistry 83, 5442-5446, 
doi:10.1021/ac200812d (2011). 
220 Cox, J. & Mann, M. MaxQuant enables high peptide identification rates, 
individualized p.p.b.-range mass accuracies and proteome-wide protein 
quantification. Nature biotechnology 26, 1367-1372, doi:10.1038/nbt.1511 (2008). 
221 Seral, C., Van Bambeke, F. & Tulkens, P. M. Quantitative analysis of gentamicin, 
azithromycin, telithromycin, ciprofloxacin, moxifloxacin, and oritavancin 
(LY333328) activities against intracellular Staphylococcus aureus in mouse J774 
macrophages. Antimicrob Agents Chemother 47, 2283-2292 (2003). 
222 Younis, W., Thangamani, S. & Seleem, M. N. Repurposing Non-Antimicrobial 
Drugs and Clinical Molecules to Treat Bacterial Infections. Current 








223 Meletiadis, J., Pournaras, S., Roilides, E. & Walsh, T. J. Defining fractional 
inhibitory concentration index cutoffs for additive interactions based on self-drug 
additive combinations, Monte Carlo simulation analysis, and in vitro-in vivo 
correlation data for antifungal drug combinations against Aspergillus fumigatus. 
Antimicrobial agents and chemotherapy 54, 602-609, doi:10.1128/AAC.00999-09 
(2010). 
224 King, A. M. et al. Aspergillomarasmine A overcomes metallo-beta-lactamase 
antibiotic resistance. Nature 510, 503-506, doi:10.1038/nature13445 (2014). 
225 Wu, Y. S., Koch, K. R., Abratt, V. R. & Klump, H. H. Intercalation into the DNA 
double helix and in vivo biological activity of water-soluble planar 
[Pt(diimine)(N,N-dihydroxyethyl-N'-benzoylthioureato)]+Cl- complexes: a study 
of their thermal stability, their CD spectra and their gel mobility. Archives of 
biochemistry and biophysics 440, 28-37, doi:10.1016/j.abb.2005.05.022 (2005). 
226 Thangamani, S., Younis, W. & Seleem, M. N. Repurposing Clinical Molecule 
Ebselen to Combat Drug Resistant Pathogens. PloS one 10, e0133877, 
doi:10.1371/journal.pone.0133877 (2015). 
227 Haste, N. M. et al. Activity of the thiopeptide antibiotic nosiheptide against 
contemporary strains of methicillin-resistant Staphylococcus aureus. J Antibiot 65, 
593-598, doi:DOI 10.1038/ja.2012.77 (2012). 
228 Okusu, H., Ma, D. & Nikaido, H. AcrAB efflux pump plays a major role in the 
antibiotic resistance phenotype of Escherichia coli multiple-antibiotic-resistance 
(Mar) mutants. J Bacteriol 178, 306-308 (1996). 
229 Lok, C. N. et al. Proteomic analysis of the mode of antibacterial action of silver 
nanoparticles. Journal of proteome research 5, 916-924, doi:10.1021/pr0504079 
(2006). 
230 Bandow, J. E., Brotz, H., Leichert, L. I., Labischinski, H. & Hecker, M. Proteomic 
approach to understanding antibiotic action. Antimicrobial agents and 
chemotherapy 47, 948-955 (2003). 
231 Wenzel, M. et al. Proteomic signature of fatty acid biosynthesis inhibition available 
for in vivo mechanism-of-action studies. Antimicrobial agents and chemotherapy 
55, 2590-2596, doi:10.1128/AAC.00078-11 (2011). 
232 Stevens, D. L. et al. Impact of antibiotics on expression of virulence-associated 
exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus 
aureus. J Infect Dis 195, 202-211, doi:Doi 10.1086/510396 (2007). 
233 Diep, B. A. et al. Effects of Linezolid on Suppressing In Vivo Production of 
Staphylococcal Toxins and Improving Survival Outcomes in a Rabbit Model of 
Methicillin-Resistant Staphylococcus aureus Necrotizing Pneumonia. J Infect Dis 
208, 75-82, doi:DOI 10.1093/infdis/jit129 (2013). 
234 Otto, M. P. et al. Effects of subinhibitory concentrations of antibiotics on virulence 
factor expression by community-acquired methicillin-resistant Staphylococcus 
aureus. J Antimicrob Chemoth 68, 1524-1532, doi:Doi 10.1093/Jac/Dkt073 (2013). 
235 Karau, M. J. et al. Linezolid Is Superior to Vancomycin in Experimental 
Pneumonia Caused by Superantigen-Producing Staphylococcus aureus in HLA 
Class II Transgenic Mice. Antimicrobial agents and chemotherapy 56, 5401-5405, 




236 Lemaire, S. et al. Restoration of susceptibility of intracellular methicillin-resistant 
Staphylococcus aureus to beta-lactams: comparison of strains, cells, and antibiotics. 
Antimicrobial agents and chemotherapy 52, 2797-2805, doi:10.1128/AAC.00123-
08 (2008). 
237 Tenover, F. C. & Goering, R. V. Methicillin-resistant Staphylococcus aureus strain 
USA300: origin and epidemiology. The Journal of antimicrobial chemotherapy 64, 
441-446, doi:10.1093/jac/dkp241 (2009). 
238 Garzoni, C. & Kelley, W. L. Staphylococcus aureus: new evidence for intracellular 
persistence. Trends in microbiology 17, 59-65, doi:10.1016/j.tim.2008.11.005 
(2009). 
239 Ellington, J. K. et al. Intracellular Staphylococcus aureus. A mechanism for the 
indolence of osteomyelitis. The Journal of bone and joint surgery. British volume 
85, 918-921 (2003). 
240 Fowler, V. G., Jr. et al. Staphylococcus aureus endocarditis: a consequence of 
medical progress. Jama 293, 3012-3021, doi:10.1001/jama.293.24.3012 (2005). 
241 Ellington, J. K. et al. Intracellular Staphylococcus aureus and antibiotic resistance: 
implications for treatment of staphylococcal osteomyelitis. Journal of orthopaedic 
research : official publication of the Orthopaedic Research Society 24, 87-93, 
doi:10.1002/jor.20003 (2006). 
242 Seleem, M. N. et al. Targeting Brucella melitensis with polymeric nanoparticles 
containing streptomycin and doxycycline. FEMS microbiology letters 294, 24-31, 
doi:10.1111/j.1574-6968.2009.01530.x (2009). 
243 Rubinstein, E., Kollef, M. H. & Nathwani, D. Pneumonia caused by methicillin-
resistant Staphylococcus aureus. Clinical infectious diseases : an official 
publication of the Infectious Diseases Society of America 46 Suppl 5, S378-385, 
doi:10.1086/533594 (2008). 
244 Deresinski, S. Vancomycin in combination with other antibiotics for the treatment 
of serious methicillin-resistant Staphylococcus aureus infections. Clinical 
infectious diseases : an official publication of the Infectious Diseases Society of 
America 49, 1072-1079, doi:10.1086/605572 (2009). 
245 Appelbaum, P. C. Microbiology of antibiotic resistance in Staphylococcus aureus. 
Clinical infectious diseases : an official publication of the Infectious Diseases 
Society of America 45 Suppl 3, S165-170, doi:10.1086/519474 (2007). 
246 Huang, V. & Rybak, M. J. Pharmacodynamics of cefepime alone and in 
combination with various antimicrobials against methicillin-resistant 
Staphylococcus aureus in an in vitro pharmacodynamic infection model. 
Antimicrobial agents and chemotherapy 49, 302-308, doi:10.1128/AAC.49.1.302-
308.2005 (2005). 
247 Drago, L., De Vecchi, E., Nicola, L. & Gismondo, M. R. In vitro evaluation of 
antibiotics' combinations for empirical therapy of suspected methicillin resistant 
Staphylococcus aureus severe respiratory infections. BMC infectious diseases 7, 
111, doi:10.1186/1471-2334-7-111 (2007). 
248 Seras-Franzoso, J. et al. Disulfide bond formation and activation of Escherichia coli 
beta-galactosidase under oxidizing conditions. Applied and environmental 




249 Jackson-Rosario, S. et al. Auranofin disrupts selenium metabolism in Clostridium 
difficile by forming a stable Au-Se adduct. Journal of biological inorganic 
chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry 
14, 507-519, doi:10.1007/s00775-009-0466-z (2009). 
250 Jackson-Rosario, S. & Self, W. T. Inhibition of selenium metabolism in the oral 
pathogen Treponema denticola. Journal of bacteriology 191, 4035-4040, 
doi:10.1128/JB.00164-09 (2009). 
251 Kryukov, G. V. & Gladyshev, V. N. The prokaryotic selenoproteome. EMBO 
reports 5, 538-543, doi:10.1038/sj.embor.7400126 (2004). 
252 O'Neill, A. J., Cove, J. H. & Chopra, I. Mutation frequencies for resistance to 
fusidic acid and rifampicin in Staphylococcus aureus. The Journal of antimicrobial 
chemotherapy 47, 647-650 (2001). 
253 Ling, L. L. et al. A new antibiotic kills pathogens without detectable resistance. 
Nature 517, 455-459, doi:10.1038/nature14098 (2015). 
254 Surewaard, B. G. et al. Staphylococcal alpha-phenol soluble modulins contribute 
to neutrophil lysis after phagocytosis. Cellular microbiology 15, 1427-1437, 
doi:10.1111/cmi.12130 (2013). 
255 Stryjewski, M. E. & Chambers, H. F. Skin and soft-tissue infections caused by 
community-acquired methicillin-resistant Staphylococcus aureus. Clinical 
infectious diseases : an official publication of the Infectious Diseases Society of 
America 46 Suppl 5, S368-377, doi:10.1086/533593 (2008). 
256 Montgomery, C. P. et al. Local inflammation exacerbates the severity of 
Staphylococcus aureus skin infection. PloS one 8, e69508, 
doi:10.1371/journal.pone.0069508 (2013). 
257 del Rio, A., Cervera, C., Moreno, A., Moreillon, P. & Miro, J. M. Patients at risk 
of complications of Staphylococcus aureus bloodstream infection. Clinical 
infectious diseases : an official publication of the Infectious Diseases Society of 
America 48 Suppl 4, S246-253, doi:10.1086/598187 (2009). 
258 Keynan, Y. & Rubinstein, E. Staphylococcus aureus bacteremia, risk factors, 
complications, and management. Critical care clinics 29, 547-562, 
doi:10.1016/j.ccc.2013.03.008 (2013). 
259 McNeil, J. C., Hulten, K. G., Kaplan, S. L. & Mason, E. O. Mupirocin resistance in 
Staphylococcus aureus causing recurrent skin and soft tissue infections in children. 
Antimicrobial agents and chemotherapy 55, 2431-2433, doi:10.1128/AAC.01587-
10 (2011). 
260 Farrell, D. J., Castanheira, M. & Chopra, I. Characterization of global patterns and 
the genetics of fusidic acid resistance. Clinical infectious diseases : an official 
publication of the Infectious Diseases Society of America 52 Suppl 7, S487-492, 
doi:10.1093/cid/cir164 (2011). 
261 Corey, G. R., Jiang, H. & Moeck, G. Dalbavancin or oritavancin for skin infections. 
The New England journal of medicine 371, 1162-1163 (2014). 
262 Shorr, A. F. et al. Analysis of the phase 3 ESTABLISH trials of tedizolid versus 
linezolid in acute bacterial skin and skin structure infections. Antimicrobial agents 




263 Debnath, A. et al. A high-throughput drug screen for Entamoeba histolytica 
identifies a new lead and target. Nat Med 18, 956-+, doi:Doi 10.1038/Nm.2758 
(2012). 
264 Harbut, M. B. et al. Auranofin exerts broad-spectrum bactericidal activities by 
targeting thiol-redox homeostasis. Proceedings of the National Academy of 
Sciences of the United States of America 112, 4453-4458, doi:DOI 
10.1073/pnas.1504022112 (2015). 
265 Aguinagalde, L. et al. Auranofin efficacy against MDR Streptococcus pneumoniae 
and Staphylococcus aureus infections. The Journal of antimicrobial chemotherapy, 
doi:10.1093/jac/dkv163 (2015). 
266 Mohamed, M. F. & Seleem, M. N. Efficacy of short novel antimicrobial and anti-
inflammatory peptides in a mouse model of methicillin-resistant Staphylococcus 
aureus (MRSA) skin infection. Drug design, development and therapy 8, 1979-
1983, doi:10.2147/DDDT.S72129 (2014). 
267 Conlon, B. P. et al. Activated ClpP kills persisters and eradicates a chronic biofilm 
infection. Nature 503, 365-370, doi:10.1038/nature12790 (2013). 
268 Hu, Y. & Coates, A. R. Enhancement by novel anti-methicillin-resistant 
Staphylococcus aureus compound HT61 of the activity of neomycin, gentamicin, 
mupirocin and chlorhexidine: in vitro and in vivo studies. The Journal of 
antimicrobial chemotherapy 68, 374-384, doi:10.1093/jac/dks384 (2013). 
269 Huang, L., Dai, T., Xuan, Y., Tegos, G. P. & Hamblin, M. R. Synergistic 
combination of chitosan acetate with nanoparticle silver as a topical antimicrobial: 
efficacy against bacterial burn infections. Antimicrobial agents and chemotherapy 
55, 3432-3438, doi:10.1128/AAC.01803-10 (2011). 
270 Mah, T. F. & O'Toole, G. A. Mechanisms of biofilm resistance to antimicrobial 
agents. Trends in microbiology 9, 34-39 (2001). 
271 Egsmose, C. et al. Patients with rheumatoid arthritis benefit from early 2nd line 
therapy: 5 year followup of a prospective double blind placebo controlled study. 
The Journal of rheumatology 22, 2208-2213 (1995). 
272 Forcade, N. A. et al. Prevalence, severity, and treatment of community-acquired 
methicillin-resistant Staphylococcus aureus (CA-MRSA) skin and soft tissue 
infections in 10 medical clinics in Texas: a South Texas Ambulatory Research 
Network (STARNet) study. Journal of the American Board of Family Medicine : 
JABFM 24, 543-550, doi:10.3122/jabfm.2011.05.110073 (2011). 
273 Odell, C. A. Community-associated methicillin-resistant Staphylococcus aureus 
(CA-MRSA) skin infections. Current opinion in pediatrics 22, 273-277, 
doi:10.1097/MOP.0b013e328339421b (2010). 
274 Skiest, D. J. & Cooper, T. W. High recurrence rate of CA-MRSA skin and soft 
tissue infections. Archives of internal medicine 167, 2527author reply 2527, 
doi:10.1001/archinte.167.22.2527-a (2007). 
275 Austin, C. P., Brady, L. S., Insel, T. R. & Collins, F. S. NIH Molecular Libraries 
Initiative. Science 306, 1138-1139, doi:10.1126/science.1105511 (2004). 
276 Thangamani, S., Mohammad, H., Younis, W. & Seleem, M. N. Drug Repurposing 





277 Chong, C. R. & Sullivan, D. J. New uses for old drugs. Nature 448, 645-646 (2007). 
278 Ashburn, T. T. & Thor, K. B. Drug repositioning: identifying and developing new 
uses for existing drugs. Nat Rev Drug Discov 3, 673-683, doi:10.1038/nrd1468 
(2004). 
279 Stevens, D. L., Maier, K. A. & Mitten, J. E. Effect of antibiotics on toxin production 
and viability of Clostridium perfringens. Antimicrobial agents and chemotherapy 
31, 213-218 (1987). 
280 Stevens, D. L. et al. Impact of antibiotics on expression of virulence-associated 
exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus 
aureus. The Journal of infectious diseases 195, 202-211, doi:10.1086/510396 
(2007). 
281 Rioja, I., Bush, K. A., Buckton, J. B., Dickson, M. C. & Life, P. F. Joint cytokine 
quantification in two rodent arthritis models: kinetics of expression, correlation of 
mRNA and protein levels and response to prednisolone treatment. Clinical and 
experimental immunology 137, 65-73, doi:10.1111/j.1365-2249.2004.02499.x 
(2004). 
282 Morones-Ramirez, J. R., Winkler, J. A., Spina, C. S. & Collins, J. J. Silver enhances 
antibiotic activity against gram-negative bacteria. Science translational medicine 5, 
190ra181, doi:10.1126/scitranslmed.3006276 (2013). 
283 Bassani, A. S. P., Banov, D. M. & Lehman, P. A. M. Evaluation of the Percutaneous 
Absorption of Promethazine Hydrochloride, In Vitro, Using the Human Ex Vivo 
Skin Model. International journal of pharmaceutical compounding 12, 270-273 
(2008). 
284 Berk, D. R. & Bayliss, S. J. MRSA, staphylococcal scalded skin syndrome, and 
other cutaneous bacterial emergencies. Pediatric annals 39, 627-633, 
doi:10.3928/00904481-20100922-02 (2010). 
285 Antonelou, M., Knowles, J., Siddiqi, S. & Sharma, P. Recurrent cutaneous 
abscesses caused by PVL-MRSA. BMJ case reports 2011, 
doi:10.1136/bcr.01.2011.3680 (2011). 
286 Payne, D. J., Gwynn, M. N., Holmes, D. J. & Pompliano, D. L. Drugs for bad bugs: 
confronting the challenges of antibacterial discovery. Nature reviews. Drug 
discovery 6, 29-40, doi:10.1038/nrd2201 (2007). 
287 Lubick, N. Tools for tracking antibiotic resistance. Environmental health 
perspectives 119, A214-217, doi:10.1289/ehp.119-a214 (2011). 
288 King, M. D. et al. Emergence of community-acquired methicillin-resistant 
Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-
tissue infections. Annals of internal medicine 144, 309-317 (2006). 
289 Diep, B. A. et al. Effects of linezolid on suppressing in vivo production of 
staphylococcal toxins and improving survival outcomes in a rabbit model of 
methicillin-resistant Staphylococcus aureus necrotizing pneumonia. The Journal of 
infectious diseases 208, 75-82, doi:10.1093/infdis/jit129 (2013). 
290 Otto, M. P. et al. Effects of subinhibitory concentrations of antibiotics on virulence 
factor expression by community-acquired methicillin-resistant Staphylococcus 





291 Karau, M. J. et al. Linezolid is superior to vancomycin in experimental pneumonia 
caused by Superantigen-Producing staphylococcus aureus in HLA class II 
transgenic mice. Antimicrobial agents and chemotherapy 56, 5401-5405, 
doi:10.1128/AAC.01080-12 (2012). 
292 Molina-Manso, D. et al. In vitro susceptibility to antibiotics of staphylococci in 
biofilms isolated from orthopaedic infections. International journal of 
antimicrobial agents 41, 521-523, doi:10.1016/j.ijantimicag.2013.02.018 (2013). 
293 Sharma-Kuinkel, B. K., Zhang, Y., Yan, Q., Ahn, S. H. & Fowler, V. G., Jr. Host 
gene expression profiling and in vivo cytokine studies to characterize the role of 
linezolid and vancomycin in methicillin-resistant Staphylococcus aureus (MRSA) 
murine sepsis model. PloS one 8, e60463, doi:10.1371/journal.pone.0060463 
(2013). 
294 Kuhl, P., Borbe, H. O., Romer, A., Fischer, H. & Parnham, M. J. Selective 
inhibition of leukotriene B4 formation by Ebselen: a novel approach to 
antiinflammatory therapy. Agents and actions 17, 366-367 (1986). 
295 Jacqueline, C. et al. Linezolid Dampens Neutrophil-Mediated Inflammation in 
Methicillin-Resistant Staphylococcus aureus-Induced Pneumonia and Protects the 
Lung of Associated Damages. The Journal of infectious diseases, 
doi:10.1093/infdis/jiu145 (2014). 
296 Mohammad, H., Mayhoub, A. S., Cushman, M. & Seleem, M. N. Anti-biofilm 
activity and synergism of novel thiazole compounds with glycopeptide antibiotics 
against multidrug-resistant Staphylococci. The Journal of antibiotics, 
doi:10.1038/ja.2014.142 (2014). 
297 Younis, W., Thangamani, S. & Seleem, M. N. Repurposing Non-antimicrobial 
Drugs and Clinical Molecules to Treat Bacterial Infections. Current 
pharmaceutical design (2015). 
298 Favrot, L. et al. Mechanism of inhibition of Mycobacterium tuberculosis antigen 
85 by ebselen. Nature communications 4, 2748, doi:10.1038/ncomms3748 (2013). 
299 Younis, W. T., S.; and Seleem, M.N. Repurposing non-antimicrobial drugs and 
clinical molecules to treat bacterial infections. Current pharmaceutical design 
(2015). 
300 CLSI. Methods for dilution antimicrobial susceptibility tests for bacteria that grow 
aerobically; approved standard M7-A7. CLSI, Wayne, PA.  (2007). 
301 Alajlouni, R. A. & Seleem, M. N. Targeting listeria monocytogenes rpoA and rpoD 
genes using peptide nucleic acids. Nucleic acid therapeutics 23, 363-367, 
doi:10.1089/nat.2013.0426 (2013). 
302 Cohen, D. J. et al. Postoperative intraperitoneal 5-fluoro-2'-deoxyuridine added to 
chemoradiation in patients curatively resected (R0) for locally advanced gastric and 
gastroesophageal junction adenocarcinoma. Annals of surgical oncology 19, 478-
485, doi:10.1245/s10434-011-1940-8 (2012). 
303 Delcour, A. H. Outer membrane permeability and antibiotic resistance. Biochimica 
et biophysica acta 1794, 808-816, doi:10.1016/j.bbapap.2008.11.005 (2009). 
304 Nakae, T. The problems in the outer membrane permeability and the antibiotic 
resistance of Pseudomonas aeruginosa. The Kitasato archives of experimental 




305 Li, X. Z., Plesiat, P. & Nikaido, H. The challenge of efflux-mediated antibiotic 
resistance in Gram-negative bacteria. Clinical microbiology reviews 28, 337-418, 
doi:10.1128/CMR.00117-14 (2015). 
306 Aeschlimann, J. R. The role of multidrug efflux pumps in the antibiotic resistance 
of Pseudomonas aeruginosa and other gram-negative bacteria. Insights from the 
Society of Infectious Diseases Pharmacists. Pharmacotherapy 23, 916-924 (2003). 
307 Cruciani, M. et al. Penetration of vancomycin into human lung tissue. J Antimicrob 
Chemoth 38, 865-869 (1996). 
308 Peltola, H., Paakkonen, M., Kallio, P. & Kallio, M. J. T. Bad Bugs, No Drugs: No 
ESCAPE Revisited Reply. Clinical Infectious Diseases 49, 993-993 (2009). 
309 Nau, R. & Eiffert, H. Modulation of release of proinflammatory bacterial 
compounds by antibacterials: potential impact on course of inflammation and 
outcome in sepsis and meningitis. Clinical microbiology reviews 15, 95-110 (2002). 
310 Diep, B. A., Equils, O., Huang, D. B. & Gladue, R. Linezolid effects on bacterial 
toxin production and host immune response: review of the evidence. Current 
therapeutic research, clinical and experimental 73, 86-102, 
doi:10.1016/j.curtheres.2012.04.002 (2012). 
311 McKee, E. E., Ferguson, M., Bentley, A. T. & Marks, T. A. Inhibition of 
mammalian mitochondrial protein synthesis by oxazolidinones. Antimicrobial 
agents and chemotherapy 50, 2042-2049 (2006). 
312 Gerson, S. L. et al. Hematologic effects of linezolid: Summary of clinical 
experience. Antimicrobial agents and chemotherapy 46, 2723-2726 (2002). 
313 Kuter, D. J. & Tillotson, G. S. Hematologic effects of antimicrobials: Focus on the 
oxazolidinone linezolid. Pharmacotherapy 21, 1010-1013 (2001). 
314 McKee, E. E., Ferguson, M., Bentley, A. T. & Marks, T. A. Inhibition of 
mammalian mitochondrial protein synthesis by oxazolidinones. Antimicrobial 
agents and chemotherapy 50, 2042-2049, doi:10.1128/AAC.01411-05 (2006). 
315 Manyan, D. R., Arimura, G. K. & Yunis, A. A. Chloramphenicol-induced erythroid 
suppression and bone marrow ferrochelatase activity in dogs. The Journal of 
laboratory and clinical medicine 79, 137-144 (1972). 
316 Parashar, S., Rao, R., Tikare, S. K. & Tikare, S. S. Chloramphenicol induced 
reversible bone marrow suppression. A case report. Journal of postgraduate 
medicine 18, 90-92 (1972). 
317 Yunis, A. A. Chloramphenicol-induced bone marrow suppression. Seminars in 
hematology 10, 225-234 (1973). 
318 Skripkin, E. et al. R chi-01, a new family of oxazolidinones that overcome 
ribosome-based linezolid resistance. Antimicrobial agents and chemotherapy 52, 
3550-3557 (2008). 
319 Yan, K. et al. Biochemical characterization of the interactions of the novel 
pleuromutilin derivative retapamulin with bacterial ribosomes. Antimicrobial 
agents and chemotherapy 50, 3875-3881 (2006). 
320 Rajamuthiah, R. et al. Repurposing Salicylanilide Anthelmintic Drugs to Combat 





321 Diep, B. A., Carleton, H. A., Chang, R. F., Sensabaugh, G. F. & Perdreau-
Remington, F. Roles of 34 virulence genes in the evolution of hospital- and 
community-associated strains of methicillin-resistant Staphylococcus aureus. The 
Journal of infectious diseases 193, 1495-1503, doi:10.1086/503777 (2006). 
322 Gordon, R. J. & Lowy, F. D. Pathogenesis of methicillin-resistant Staphylococcus 
aureus infection. Clinical infectious diseases : an official publication of the 
Infectious Diseases Society of America 46 Suppl 5, S350-359, doi:10.1086/533591 
(2008). 
323 Guo, S. & Dipietro, L. A. Factors affecting wound healing. Journal of dental 
research 89, 219-229, doi:10.1177/0022034509359125 (2010). 
324 McNeil, J. C., Hulten, K. G., Kaplan, S. L. & Mason, E. O. Decreased 
susceptibilities to Retapamulin, Mupirocin, and Chlorhexidine among 
Staphylococcus aureus isolates causing skin and soft tissue infections in otherwise 
healthy children. Antimicrobial agents and chemotherapy 58, 2878-2883, 
doi:10.1128/AAC.02707-13 (2014). 
325 Ellington, M. J. et al. Emergent and evolving antimicrobial resistance cassettes in 
community-associated fusidic acid and meticillin-resistant Staphylococcus aureus. 
International journal of antimicrobial agents, 
doi:10.1016/j.ijantimicag.2015.01.009 (2015). 
326 Rangel-Vega, A., Bernstein, L. R., Mandujano-Tinoco, E. A., Garcia-Contreras, S. 
J. & Garcia-Contreras, R. Drug repurposing as an alternative for the treatment of 
recalcitrant bacterial infections. Frontiers in microbiology 6, 282, 
doi:10.3389/fmicb.2015.00282 (2015). 
327 Frampton, J. E. & Keating, G. M. Celecoxib: a review of its use in the management 
of arthritis and acute pain. Drugs 67, 2433-2472 (2007). 
328 McCormack, P. L. Celecoxib: a review of its use for symptomatic relief in the 
treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. Drugs 
71, 2457-2489, doi:10.2165/11208240-000000000-00000 (2011). 
329 Bensen, W. G. Antiinflammatory and analgesic efficacy of COX-2 specific 
inhibition: from investigational trials to clinical experience. The Journal of 
rheumatology. Supplement 60, 17-24 (2000). 
330 Pereira, P. A. et al. Celecoxib improves host defense through prostaglandin 
inhibition during Histoplasma capsulatum infection. Mediators of inflammation 
2013, 950981, doi:10.1155/2013/950981 (2013). 
331 Chiu, H. C. et al. Pharmacological exploitation of an off-target antibacterial effect 
of the cyclooxygenase-2 inhibitor celecoxib against Francisella tularensis. 
Antimicrobial agents and chemotherapy 53, 2998-3002, doi:10.1128/AAC.00048-
09 (2009). 
332 Kalle, A. M. & Rizvi, A. Inhibition of bacterial multidrug resistance by celecoxib, 
a cyclooxygenase-2 inhibitor. Antimicrobial agents and chemotherapy 55, 439-442, 
doi:10.1128/AAC.00735-10 (2011). 
333 Annamanedi, M. & Kalle, A. M. Celecoxib sensitizes Staphylococcus aureus to 





334 Cho, J. S. et al. Noninvasive in vivo imaging to evaluate immune responses and 
antimicrobial therapy against Staphylococcus aureus and USA300 MRSA skin 
infections. The Journal of investigative dermatology 131, 907-915, 
doi:10.1038/jid.2010.417 (2011). 
335 Cho, J. S. et al. IL-17 is essential for host defense against cutaneous Staphylococcus 
aureus infection in mice. The Journal of clinical investigation 120, 1762-1773, 
doi:10.1172/JCI40891 (2010). 
336 Mohamed, M. F. & Seleem, M. N. Efficacy of short novel antimicrobial and anti-
inflammatory peptides in a mouse model of methicillin-resistant Staphylococcus 
aureus (MRSA) skin infection. Drug Des Dev Ther 8, 1979-1983, doi:Doi 
10.2147/Dddt.S72129 (2014). 
337 Aryee, A. & Price, N. Antimicrobial stewardship - can we afford to do without it? 
British journal of clinical pharmacology 79, 173-181, doi:10.1111/bcp.12417 
(2015). 
338 Vaara, M. Polymyxins and their novel derivatives. Curr Opin Microbiol 13, 574-
581, doi:10.1016/j.mib.2010.09.002 (2010). 
339 Vaara, M. et al. A novel polymyxin derivative that lacks the fatty acid tail and 
carries only three positive charges has strong synergism with agents excluded by 
the intact outer membrane. Antimicrob Agents Chemother 54, 3341-3346, 
doi:10.1128/AAC.01439-09 (2010). 
340 Velkov, T. et al. Surface changes and polymyxin interactions with a resistant strain 
of Klebsiella pneumoniae. Innate Immun, doi:10.1177/1753425913493337 (2013). 
341 McFarland, M. M., Scott, E. M. & Li Wan Po, A. Time-survival studies for 
quantifying effects of azlocillin and tobramycin on Pseudomonas aeruginosa. 
Antimicrobial agents and chemotherapy 38, 1271-1276 (1994). 
342 White, A. R., Comber, K. R. & Sutherland, R. Comparative bactericidal effects of 
azlocillin and ticarcillin against Pseudomonas aeruginosa. Antimicrobial agents 
and chemotherapy 18, 182-189 (1980). 
343 Patrzykat, A., Friedrich, C. L., Zhang, L., Mendoza, V. & Hancock, R. E. Sublethal 
concentrations of pleurocidin-derived antimicrobial peptides inhibit 
macromolecular synthesis in Escherichia coli. Antimicrobial agents and 
chemotherapy 46, 605-614 (2002). 
344 Ulvatne, H., Samuelsen, O., Haukland, H. H., Kramer, M. & Vorland, L. H. 
Lactoferricin B inhibits bacterial macromolecular synthesis in Escherichia coli and 
Bacillus subtilis. FEMS microbiology letters 237, 377-384, 
doi:10.1016/j.femsle.2004.07.001 (2004). 
345 Freer, E. et al. Brucella-Salmonella lipopolysaccharide chimeras are less permeable 
to hydrophobic probes and more sensitive to cationic peptides and EDTA than are 
their native Brucella sp. counterparts. Journal of bacteriology 178, 5867-5876 
(1996). 
346 Tindall, E. Celecoxib for the treatment of pain and inflammation: the preclinical 





347 Kumar, V., Kaur, K., Gupta, G. K., Gupta, A. K. & Kumar, S. Developments in 
synthesis of the anti-inflammatory drug, celecoxib: a review. Recent patents on 
inflammation & allergy drug discovery 7, 124-134 (2013). 
348 Wilgus, T. A., Vodovotz, Y., Vittadini, E., Clubbs, E. A. & Oberyszyn, T. M. 
Reduction of scar formation in full-thickness wounds with topical celecoxib 
treatment. Wound repair and regeneration : official publication of the Wound 
Healing Society [and] the European Tissue Repair Society 11, 25-34 (2003). 
349 Brynildsen, M. P., Winkler, J. A., Spina, C. S., MacDonald, I. C. & Collins, J. J. 
Potentiating antibacterial activity by predictably enhancing endogenous microbial 
ROS production. Nature biotechnology 31, 160-165, doi:10.1038/nbt.2458 (2013). 
350 Perlin, D. S. Mechanisms of echinocandin antifungal drug resistance. Annals of the 
New York Academy of Sciences 1354, 1-11, doi:10.1111/nyas.12831 (2015). 
351 Perlin, D. S., Shor, E. & Zhao, Y. Update on Antifungal Drug Resistance. Current 
clinical microbiology reports 2, 84-95, doi:10.1007/s40588-015-0015-1 (2015). 
352 Pfaller, M. A. Antifungal drug resistance: mechanisms, epidemiology, and 
consequences for treatment. The American journal of medicine 125, S3-13, 
doi:10.1016/j.amjmed.2011.11.001 (2012). 
353 Sanguinetti, M., Posteraro, B. & Lass-Florl, C. Antifungal drug resistance among 
Candida species: mechanisms and clinical impact. Mycoses 58 Suppl 2, 2-13, 
doi:10.1111/myc.12330 (2015). 
354 Brown, G. D. et al. Hidden killers: human fungal infections. Sci Transl Med 4, 
165rv113, doi:10.1126/scitranslmed.3004404 (2012). 
355 Vandeputte, P., Ferrari, S. & Coste, A. T. Antifungal resistance and new strategies 
to control fungal infections. Int J Microbiol 2012, 713687, 
doi:10.1155/2012/713687 (2012). 
356 Butts, A. & Krysan, D. J. Antifungal drug discovery: something old and something 
new. PLoS Pathog 8, e1002870, doi:10.1371/journal.ppat.1002870 (2012). 
357 Thangamani, S. et al. Antibacterial activity and mechanism of action of auranofin 
against multi-drug resistant bacterial pathogens. Scientific reports 6, 22571, 
doi:10.1038/srep22571 (2016). 
358 Thangamani, S., Mohammad, H., Abushahba, M. F., Sobreira, T. J. & Seleem, M. 
N. Repurposing auranofin for the treatment of cutaneous staphylococcal infections. 
International journal of antimicrobial agents 47, 195-201, 
doi:10.1016/j.ijantimicag.2015.12.016 (2016). 
359 Fuchs, B. B. et al. Inhibition of bacterial and fungal pathogens by the orphaned 
drug auranofin. Future medicinal chemistry 8, 117-132, doi:10.4155/fmc.15.182 
(2016). 
360 Stylianou, M. et al. Antifungal application of nonantifungal drugs. Antimicrobial 
agents and chemotherapy 58, 1055-1062, doi:10.1128/AAC.01087-13 (2014). 
361 da Silva, A. R. et al. Berberine Antifungal Activity in Fluconazole-resistant 
Pathogenic Yeasts: Action Mechanism Evaluated by Flow Cytometry and Biofilm 






362 Canton, E., Peman, J., Gobernado, M., Viudes, A. & Espinel-Ingroff, A. Patterns 
of amphotericin B killing kinetics against seven Candida species. Antimicrobial 
agents and chemotherapy 48, 2477-2482, doi:10.1128/AAC.48.7.2477-2482.2004 
(2004). 
363 Rane, H. S., Bernardo, S. M., Walraven, C. J. & Lee, S. A. In vitro analyses of 
ethanol activity against Candida albicans biofilms. Antimicrobial agents and 
chemotherapy 56, 4487-4489, doi:10.1128/AAC.00263-12 (2012). 
364 Pierce, C. G. et al. A simple and reproducible 96-well plate-based method for the 
formation of fungal biofilms and its application to antifungal susceptibility testing. 
Nature protocols 3, 1494-1500, doi:10.1038/nport.2008.141 (2008). 
365 Dongari-Bagtzoglou, A., Kashleva, H., Dwivedi, P., Diaz, P. & Vasilakos, J. 
Characterization of mucosal Candida albicans biofilms. PloS one 4, e7967, 
doi:10.1371/journal.pone.0007967 (2009). 
366 Amberg, D. C., D. Burke, and J. N. Strathern. Methods in Yeast Genetics. A Cold 
Spring Harbor Laboratory Course Manual  Cold Spring Harbor Laboratory Press 
( 2005). 
367 Smith, A. M. et al. Quantitative phenotyping via deep barcode sequencing. Genome 
research 19, 1836-1842, doi:10.1101/gr.093955.109 (2009). 
368 Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package 
for differential expression analysis of digital gene expression data. Bioinformatics 
26, 139-140, doi:10.1093/bioinformatics/btp616 (2010). 
369 Gamberi, T. et al. Evidence that the antiproliferative effects of auranofin in 
Saccharomyces cerevisiae arise from inhibition of mitochondrial respiration. The 
international journal of biochemistry & cell biology 65, 61-71, 
doi:10.1016/j.biocel.2015.05.016 (2015). 
370 Hasson, S. A. et al. Substrate specificity of the TIM22 mitochondrial import 
pathway revealed with small molecule inhibitor of protein translocation. Proc Natl 
Acad Sci U S A 107, 9578-9583, doi:10.1073/pnas.0914387107 (2010). 
371 Dabir, D. V. et al. A small molecule inhibitor of redox-regulated protein 
translocation into mitochondria. Developmental cell 25, 81-92, 
doi:10.1016/j.devcel.2013.03.006 (2013). 
372 Glick, B. S. & Pon, L. A. Isolation of highly purified mitochondria from 
Saccharomyces cerevisiae. Methods Enzymol 260, 213-223 (1995). 
373 Dabir, D. V. et al. A role for cytochrome c and cytochrome c peroxidase in electron 
shuttling from Erv1. The EMBO journal 26, 4801-4811, 
doi:10.1038/sj.emboj.7601909 (2007). 
374 Mylonakis, E., Ausubel, F. M., Perfect, J. R., Heitman, J. & Calderwood, S. B. 
Killing of Caenorhabditis elegans by Cryptococcus neoformans as a model of yeast 
pathogenesis. Proceedings of the National Academy of Sciences of the United States 
of America 99, 15675-15680, doi:10.1073/pnas.232568599 (2002). 
375 Chandra, J. et al. Biofilm formation by the fungal pathogen Candida albicans: 





376 Chandra, J. & Mukherjee, P. K. Candida Biofilms: Development, Architecture, and 
Resistance. Microbiology spectrum 3, doi:10.1128/microbiolspec.MB-0020-2015 
(2015). 
377 Mathe, L. & Van Dijck, P. Recent insights into Candida albicans biofilm resistance 
mechanisms. Current genetics 59, 251-264, doi:10.1007/s00294-013-0400-3 
(2013). 
378 Giaever, G. et al. Chemogenomic profiling: identifying the functional interactions 
of small molecules in yeast. Proceedings of the National Academy of Sciences of 
the United States of America 101, 793-798, doi:10.1073/pnas.0307490100 (2004). 
379 Roemer, T., Davies, J., Giaever, G. & Nislow, C. Bugs, drugs and chemical 
genomics. Nature chemical biology 8, 46-56, doi:10.1038/nchembio.744 (2012). 
380 Hoepfner, D. et al. High-resolution chemical dissection of a model eukaryote 
reveals targets, pathways and gene functions. Microbiological research 169, 107-
120, doi:10.1016/j.micres.2013.11.004 (2014). 
381 Hillenmeyer, M. E. et al. The chemical genomic portrait of yeast: uncovering a 
phenotype for all genes. Science 320, 362-365, doi:10.1126/science.1150021 
(2008). 
382 Giaever, G. et al. Genomic profiling of drug sensitivities via induced 
haploinsufficiency. Nature genetics 21, 278-283, doi:10.1038/6791 (1999). 
383 Nijman, S. M. Functional genomics to uncover drug mechanism of action. Nature 
chemical biology 11, 942-948, doi:10.1038/nchembio.1963 (2015). 
384 Lee, A. Y. et al. Mapping the cellular response to small molecules using 
chemogenomic fitness signatures. Science 344, 208-211, 
doi:10.1126/science.1250217 (2014). 
385 Rissler, M. et al. The essential mitochondrial protein Erv1 cooperates with Mia40 
in biogenesis of intermembrane space proteins. Journal of molecular biology 353, 
485-492, doi:10.1016/j.jmb.2005.08.051 (2005). 
386 Banci, L. et al. MIA40 is an oxidoreductase that catalyzes oxidative protein folding 
in mitochondria. Nature structural & molecular biology 16, 198-206, 
doi:10.1038/nsmb.1553 (2009). 
387 Bihlmaier, K. et al. The disulfide relay system of mitochondria is connected to the 
respiratory chain. The Journal of cell biology 179, 389-395, 
doi:10.1083/jcb.200707123 (2007). 
388 Lisowsky, T. Dual function of a new nuclear gene for oxidative phosphorylation 
and vegetative growth in yeast. Molecular & general genetics : MGG 232, 58-64 
(1992). 
389 Neal, S. E. et al. Mia40 Protein Serves as an Electron Sink in the Mia40-Erv1 
Import Pathway. The Journal of biological chemistry 290, 20804-20814, 
doi:10.1074/jbc.M115.669440 (2015). 
390 Bourens, M. et al. Role of twin Cys-Xaa9-Cys motif cysteines in mitochondrial 
import of the cytochrome C oxidase biogenesis factor Cmc1. The Journal of 
biological chemistry 287, 31258-31269, doi:10.1074/jbc.M112.383562 (2012). 
391 Mesecke, N. et al. A disulfide relay system in the intermembrane space of 





392 Parsonage, D. et al. X-ray structures of thioredoxin and thioredoxin reductase from 
Entamoeba histolytica and prevailing hypothesis of the mechanism of Auranofin 
action. Journal of structural biology 194, 180-190, doi:10.1016/j.jsb.2016.02.015 
(2016). 
393 Ullrich, V., Weber, P., Meisch, F. & von Appen, F. Ebselen-binding equilibria 
between plasma and target proteins. Biochem Pharmacol 52, 15-19 (1996). 
394 Haenen, G. R., De Rooij, B. M., Vermeulen, N. P. & Bast, A. Mechanism of the 
reaction of ebselen with endogenous thiols: dihydrolipoate is a better cofactor than 
glutathione in the peroxidase activity of ebselen. Mol Pharmacol 37, 412-422 
(1990). 
395 Cotgreave, I. A., Morgenstern, R., Engman, L. & Ahokas, J. Characterisation and 
quantitation of a selenol intermediate in the reaction of ebselen with thiols. Chem 
Biol Interact 84, 69-76 (1992). 
396 Hattori, R. et al. Effect of ebselen on bovine and rat nitric oxide synthase activity 
is modified by thiols. Jpn J Pharmacol 72, 191-193 (1996). 
397 Kade, I. J., Balogun, B. D. & Rocha, J. B. In vitro glutathione peroxidase mimicry 
of ebselen is linked to its oxidation of critical thiols on key cerebral suphydryl 
proteins - A novel component of its GPx-mimic antioxidant mechanism emerging 
from its thiol-modulated toxicology and pharmacology. Chem Biol Interact 206, 
27-36, doi:10.1016/j.cbi.2013.07.014 (2013). 
398 Yang, C. F., Shen, H. M. & Ong, C. N. Ebselen induces apoptosis in HepG(2) cells 
through rapid depletion of intracellular thiols. Arch Biochem Biophys 374, 142-152, 
doi:10.1006/abbi.1999.1574 (2000). 
399 Zembowicz, A., Hatchett, R. J., Radziszewski, W. & Gryglewski, R. J. Inhibition 
of endothelial nitric oxide synthase by ebselen. Prevention by thiols suggests the 
inactivation by ebselen of a critical thiol essential for the catalytic activity of nitric 
oxide synthase. J Pharmacol Exp Ther 267, 1112-1118 (1993). 
400 Cai, W., Wu, J., Xi, C., Ashe, A. J., 3rd & Meyerhoff, M. E. Carboxyl-ebselen-
based layer-by-layer films as potential antithrombotic and antimicrobial coatings. 
Biomaterials 32, 7774-7784, doi:10.1016/j.biomaterials.2011.06.075 (2011). 
401 Wojtowicz, H. et al. Azaanalogues of ebselen as antimicrobial and antiviral agents: 
synthesis and properties. Farmaco 59, 863-868, doi:10.1016/j.farmac.2004.07.003 
(2004). 
402 Ngo, H. X., Shrestha, S. K. & Garneau-Tsodikova, S. Identification of Ebsulfur 
Analogues with Broad-Spectrum Antifungal Activity. ChemMedChem, 
doi:10.1002/cmdc.201600236 (2016). 
403 Billack, B. et al. Evaluation of the antifungal and plasma membrane H+-ATPase 
inhibitory action of ebselen and two ebselen analogs in S. cerevisiae cultures. J 
Enzyme Inhib Med Chem 25, 312-317, doi:10.3109/14756360903179419 (2010). 
404 Azad, G. K. et al. Ebselen induces reactive oxygen species (ROS)-mediated 
cytotoxicity in Saccharomyces cerevisiae with inhibition of glutamate 






405 Azad, G. K., Balkrishna, S. J., Sathish, N., Kumar, S. & Tomar, R. S. 
Multifunctional Ebselen drug functions through the activation of DNA damage 
response and alterations in nuclear proteins. Biochem Pharmacol 83, 296-303, 
doi:10.1016/j.bcp.2011.10.011 (2012). 
406 Odds, F. C., Brown, A. J. & Gow, N. A. Antifungal agents: mechanisms of action. 
Trends Microbiol 11, 272-279 (2003). 
407 Lewis, R. E. Current concepts in antifungal pharmacology. Mayo Clin Proc 86, 
805-817, doi:10.4065/mcp.2011.0247 (2011). 
408 Shi, H., Liu, S., Miyake, M. & Liu, K. J. Ebselen induced C6 glioma cell death in 
oxygen and glucose deprivation. Chem Res Toxicol 19, 655-660, 
doi:10.1021/tx0502544 (2006). 
409 Grant, C. M. & Dawes, I. W. Synthesis and role of glutathione in protection against 
oxidative stress in yeast. Redox Rep 2, 223-229, 
doi:10.1080/13510002.1996.11747054 (1996). 
410 Grant, C. M., MacIver, F. H. & Dawes, I. W. Glutathione is an essential metabolite 
required for resistance to oxidative stress in the yeast Saccharomyces cerevisiae. 
Curr Genet 29, 511-515 (1996). 
411 Low, C. Y. & Rotstein, C. Emerging fungal infections in immunocompromised 
patients. F1000 Med Rep 3, 14, doi:10.3410/M3-14 (2011). 
412 Jarvis, J. N. & Harrison, T. S. HIV-associated cryptococcal meningitis. Aids 21, 
2119-2129, doi:10.1097/QAD.0b013e3282a4a64d (2007). 
413 Wisplinghoff, H. et al. Nosocomial bloodstream infections in US hospitals: 
analysis of 24,179 cases from a prospective nationwide surveillance study. Clin 
Infect Dis 39, 309-317, doi:10.1086/421946 (2004). 
414 Gudlaugsson, O. et al. Attributable mortality of nosocomial candidemia, revisited. 
Clin Infect Dis 37, 1172-1177, doi:10.1086/378745 (2003). 
415 Spector, D., Labarre, J. & Toledano, M. B. A genetic investigation of the essential 
role of glutathione: mutations in the proline biosynthesis pathway are the only 
suppressors of glutathione auxotrophy in yeast. J Biol Chem 276, 7011-7016, 
doi:10.1074/jbc.M009814200 (2001). 
416 Yadav, A. K. et al. Glutathione biosynthesis in the yeast pathogens Candida 
glabrata and Candida albicans: essential in C. glabrata, and essential for virulence 
in C. albicans. Microbiology 157, 484-495, doi:10.1099/mic.0.045054-0 (2011). 
417 Gostimskaya, I. & Grant, C. M. Yeast mitochondrial glutathione is an essential 
antioxidant with mitochondrial thioredoxin providing a back-up system. Free Radic 
Biol Med 94, 55-65, doi:10.1016/j.freeradbiomed.2016.02.015 (2016). 
418 Lee, J. C. et al. The essential and ancillary role of glutathione in Saccharomyces 
cerevisiae analysed using a grande gsh1 disruptant strain. FEMS Yeast Res 1, 57-
65 (2001). 
419 Bourbouloux, A., Shahi, P., Chakladar, A., Delrot, S. & Bachhawat, A. K. Hgt1p, 
a high affinity glutathione transporter from the yeast Saccharomyces cerevisiae. J 
Biol Chem 275, 13259-13265 (2000). 
420 Thakur, A., Kaur, J. & Bachhawat, A. K. Pgt1, a glutathione transporter from the 





421 Desai, P. R. et al. Glutathione utilization by Candida albicans requires a functional 
glutathione degradation (DUG) pathway and OPT7, an unusual member of the 
oligopeptide transporter family. J Biol Chem 286, 41183-41194, 
doi:10.1074/jbc.M111.272377 (2011). 
422 Bertoti, R. et al. Glutathione protects Candida albicans against horseradish volatile 
oil. J Basic Microbiol, doi:10.1002/jobm.201600082 (2016). 
423 Maras, B. et al. Glutathione metabolism in Candida albicans resistant strains to 
fluconazole and micafungin. PLoS One 9, e98387, 
doi:10.1371/journal.pone.0098387 (2014). 
424 Lemar, K. M. et al. Diallyl disulphide depletes glutathione in Candida albicans: 



















2010-Present     PhD                        Microbiology and Immunology Graduate Program,                   
                                                                     College of Veterinary Medicine, Purdue University. 
 
2005-2009         D.V.M                   Madras Veterinary College,  
                                                         Tamilnadu Veterinary and Animal Sciences                       
                                                         University, India. 
 
Post Graduate Employment 
        
2013-2016         Teaching Assistant    Animal Disease Diagnostic Laboratory (ADDL),  
                                                             College of Veterinary Medicine, Purdue University 
                        
 
2010-2012         Research Assistant     Laboratory of Immunology and Hematopoiesis,   
                                                             College of Veterinary Medicine, Purdue University 
 
Awards/Honors 
 First place in poster presentation at “The 29th Annual Phi Zeta Research Day”, 
Purdue University, West Lafayette, IN, April 11, 2016. 
 First place in poster presentation at Indiana Branch of American Association for 
Microbiologist (IBASM) conference, Fort Wayne, IN, April 2, 2016. 
 American Association of Veterinary Laboratory Diagnosticians (AAVLD) travel 





 Third Place in oral presentation for “Clinical investigation of a case with recurrent 
regurgitation” at Phi Zeta research conference, Madras Veterinary College, 
Chennai, India. April 26, 2008. 
 
Presentations  
1. W.Yonis, S. Thangamani, M. Hostetler,  López-Pérez, C. Steussy, M.Lipton, C. 
Stauffacher , M. Wael Abd Al-Azeem & M.N.Seleem(2016 ) Class II HMG-CoA 
Reductase Inhibitors targeting gram positive pathogens. The 29th Annual Phi Zeta 
Research Day , West Lafayette, IN, USA. April 11, 2016. 
 
2. S. Thangamani, Haroon Mohammad, Mostafa F.N. Abushahba, Paschoal 
Sobreira Tiago Jose, Lake Paul, Hedrick Victoria and Mohamed N. Seleem. 
Repurposing  auranofin, an FDA approved antirheumatic drug,  for the treatment 
of staphylococcal infections The 29th Annual Phi Zeta Research Day, West 
Lafayette, IN, USA. April 11, 2016. 
 
3. W.Yonis, S. Thangamani, M. Hostetler,  López-Pérez, C. Steussy, M.Lipton, C. 
Stauffacher , M. Wael Abd Al-Azeem & M.N.Seleem,   Class II HMG-CoA 
Reductase Inhibitors targeting gram positive pathogens. Indiana Branch of 
American Society for Microbiology, Fort Wayne, IN. April 1-2, 2016. 
 
4. S. Thangamani, Haroon Mohammad, Mostafa F.N. Abushahba, Paschoal 
Sobreira Tiago Jose, Lake Paul, Hedrick Victoria and Mohamed N. Seleem. 
Repurposing  auranofin, an FDA approved antirheumatic drug,  for the treatment 
of staphylococcal infections. Indiana Branch of American Society for Microbiology, 
Fort Wayne, IN. April 1-2, 2016. 
 
5. Waleed Younis, S. Thangamani, Ahmed A. Hassan and Mohamed N. Seleem. 
Repurposing FDA- approved drugs to combat drug-resistant bacteria, Health and 
Disease Symposium, Purdue University, West Lafayette, IN, USA. March 28, 2016. 
  
6. S. Thangamani, Haroon Mohammad, Mostafa F.N. Abushahba, Paschoal 
Sobreira Tiago Jose, Lake Paul, Hedrick Victoria and Mohamed N. Seleem. An 
FDA approved antirheumatic drug to target MRSA infections. Health and Disease 
Symposium, Purdue University, West Lafayette, IN, USA. March 28, 2016. 
 
7. Waleed Younis, S. Thangamani, Ahmed A. Hassan and Mohamed N. Seleem. 
Repurposing non-antimicrobial drugs to combat multidrug-resistant bacteria, ISS 
Research symposium, Purdue University. March 8, 2016.  
 
8. W.Yonis, S. Thangamani, M. Hostetler,  López-Pérez, C. Steussy, M.Lipton, C. 
Stauffacher , M. Wael Abd Al-Azeem & M.N.Seleem,   Class II HMG-CoA 
Reductase Inhibitors targeting gram positive bacteria, Sigma Xi Graduate Student 




9. S. Thangamani, Haroon Mohammad, Mostafa F.N. Abushahba, Paschoal 
Sobreira Tiago Jose and Mohamed N. Seleem. Repurposing auranofin for the 
treatment of cutaneous staphylococcal infections. Sigma Xi Graduate Student 
Research Poster Award Competition, West Lafayette, IN, USA. March 2,  2016. 
  
10. W.Younis, S. Thangamani & M. N. Seleem. Teaching an Old drug a new trick. 
Sigma Xi Graduate Student Research Poster Award Competition, West Lafayette, 
IN, USA. February 18, 2015. 
 
11. W.Younis, S. Thangamani & M. N. Seleem. Repurposing non-antimicrobial drugs 
and clinical molecules to treat bacterial infections. The 28th Annual Phi Zeta 
Research Day, West Lafayette, IN. USA April 13, 2015. 
 
12. W.Yonis, S. Thangamani, M. Hostetler,  López-Pérez, C. Steussy, M.Lipton, C. 
Stauffacher , M. Wael Abd Al-Azeem & M.N.Seleem. Class II HMG-CoA 
Reductase Inhibitors targeting multi-drug resistant Staphylococcus aureus. Health 
and Disease, West Lafayette, IN, USA. March 5th, 2015. 
 
13. S. Thangamani, Waleed Younis  and Mohamed Seleem.“ Drug Repurposing: 
Ebselen to target MRSA.” Phi-zeta research conference, Purdue University. April 
13, 2015. 
 
14. S. Thangamani, Waleed Younis  and Mohamed Seleem. “Ebselen: a novel topical 
antibacterial agent for Staphylococcal infections”. Health and Disease Symposium, 
Purdue University. March 5, 2015. 
 
15. S. Thangamani, Waleed Younis  and Mohamed Seleem. “Repurposing ebselen for 
treatment of multidrug-resistant staphylococcal infections”. Office of 
Interdisciplinary Graduate Program-Spring Reception”, Purdue University. April 
1, 2015. 
 
16. S. Thangamani, Waleed Younis  and Mohamed Seleem. “Ebselen as a novel 
antibacterial agent against methicillin-resistant Staphylococcus aureus”.  Sigma 
Xi Graduate research competition, Purdue University, Feb 18, 2015. 
 
17. S. Thangamani, Paulo Gomes and Kenitra Hammac. Prevalence and antibiotic 
susceptibility dynamics of bacterial isolates from canine skin infections at a Purdue 
veterinary teaching hospital (2004–2013). Kansas city, MO, Oct 16-22, 2014. 
 
18. M. Nepal, S. Thangamani, M.N. Seleem, J. Chmielewski. Coupling Antimicrobial 
Action of a  Novel Unnatural Cationic Amphiphilic Polyproline Helix with its Cell 
Penetrating Ability to Target Intracellular Bacteria. 2014 H.C. Brown Lectures, 






19. M. Nepal, S. Thangamani, M.N. Seleem, J. Chmielewski. Coupling Antimicrobial 
Action of a  Novel Unnatural Cationic Amphiphilic Polyproline Helix with its Cell 
Penetrating Ability to Target Intracellular Bacteria. The 28th Annual Symposium 
of The Protein Society, San Diego, July 27-30, 2014. 
 
20. Mostafa F.N. Abushahba, S. Thangamani, H. Mohammad , Asmaa A.A Hussein 
and Mohamed N. Seleem. “Novel antisense therapeutics for treatment of 
intracellular pathogens” Phi-zeta research conference, Purdue University. April 14, 
2014. 
 
21. S. Thangamani, Mostafa F.N. Abushahba and Mohamed Seleem. “Repurposing 
non-antibiotics FDA approved drugs to treat Staphylococcal infections” Phi-zeta 
research conference, Purdue University. April 14, 2014. 
 
22. S. Thangamani, Mostafa F.N. Abushahba Maha I Hamed and Mohamed Seleem. 
“Beating Bad bugs  with old drugs”., Health and Disease Symposium, Purdue 
University. March 31, 2014. 
 
23. S. Thangamani, Mostafa F.N. Abushahba Maha I Hamed and Mohamed Seleem. 
“Old drug up to new trick in fighting resistant bacteria”.  Office of Interdisciplinary 
Graduate Program-Spring Reception”, Purdue University. April 2, 2014. 
 
24. S. Thangamani, Maha I Hamed and Mohamed Seleem. “Old drug for Bad 
bugs”.  Sigma Xi  Graduate research competition, Purdue University, Feb 12, 2014. 
 
25. S. Thangamani, Maha I Hamed and Mohamed Seleem. “Teaching an old drug a 
new trick”. Next Generation Scholars, Purdue University. Nov 19, 2013. 
 
26. Ashley, S. Thangamani, M.H.Kim and C.H.Kim, “Deep tissue Imaging of 
intestine by Multiphoton Microscopy”, Phi zeta day, Purdue University, Purdue 
University. April, 2012. 
 
27. Kimberley Jen, M.H.Kim, S. Thangamani, and C.H.Kim. “Intravital Imaging of 
intestine by Two-Photon Microscopy”. Phi zeta day, Purdue University. Phi-zeta 
research conference, Purdue University. April, 2011. 
 
28. S. Thangamani and Parimol Roy. “Antimicrobial activity of Jatropha curcas 
against Bacillus anthracis”. National conference on current trends in medicinal 
plants research and herbal technology,  Chennai, India, July 10, 2008. 
 
29. S. Thangamani and L.Nagarajan.“Clinical investigation of a case with Recurrent 
Regurgitation”. Phi-zeta Research Day, Madras Veterinary College, Chennai, India. 






30. S. Thangamani and Pugazhendhi. “Antibiotic Residues in Milk”. National 
conference on safety assessment and Consumer protection with reference to dairy 
and food industry, Chennai, India, Oct 21, 2007. 
 
Adhoc reviewer  
1. International Journal of Nanomedicine 
2. Scientific reports 
3. Current Pharmaceutical Design 
4. PLoS ONE  
5. Asian Pacific Journal of Tropical Disease 
6. Journal of Bacteriology & Parasitology 











1. Thangamani S, Mohammad H, Abushahba MF, Hamed MI, Sobreira TJ, Hedrick 
VE, Paul LN, Seleem MN. Antibacterial activity and mechanism of action of 
auranofin against multi-drug resistant bacterial pathogens. Scientific Reports. 2016 
Mar 3;6:22571. 
(Impact Factor: 5.5) 
 
2. Thangamani S, Mohammad H, Abushahba MF, Hamed MI, Sobreira TJ, Hedrick 
VE, Paul LN, Seleem MN. Repurposing auranofin for the treatment of cutaneous 
staphylococcal infections. International journal of antimicrobial agents and 
chemotherapy. 2016 Jan 23; S0924-8579(16)00012-1 (Impact Factor: 4.2) 
 
3. Abushahba MF, Mohammad H, Thangamani S, Hussein AA, Seleem MN. Impact 
of different cell penetrating peptides on the efficacy of antisense therapeutics for 
targeting intracellular pathogens. Scientific Reports. 2016 Feb 10;6:20832. (Impact 
Factor: 5.5) 
 
4. Thangamani S, Mohammad H, Abushahba MF, Hamed MI, Sobreira TJ, Hedrick 
VE, Paul LN, Seleem MN. Exploring simvastatin, an antihyperlipidemic drug, as a 
potential topical antibacterial agent. Scientific Reports. 2015 Nov 10;5:16407. 
(Impact Factor: 5.5) 
 
5. Thangamani S, Nepal M, Chmielewski J, Seleem MN. Antibacterial activity and 
therapeutic efficacy of Fl-P(R)P(R)P(L)-5, a cationic amphiphilic polyproline 
helix, in a mouse model of staphylococcal skin infection. Drug Des Devel Ther. 
2015 Oct 22;9:5749-54. (Impact Factor: 3.5) 
 
6. Thangamani S, Younis W, Seleem MN. Repurposing celecoxib as a topical 





7. Thangamani S, Younis W, Seleem MN. Repurposing Clinical Molecule Ebselen 
to Combat Drug Resistant Pathogens. PLoS One. 2015 Jul 29;10(7):e0133877 
(Impact Factor: 3.2) 
 
8. Thangamani S, Younis W, Seleem MN. Repurposing ebselen for treatment of 
multidrug-resistant staphylococcal infections. Scientific Reports. 2015, Jun 
26;5:11596 (Impact Factor: 5.5) 
 
9. Younis W, Thangamani S, Seleem MN. Repurposing Non-antimicrobial Drugs 
and Clinical Molecules to Treat Bacterial Infections. Current Pharmaceutical 
Design. 2015, May 6. (Impact Factor: 3.5) 
 
10. Nepal M, Thangamani S, Seleem MN, Chmielewski J. Targeting intracellular 
bacteria with an extended cationic amphiphilic polyproline helix. Organic and 
Biomolecular Chemistry. 2015, Apr 30. (Impact Factor: 3.3) 
 
11. Mohammad H, Thangamani S, Seleem MN. Antimicrobial peptides and 
peptidomimetics - potent therapeutic allies for staphylococcal infections. Current 
Pharmaceutical Design. 2015;21(16):2073-88. (Impact Factor: 3.5) 
 
12. Thangamani S, Mohammad H, Younis W, Seleem MN. Drug repurposing for the 
treatment of staphylococcal infections. Current Pharmaceutical Design. 
2015;21(16):2089-100. (Impact Factor: 3.5) 
 
13. Thangamani S*, Kim M*, Son Y, Huang X, Kim H, Lee JH, Cho J, Ulrich B, 
Broxmeyer HE, Kim CH. Cutting edge: progesterone directly up regulates vitamin 
d receptor gene expression for efficient regulation of T cells by calcitriol. Journal 
of  Immunology. 2015 Feb 1;194(3):883-6. (* Co-first authors) (Impact Factor: 
5.5) 
 
14. Wang C*, Thangamani S*, Kim M, Gu BH, Lee JH, Taparowsky EJ, Kim CH. 
BATF is required for normal expression of gut-homing receptors by T helper cells 
in response to retinoic acid. Journal of Experimental Medicine. 2013 Mar 
11;210(3):475-89. 
(* Co-first authors) (Impact Factor: 14.3) 
 
15. Chang J, Thangamani S, Kim MH, Ulrich B, Morris SM Jr, Kim CH. Retinoic 
acid promotes the development of Arg1-expressing dendritic cells for the regulation 
of T-cell differentiation. European Journal of Immunology. 2013 Apr;43(4):967-
78 (Impact Factor: 4.5) 
 
16. Thangamani S, M. Maland, H. Mohammad, P. Pascuzzi, L. Avramova, C. 
Koehler, T. R. Hazbun and M. N. Seleem. Repurposing approach identifies 
auranofin with broad spectrum antifungal activity that targets Mia40-Erv1 pathway, 




17. Thangamani S, H. E. Eldesouky, H. Mohammad, P. Pascuzzi, L. Avramova, T. R. 
Hazbun and M. N. Seleem. Ebselen exerts antifungal activity by regulating 
glutathione (GSH) and reactive oxygen species (ROS) production in fungal cells. 
“BBA- General Subjects”-Under Review 
 
